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The absence of a mouse model and successful in vitro cultivation systems for haemoplasmas have 
been a major hindrance in their research, impacting our understanding of haemoplasma 
pathobiology and delaying diagnostic means and vaccination strategies.  
Rodent haemoplasmas were sourced from wild-caught field mice (Apodemus spp.) and 16S rRNA 
gene sequences used for identification and phylogenetic classification within the haemotropic 
Mycoplasma species. Novel rodent haemoplasmas were successfully passaged into 
immunocompetent, SPF Wistar rats and C57BL/6 mice. Haemoplasma-species specific quantitative 
polymerase chain reaction (qPCR) assays were developed for Mycoplasma haemomuris and 
Eperythrozoon coccoides and duplexed with an internal control qPCR to monitor infection in mice. 
Infection kinetics, partial protection from re-infection with the same isolate of M. haemomuris, and 
a lack of cross-protection resulting from previous E. coccoides-infection were described. Additionally, 
M. haemomuris was shown to induce anaemia during primary infection of mice.   
To assess the use of M. haemomuris-induced haemoplasmosis of mice as a surrogate model for 
feline infection with Mycoplasma haemofelis, a cytokine signature of naïve infection and protection 
from re-infection was identified using a bead-based cytokine immunoassay. Principal component 
analysis identified a Th-17-driven immune response during naïve infection.  
Using the mouse model of haemoplasma infection to generate viable M. haemomuris organisms, in 
vitro cultivation was attempted in liquid culture and mice used to assess in vitro survival of M. 
haemomuris by inoculating infected culture media into naïve mice and subsequent monitoring for 
infection by qPCR. Mycoplasma haemomuris remained viable for 8 consecutive days of in vitro 
cultivation and replenishment of culture media with fresh mouse blood resulted in in vitro growth of 
M. haemomuris for four consecutive days.  
The newly established mouse model of haemoplasma infection and first ever successful in vitro 
cultivation of a haemoplasma will help further haemoplasma research in a range of veterinary 
relevant species.  
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1.1 PHYLOGENY OF HAEMOTROPIC MYCOPLASMAS 
1.1.1 First identification and phylogenetical classification 
Haemoplasmas (haemotropic mycoplasmas) are small (0.3 to 0.9µm), wall-less bacteria that show 
erythrocyte tropism in various mammalian host species and are able to induce clinical disease 
(mainly anaemia) or remain asymptomatic for prolonged periods of time (1). They were first 
reported by Mayer et.al. in 1921 as ‘bacteria-like’ organisms causing anaemia in rats and 
subsequently named Bartonella muris. Similar small (< 1µm) bacteria, adhering to erythrocytes and 
causing anaemia, were later found in splenectomised mice (2) and dogs (3) and non-splenectomised 
sheep (4), cattle (5), cats (6) and pigs (7). Initially, these organisms were identified as Bartonella spp. 
and Eperythrozoon spp. and the Bartonella-named organisms later transferred to Haemobartonella 
gen. nov. to allow differentiation from other disease-causing Bartonella genus bacteria (8). Bacteria 
of the genus Haemobartonella were differentiated from those of the genus Eperythrozoon by 
differences in their microscopic appearance, as Eperythrozoon organisms could be seen unattached 
to erythrocytes on blood smears and as ‘ring forms’ (1, 9).  
1.1.2 Phylogenetic re-classification and ongoing disputes 
Haemobartonella and Eperythrozoon species were first classified within the family of 
Anaplasmataceae in the Rickettsiales order. However, they differed from Anaplasmataceae by their 
lack of a cell wall and lack of motility organelles, their inability to form inclusion bodies, their intra-
erythrocyte replication and their intrinsic resistance to penicillin (10). These differences led to a 
revision of species names and transfer of several species previously named Haemobartonella 
(Haemobartonella muris, Haemobartonella felis, Eperythrozoon suis and Eperythrozoon wenyonii) to 
new genera within the order Mycoplasmatales (class Mollicutes), family Mycoplasmataceae (1), 
despite significant dissimilarity to other mycoplasmas in this family (11). These transfers led to all 
haemoplasmas being given Candidatus designation, which is typically reserved for incompletely 
described taxa, but the status was maintained due to the inability to grow haemoplasmas in vitro. 
However, the Candidatus designation was later dropped for Mycoplasma haemomuris, Mycoplasma 
haemofelis, Mycoplasma suis and Mycoplasma wenyonii (12), as these species previously existed. 
Mycoplasma ovis, formerly named Eperythrozoon ovis (4) was later transferred to the genus 
Mycoplasma as well (13) whilst Eperythrozoon coccoides retained its name (14, 15). Ongoing 
phylogenetic controversy exists due to two genera (Mycoplasma and Eperythrozoon) being used to 
describe very closely related organisms. The controversy is unlikely to be resolved until whole 
genome sequences and in vitro cultivation systems can be derived for all species affected (11) and 
may potentially require formation of a novel haemoplasma genus (16, 17).  
1.1.3 Phylogenetic characteristics of haemoplasmas 
With the availability of rapid deoxyribonucleic acid (DNA) sequencing, gene sequences that are 
present in all prokaryotes have been used to describe haemoplasma phylogenetic relationships. The 
16S rRNA gene is highly conserved amongst prokaryotes and occurs at least once in each bacterial 
genome. Thus, sequence identities of the 16S rRNA gene can be used to measure taxonomic 
diversity. Based on sequence identities, thresholds have been proposed for separation of species, 
genus, family, order, class and phylum (18); 86.2% for family, 94.5% for genus (18), and 97% to 99% 
for species resolution (19) with 98.65% being a widely used threshold and identities above 97% 
warranting further investigation (20).  These thresholds contribute to ongoing disputes over the 
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phylogenetic classification of haemoplasmas as they have between 74% and 77% 16S rRNA sequence 
identity to the reference strain of the Mycoplasma genus, leading to some authors rejecting their 
classification within this genus (21).  
Phylogenetic trees can be produced using 16S rRNA gene sequence. Traditionally the neighbour-
joining method was used to cluster phylogenetic identities based on the number of DNA base 
substitutions; the number is then reflected in the length of a branch (22). With more advanced 
computing, these simple clustering algorithms have been replaced with evolutionary models 
(accounting for reversals or convergence) that work by repeated sampling of data (bootstrapping) to 
create a phylogenetic tree based on the maximum likelihood (relating to the number of iterations 
where certain branches have formed) method (23). Based on 16S rRNA gene-derived phylogenetic 
trees, and irrespective of phylogenetic methodology used, the haemoplasmas cluster with the 
pneumoniae-group of the Mycoplasma genus, but reside within their own clade. They do split into 
two subgroups that have been named after their feline representatives, M. haemofelis and 
‘Candidatus Mycoplasma haemominutum’ although the porcine pathogen M. suis is also used to 
refer to the latter group of haemoplasmas (1, 24-26). Phylogenetic trees based on the RNase P RNA 
gene (rnpB) have shown similar relationships (17).   
However, the 16S rRNA gene (and even more so rnpB) is small, comprising around 1,500 base pairs 
and thus has limited positions available for base substitutions (27). In situ hybridisation of genomic 
DNA to DNA of a reference species (DNA-DNA hybridisation; DDH) has been used to resolve species 
above the 97% threshold and is still highly recommended to resolve species that share more than 
98.2% 16S rRNA gene sequence identity. The DDH methodology however is time-consuming and 
only available for organisms that can be grown in pure culture to obtain the required genomic DNA 
(28).  Alternatively, multi-locus sequence analysis (MLSA) has been established as a phylogenetic 
approach to increase the available number of mutations by combining individually sequenced 
housekeeping genes (23, 29). Whole-genome phylogeny is another method that can be applied if 
whole genome sequences are available, but typically requires culturable organisms to generate the 
material required and is not widely established (30). Hicks, Barker (16) applied MLSA to 
haemoplasma phylogeny using fragments of the housekeeping genes glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) and heat-shock protein 70 (DNAK); this study also suggested that 
haemoplasmas should indeed form their own genus. The phylogeny showed that the very closely 
related species of M. haemofelis and M. haemocanis (16) shared > 99% of their 16S rRNA gene (24), 
and an average of 94.9% of their rnpB gene sequences (31). However, the number of gene 
sequences per putative species for phylogenetic studies was relatively small and comprised one to 
12 (M. haemofelis only) sequences per species (16, 17, 26). Thus, expected variations within the 
same species might have been underestimated, as has been described for other bacteria (32).   
1.1.4 Haemoplasmas identified so far 
Haemoplasma species identified from their respective hosts and sufficiently different from one 








Current species* name Host animal(s) 
Mycoplasma haemomuris (12) 
Eperythrozoon coccoides** (14) 
‘Mycoplasma haemomuris-like haemoplasma’ (33) 
Murine rodents (rats and mice) 
‘Mycoplasma haemomuris-like haemoplasma’ #2 (34, 35) 
‘Candidatus Mycoplasma turicensis’-like haemoplasma (35, 36) 
Other muroid rodents (e.g. hamsters, 
harvest mice and voles) 
Mycoplasma haemofelis (1) 
‘Candidatus Mycoplasma haemominitum’ (37) 
‘Candidatus Mycoplasma turicensis’ (38) 
‘Candidatus Mycoplasma haematoparvum-like haemoplasma’ (39) 
Cats (including wild felids) 
Mycoplasma haemocanis (24)  
‘Candidatus Mycoplasma haematoparvum’ (40) 
Dogs (including foxes and wolves) 
 
Mycoplasma suis (12) 
Eperythrozoon parvum** (7) 
Pigs (including wild boars)  
 
Mycoplasma ovis (13) 
‘Candidatus Mycoplasma haemovis’ (41) 
‘Candidatus Mycoplasma erythrocervae’ (42) 
Mycoplasma wenyonii (43) 
Sheep and goats 
‘Candidatus Mycoplasma haemolamae’ (24) Camelids  
‘Candidatus Mycoplasma haematorandirangferis’ (44) 
‘Candidatus Mycoplasma haemocervae’ (45) 
‘Candidatus Mycoplasma erythrocervae’ (45) 
‘Mycoplasma ovis-like haemoplasma’ (46) 
‘Mycoplasma wenyonii-like haemoplasma’ (47) 
Deer 
Mycoplasma wenyonii (12) 
‘Candidatus Mycoplasma haemobos’ **** (48) 
Cattle (including water buffalos) 
‘Mycoplasma haemocanis-like haemoplasma’ #2 (49) Black bears 
‘Candidatus Mycoplasma kahaneii’ (50) 
‘Candidatus Mycoplasma aoti’ (51) 
‘Candidatus Mycoplasma haemomacaque’ (52) 
‘Candidatus Mycoplasma haemomacaque’-like haemoplasma (53) 
‘Candidatus Mycoplasma kahaneii’-like haemoplasma (54) 
Primates 
‘Candidatus Mycoplasma haemodidelphidis’ (24) Opossum 
‘Candidatus Mycoplasma haemomeles’ (55) Badger 
‘Candidatus Mycoplasma haemozalophi’ (56) Sea lions 
‘Candidatus Mycoplasma haemohominis’-like haemoplasmas (57) Bats 
‘M. coccoides-like haemoplasma’ (58) Capybara 
‘Candidatus Mycoplasma haemohominis’ (59) 
Mycoplasma haemofelis-like haemoplasma (60) 
Mycoplasma suis-like haemoplasma (61) 
Humans 
‘Candidatus Mycoplasma haemominutum’-like haemoplasma (62) Chelonians 
‘Mycoplasma suis-like haemoplasma’ and ‘Mycopplasma wenyonii-like’ haemoplasma (63) Non-mammalian host*** (ambrosia 
beetle) 
Table 1 Haemoplasma species identified so far. *Species that have been assigned taxonomic names are listed in full and 
other isolates identified by their closest, named relative (<98.2 % 16S rRNA gene sequence identity). **Eperythrozoon 
coccoides and Eperythrozoon parvum have been placed within the genus Mycoplasma by various authors. *** 
Haemoplasmas have been found in blood-sucking arthropods such as ticks and fleas but are not listed separately as 
haemoplasmas were identical with haemoplasmas found in mammals. **** Synonym: ‘Candidatus Mycoplasma 
haemobovis’ (64).  
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Additional diverse haemoplasma species and strains, depending on 16S rRNA gene identity 
thresholds, have been reported in a number of wild carnivores such as weasels, stone martens, 
badgers, wolves and foxes (65). Multiple novel haemoplasma species have also been found in bears 
(66), non-human primates (67), rodents (35, 68), bats (69) and raccoons (70), but not included in 
Table 1 due to lacking discriminatory power over related species and/or strains. A haemoplasma 
organism has also been found in horses, sharing 98.2% of its 16S rRNA gene sequence with  ‘Ca. M. 
haemobos’ (71).  
1.1.5 Characteristics of haemoplasma genomes 
Nine haemoplasma whole genomes sequences have been reported, as listed in Table 2. 
Haemoplasma genomes comprise a single circular chromosome and utilise the UGA-codon to 
encode tryptophan, which is common to the Mycoplasmas (72, 73). The genome of ‘Ca. M. 
haemominutum’ could not be closed, likely due to secondary structure surrounding the origin of 
replication (74), and the genome of ‘Ca. M. haemobos’ is published in draft form of 18 overlapping 
sequence reads (contigs) and has not yet been fully annotated (73).  










Mycoplasma haemofelis  
(75, 76) 
1,147,259  38.9 1580 - 1593 71.5 – 72.4 
‘Candidatus Mycoplasma haemobos’  
(73) 
935,638 30.5 n/a n/a 
Mycoplasma haemocanis  
(77) 
919,992 35.0 1173 63.0 
Mycoplasma haemolamae  
(78) 
756,845 39.3 925 49.1 
Mycoplasma suis  
(79, 80) 
742,431 31.1 794 - 845 37.4 – 42.8 
Mycoplasma ovis  
(81) 
702,511 31.7 801 32.4 
Mycoplasma wenyonii  
(82) 
650,228 33.9 652 40.3 
‘Candidatus Mycoplasma haemominutum’  
(74) 
513,880 35.5 547 24.5 
Mycoplasma parvum  
(83) 
564,395 27.0 581 26.0 
Table 2 Haemoplasma species with whole genome sequences available for genomic analysis. The genome of ‘Candidatus 
Mycoplasma haemominutum’ has been published as discontinuous and the genome of ‘Candidatus Mycoplasma haemobos’ 
(synonum to ‘Candidatus Mycoplasma haemobovis’) is currently published as a draft genome sequence, comprising 18 
contigs.  
Their genomes comprise 547 to 1,593 coding sequences and within them, a high percentage of 
paralogous repeat sequences (homologous genes arising through gene duplication, considered a 
driving factor in bacterial evolution) (72). These sequences are organised in families of up to 800 
sequences (in M. haemofelis) and are correlated with genome size. Most of them are hypothetical 
proteins of unknown function (72) but are thought to play a role in immune evasion as some of them 
have been demonstrated to be immunogenic in M. suis (84) and M. haemofelis (85), which are the 
two most studied haemoplasmas. Such paralogous gene families have been shown to contribute to 
phase variation of antigenic proteins in other Mycoplasma spp. (86-88). Phase variation could be 
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associated with the cycling of haemoplasma copies in blood over time seen in M. haemofelis-
infected cats (89, 90).  
Immunogenic haemoplasma proteins have been identified in M. suis (84, 91-93) and M. haemofelis 
(94); these have been protein-folding machinery proteins (e.g. DNAK and its cofactor heat-shock-
protein-24) or glycolysis pathway proteins (e.g. GAPDH, enolase) or other core metabolic enzymes 
(e.g. inorganic pyrophosphatase). The finding that haemoplasma core metabolic enzymes can be 
involved in pathogenicity and hence become immunogenic in their hosts highlights the multi-use of 
these proteins by haemoplasmas (called ‘moonlighting’) and is described for other Mycoplasma spp. 
(95, 96). However, the number of haemoplasma proteins that have an orthologous (genes arisen 
from a common ancestor in multiple species) protein annotated within the Clusters of Orthologous 
Groups (COG) database (http://www.ncbi.nlm.nih.gov/COG) is low, only 295 to 319, except for the 
related M. haemofelis and M. haemocanis species, whose genomes encode about three times as 
many COG-identified proteins (72). No data on COG-identified proteins are available for ‘Ca. M. 
haemobos’ (73). The low level of similarity to known proteins and the unculturable status of the 
haemoplasmas is a significant problem for in silico prediction of haemoplasma proteins and 
immunogenic epitopes for use vaccines or serological assays.  
1.2 HAEMOPLASMA INFECTION AND CLINICAL HAEMOPLASMOSIS IN MAMMALS 
Haemoplasma infection has been detected in a variety of livestock and companion animal species as 
summarised in Table 1. Haemoplasma infection is not always associated with clinical disease; this is 
largely dependent on the haemoplasma species and sometimes the host immune system (97). The 
pathogenesis of haemoplasma infection and development of clinical haemoplasmosis have been 
studied mostly in cats for feline haemoplasmas, including data on detection, prevalence and risk 
factors (89, 98-105), genomics (16, 25, 26, 74, 75, 106), proteomics and immunology (94, 107-110). 
Similar studies exist in pigs, including M. suis detection and prevalence (111, 112), pathogenesis 
(113-116), proteomics and vaccine candidates (84, 117-121) whilst other haemoplasma species are 
less studied. As this thesis is aimed to further knowledge on feline haemoplasma infection and 
prevention of clinical haemoplasmosis in cats, data on feline haemoplasma species will be discussed, 
followed by translational aspects of porcine haemoplasma infection and clinical haemoplasmosis 
caused by M. suis.   
1.2.1 Feline clinical haemoplasmosis and haemoplasma infection  
In cats, clinical haemoplasmosis was previously referred to as ‘feline infectious anaemia’ (122), but 
to avoid confusion with other infectious causes of anaemia in cats, this term is no longer used. For 
the purpose of this thesis, the term ‘haemoplasmosis’ alone refers to haemoplasma infection, with 
or without clinical disease.  
Three haemoplasma species are known to infect cats, with M. haemofelis the most likely to cause 
clinical disease such as pyrexia and (sometimes fatal) anaemia (123). The species ‘Ca. M. 
haemominutum’ is rarely associated with clinical disease but, similarly to ‘Ca. M. turicencis’, may 
cause reductions in erythrocyte count and haemoglobin concentration (90). ‘Candidatus M. 
turicensis’ has been reported to cause more severe clinical haemoplasmosis in immunocompromised 
cats, but can also cause disease in immunocompetent cats (38, 124). Clinical haemoplasmosis 
manifests as lethargy, pyrexia, inappetence, weight loss and anaemia signs such as pallor, pica, 
haemic heart murmur and tachypnoea. Hepatosplenomegaly is reported, and icterus is uncommon 
(90). Two more haemoplasma species have been reported in cats; ‘Ca. M. haematoparvum-like 
haemoplasma’ that has yet to be described fully or shown to be associated with disease (39, 125), 
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and M. haemocanis that was reported to be successfully passaged through cats to then infect dogs, 
although clinical disease was not seen in the M. haemocanis-inoculated cats (126).  
Prevalences of the three most common feline haemoplasmas, as determined by quantitative 
polymerase chain reaction (qPCR), have been reported from various geographical locations and 
range from 0.4 – 46.6% for M. haemofelis, 10 – 32.1% for ‘Ca. M. haemominitum’ and 0.4 – 26% for 
‘Ca. M. turicensis’ as reviewed by Tasker (123). Higher prevalences of haemoplasma infection are 
generally reported for warmer climates (39, 102, 127, 128) and can sometimes coincide with higher 
prevalences of arthropod vectors within a country (102).  
The finding of infections with all three haemoplasma species in cats without clinical suspicion of 
haemoplasmosis shows the presence of a carrier state that likely presents a source of infection for 
naïve cats (106, 129, 130); the carrier status most commonly occurs with ‘Ca. M. haemominutum’ 
and this may contribute to its high prevalence (131).  
Antibiotic therapy for feline clinical haemoplasmosis typically comprises tetracyclines or 
flouroquinolones, and these treatments can result in rapid resolution of clinical signs caused by M. 
haemofelis following a two to four-week course of oral antibiotics, however M. haemofelis infection 
is not usually cleared from blood (89, 103, 130, 132-134). Clearance of M. haemofelis infection has 
only been recently demonstrated with one protocol; oral doxycycline for four weeks followed by oral 
marbofloxacin for two weeks if bacteraemia (positive qPCR results) persisted (135). Treatment of 
‘Ca. M. haemominutum’ with oral marbofloxacin is also reported to reduce bacterial loads (136), but 
due to the lack of clinical signs with this species it remains less studied. Infection with ‘Ca. M. 
turicensis’ was reported to respond to either oral doxycycline for two weeks or consecutive 
doxycycline then marbofloxacin administration (124), but in contrast to M. haemofelis-associated 
clinical haemoplasmosis, clinical signs can resolve without therapy (102).  
The anaemia of clinical haemoplasmosis is thought to be mediated through damage to the 
erythrocyte membrane as haemoplasmas attach themselves and subsequently induce haemolysis 
and removal of infected erythrocytes in the spleen (123). One study demonstrated that cold-reactive 
(4°C) autoantibodies appeared as early as 8 days post-inoculation with M. haemofelis, coinciding 
with the development of anaemia, but warm-reactive (37°C) autoantibodies were only found 22 
days post-inoculation, by which time a regenerative anaemia was present (90). Additionally, another 
study only demonstrated autoagglutination of erythrocytes when sera of M. haemofelis-infected 
cats and infected erythrocytes were combined, or when sera of M. haemofelis-infected cats and 
erythrocytes treated with neuraminidase (to alter their surface) were combined (137). This 
suggested that antibodies are directed at haemoplasma epitopes or altered erythrocyte surface 
epitopes but not to normal erythrocytes. Autoantibodies on erythrocytes were not demonstrated in 
‘Ca. M. haemominutum’ nor ‘Ca. M. turicensis’ infection, although this may be due to insensitive 
methods used (Coombs’ testing) for their detection in the study  (90).  
Due to limitations in the feline host size and hence blood volume (for e.g. collection of large volumes 
of haemoplasma-infected blood) and ethical considerations, studies targeting the feline host-
pathogen interaction and haemoplasma protein expression have been greatly hindered by the lack 
of an in vitro cultivation system to study at least some of these interactions outside of the natural 
feline host. No vaccination studies have been reported although passive immunisation (using 
convalescent plasma from M. haemofelis-infected cats) showed no protection when transferred to 
naïve cats prior to inoculation with M. haemofelis (138).  
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1.2.2 Porcine clinical haemoplasmosis and haemoplasma infection  
Porcine clinical haemoplasmosis (previously porcine eperythrozoonosis) has been described as a 
febrile disease of swine with anaemia, icterus and haemagglutination that could be controlled 
through oxytetracycline treatment and hygienic measures, including control of lice (139). Two 
species of haemoplasmas have been described to infect pigs; M. suis and Eperythrozoon parvum, 
however the latter has no known pathogenicity (83). Mycoplasma suis is found in pigs worldwide 
and has also been found in wild boars in Europe (113). Acute infection causes potentially fatal 
haemolytic anaemia but chronic infection is linked to poor growth and reproductive performance 
and poses a significant economic risk to the swine industry (112). Prevalence determined by qPCR 
ranges from 13.0% to 18.2% but less data are available than for feline haemoplasma infection (113).  
In contrast to feline clinical haemoplasmosis (typically caused by M. haemofelis), M. suis has been 
reported to invade erythrocytes (115), cause endothelial damage and result in hypoglycaemia due to 
excess glucose consumption in the host (113). Two M. suis immunogenic adhesion proteins have 
been identified that represent ‘moonlighting’ proteins of the glycolysis pathway; MSG1 (GAPDH) and 
α-enolase (91, 93) and M. suis DNAK has also been shown to be expressed during acute infection, 
and it elicits an immune response in pigs (119). Adhesion of M. suis to porcine erythrocytes alters 
their membranes and induces eryptosis (programmed cell death of erythrocytes and subsequent 
removal by the spleen) and limits clinical disease and anaemia in low-virulence strains that do not 
result in sudden intravascular haemolysis (140). Anaemia has been associated with warm-reactive 
erythrocytic IgG autoantibodies (141, 142). Mycoplasma suis also appears to contribute to a 
coagulopathy through its close association with endothelial cells, and M. suis appears to form 
biofilm-like colonies with erythrocytes and the endothelium, contributing to immune-evasion (114). 
Experimental vaccination attempts with recombinant M. suis MSG1 resulted in measurable immune 
responses but were not protective against M. suis challenge (120).  
Due to their large size and availability for use in research, and the ability to be able to repeatedly 
sample them for quite large volumes of blood, pigs can be more amenable to haemoplasma research 
than cats. However, ethical considerations still exist with their use.  Additionally, our understanding 
of their host-pathogen interaction is still very limited by the lack of an in vitro cultivation system for 
porcine haemoplasmas that would allow us to study endothelial and erythrocyte targeting outside of 
the host (113, 117).   
1.2.3 Haemoplasma infection and clinical haemoplasmosis in other companion and livestock 
animals 
In dogs M. haemocanis, and even more so ‘Ca. M. haematoparvum’, appear only able to cause 
clinical anaemia in immunosuppressed (e.g. splenectomised) animals and hence have not received 
much scientific interest beyond eradication from kennel-raised research colonies (143) or individual 
case reports (144, 145). Prevalence, as detected by qPCR, varies from 0.8 to 26.2% for M. 
haemocanis (146, 147)  and 0.3 to 33.4 % for ‘Ca. M. haematoparvum (148, 149), with higher 
prevalences generally in warmer climates. The latter supports the hypothesis that arthropod vectors, 
especially Rhipicephalus sanguineus (brown dog tick), are involved in transmission (150). However, 
Aktas and Ozubek (147) were unable to detect canine haemoplasma DNA in unfed Rhipicephalus 
spp. ticks collected from the same habitat as a Turkish shelter dog population with a high 
haemoplasma prevalence. A similar survey of partially-fed ticks collected from dogs in the UK also 




Clinical haemoplasmosis caused by M. ovis has been described in anaemic lambs in association with 
poor growth or even death (152), but M. ovis may not cause clinical signs in adult sheep (153). 
Caprine clinical disease appears to be more severe but less commonly investigated (13). Hornok, 
Meli (41) found concurrent haemoplasma infection with M. ovis and a novel haemoplasma ‘Ca. M. 
haemovis’ in sheep with haemolytic anaemia. Haemoplasma prevalence, as determined by qPCR, in 
sheep ranges from 14.1% to 45.8% with similar percentages (6.2% to 44.1%) reported in goats (42, 
43, 154, 155). However, prevalence data are limited to selected geographical locations. Research is 
currently focused on sheep as clinical haemoplasmosis can be fatal and is difficult to clear with 
tetracyclines (42, 43, 156, 157). Subclinical infection with one or more haemoplasmas, including ‘Ca. 
M. erythrocervae’, is also an emerging problem in sheep used for medical research as infection has 
been shown to alter haematological parameters and erythrocyte osmotic fragility (42). Bovine 
clinical haemoplasmosis, caused by M. wenyonii and the more recently discovered ‘Ca. M. 
haemobos’, is associated with clinical signs such as depression, pyrexia and reduced milk production 
(158, 159). Regional qPCR prevalences range from 4.9 to 38.5% for M. wenyonii (160, 161) and 38.1 
to 64.2% for ‘Ca. M. haemobos’ (160, 162). The pathophysiology of bovine clinical haemoplasmosis is 
poorly understood as some studies only report fatal disease in conjunction with Anaplasma spp. 
infection (163, 164). Bovine haemoplasmas are considered an emerging pathogen in Northern 
Europe (161, 165). 
In camelids, limited data are available but experimental infection with ‘Ca. M. haemolamae’ has 
resulted in mild, transient anaemia and pyrexia (166). Prevalence data is limited to selected regions 
and ranges from 9.26 to 19.3% in clinically healthy South American llamas and alpacas (167). Meli, 
Kaufmann (168) reported 11 of 24 clinically healthy Swiss alpacas to be ‘Ca. M. haemolamae’ 
infected, and Crosse, Ayling (169) found 38 of 131 UK alpacas were infected; however both of these 
studies were described following individual deaths in the group and hence prevalences may be 
higher than expected.  
In contrast to other haemoplasmas, with the potential exception of M. suis for which vertical 
transmission had been suspected in earlier studies (139, 170), transplacental transmission of 
haemoplasmas has only been demonstrated for ‘Ca. M. haemolamae’  (171, 172) and the bovine 
haemoplasmas M. wenyonii and ‘Ca. M. haemobos’ (165, 173, 174).  
1.2.4 Zoonotic potential of haemoplasmas 
Haemoplasma infection of humans is limited to small studies and case reports of 
immunocompromised individuals or individuals with reported close contact to animals (52). 
However, human haemoplasmas represent emerging zoonotic pathogens, especially in view of their 
association with warmer climates and respective availability of arthropod vectors (52). Santos and 
Santos (60) detected a M. haemofelis-like haemoplasma in a human immunodeficiency virus (HIV)-
infected patient and Steer and Tasker (59) reported a novel haemoplasma named ‘Candidatus 
Mycoplasma haemohominis’, related to rodent haemoplasmas, in a potentially 
immunocompromised patient. Sykes, Lindsay (175) reported two strains of an M. ovis-like 
haemoplasma in a veterinarian co-infected with Bartonella henselae, the same co-pathogen that was 
also found in a veterinarian infected with a ‘Ca. M. haematoparvum’-like haemoplasma (176). Maggi 
and Compton (52) confirmed haemoplasma infection in individuals with close contact to animals, in 
9 of 193 individuals that self-reported chronic illness. Eight of these nine infections were due to the 
M. ovis-like haemoplasma and one due to a ‘Ca. M. haematoparvum’-like haemoplasma. Following 
up the potential association of chronic disease with haemoplasma infection, the same study found 
two infections (one M. ovis-like and one E. coccoides-like) in a cohort of 296 patients recruited from 




A M. suis-like haemoplasma was found in an anaemic patient in China (177) and in 32 of 65 
veterinarians and farm workers on Chinese pig farms with a high M. suis prevalence. However, the 
genotypes were not identical (98% sequence identity on a partial 16S rRNA gene fragment) so 
interspecies pig-human transmission could not be proven (61).  
1.3 DETECTION OF HAEMOPLASMA INFECTION 
1.3.1 Blood smear examination 
Haemoplasmas traditionally were diagnosed based on light microscopic examination of blood 
smears stained with a Romanowsky-type stain. When visible they appeared as small (< 1µm) 
pleomorphic rods or cocci that were found either alone or in short chains on the erythrocyte surface 
(7, 126, 178). However, differentiation from artefacts or other erythrocyte inclusion bodies (e.g. 
Howell-Jolly bodies (179)) was difficult and false positive results were common (180).  
Following the development of more sensitive diagnostic molecular techniques, the sensitivity of 
blood smear examination was found to low, down to 11.1% in one study (128) and 21.3% (111) and 
37.4% (165) in others. 
1.3.2 Polymerase chain reaction (PCR)-based detection methods 
Polymerase chain reaction allows the amplification of specific sections of DNA (181). The method 
has dramatically improved diagnostic sensitivity and specificity for pathogen detection, especially 
pathogens that are unculturable or grow slowly.  
Typically, PCR assays target hypervariable regions in otherwise conserved genes, e.g. the 16S rRNA 
gene, as their sequences are readily available and do not require whole genomes or knowledge of 
the specific bacterial strain (182). Several PCR assays have been developed for haemoplasmas, 
including M. haemofelis (130), M. haemomuris (183) and M. suis (184). Primer design to less variable 
regions, that are still specific to haemoplasma genomes, allows the development of generic 
haemoplasma PCR assays to detect previously unknown haemoplasma species (185).  
Quantitative PCR (qPCR) employs exponential amplification, like conventional PCR, but includes the 
use of an additional DNA sequence (probe) to bind to the amplified region; this probe fluoresces 
proportionally to the amount of amplified DNA, allowing quantification of the original bacterial DNA 
within the sample (186). As probes can be designed to fluoresce at different wavelengths, these 
assays can be duplexed with a host housekeeping gene to confirm the absence of PCR inhibitors and 
the presence of amplifiable DNA in the sample, as currently used for some feline and canine 
haemoplasma qPCRs (100, 104, 187). More recently, qPCR assays targeting protein-coding genes 
have been designed for bovine haemoplasmas; but the use of these is potentially limited to the 
individual strain, as protein-coding sequences are typically not included in sequencing surveys and 
hence intra-species variability of the assay target regions cannot readily be assessed (161, 188). 
Quantitative PCR detection allows monitoring of infection kinetics following experimental infection 
with haemoplasmas.  Following experimental intravenous infection, M. haemofelis is detectable by 
qPCR after one to two days, after which rapid growth and cycling bacteraemia (> 4 log-fold 
increases/decreases) occur (103, 189). This cycling is not seen in ‘Ca. M. haemominutum’ (136) nor 
‘Ca. M. turicensis’ infection (124). Peak bacteraemia is typically reached after two weeks and 
coincides with the onset of clinical anaemia (90) with M. haemofelis. Infection with ‘Ca. M. 
haemominutum’ reaches similar levels of bacteraemia as M. haemofelis infection (approximately 
1.0E+09 genome copies per ml blood) whilst ‘Ca. M. turicensis’ infection has much lower 
bacteraemia (1.0E+06 genome copies per ml blood) (90). Acute infection can be followed by a carrier 
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state in M. haemofelis, ‘Ca. M. haemominutum’ (90) and sometimes ‘Ca. M. turicensis’ infection 
(129), which can last for months. A low-dose subcutaneous infection model has been described for 
M. haemofelis by Baumann, Novacco (189) that resulted in a longer lag-phase after inoculation; cats 
became qPCR positive 19 days following inoculation compared to five days following intravenous 
inoculation (90).  
The infection kinetics of M. suis are less investigated but rapid increases of bacterial loads following 
experimental intramuscular infection (up to 1.0E+11 genome copies per ml blood) have been 
described. Peak bacteraemia coincides with the onset of clinical signs at 15 days following 
inoculation and levels remain high for months (120). 
Recently, Cohen, Shemesh (34) described the infection kinetics for a novel M. haemomuris-like 
haemoplasma in gerbils with persistent infection occurring for 700 days (the study duration); 
infection was first detectable at 15 days post-inoculation and peaked 10 to 30 days later at 1.0E+09 
genome copies per ml blood, followed by a gradual decline (> 6 log-fold decrease over three 
months). Anaemia and potential cycling of bacterial loads were not assessed (34).  
1.3.3 Other stain-based methods 
In other blood-borne pathogens, such as Plasmodium spp., combined DNA-stains and mitochondrial 
membrane potential stains allow specific and sensitive detection of parasitaemia using flow 
cytometry to differentiate parasitized erythrocytes from inclusion bodies or other blood cells (190). 
Sánchez-Pérez, Brown (191) reported the use of flow cytometry using a DNA stain to monitor 
response to therapy in M. haemofelis clinical haemoplasmosis. However, as haemoplasmas lack 
organelles (such as mitochondria that would allow the use of specific stains), erythrocytic Howell-
Jolly bodies and DNA remnants cannot be easily differentiated from haemoplasmas, as is possible for 
Plasmodium spp. using the mitochondrial potential stain. Other DNA stains alone, such as acridine 
orange, do not have increased diagnostic sensitivity when compared to light microscopy using 
Romanovsky-type stains (111, 165).  
1.3.4 Serology 
Serological detection assays require the production of specific antibodies against pathogen proteins 
or the production of immunogenic protein epitopes. In contrast to direct pathogen detection, 
serology is limited by the need for seroconversion and formation of specific antibodies, and positive 
results can occur due to previous exposure or in chronic carriers in the absence of overt 
bacteraemia.  Techniques, such as enzyme-linked immunosorbent assays (ELISAs), have been 
adapted for patient-side use to allow rapid detection of infection (192). Crude haemoplasma antigen 
preparations have been used previously to develop serological assays but had poor sensitivity and 
specificity (193-195). Reliable haemoplasma serological assays require knowledge of immunogenic 
haemoplasma proteins, which is hindered by the absence of an in vitro cultivation system and 
available whole genome sequences.  
Hoelzle, Hoelzle (142) identified eight immunogenic M. suis proteins using sera from acutely infected 
pigs, three of which were consistently immunoreactive over the course of infection. The group went 
on to develop sensitive ELISAs for experimental M. suis detection using M. suis DNAK and GAPDH 
proteins, but broader diagnostic use was limited by cross-reactive and autoreactive antibodies 
during acute clinical haemoplasmosis (91, 121).  
Guimaraes, Santos (84) developed a multiplex microbead immunoassay, coupling three 
recombinantly expressed M. suis immunogenic proteins (heat-shock-protein-24, NADP-dependent 
glyceraldehyde-3-phosphate dehydrogenase and one member of the paralogous repeat family) to 
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microscopic beads for flow cytometric detection. The resulting assay resulted in apparent increased 
sensitivity (78.43%), compared to qPCR (9.8%), however cross-reactivity to other pathogens was not 
assessed.  
Immunogenic proteins have also been identified for M. haemofelis by Barker, Helps (94), who 
identified M. haemofelis DNAK to be highly immunogenic and developed an ELISA-based assay that 
had increased sensitivity (31.1%) over qPCR (9.8%). The ELISA was later shown to cross-react with 
antibodies against ‘Ca. M. turicensis’ infection (129), but cross-reactivity to other pathogens was  
limiting its clinical use (94). Similarly, M. haemofelis GAPDH, and a number of other unidentified 
protein/protein fragments were found to be immunogenic in another preliminary study (196) that 
did not further evaluate diagnostic sensitivity and specificity.  
Messick and Santos (85) identified several immunogenic M. haemofelis protein epitopes by 
screening whole-genome expression libraries and found five to be reactive to plasma derived from 
M. haemofelis-infected cats and not reactive to naïve cats, but further evaluation was not reported.  
No studies on immunoreactive proteins of other haemoplasma species have been performed with 
the exception of M. haemomuris that had five major antigens identified on western blot (197). 
However, identification of the antigens, and potential interference of autoantibodies on the assay, 
could not be assessed as whole genome sequences were not available for M. haemomuris (197). 
1.4 HOST SPECIFICITY, TRANSMISSION AND TRANSLATIONAL ASPECTS OF HAEMOPLASMAS 
1.4.1 Host specificity of mycoplasmas 
Mycoplasmas are generally host specific unless other factors, such as immunosuppression, allow 
them to cross wider species barriers (198). There is some evidence that genetically more 
heterogenous Mycoplasma species (e.g. M. gallisepticum) might be able to infect a wider host range 
(199). However, this evidence is based on identification of rather short bacterial DNA sequences 
from various hosts rather than actual inter-species transmission experiments with the same 
pathogen, and hence might reflect incomplete phylogenetic resolution of isolates (198).  
1.4.2 Host specificity and transmission of haemoplasmas 
The veterinary haemoplasmas also appear to be generally host specific (26). One study recently 
reported natural infection of M. haemocanis of a feline host, however this was based on 16S rRNA 
sequencing alone that cannot differentiate M. haemocanis from M. haemofelis (200).  
A haemoplasma closely related to M. suis has been reported to infect farm workers and 
veterinarians in China, however published sequences of this isolate reflect a more heterogenous 
phylogenetic distribution than would be expected with one haemoplasma species (61). A 
haemoplasma closely related to M. haemofelis has been found in an immunocompromised human 
(60), as has an M. ovis-like haemoplasma (175). There is also some evidence to suggest that other 
haemoplasmas of non-human origin are possibly able to infect immunocompromised humans, as 
reported by Steer, Tasker (59). Yuan, Zhu (201) also found a M. wenyonii-like haemoplasma in pigs in 
China that were consistently negative on M. suis-targeting PCR assays. Fu, Shi (202) recently 
reported a 26.2% prevalence of ‘Ca. M. turicencis’-like haemoplasma in clinically healthy pigs.  
However, very few strains of haemoplasmas have been fully characterised following isolation from 
their respective hosts. Given their wide distribution and underexplored genetic variability, 
interspecies transmission of haemoplasmas, or the presence of closely related and not fully 
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phylogenetically resolved haemoplasmas of species-specific pathogenicity, can equally not be ruled 
out (198).  
To complicate matters, the natural transmission of haemoplasmas and the role of potential 
arthropod vectors remains unclear. Before PCR development, the louse Polyplax serrata was 
suggested as the natural vector for E. coccoides in mice as it survived up to 24 hours in fasted lice 
(203), but amplification within the louse host was then not demonstrated by PCR (204). The cat flea 
Ctenocephalides felis can contain ‘Ca. M. haemominutum’ DNA (e.g. fleas collected from cats in the 
UK (205)) and Canadian fleas can contain M. haemofelis and ‘Ca. M. haemominutum’ DNA (206). 
Transmission experiments using diluted blood samples containing ‘Ca. M. turicensis’ inoculated 
subcutaneously into naïve cats to mimic flea-bites, showed infection in 4 out of 5 inoculated cats 
(207), suggesting that flea transmission could be possible. However, when fleas that were fed on M. 
haemofelis and ‘Ca. M. haemominutum’-infected cats then fed on 6 naïve cats in another study, 
transient M. haemofelis bacteraemia occurred in only one cat (208). Vectors have been further 
explored by Willi, Boretti (131) who found M. haemofelis, ‘Ca. M. haemominutum’ and ‘Ca. M. 
turicensis’ DNA in cat fleas, Ixodes spp. and Rhipicephalus spp. ticks collected from cats, but not in 
any unfed ticks collected from vegetation, suggesting that ticks may not act as biological vectors. 
Rodents were commonly positive for E. coccoides, but not feline haemoplasmas in the same study 
(131). Carriage of all three feline haemoplasmas was also reported in a small number of ticks 
collected from cats in the UK (209). No haemoplasmas were found in ticks collected from vegetation 
in Hungary (210) or apparently unfed ticks collected from dogs in the UK (151). There is however one 
report of ‘Ca. M. haemominutum’ being detected in an unfed Ixodes ovatus tick in Japan (211).  
In dogs, the tick R. sanguineus was assumed to be a natural vector of M. haemocanis (150). In a later 
study, using PCR, Tosa (Japanese fighting) dogs had a high prevalence of M. haemocanis with only 1 
of 25 sampled male dogs being PCR-negative, compared to a prevalence of only 1.4% within the 
normal dog population in the same region (212), suggesting bite wounds as a possible route of 
transmission. 
Social contact or inoculation with saliva/ingestion of haemoplasma-infected blood was not able to 
transmit M. haemofelis nor ‘Ca. M. haemominutum’ infection in cats (207) although free-roaming 
lifestyle and male gender are reported risk factors for feline haemoplasma infection (98, 102, 106, 
128, 146, 200). 
Transplacental transmission has not been conclusively evaluated for cats or dogs, but blood 
contaminated semen may transmit porcine haemoplasmas (213). Blood transfusion transmission of 
haemoplasmas has been suggested by Gary, Richmond (214) for M. haemofelis and ‘Ca. M. 
haemominutum’, but anticoagulated haemoplasma-infected blood was only able to establish lasting 
infection if inoculated after 24 hours at 4°C, whilst blood stored for one week only resulted in brief 
detection of ‘Ca. M. haemominutum’ and no detection of M. haemofelis in the inoculated, naïve cats 
(214).  
Few attempts have been made to assess host specificity using inter-host-species transmission 
experiments. Inoculation of M. haemofelis-infected feline blood did not establish infection in 
splenectomised mice, rats or dogs (122), nor in ruminants (215), but infection was based on blood-
smear detection only. When inoculated with M. haemocanis-infected blood, cats did not show any 
signs of infection (anaemia or detectable organisms on blood smears) but these cats were able to 
infect naïve dogs through inoculation of their blood suggesting they were M. haemocanis carriers, 
but this study again only ‘confirmed’ infection by blood smear examination (126). More recently two 
healthy juvenile mice, two guinea pigs and one rabbit were inoculated with M. haemofelis-infected 
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blood and monitored by qPCR but no evidence of infection was found (216). One gerbil did amplify 
M. haemofelis 13 weeks after intraperitoneal inoculation, but bacteraemia was short-lived (Hicks, 
unpublished). Healthy laboratory mice did not amplify M. suis following intraperitoneal inoculation 
of M. suis-infected porcine blood (217).  
1.5 RODENT MODELS IN INFECTIOUS DISEASE RESEARCH 
1.5.1 Justification for animal models 
With clinical haemoplasmosis being most relevant in cats and pigs, an alternative, smaller model of 
infection is highly desirable, especially in view of the unculturable status of haemoplasmas. In 
emerging diseases in humans, when there is a similar lack of data on pathogenesis and prevention of 
the disease, mouse models can provide vital insights into understanding disease mechanisms and aid 
the development of vaccines (218). Typically smaller animal models, such as murine models, are 
chosen based largely on their lesser cost and ethical burden and the ability to eliminate extrinsic and 
intrinsic factors within a study group by using inbred or even genetically modified strains (219). 
Ultimately, however, the aim would be for animal models to be replaced by non-animal methods, to 
refine them to use less invasive means and to reduce the number of animals required, as defined by 
the ‘3R principle’ (220).  
1.5.2 Definition of rodent model  
In human medicine, animal or rodent models are “meant to emulate the biological phenomenon for 
a disease occurring in humans” (218). In veterinary research, without translational aspects, rodent 
models are less common but the same principles of extrapolation of data from one species to 
another may be applied.  
When defining animal models, different criteria have been used to justify using research animals  
(218). Models should be homologous (i.e. share genetic similarities) in the response to the studied 
disease, and they should also resemble the clinical disease irrespective of its origin (referred to as 
analogy) and have high fidelity. Fidelity refers to how close the target species and the model are 
related and how much of the collected data (e.g. clinical outcomes after interventions) can be 
extrapolated (218). Homology and analogy generally describe the (animal) model species but may 
also be described for the pathogen when working with infectious agents. 
In disease models involving highly adapted pathogens, using a naturally occurring pathogen, adapted 
to the model species (e.g. mouse) may require a higher degree of extrapolation as two different host 
species and two different species of pathogens are involved. However, depending on the research 
objective, using pathogens adapted to the model species may present a better model of the disease 
than infection of the model species with a less adapted ‘unnatural’ pathogen. For example, the 
feline immunodeficiency virus (FIV) model in cats is more suitable to assess HIV-related drugs as 
chimpanzees, despite being able to become infected with HIV do not develop disease like FIV-
infected cats and HIV-infected humans (221). The use of naturally adapted pathogens in model 
species are called surrogate models and are defined by the substitution of an infectious agent by one 
that is more adapted to the host species in which it is to be investigated, and it may or may not be 
genetically related to the primary pathogen being investigated (222).  
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1.6 IN VITRO CULTIVATION OF THE HAEMOPLASMAS 
1.6.1 Why cultivate haemoplasmas? 
The absence of an in vitro cultivation system to generate more viable organisms is a major hindrance 
in haemoplasma research. Whilst development of a mouse model of haemoplasma infection may 
alleviate some of the ethical and financial challenges of only being able to grow haemoplasmas in 
their host animals, the mouse model would still not offer a feasible means of generating large-scale 
numbers of haemoplasmas for proteomics research or whole genome sequencing, as the size of 
laboratory mice precludes collection of large volumes of blood.  
1.6.2 Known growth characteristics of related Mycoplasma species 
Mycoplasmas are the smallest self-replicating free-living organisms and are currently thought to 
have developed from gram-positive bacteria of the class Firmicutes by reductive evolution (223). Due 
to their reduced small genomes, they lack certain metabolic capacities and in vitro cultivation has 
historically been very difficult. For instance, Mycoplasma spp. typically lack the ability to synthesise 
fatty acids or amino acids and require supplementation in the form of yeast extract or serum 
components (223). Prior to having whole genome sequences available, their nutritional 
requirements could only be determined by exclusion, leading to only one Mycoplasma species, 
Mycoplasma laidlawii, being cultivable in a defined medium that did not contain serum but that 
required the addition of nucleotides and fatty acids (224). However, even today, in vitro cultivation 
of many human pathogenic Mycoplasma spp. such as Mycoplasma pneumoniae (225) or 
Mycoplasma genitalium (226), require the addition of serum and other undefined extracts. As serum 
is a widely used additive for nutrient-rich cell culture media, mycoplasmas have gained importance 
as cell culture contaminants (227), and, due to their small size and tendency to form nanoforms in 
suboptimal growth environments (228), they typically cannot be removed by standard filtration from 
serum, which thus acts as source of mycoplasmas into culture media (229) 
The genus Phytoplasma is also in the class Mollicutes but typically infects plants (230). A two-step 
Phytoplasma spp. in vitro cultivation system was recently reported but not described due to patent 
restrictions (231). A later publication by the same group compared their patented media 
compositions to commercially available media and confirmed growth in nutrient-rich Mycoplasma 
media, containing high salt concentration, horse serum, tryptone, soya peptone and incubation 
under microaerophilic conditions (127). Typically, Mycoplasma spp. grow in aerobic environments 
(232). The in vitro cultivation of spiroplasmas, another genus within the Mollicutes, faced similar 
problems although Spiroplasma citri, a plant pathogen, was able to grow in serum-free and yeast 
extract-free growth media (233). Most spiroplasmas require more complex media however, 
including insect cell lines in one case (234).  
1.6.3 Previous attempts at cultivating haemoplasmas  
Ever since their discovery in 1921 (235), researchers have tried to establish in vitro cultivation 
systems of haemoplasmas as an important means to further bacteriological research. Before PCR 
and molecular characterisation were available, various attempts to isolate M. haemomuris from rats 
for in vitro cultivation failed, as reviewed by Weinman (236). Ford and Eliot (237) described M. 
haemomuris as the causative pathogen of rat anaemia, but cultivation attempts in liquid, serum-
containing media were inconclusive and likely comprised contaminants. The same research group 
later also failed to cultivate E. coccoides in identical media (238). Noguchi (239) reported isolating an 
organism from anaemic rats (M. haemomuris) in liquid ‘leptospira medium’ (containing rabbit 
serum, peptone and meat extract) that did not grow on other media available at the time. However, 
Noguchi failed to reproduce overt anaemia in rats inoculated with the subcultures. Marmorston-
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Gottesman and Perla (240) obtained so-called ‘growth’ of M. haemomuris in Noguchi’s ‘leptospira 
medium’ very rarely, but when they inoculated healthy rats with the cultured organism, they could 
only occasionally see organisms on blood smears. Additionally they were unable to demonstrate that 
their rats were free of M. haemomuris infection before inoculation. Seamer (9) reported the 
successful propagation (up to 16 consecutive passages) of E. coccoides in chicken embryos, which, 
when inoculated into mice, caused infection based on blood smear examination. However, Rikihisa, 
Kawahara (197) attempted to repeat the methodology of chicken embryo-inoculation of M. 
haemomuris and could not reproduce the results, despite PCR-based methods of detection being 
used. Hence, it is controversial whether the early reports of successful in vitro cultivation or 
propagation in chicken embryos truly represented organism survival and growth outside of the 
natural host.  
Nonaka, Thacker (241) explored the in vitro cultivation of M. suis in various media and used different 
anticoagulants e.g. heparin and ethylenediaminetetraacetic acid (EDTA). They proposed an in vitro 
cultivation system based on serum-containing Eagle’s medium and that EDTA caused M. suis to 
detach from erythrocytes and to lose its ability to infect. However, these findings were obtained by 
measuring glucose-consumption and examination of culture sediments by light microscopy only, 
which cannot be viewed as proof of successful in vitro propagation without further specific 
quantification of the cultured organisms. More recently Schreiner, Hoelzle (242) used an in vitro 
cultivation approach that was informed by genomic data being available for M. suis; they 
supplemented mycoplasma media (SP-4 and Hayflick’s medium) with iron-carrier proteins, but could 
only establish maintenance of organism numbers and did not show viability of the ‘maintained’ 
organisms. In 2015, Hicks (216) attempted in vitro cultivation of M. haemofelis with hypoxanthine-
supplemented specialist mycoplasma media described by Windsor and Windsor (243), but the 
initially observed growth over 4 days of culture could not be reproduced and viability of the cultured 
M. haemofelis was again not assessed.  
1.7 OBJECTIVES OF STUDY 
1.7.1 Rodent model of haemoplasma infection 
A) To isolate and characterise rodent haemoplasmas from wild-caught animals in order to obtain 
viable inocula to infect laboratory rodents (Chapter 2). 
B) To infect laboratory rodents with haemoplasmas sourced from wild-caught animals and monitor 
infection kinetics following naïve infection (Chapter 3). 
C) To assess whether protection from re-infection with the same haemoplasma species or cross-
protection occurs in the rodent model of haemoplasma infection (Chapter 3). 
D) To establish a rodent model of haemoplasma infection and haemoplasmosis by characterising the 
rodent immune response to infection and pathological changes following infection (Chapter 4). 
E) To identify the cytokine profile associated with protection from re-infection in the rodent model 
in order to guide further studies into haemoplasma immunology and vaccination (Chapter 4). 
1.7.2 In vitro cultivation of haemoplasmas 
F) To assess the viability of rodent haemoplasmas under in vitro conditions and identify in vitro 




2 ISOLATION AND IDENTIFICATION OF RODENT HAEMOPLASMAS AND 
INFECTION OF LABORATORY RODENTS 
2.1 INTRODUCTION 
2.1.1 Rationale for a murine model using rodent haemoplasmas 
In the absence of an in vitro cultivation system (1.5), the establishment of a rodent model is highly 
desirable. The “3R principle” calls for researchers to replace animals, reduce their numbers and 
refine their experiments to produce valid data at minimal costs for the animals used (244). A rodent 
model of haemoplasma infection and haemoplasmosis would allow haemoplasma research with 
reduced ethical concerns of using research cats or other ‘higher’ animals, and the increased costs 
accompanying their use. An animal model using a less costly and more widely used laboratory 
animal model species would also allow the use of more laboratory research tools. Furthermore, as 
inbred strains are widely available in rodent species, studies using these strains as hosts can better 
limit individual variation when studying haemoplasma infection (1.4.3). This is a key requirement in 
defining complex immunological systems associated with infection and could help the development 
of vaccines and rapid serological assays. Having a relatively inexpensive source of viable 
haemoplasmas readily available would also benefit further research into in vitro cultivation and 
other ex vivo experiments.  
With over 400 genetically stable inbred strains, typically raised under specified-pathogen-free (SPF) 
conditions, mice represent the most commonly employed animal model of disease worldwide (245). 
Furthermore, laboratory methods and reagents to study their immune system are relatively cheap 
and readily available. One inbred strain has been used in many disease models and as a wild type for 
genetically modified mice. This strain, C57BL/6, was established in 1921 after over twenty 
generations of inbreeding and has been maintained in various locations throughout the world (246). 
About 200 strains of rats are available. They are larger and usually more expensive than mice, but 
allow more serial samples to be taken, potentially reducing total animal numbers as experiments can 
be designed with each animal serving as its own control. This also allows the use of more genetically 
diverse (outbred) strains, which better reflect situations of naturally acquired infection. (246). Wistar 
rats (an outbred strain) represent the most commonly used strain of rat in medical research (247).  
Surrogate models appear best suited to establish a rodent model of haemoplasma infection and/or 
haemoplasmosis as species-specific infection and pathogenicity must be considered in model 
selection (see 1.4). When replacing one naturally evolved host/pathogen combination with a 
physiologically and genetically related combination, data from the model might be extrapolated 
more readily than when using a non-adapted bacterial pathogen. However, identifying reasons for 
the lack of infection or pathogenicity of less adapted isolates (i.e. isolated from other species) is also 
of interest and may guide therapeutic or preventative reasoning.  
2.1.2 Previous attempts to establish rodent models using non-rodent haemoplasma species 
Attempts at creating rodent models using non-rodent haemoplasmas concentrated on using the 
most pathogenic haemoplasmas of cats and pigs, attempting to create a model using M. haemofelis 
and M. suis respectively.  Reports from China suggest model establishment is possible using M. suis 
inoculation of Kunming mice. However, full methodologies are only described in the Chinese 
language and methods of monitoring infection appear to be semi-quantitative at best (248, 249). 
Furthermore, successful laboratory passages of M. suis into laboratory mice could not be repeated 
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by European research groups using quantitative methods of monitoring infection after inoculation of 
laboratory mice (216, 217). More specifically, M. suis was unable to establish infection in mice after 
inoculation of infected porcine blood but remained detectable for a few days following inoculation 
(217). Inoculation of fresh DMSO-preserved feline blood infected with M. haemofelis did not result 
in establishment of infection in juvenile mice, guinea pigs and rabbits (216).  
2.1.3 Rodent haemoplasma infection 
Rodent haemoplasma infection was first reported in 1921, as Haemobartonella muris in the blood of 
anaemic rats (235). The organism, also referred to as Bartonella muris at the time, could be 
transferred into normal laboratory rats through intraperitoneal inoculation of infected blood (237, 
239). Infection rarely produced disease in otherwise healthy adult rats (236), but was able to induce 
anaemia in otherwise healthy, young (3-week old) rabbits, guinea pigs and mice through 
intraperitoneal inoculation of infected blood culture preparations (240). Experimental infection of 
rats was found to produce severe anaemia in combination with splenectomy, reaching mortality 
rates of up to 70 % (250).  
Another eperythrocytic pathogen was found in 1928 in mice in Germany (2). The pathogen was 
referred to as Eperythrozoon coccoides and described as a “disease of white laboratory mice” and 
field mice that could be activated by splenectomy (2). In another later study, blood smear 
examination with Romanowsky-type stains revealed coccoid/ring-shaped bodies adherent to red 
cells of mice or free in the plasma, two to four days after splenectomy, but without overt clinical 
signs (238). The lack of clinical signs and the cytology (ring shape), that were later found to be 
artefacts (238), led to E. coccoides and M. haemomuris being considered separate species (236). 
Despite the ability of these two organisms to cross the species barrier between rats and mice (10, 
240), H. muris was long considered a disease of rats whereas E. coccoides was considered a mouse 
pathogen (10, 194, 251, 252).  
Eperythrozoon coccoides was considered a complicating factor in laboratory studies assessing the 
mouse immune response to non-haemoplasma infectious agents (252). Despite several studies on 
the immune response to E. coccoides infection, no surrogate model for veterinary haemoplasma 
infection was maintained (253-255).  
Prior to the development of PCR in 1983 (256), specific and sensitive molecular diagnostic 
techniques were mostly unavailable, and haemoplasma experiments were based on observations 
using light microscopy, which is known to be unreliable (130, 257). In 1985, a Japanese research 
group (197) was able to passage M. haemomuris isolates from splenic suspensions of wild field mice 
(Apodemus argenteus) into ddY (outbred strain) laboratory mice, resulting in splenomegaly, 
inappetence and death. Isolates could be maintained in vivo by serial intraperitoneal injection of 
splenic cell suspensions, obtained 10 days post inoculation of the laboratory mice. Aliquots of these 
suspensions were then cryopreserved for future use. In 1997, these M. haemomuris (at the time also 
named H. muris) isolates were further passaged into Balb/C laboratory mice, producing similar 
outcomes of splenomegaly, anorexia and death seven to ten days post inoculation (197). Passage 
into Wistar rats was considered unsuccessful but PCR detected the presence of M. haemomuris DNA 
in their spleens seven to ten days post inoculation (197). However, another haemoplasma species, 
related but not identical to M. haemomuris, was found in a wild rat in another Japanese prefecture 
and was described as a novel species based on 16S rRNA gene sequencing (33). The same group 
went on to identify seven further isolates in rats and mice and proposed “subspecies ratti” and 
“subspecies musculi” within the species M. haemomuris (258). These subspecies currently hold 
‘Candidatus’ status due to lack of comparative data available from other rodent haemoplasma 
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isolates (11). However, none of these rodent haemoplasma isolates was developed into a surrogate 
model of haemoplasma infection as it occurs in other veterinary relevant species.  
2.1.4 Rationale for catching wild rodents 
Our attempts to source cryopreserved, viable rodent haemoplasmas from research groups in Japan 
as discussed in 2.1.3, were unsuccessful. Haemoplasmas are considered fragile outside of their host 
(11, 197, 237) and infection of laboratory mice require otherwise innocuous samples for 
intraperitoneal inoculation without harming the animal. This minimises the use of blood or other 
possibly infected organ samples from collaborating groups as they could not be considered for 
attempts of rodent model establishment due to the lack of adequate sample collection, aseptic 
technique and cryopreservation (259).  
Naturally occurring rodent haemoplasma infection has been described worldwide (34-36, 197, 258, 
260) with haemoplasma infection rates as high as 21 out of 37 (57%) sampled mice (Mus musculus) 
reported (36). Despite no haemoplasma prevalence data of wild rodents being available from the 
UK, the findings by Hornok et al. suggest that rodent haemoplasmas are common and that sampling 
of wild rodents may provide a source of viable haemoplasmas for the attempted establishment of a 
surrogate model of haemoplasma infection or haemoplasmosis in veterinary relevant species.  
2.1.5 Objectives 
The objectives of this study were to capture wild Muroidea spp. (including Mus musculus, Apodemus 
spp. and Microtus spp.) in order to cryopreserve their blood in a way considered suitable for 
haemoplasma viability conservation. Generic haemoplasma PCR screening assays were used to 
detect rodent haemoplasma infection in sampled rodents that also had blood samples 
cryopreserved. Any positive samples were further characterised by sequencing and passaging into 
laboratory rodents (mice and rats) with the aim of establishing a surrogate model of haemoplasma 
infection and haemoplasmosis. Additionally, M. suis was evaluated for its species-specificity by trying 
to establish its infection in immunocompetent mice. Infection was monitored by specific, 
quantitative methods (generic haemoplasma qPCR, 1.2.5.2). These experiments were the first step 
to establish and validate a rodent model of haemoplasma infection with the aim to help further 




2.2 MATERIALS AND METHODS 
2.2.1 Obtaining haemoplasmas through trapping of wild muroid species 
2.2.1.1 Animals 
Wild muroid species were identified by visual inspection upon removal from live traps. No species of 
any other classification than “least concern”, as categorized by the International Union for 
Conservation of Nature (IUCN), was included in this study.  
2.2.1.1.1 Ethical approval 
All studies involving live trapping of muroid species were subject to ethical review (Animal Welfare 
Ethical Review Body of the University of Bristol) and approved under investigation licence 
UB/16/046. More specifically, this licence allowed wild capture and killing by cervical dislocation of 
the following species: Mus musculus domesticus (house mouse), Apodemus sylvaticus, Apodemus 
flavicollis (field mice) and Microtus agrestis (common vole). Our approved licensure was restricted to 
muroids being killed within 60 minutes of trap collection and a radius of up to 2 miles around the 
laboratory. 
2.2.1.1.2 Trapping protocols for wild muroid species 
Twelve Longworth small mammal live traps (NHBS Ltd, Totnes, UK) were loosely filled with hay and 
teaspoon-sized amounts of rolled oats, peanut butter and a piece of cucumber or apple (the latter 
having a high water content to provide a ‘short-term water supply’). The radius in which the traps 
were placed included a veterinary teaching hospital, comprising small, large and farm animal 
facilities and various laboratory, storage and student housing facilities as well as hay barns and 
adjacent farmland. Buildings as well as open areas were included. Trap placement was adjusted 
weekly, based on trapping success and concurrent use of commercial rodent bait placements by 
others within the trapping area. Total trapping time was one month. Traps were monitored daily and 
inspected for captured wildlife as indicated by a closed front flap. Traps containing captured wildlife 
were returned to the laboratory within 60 minutes of collection and opened inside a clear 
polypropylene (PP) bag (Fisherbrand™, Clear Autoclave Bags, Thermo Fisher Scientific, UK) to avoid 
escape. Non-target species (i.e. molluscs, common shrews) and any target species showing obvious 
signs of late pregnancy or lactation were returned to the wild. Target muroid specimens were killed 
by cervical dislocation following fixation within a corner of the PP bag.  
2.2.1.1.3 Blood sampling and cryopreservation 
2.2.1.1.3.1 Blood samples for future inoculations 
Immediately following cervical dislocation (2.2.1.1.2), muroids were removed from the PP bag and 
blood was collected through cardiac puncture with a 1ml heparinised syringe (Blood Gas Sampler, 
Westmed, USA, containing 25IU balanced heparin per syringe) equipped with a 5/8-inch 23G needle 
(Terumo®, Zhejang Kindly Medical Devices Ltd., PRC). Samples of approximately 100µl blood were 
mixed with 20% dimethyl sulfoxide (Fisher BioReagents™, Fisher scientific, UK) and frozen on dry ice. 
These samples were subsequently stored at -80°C for 31 to 52 days until their use in laboratory 
rodent inoculation (2.2.3.3.3 and 2.2.3.5). 
2.2.1.1.3.2 Blood samples for haemoplasma screening qPCR 
An additional sample of approximately 20µl of heparinised blood was obtained by expelling residual 
blood from the 1ml heparinised syringe (as described in 2.2.1.1.3.1) into a clean 1.5ml tube. Samples 
were frozen at -20°C until DNA extraction.  
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2.2.1.2 Screening for haemoplasma infection using a generic haemoplasma qPCR assay 
2.2.1.2.1 DNA extraction  
DNA was extracted manually, using silica membrane single-spin columns (NucleoSpin® Blood, 
Macherey-Nagel, UK). In brief, samples were defrosted and 10 µl of blood was diluted with 
phosphate-buffered saline (PBS) to a final volume of 200µl. Twenty-five µl of Proteinase K and 200µl 
of lysis buffer (BQ1) were added and the mixture incubated at 70°C for 20 minutes in a shaking 
incubator. Ethanol was added to a final volume of 410µl, mixed thoroughly and loaded onto a silica 
membrane column. The column was spun at 10,000 x g for one minute. The flow-through was 
discarded, 500µl of wash buffer 1 (‘BW’) was added and spun through the column at 10,000 x g for 
one minute. This was followed by an additional wash with 600µl wash buffer 2 (‘B5’) and spinning at 
10,000 x g for two minutes to dry the silica membrane. Fifty µl of elution buffer (‘BE’) was brought to 
70°C and loaded centrally onto the silica membrane and incubated for five minutes at room 
temperature (RT). After spinning at 10,000 x g for one minute, the column was discarded and the 
flow-through subject to generic qPCR and conventional PCR as outlined below. Samples not 
processed immediately were stored at -20°C until use.  
2.2.1.2.2 Generic haemoplasma qPCR for rodent haemoplasmas 
Two generic haemoplasma qPCR assays, as previously described (185),  were used to screen for 
haemoplasma infection. The primers and probes for these assays had been designed to target a 
conserved region within several haemoplasma 16S rRNA genes with one assay amplifying the so-
called ‘haemofelis’ (HF-) group of haemoplasma species (which contains M. haemofelis) and the 
other the so-called ‘haemominutum’ (HM-) group of haemoplasma species (which contains ‘Ca. M. 
haemominutum’) (Table 3). However, cross-reactions of HF-group and HM-group species have been 
reported for these assays (the HF-group assay amplifying HM-group species more easily than vice 
versa) (185) and the HF-group assay was also found to amplify Spiroplasma spp. DNA in ticks (151). 
Primers and probes from a previously validated feline gene-specific PCR (261) were used as a host 
internal control to monitor for successful DNA extraction, confirm a lack of PCR inhibitors and that 
the qPCR set-up had been successful (Table 3). This assay had originally been designed to amplify the 
feline housekeeping gene glyceraldehyde-3-phosphate dehydrogenase (GAPDH) as well as its cDNA 
equivalent (261), and the targeted region was known to be identical in the mouse GAPDH gene, and 
at least similar in other rodents (216). Primers and probes were synthesised by Invitrogen, UK and 
the TaqMan probes were labelled with 6-carboxyfluorescein (FAM) at the 5’ end and a Black Hole 
Quencher (BHQ)1 at the 3’ end.  
Assay Forward Primer 5’-3’ Sense Taqman Probe 5’-3’ Reverse Primer 5’-3’ 















Table 3 Primers and probes (oligonucleotide) sequences used for quantitative detection of the so-called ‘haemofelis’ (HF)-
group and the so-called ‘haemominutum’ (HM)-group and of host genomic DNA for the glyceraldehyde-3-phosphate 
dehydrogenase (GAPDH) gene. HF, haemofelis; HM, haemominutum; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; 
FAM, 6-carboxyfluorescein; BHQ, Black Hole Quencher. 
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2.2.1.2.2.1 Quantitative PCR conditions 
Each qPCR consisted of 2X GoTaq (Promega, Southampton, UK), 4.5mM MgCl2, forward and reverse 
primers and probes for each of the three (HF-group, HM-group, GAPDH) assays (Table 3) with water 
to a final volume of 20μl. Probes were added to a final concentration of 100nM for the HF-group and 
HM-group assays and to a final concentration of 25nM for the GAPDH assay. Each primer was added 
to a final concentration of 200nM for the HF-group and HM-group assays, and 100nM final 
concentration for the GAPDH assay. Master mix reagents were aliquoted into 96-well PCR plates and 
5µl of the eluted DNA sample was added to each well. As the same FAM fluorophore was used for 
both the generic haemoplasma HF-group and HM-group 16S rRNA gene and GAPDH gene qPCR 
assays, these reactions had to be run as parallel singleplexes, but were always maintained on the 
same qPCR plate. Positive control samples of known M. haemofelis/feline GAPDH gene copy 
numbers and negative control samples (water) were included on each plate. All qPCRs were 
performed on the same Mx3005P qPCR thermal cycling system (Agilent, UK) under the following 
conditions: Initial incubation for two mins at 95°C followed by 40 cycles of denaturation at 95°C for 
15 seconds and annealing/extension at 60°C for 30 seconds. Fluorescence was detected at 520nm at 
the end of each annealing/extension phase.  
2.2.1.2.2.2 Analysis of qPCR data 
Analysis was carried out using the MxPro™ v4.10 software package (Stratagene, LaJolla, California, 
USA). Threshold fluorescence was set at 1000 relative fluorescence units (Rf) for both the HF-group 
and HM-group 16S rRNA gene qPCRs and the GAPDH gene qPCR. Data were imported into Excel 
(Microsoft® 2013) for subsequent analysis.  
2.2.1.2.2.2.1 Normalisation of haemoplasma threshold cycle (Ct) values 
Haemoplasma threshold cycle (Ct) values were normalised against host (GAPDH) Ct values to 
account for any variation in extraction efficiency, using the following formula: 
Normalised haemoplasma Ct values = Ct – ΔCtH 
where ΔCtH = Ct (host GAPDH) – 20 
The arbitrary Ct value of ‘20’ was chosen as it was the closest integer to typical Ct values observed 
for DNA extraction from 10µl of blood and qPCR detection of host GAPDH (2.2.1.2). All haemoplasma 
Ct values were subsequently normalised to the host (GAPDH) Ct value of 20. 
2.2.1.2.2.2.2 Calculation of relative haemoplasma genome copy numbers 
Relative haemoplasma genome copy numbers were calculated using the formula: 
Relative haemoplasma genome copy number = (1+E)ΔCt 
where ΔCT = 40 – Ct and E = qPCR assay efficiency 
A PCR amplification follows an exponential curve that doubles the amount of product each cycle, 
assuming an efficiency of 1 (or 100%). The amplification can hence be expressed as 2Ct or (1+1)Ct. In 
relative quantification, a high Ct value (i.e. 40 cycles) is chosen to define the presence of a single 
copy of template DNA and the Ct differences to that value (ΔCT) are then used to calculate relative 
copy numbers. Assay efficiencies were 1.005 for the HF-group and 0.974 for the HM-group qPCR 
assays respectively (185). 
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2.2.2 Identification of rodent haemoplasma species 
2.2.2.1 Amplification of additional rodent haemoplasma DNA  
2.2.2.1.1 Origin of samples 
The DNA samples used in the initial rodent haemoplasma species identification studies were derived 
from the original wild muroids following extraction from whole blood (2.2.1.2.1). For some of the 
subsequent amplification and sequencing reactions, DNA extracted from blood samples taken from 
laboratory animals during the first passages of cryopreserved wild rodent haemoplasma species was 
used instead.  
2.2.2.1.2 Primers and PCR conditions to generate additional DNA sequence data  
All primers were ordered from Metabion, Germany and reconstituted to 100μM prior to use. 
2.2.2.1.2.1 Ribosomal gene fragment amplification and sequencing 
2.2.2.1.2.1.1 Primers used for ribosomal gene fragment amplification 
The 16S rRNA gene, the internally transcribed spacer region (ITS, intergenic spacer) and the 23S 
rRNA gene were targeted for amplification using generic Mycoplasma spp. primers and generic 
haemoplasma primers in various combinations. The primer sequences are given in Table 4. and their 
respective locations in relation to the ribosomal gene sequences is illustrated in Figure 1.  
Primer name Primer sequence 5’-3’ 
8-F1 AGAGTTTGATCCTGGCTCAG  
1492-R1 GGTTACCTTGTTACGACTT  






1309-F4 GTTCCCAGGTCTTGTACACA  
2144-mod-R4 CAGTACTTGTTCACTATCGGTA  
1446-R5 TACCTTGTTACGACTTAACT 
1682-R6 TCGGCTCCATTTTCCAAGGC  
2144-R7 CAGTACTTGTTCACTGGTA 
Table 4 Primer sequences used to amplify ribosomal 16S rRNA, internally transcribed spacer region and 23S rRNA gene 
fragments from rodent haemoplasma species obtained initially from wild muroids. The suffix -F indicates a forward primer 
and -R indicates a reverse primer. These primer sequences were derived from the publications identified by superscript 
numbers as follows: 1, Pitulle, Citron (262); 2, Criado-Fornelio, Martinez-Marcos (263); 3, Tasker, Peters (185); 4, Sasaoka, 
Suzuki (264); 5, Sashida, Sasaoka (33); 6, Harasawa, Hotzel (265); 7, Sashida, Sasaoka (258).  
 
Figure 1 Schematic diagram illustrating the location of the primer sequences used to amplify ribosomal 16S rRNA, internally 
transcribed spacer region and 23S rRNA gene fragments. The primer sequences and references are given in Table 4. ITS 
indicates the internally transcribed spacer region. The suffix-F indicates a forward primer and -R indicates a reverse primer 
and arrows indicate the direction of amplification. 
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2.2.2.1.2.1.2 PCR conditions 
Each PCR consisted of 2X GoTaq (Promega, UK), a final concentration of 4.5mM MgCl2, 200nM each 
of forward and reverse primers with water to a volume of 20µl to which 5µl of template DNA was 
added. Reactions were carried out on a MJ Research PTC-200 Peltier Thermal Cycler (Bio-Rad, UK) 
under the following conditions: Initial incubation at 95°C for 2 minutes followed by 45 cycles of 
denaturation at 95°C for 10 seconds, annealing at 50°C for 30 seconds and elongation at 72°C for 60 
or 90 seconds followed by a final extension step of 72°C for 5 minutes. Negative controls (water) 
were included in each setup and positive controls (M. haemofelis or ‘Ca. M. haemominutum’) were 
used with the respective assays (i.e. HF-group and HM-group respectively).  
2.2.2.1.3 Separation and visualisation of DNA on agarose gels 
2.2.2.1.3.1 Gel preparation 
Agarose electrophoresis gels were prepared on the day of use or the day before and kept 
refrigerated at 4°C until use. Gels were prepared by mixing Tris Acetate-EDTA (TAE) buffer (Fluka 
Analytical, Sigma Aldrich) with 1 to 2% (w/v) agarose powder (Sigma-Aldrich) and the mixture was 
then brought to a boil. Upon cooling to approximately 45°C, 0.1µg/ml ethidium bromide (Bio-Rad 
Labs., UK) was added and after gentle mixing, the gels were poured as required.  
2.2.2.1.3.2 Electrophoresis conditions 
Samples of 5 µl PCR product were mixed with 1µl of loading buffer (DNA Gel Loading Dye (6X), 
Thermo Fisher, UK) immediately before loading onto the gel. EasyLadder 1TM (Bioline Ltd., London, 
UK) was used in duplicate on each gel to estimate amplicon size and confirm electrophoresis. Gels 
were submerged in TAE buffer and run at 50 to 80V for 30 to 90 minutes using a Horizon 11-14 or 58 
gel electrophoresis system (Gibco BRL Life Technologies) with a Model 200/2.0 (Bio Rad Labs., UK) 
power supply unit.  
2.2.2.1.3.3 Visualisation 
Bands of DNA were visualised under ultraviolet light (BioDoc-It, Ultra-violet Products Ltd, UK) or blue 
light (Dark ReaderTM, Clare Chemical Research, USA) if downstream PCR applications (2.2.2.1.4) were 
planned.  
2.2.2.1.4 Sampling for re-amplification PCR or nested PCR 
When multiple bands were visualised following electrophoresis of PCR products, the following was 
performed in order to try and help further purify and re-amplify the product of choice for 
sequencing.  The band closest in size to the expected size of the PCR product was ‘stabbed’ with a 
sterile needle that was then briefly submerged into a PCR master mix containing the same primers 
as previously or nested primers (using primers within the desired amplicon as based on Figure 1) to 
purify and/or amplify a more specific segment for sequencing.  
2.2.2.1.4.1 Re-amplification PCR conditions 
Whenever re-amplification was required, PCR conditions were identical to the original PCR 
(2.2.2.1.2.1.2) but reduced by 20 cycles whilst the annealing temperature was increased to 55°C to 
increase specificity.  
2.2.2.2 Sequencing of rodent haemoplasma DNA 
2.2.2.2.1 Purification of amplicons 
Only strong, individual bands were considered suitable for sequencing reactions.  Amplicons 
resulting from 2.2.2.1.2.1.2 and 2.2.2.1.4.1 were diluted 1:10 in nuclease-free water.  
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2.2.2.2.2 Sample submission for automated Sanger sequencing 
Samples and primers were shipped at room temperature to DNA Sequencing and Services (College 
of Life Sciences, University of Dundee, Scotland, www.dnaseq.co.uk) for automated Sanger 
sequencing, according to their recommended submission protocols.  
2.2.2.2.2.1 Sequencing primers 
The primers used for sequencing were the same as those used for PCR amplification of the gene 
segments (2.2.2.1.2). Sequence readouts were obtained from both ends of the amplicon to allow for 
a consensus sequence to be generated and help resolve any discrepancies.  
2.2.2.3 Phylogeny of novel rodent haemoplasma sequences 
2.2.2.3.1 Clean-up of sequence data 
Electropherogram files were viewed using Bioedit v 7.2.5. (266) and inspected for any ambiguous 
readouts. Primers used to amplify and sequence the amplicon were aligned to the readout and 
removed from the resulting DNA sequence to account for stochastic elimination of mismatches on 
the respective primer-binding sites (as a few mismatches on the original template DNA could have 
been replaced by primer-generated amplicons during cycling reactions).  
2.2.2.3.2 Comparison of DNA sequence data to online databases 
Resulting consensus sequences were queried against the NCBInr nucleotide sequence database 
using the Basic Local Alignment Search Tool (BLAST) programmes (267) on the National Center for 
Biotechnology Information (NCBI) server (https://blast.ncbi.nlm.nih.gov/Blast.cgi).  
2.2.2.3.3 Construction of multiple sequence alignments 
Multiple sequence alignments (MSA) of the 16S rRNA genes, ITS and 23S rRNA genes were 
generated using Mega7 (268) and the ClustalW algorithm (269), using the newly obtained DNA 
sequence readouts and previously published haemoplasma and Mycoplasma species sequences 
downloaded from Genbank (https://www.ncbi.nlm.nih.gov/genbank/). Accession numbers for these 
downloaded sequences are given within the results. 
2.2.2.3.4 Construction of phylogenetic trees 
Maximum-likelihood phylogenetic trees were constructed based on the Tamura-Nei model (270) 
using Mega7 (268) and treating nucleotide sequences as non-protein coding in inference of 
evolutionary history. Gaps were treated by complete deletion and phylogeny tested by the 
bootstrap method, set to 1000 replications. 
2.2.2.3.5 Secondary structure prediction of RNA 
Secondary structures were predicted using the Vienna RNA Websuite (271) using the method by 
Mathews and Zuker (272). Centroid representations were chosen over minimum free energy (MFE) 
predictions as they have been demonstrated to yield better accuracy in overall base pairing (273). 
2.2.3 Infection of laboratory rodents with rodent haemoplasmas  
2.2.3.1 Animals 
2.2.3.1.1 Ethical approval 
All studies involving infection of laboratory rodents were subject to ethical review (Animal Welfare 




2.2.3.1.2 Laboratory mice 
Eight female, nine-week-old, SPF C57BL/6 mice were sourced from Harlan Laboratories UK Ltd., 
Loughborough, UK. 
2.2.3.1.3 Laboratory rats 
Three female, ten-week-old, SPF Wistar rats were sourced from Charles River Laboratories UK, Ltd., 
Margate, UK. 
2.2.3.2 Housing conditions 
2.2.3.2.1 Housing conditions for laboratory mice 
Mice were housed in standard cages allowing for group sizes of up to four animals per cage. Cages 
were placed on an individually ventilated cage (IVC) unit and supplied with a standard laboratory 
diet (Lab Diet®, London, UK). Ambient temperature and humidity were monitored according to 
Home Office regulations (274). After haemoplasma inoculation, mice were monitored 2 to 3 times 
daily for any signs of ill health such as pallor, inappetence or ruffled fur.  
2.2.3.2.2 Housing conditions for laboratory rats 
Rats were housed in standard cages allowing for group sizes of up to three animals per cage. Rats 
were housed separately from other laboratory rodents and supplied with a standard laboratory diet 
(Lab Diet®, London, UK). Ambient temperature and humidity were monitored according to Home 
Office regulations (274). Upon entering the experiment (haemoplasma inoculation), rats were 
separated to eliminate possible haemoplasma transmission between experimental groups. Rats 
were monitored at least once a day for any signs of ill health such as pallor, inappetence or ruffled 
fur.  
2.2.3.3 Acclimatisation, identification and screening for pre-existing haemoplasma infection in 
laboratory rodents 
2.2.3.3.1 Acclimatisation and unique identification of laboratory rodents 
Before entering any experiment, laboratory rodents were placed in the required groups and allowed 
an acclimatisation period of 4 to 7 days. 
2.2.3.3.1.1 Identification of laboratory mice 
Mice were uniquely identified by ear-notching procedures. In brief, mice had a 1mm punch removed 
from their outer ear pinnae, using a designated apparatus (Fisherbrand™ Animal Ear-Punch, Fisher 
scientific, UK) and were subsequently assigned a number within the cage: Mouse 1: left ear 
punched; mouse 2: right ear punched; mouse 3: no ear punch and mouse 4: both ears punched. This 
numbering system was maintained for all studies involving laboratory mice.  
2.2.3.3.1.2 Identification of laboratory rats 
Rats were uniquely identified by drawing circular markings on the proximal third of their tails (one 
circle = rat 1, two circles = rat 2, three circles = rat 3) which was renewed as necessary when 
markings began to fade.  
2.2.3.3.2 Blood sampling procedures 
2.2.3.3.2.1 Blood sampling in laboratory mice 
Mice were habituated to blood sampling using a minimal restraint technique to allow serial blood 
sampling in the subsequent stages of the study. All mouse handling for blood sampling took place 
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within a fume extraction hood to avoid escape and contamination of the mouse facilities with 
infectious organisms.  
All mice were habituated to various biscuits and cereal treats in the cage (Figure 2, Panel A). Mice 
were picked up from within the cages by allowing them to enter a cardboard tube and then raising 
the tube out of the cage, whenever possible, to avoid any potential additional stress, as 
recommended by current NC3R guidelines for mouse handling (275). Mice were also habituated to 
being positioned on a wire rack (as used to cover the top of the cage) with gentle touching of just 
the tail, whilst having access to treats that were just in front of the wire rack (see Figure 2, Panel B). 
The same treats were fed to all study mice on any given day. Daily blood sampling took place within 
a two-hour window (9am to 11am) for regular sampling intervals close to twenty-four hours. For the 
blood sampling procedure, mice were allowed to hold on to the wire rack and nibble on a treat 
placed in front of them, whilst gentle restraint was applied to the tail. The tail was then lifted and a 
tiny incision made over the lateral or the ventral tail vein using a scalpel blade (15 N/S, Swann 
Morton Ltd., Sheffield, UK) to allow a droplet of blood to form on the tail (Figure 2, Panel C). Gentle 
movement of the tail was used to encourage blood flow if the droplet did not appear quickly. The 
blood droplet was collected, by capillary action, into a heparinised (Haematocrit tubes, 80IU/ml Na-
heparinised, Hawskley & Sons, Lancing, UK) microcapillary tube. Plain tubes were used for some 
studies. These microcapillary tubes were pre-labelled with a 10µl marking and upon filling of a tube 
with blood to that mark, the tube was placed into a clean 1.5ml tube containing 90µl of sterile PBS, 
and flushed with the PBS using a 1ml syringe (BD Plastipak™, Becton Dickinson S.A., Spain) and 
butterfly catheter tubing (Tro-Venoset, Troge Medical GmbH, Hamburg, Germany) so that the 100µl 
of blood/PBS mixture was all in the 1.5ml tube (Figure 3). The mice were then placed back into the 
cage and monitored for ongoing blood loss with the cage in a quiet location for approximately thirty 





Figure 2 Minimal restraint technique for blood sampling in mice.  
Habituation of mice to biscuit/cereal treats within the cage (Panel A) and on wire rack (Panel B); 
Panel C: Blood droplet formation on the ventral aspect of the tail.  
 
Figure 3 Empty microcapillary tube and equipment used for flushing of blood from the microcapillary tubes. Eppendorf 
tubes were labelled and pre-filled with 90µl of PBS and opened prior to blood collection; the microcapillary tubes were filled 
with blood to a 10µl label mark and then placed into the Eppendorf tubes containing the PBS. A 1ml syringe was attached to 
a 23G butterfly catheter with the tube cut to leave approximately 2.5cm of tubing, as shown. The tubing was attached to 
the microcapillary tube and PBS flushed through by aspiration and expulsion so that the 100µl of mixed blood and PBS was 
expelled into the Eppendorf tube, ready for further analysis.  
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2.2.3.3.2.2 Blood sampling in laboratory rats 
Blood sampling in rats was carried out following a habituation phase (approximately one week) to 
allow the rats to become familiar with being handled by the experimenter. Rats were encouraged to 
allow human interaction by hand-feeding them biscuit treats within the cage and tolerate being 
picked up in return for further treats.  
For the blood sampling procedure, rats were picked up and placed into a single use polypropylene 
bag (Transpack Ltd., Southhampton, UK), that had been cut and heat-sealed into conical shape with 
a 1cm hole cut at the tip to allow for air supply to the rat’s face (Figure 4, Panel A). The cone was 
held closed at the base of the rat’s tail and the rat was then placed on a soft surface (Figure 4, 
Panels B and C). A small stab incision was made with a 20G needle (Terumo) in the ventral tail vein, 
allowing a droplet of blood to form. Blood was then collected into a microcapillary tube as described 
for mice (see 2.2.3.3.2.1). This technique allowed for blood sampling from the rats with minimal 
restraint, avoiding compression of airways. Rats were subsequently released back into the cage, 
given a treat and monitored for ongoing blood loss for approximately thirty minutes.  
 
Figure 4 One-person, minimal chest compression restraint technique for blood sampling in rats. 
Panel A: Custom-made single use, conical polypropylene bag with the tip cut off to allow for enough air supply without 
compressing internal organs/airways during restraint.  
Panels B and C: Restraint of rat inside the bag for blood sampling. Rats were subsequently placed onto a soft surface and 
blood sampled by making a small stab incision at the ventral aspect of the tail and allowing a blood droplet to form. 
Following blood sampling, rats were released from the bags and fed a biscuit treat.  
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2.2.3.3.3 Detection of haemoplasmas in laboratory mouse blood samples pre-infection 
In mice, the blood and PBS samples underwent DNA extraction and subsequent generic 
haemoplasma qPCR and GAPDH qPCR as described in 2.2.1.2.  Analysis of qPCR data (2.2.1.2.2.2) was 
as previously described regarding normalisation and calculation of relative haemoplasma genome 
copy numbers.  
2.2.3.3.4 Detection of haemoplasmas in laboratory rat blood samples pre-infection  
In rats, blood and PBS samples underwent DNA extraction and generic haemoplasma qPCR detection 
and copy number calculation as described for mice (2.2.3.3.3). The host internal control GAPDH 
qPCR assay (2.2.1.2 and Table 3) was adjusted for sequence differences between the rat GAPDH 
gene sequence and the feline/mouse GAPDH gene (216). The modified reverse primer sequence is 
given below (Table 5). Primer synthesis was carried out by Invitrogen, ThermoFisher, UK.  
Assay Forward Primer 5’-3’ Sense Probe 5’-3’ Reverse Primer 5’-3’ 
Host internal 
control (rat GAPDH) 
GCTGCCCAGAACATCATCC FAM-TCACTGGCATGGCCTTCCGT-BHQ1 GTCAGATCCACAACGGAT  
Table 5 Primers and probe (oligonucleotide) sequences used for quantitative detection of rat host genomic DNA for the 
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) gene. Bases modified from the feline/mouse GAPDH qPCR assay 
(Table 3) are shown in bold and shaded text. 
GAPDH; glyceraldehyde-3-phosphate dehydrogenase; FAM, 6-carboxyfluorescein; BHQ, Black Hole Quencher. 
2.2.3.4 Inoculation of laboratory mice with rodent haemoplasmas 
Eight nine-week-old, SPF, female C57BL/6 mice were used for primary passaging of three novel 
rodent haemoplasma samples (each obtained from three different wild-caught rodents (2.2.1)) and 
for a porcine-derived M. suis sample (kindly donated by Prof. Hoelzle, Univerisität Hohenheim, 
Germany). Mice were split into four groups, each containing 2 mice, and each group was inoculated 
with either M. suis or one of three novel, rodent haemoplasma isolates and subsequently monitored 
for haemoplasma infection by qPCR.  
2.2.3.4.1 Inoculation procedure in mice 
Mice were inoculated intraperitoneally with the cryopreserved inoculum. Frozen inocula were 
allowed to defrost at room temperature for 5 to 10 minutes, diluted in PBS 1:2 and drawn up into a 
sterile 1ml syringe. Using a 5/8-inch 23G needle (Terumo), the inocula were inoculated into each 
mouse intraperitoneally. Mice were subsequently monitored for adverse reactions for thirty 
minutes. 
2.2.3.4.2 Description of inocula used for inoculation of laboratory mice 
Origin and composition of inocula used to inoculate the laboratory mice is given in Table 6.  
Organism Origin Cryopreservation Dilution ratio 
of inoculum 
in PBS 
Inoculum dose in 





Mycoplasma suis Blood collected from pig 
infected with M. suis 
20% DMSO (v/v) 1:2 8.69E+10  2 
Mycoplasma 
haemomuris 
Blood from a wild-
caught Apodemus spp.  





Blood from a wild-
caught Apodemus spp.  






Blood from a wild-
caught Apodemus spp.  
20% DMSO (v/v) 1:2 3.79E+05  2 
Table 6 Origin and composition of inocula used to inoculate the laboratory mice. The M. suis inoculum was kindly donated 
by Prof. Hoelzle, Univerisität Hohenheim, Germany and shipped to the University of Bristol on dry ice and kept at -80°C until 
use. Inoculum doses were calculated as in 2.2.1.2.2.2. DMSO, dimethyl-sulfoxide. 
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2.2.3.5 Inoculation of laboratory rats with rodent haemoplasmas  
Three ten-week-old, SPF, female Wistar rats were used for passaging of three novel rodent 
haemoplasma isolates. As the original wild-caught rodent samples were inoculated into mice (Table 
6), the rat experiment comprised a second passage of these novel rodent haemoplasma isolates, 
using samples derived from these mice. Each rat received one of the three haemoplasma isolates 
and was subsequently monitored for infection by qPCR.  
2.2.3.5.1 Inoculation procedure in rats 
Rats were inoculated intraperitoneally with cryopreserved inoculum. Frozen inocula were allowed to 
defrost at room temperature for 5 to 10 minutes and drawn up into a sterile 1 ml syringe. The 
inocula were inoculated into each rat intraperitoneally using a 5/8-inch 23G needle (Terumo). Rats 
were subsequently monitored for adverse reactions for thirty minutes.  
2.2.3.5.2 Description of inocula used for inoculation of laboratory rats 
Composition of the inocula used to inoculate the laboratory rats is given in Table 7.  
Organism Origin Cryopreservation Dilution ratio of 
inoculum in PBS 
Inoculum 
dose (in 






Blood collected from C57BL/6 
mouse (first passage) 
20% DMSO (v/v) - 3.26E+07 1 
Eperythrozoon 
coccoides 
Blood collected from C57BL/6 
mouse (first passage) 




Blood collected from C57BL/6 
mouse (first passage) 
20% DMSO (v/v) - 5.27E+06 1 
Table 7 Inoculum composition and groups for primary rat infection experiment. Rats were housed together until the 
beginning of the experiment and housed separately, once inoculated. Inoculum doses were calculated as in 2.2.1.2.2.2. 
DMSO, dimethyl-sulfoxide. 
2.2.3.6 Monitoring of laboratory rodents for haemoplasma infection 
2.2.3.6.1 Blood sampling regime in mice and rats (primary laboratory passages) 
2.2.3.6.1.1 Monitoring via serial blood sampling for qPCR of mice 
Serial blood sampling took place on days 0, 4, 7, 8, 11, 15, 17, 18, 24 and 35 post haemoplasma 
inoculation using the methodology described earlier (2.2.3.3.2.1) with heparinised microcapillary 
tubes.  The mixture of heparinised blood and PBS was stored at 4°C for up to 24 hours until further 
processing.  
2.2.3.6.1.2 Monitoring via serial blood sampling for qPCR of rats 
Serial blood sampling procedures took place on days 0, 2, 4, 6, 8, 10, 11, 12, 14, 16, 17, 18, 21, 22, 23 
and 24 post haemoplasma inoculation, using the methodology described above (2.2.3.3.2.2) with 
heparinised microcapillary tubes. The mixture of heparinised blood and PBS was stored at 4°C for up 
to 24 hours until further processing. 
2.2.3.6.2 Determination of relative rodent haemoplasma blood copy numbers in mice and rats 
The method used for DNA extraction (2.2.1.2.1) from the blood samples, and the qPCRs used for 
haemoplasma screening in mice (2.2.3.3.3) and rats (2.2.3.3.4) were as described previously. DNA 
samples from mice, inoculated with blood containing M. suis were analysed using the HM-group 
generic assay and all other mice and rats were analysed using the HF-group generic assay as dictated 
by phylogeny and previous detection of the novel isolates (2.3.2.3). Threshold fluorescence and data 
31 
 
generation, normalisation of relative genome copy numbers and calculation of relative copy 
numbers, using normalised Ct values, was carried out as described above (2.2.3.3.3).  
2.2.3.7 Collection of inocula from rodents for use in further studies 
Mice were killed by exsanguination under terminal anaesthesia at perceived timepoints of high 
haemoplasma parasitaemia to collect inocula for future studies. Mice inoculated with M. 
haemomuris were killed on day 8 post infection and mice inoculated with E. coccoides were killed on 
days 18 and 35 post infection. No inocula were sourced from the mice inoculated with M. suis, as 
long-standing infection was not successful, and these mice were subsequently rehomed in 
accordance with regulatory procedures (2.2.3.1.1).  
The protocol for exsanguination comprised putting the mouse into an induction chamber and 
exposing it to halothane (Sigma-Aldrich Company Ltd., Gillingham, UK) in oxygen at 3% (v/v). Upon 
induction of general anaesthesia, as indicated by a lack of pain perception and spinal reflexes as 
assessed by withdrawal and tail-flick responses, the mouse was placed in dorsal recumbency and a 
mask connected to the anaesthetic machine was placed over the mouse’s mouth and nose. 
Halothane concentration was subsequently reduced to 2% (v/v) or maintained as required for 
general anaesthesia. Using a 1ml heparinised syringe (Blood Gas Sampler, Westmed, USA, containing 
25IU balanced heparin per syringe) and a 5/8-inch 23G needle (Terumo) mice were exsanguinated by 
cardiac puncture by inserting the needle at a 30° angle aiming craniodorsally underneath the 
xiphoid. Care was taken to avoid multiple needle sticks to reduce contamination and haemolysis. 
Post-mortem examinations were carried out on all killed mice. Splenomegaly was defined as a 
splenic weight over 0.4% bodyweight (276). 
Rats had aliquots of 100µl of heparinised blood taken for cryopreservation at various days during the 
experiment as described above (2.2.3.3.2.2) and were subsequently rehomed in accordance with 
regulatory procedures (2.2.3.1.1) as no long-standing infection was established in rats.  
Collected blood samples from rats and mice were mixed with 20% DMSO (v/v) and frozen on dry ice 
before transferring them to a freezer at -80°C as described for blood samples from wild-caught 





2.3.1 Trapping and sampling 
Twenty-one wild muroids were trapped during the observation period. Six were identified as 
Microtus spp. (i.e. voles) and 15 as Apodemus spp. (i.e. field mice). Five of the 15 blood samples 
obtained from the Apodemus spp. yielded positive results on the HF-group qPCR assay. Three of 
these five samples also had (weak) positive results on the HM-group qPCR assay (data not shown) , 
which was attributed to cross-reaction of the qPCR assay as has been previously reported (185). 
Sample origin, calculated normalised relative haemoplasma copy numbers and eventual sample 
identification (see 2.3.2) are given in Table 8.  
Sample origin Normalised relative 16S 
rRNA gene copies per µl 
blood  
Sample identification 
Apodemus spp. #6 2.86E+03 Mycoplasma haemomuris (100% identity/coverage, E value 3E-29, 
AB820289.1) 
Apodemus spp. #8 2.86E+04 Mycoplasma haemomuris (100% identity/coverage, E value 3E-29, 
AB820289.1) 
Apodemus spp. #9 3.43E+03 Putative rodent haemoplasma (Mastomys erythroleucus isolate, 
90% identity, 97% coverage, E value 2E-16, KU697344.1) 
Apodemus spp. #13 7.57E+03 Putative rodent haemoplasma (Mastomys erythroleucus isolate, 
100% identity/coverage, E value 3E-29, KU697344.1) 
Apodemus spp. #18 3.91E+03 Eperythrozoon coccoides (100% identity/coverage, E value: 6E-37, 
AY171918.1) 
Table 8 Description of haemoplasma isolates from wild-caught Apodemus spp. (field mice). Normalised relative genome 
copy numbers/µl blood were based on HF-group assay and calculated as described earlier (see 2.2.1.2.2.2.2). Sample 
identification was based on the following: the primer sequences were removed from the original 113 base pair PCR 
amplicon derived from the positive generic HF-group haemoplasma leaving a 74 base pair amplicon to query against the 
BLASTnr database for identification. As indicated, all amplicon sequences except for isolate #9 were covered 100% within 
the database which means identity was calculated over the entire sequence.  
2.3.2 Identification and phylogeny of novel rodent haemoplasma isolates 
2.3.2.1 Initial identification following qPCR screening 
Samples positive on the HF-group qPCR assay were initially identified based on data obtained 
following sequencing of the 16S rRNA gene 113 base pair amplicon derived from the qPCR assay, and 
results are shown in Table 8. The 74 base pair sequences (amplicon without primers) used for 
BLASTn queries are given in Appendix B, Table A-B1.  
Two of the samples (#6 and #8) were identified as M. haemomuris, one (#18) as E. coccoides and two 
(#9 and #13) most resembled rodent haemoplasma isolates described from multimammate mice 
(Mastomys erythroleycus) and other unidentified rodents in Senegal, Brazil and other locations 
worldwide. Sample #13 was also found to be 99% identical with a previously unpublished “vole 
haemoplasma species”, isolated from wild-caught voles in the UK (277).  
Further sequence data were required as sample #9 also had 88% identity to M. haemofelis/M. 
haemocanis species (Genbank accession numbers MH447082.1 and MG594502.1 respectively) and 
sample #18 had 100% identity to ‘Ca. Mycoplasma turicensis’ (accession number Y046312.1), 
reflecting the high sequence conservation of the assay’s target region that was below the variation 
required for species-resolution. 
2.3.2.2 Derivation of further ribosomal gene sequences 
Following initial identification based on the short HF-group qPCR product sequences, all of the novel 
rodent haemoplasma isolates (Table 8) had longer 16S rRNA gene sequences of approximately 600 
base pair length amplified, using primers 313-HBT-F and 908-HBT-R (263). This was required due to 
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the small size of the previously used amplicon (Table 8) that did not reliably identify isolates at 
species level. Upon BLASTn queries of the cleaned sequence readouts, isolates #6 and #8 were found 
to have 99% identity to M. haemomuris (AB820289.1 and others). Isolate #9 had 94% identity with a 
haemoplasma species (KT215638.1) isolated from the spleens of Brazilian wild rodents (68) and 92% 
identity with M. haemomuris followed by ‘Ca. Mycoplasma haemomacaque’ at 91% identity. Isolate 
#13 had 99% identity with another sample (KT215630.1) from the same Brazilian biome sampled by 
Gonçalves et al. 2015. Isolate #13 had 96% identity with M. haemomuris, followed by ‘Ca. 
Mycoplasma haemohominis’ with 95% identity. It also had 99% identity with the previously 
mentioned unpublished “vole haemoplasma” isolate and 98% 16S rRNA gene identity with a gerbil 
haemoplasma isolate in Israel (278). Isolate #13 was subsequently termed “M. haemomuris-like 
haemoplasma” relating to its closest phylogenetical neighbour. Isolate #18 had 99% identity with E. 
coccoides (AY171918.1).  
Three of these novel rodent haemoplasma isolates (#6, #13 and #18) were chosen for passaging into 
laboratory mice (2.2.3) and further sequencing work. The resulting DNA sequences for the partial 
16S, the ITS region and the partial 23S rRNA genes of these isolates comprised 2041 base pairs for 
M. haemomuris #6, 1626 base pairs for M. haemomuris-like #13 and 1327 base pairs for E. coccoides 
#18 and are given in Appendix B. Based on the near complete 16S rRNA gene sequences, species 
identity was 98% to the Brazilian rodent haemoplasma (KT215638.1 and others) for isolate #13. 
Considering increased coverage, this isolate was now 97% identical to the proposed subspecies 
‘ratti’ and 95% identical to the proposed subspecies ‘musculi’ of M. haemomuris. The E. coccoides 
isolate #18 was 97% identical to other E. coccoides isolates and M. haemomuris isolate #6 was 99% 
identical to the proposed subspecies ‘ratti’ and ‘musculi’ of the same genus. Species identification 
based on ITS or 23S rRNA gene sequences was unsuccessful due to the lack of sequence data 
available from other studies for comparison.  
2.3.2.3 16S rRNA gene phylogeny of the novel rodent haemoplasma isolates 
Phylogenetic relationships between the three novel rodent haemoplasma isolates obtained in this 
study for further passaging, and previously published haemoplasmas based on near complete 16S 
rRNA gene sequences are illustrated in Figure 5. A phylogenetic tree, constructed using a 464 base 
pair sequence within a variable region of the 16S rRNA gene that was available for all five novel- and 
several previously isolated rodent haemoplasmas did not reliably resolve established species such as 





Figure 5 Phylogenetic tree of near complete/complete 16S rRNA gene sequences of novel and previously published 
haemoplasma sequences, rooted by other Mycoplasma spp. and Clostridium perfringens. Evolutionary history was inferred 
using the maximum likelihood method based on the Tamura-Nei model (270)  and conducted in Mega7 (268). The dataset 
was sampled 1000 times and bootstrap values are given as percentages where nodes occur. The scale bar indicates 
evolutionary distance. Accession numbers are given next to species names. The novel rodent haemoplasma isolates derived 
from the current study (Langford #6, #13 and #18 as well as a previously unpublished ‘vole haemoplasma’ isolate (277)) are 
highlighted in blue. HF, haemofelis group of haemoplasmas; HM, haemominutum group of haemoplasmas  
Based on this 16S rRNA gene sequence phylogeny, isolate #13 formed a “vole cluster” independently 
to other M. haemomuris isolates, and isolate #18 was confirmed as mostly likely being E. coccoides. 
Isolate #6 clustered with two M. haemomuris isolates included in the analysis but appeared closer to 
the Shizuoka strain. The Shizuoka strain was originally isolated from field mice and was proposed as 
a subspecies within M. haemomuris based on sequence data from the ITS region and rnpB genes 
(279, 280).  
2.3.2.4 Internallly transcribed spacer region phylogeny of M. haemomuris isolates 
The highly variable ITS region between the 16S and 23S rRNA genes was targeted to closer 
determine the relationships of the novel M. haemomuris isolate to other rodent haemoplasma 
isolates. As amplification of ITS failed for E. coccoides #18, only ITS sequence data from isolates #13 
and #6 were included. Sequence alignment of the ITS region (equivalent to positions 548178 to 
548403 of M. haemofelis accession number FR773153.2) of our novel rodent haemoplasmas and 




Figure 6 Nucleotide sequence alignment of the internally transcribed spacer (ITS) sequences of the novel rodent 
haemoplasma isolates (#6, #13) and previously published haemoplasma species within the HF-group of haemoplasmas. 
Sequences were aligned using Clustal W in Mega7 (268). Dashes indicate gaps between adjacent nucleotides caused by the 
alignment. Sequences are equivalent to positions 548178 to 548403 on M. haemofelis accession number FR773153.2. The 
‘Box A’ and ‘Box B’ internal promotor motifs (281) are indicated with arrows/dashes within the alignment. Box A was 
present in all isolates but Box B missing in isolate 13. Ca., Candidatus.  
The novel rodent haemoplasma isolate #6 appeared to reside within the M. haemomuris-group of 
isolates, with 93 % identity to the ‘Ca. Mycoplasma haemomuris subspecies ratti’ group of isolates 
and 90 % identity to the ‘Ca. Mycoplasma haemomuris subspecies musculi’ group (as determined via 
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BLASTn queries). Other closely related species listed in Figure 6 demonstrated similar levels of 
sequence conservation (i.e. M. haemofelis and M. haemocanis; both 94% identity). The novel rodent 
haemoplasma isolate #13 demonstrated higher variability, with the conserved ‘Box A’-like and ‘Box 
B’-like regions (281, 282) conserved for isolate #6 but disrupted by additional nucleotides for isolate 
#13. Hypothetical secondary structures of the ITS regions for the novel isolates are shown in Figure 7 
and Figure 8 and hypothetical structure predictions of the conserved ‘Box A’-like and ‘Box B’-like 
regions within the ITS are given in Figure 9. 
 
Figure 7 Secondary structure prediction of the internally transcribed spacer (ITS) region of the novel M. haemomuris isolate 
#6. Centroid representations were calculated, using the Vienna RNA Websuite (Lorenz et al. 2011) after the method by 
Mathews and Zuker (Mathews et al. 2004). Centroid representations were chosen over minimum free energy (MFE) 





Figure 8 Secondary structure prediction of the internally transcribed spacer (ITS) region of M. haemomuris-like 
haemoplasma isolate #13. Centroid representations were calculated, using the Vienna RNA Websuite (Lorenz et al. 2011) 
after the method by Mathews and Zuker (Mathews et al. 2004). Centroid representations were chosen over minimum free 
energy (MFE) predictions as they have been demonstrated to yield better accuracy in overall base pairing (Rogers and 
Heitsch 2016). 
 
Figure 9 Hypothetical secondary structure of ‘Box A’-like and ‘Box B’-like sequences (281, 282) within the internally 
transcribed spacer (ITS) region of the two novel rodent haemoplasma isolates Langford Isolate #6 and #13. M. haemofelis 
accession number FR773153.2 is shown for comparison. Centroid representations were calculated, using the Vienna RNA 
Websuite (Lorenz et al. 2011) after the method by Mathews and Zuker (Mathews et al. 2004). Isolate #13 had a less 
conserved primary sequence but secondary structure still revealed two conserved loops that could serve as internal 







Phylogenetic relationships within the HF-group of haemoplasmas, based on the highly variable ITS 
region and concentrating on previously published M. haemomuris-isolates, are given in Figure 10. 
 
 
Figure 10 Phylogenetic tree of internally transcribed spacer (ITS) sequences from rodent haemoplasma isolates, rooted by 
other haemoplasmas from within the HF-group. Evolutionary history was inferred using the maximum likelihood method 
based on the Tamura-Nei model (270) and conducted in Mega7 (268). The dataset was sampled 1000 times and bootstrap 
values are given as percentages where nodes occur. Nodes with support values of less than 50 were left in place for 
illustrative reasons. The scale bar indicates evolutionary distance. Accession numbers are given next to species names. 
Isolates derived from this study are highlighted in blue. 
Isolate #6 barely split from the ‘Ca. M. haemomuris subspecies ratti’ group of isolates (branch 
support of 34%) but was well differentiated from the isolates, previously identified from Japanese 
field mice. Isolate #13 remained an isolated species within the HF-group haemoplasmas when 
assessing the ITS region.  
2.3.3 Haemoplasma passaging into laboratory rodents 
2.3.3.1 Initial passage of novel rodent haemoplasmas into laboratory mice 
2.3.3.1.1 Clinical signs and post-mortem examinations 
No clinical signs of ill health were noted in any mice throughout the experiment.  
Both mice, successfully infected with M. haemomuris (isolate #6), showed splenomegaly (defined as 
splenic weight above 0.4% bodyweight) at the time of exsanguination at eight days post inoculation. 
Splenic weights were 1.6 and 1.5% bodyweight. One of the two mice, having successfully yielded 
amplication of a novel M. haemomuris-like haemoplasma (isolate #13), had splenomegaly (splenic 
weight of 1.6% bodyweight) at the time of killing at eight days post inoculation and in the absence of 
other significant post-mortem findings. The second M. haemomuris-like haemoplasma-infected 
mouse had no abnormal findings on post-mortem examination on the same day (splenic weight 
comprising 0.6% bodyweight). One of the two mice inoculated with E. coccoides (isolate #18) had no 
abnormal post-mortem findings at 18 days post inoculation and no data ere available for the second 
E. coccoides-inoculated mouse as it was rehomed after the experiment following repeatedly 
negative qPCR results.  
39 
 
2.3.3.1.2 Haemoplasma genome copies in mouse blood samples 
Normalised relative haemoplasma (M. haemomuris, M. haemomuris-like haemoplasma, E. coccoides 
and M. suis) genome copies per µl blood after inoculation of naïve C57BL/6 mice are shown in Figure 
11.  
 
Figure 11 Haemoplasma genome copies during initial passaging into C57BL/6 mice. Days post inoculation are plotted on 
the x-axis and normalised relative haemoplasma genome copies per µl blood are plotted on the y-axis. Connected dots 
represent individual mice. Solid grey lines: M. suis; solid light blue lines: M. haemomuris; dashed dark blue lines: M. 
haemomuris-like haemoplasma; dotted dark blue lines: E. coccoides; Mice inoculated with M. haemomuris and M. 
haemomuris-like haemoplasma were killed on day 8 of the experiment and one mouse, inoculating with E. coccoides was 
killed on day 18 as indicated by the termination of the lines. As zero values cannot be plotted on logarithmic scales, values 
of one (1.0E+00) haemoplasma copy per µl blood (and qPCR reaction) are treated as the equivalent of zero on this and 
subsequent graphs within this chapter. 
None of the mice had haemoplasma DNA detected in pre-infection blood samples before entering 
the experiment. Both mice inoculated with the M. haemomuris-like haemoplasma isolate amplified 
the organism to 3.00E+05 and 1.17E+06 genome copies per µl blood within 4 days post inoculation. 
Haemoplasma genome copies then dropped sharply (1.25E+03 and 3.38E+03 per µl respectively) on 
day 7 and mice were exsanguinated for future inocula on day 8 of the experiment. Mice inoculated 
with the M. haemomuris isolate showed a later amplification (reaching 4.05E+03 and 1.33E+04 
haemoplasma genome copies per µl blood on day 7) and also were exsanguinated on day 8. 
Eperythrozoon coccoides-inoculated mice showed a more erratic pattern of amplification with the 
first mouse only amplifying the organism to 25 haemoplasma genome copies per µl blood on day 18 
post inoculation, and the second mouse exsanguinated on day 18 of the experiment whilst 
harbouring 2.67E+03 haemoplasma genome copies per µl blood.  
The two mice inoculated with M. suis had detectable M. suis genome copies by qPCR only within the 
first week of the experiment with maximums of 14 and 9 M. suis genome copies per µl blood 
reached on day 7 respectively.  
2.3.3.2 Initial passage of rodent haemoplasmas into laboratory rats 
2.3.3.2.1 Clinical signs and post-mortem examinations 
No clinical signs of ill health were noted in any rats throughout the experiment. As rats were 
rehomed following the experiment, no post-mortem examinations were carried out.  
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2.3.3.2.2 Haemoplasma blood copies in rat blood samples 
Normalised relative haemoplasma (M. haemomuris, M. haemomuris-like haemoplasma and E. 
coccoides) genome copies per µl blood after inoculation into naïve Wistar rats are shown in Figure 
12.  
 
Figure 12 Haemoplasma genome copies during initial passaging into Wistar rats. Days post inoculation are plotted on the x-
axis and normalised relative haemoplasma genome copies per µl blood are plotted on the y-axis. Connected dots represent 
individual rats; solid light blue line: M. haemomuris; dashed blue line: M. haemomuris-like haemoplasma; dotted blue line: 
E. coccoides.  
None of the three rats had haemoplasma DNA detected in their pre-infection blood samples, before 
entering the experiment. One rat, inoculated with M. haemomuris amplified the organism to 
1.42E+04 genome copies per µl blood on day 14 post inoculation, followed by a rapid decline until 
becoming undetectable by day 21 post inoculation. The remaining two rats, inoculated with M. 
haemomuris-like haemoplasma and E. coccoides containing blood samples, did not have detectable 





2.4.1 Identification of wild-caught rodent haemoplasma isolates 
Five rodent haemoplasmas were successfully isolated from wild-caught field mice (Apodemus spp.). 
Based on near-complete 16S rRNA gene sequences, these were identified as M. haemomuris (two 
isolates, both 99% identity to published M. haemomuris 16S rRNA gene sequences), E. coccoides 
(one isolate, 97% identity) and two previously unnamed rodent haemoplasmas that failed to reach 
the 97% threshold of 16S rRNA gene sequence identity with a named species (283). Identification 
and phylogeny based on a 464 base pair PCR amplicon from a variable region within the 16S rRNA 
gene was only extended to include further sequence data for three of the five isolates that were 
considered for further passaging into laboratory rodents to establish a model of M. haemofelis 
infection with a phylogenetically related haemoplasma species. This lack of obtaining further 
sequence data for the remaining isolates potentially delayed the discovery and description of a novel 
species within the rodent haemoplasmas which is especially true for isolate #9 that did not show 
significant similarities with any named haemoplasma species.  
Haemoplasma phylogeny based on 16S rRNA gene sequences alone lacks resolving power due to this 
gene being highly conserved (26, 31), and traditionally phylogeny has been expanded to include 
other ribosomal genes such as rnpB or the ITS (17, 264) to give more reliable data on the relatedness 
of the species being analysed. The threshold of 97% identity using 16S rRNA gene sequence has also 
been recently revised with a more stringent threshold of 99% suggested for bacterial species-
determination (19). Using this 99% threshold, only the M. haemomuris isolate #6 can successfully be 
described as identified, whereas the E. coccoides isolate #18 might still comprise a novel rodent 
haemoplasma species. As an alternative to 16S rRNA gene sequences, protein-coding gene 
sequences can be used for high-resolution phylogeny as they tend to be less conserved at a 
nucleotide level than ribosomal RNA genes. However, there are associated difficulties in obtaining 
such sequences from haemoplasmas in the first place due to the difficulties in amplifying more 
variable regions (16). Evolutionary reconstructions based on such expanded sequences can limit 
construction of phylogenetic trees as only those species for which sequence data are available can 
be included. At the time of the studies described in this thesis, whole genome sequences were 
available for nine haemoplasma species (1.1) but these did not include any rodent haemoplasmas 
nor more recently reported haemoplasma species/isolates within the HF-group of haemoplasmas, 
such as ‘Ca. M. haemohominis’, ‘Ca. M. haemomacaque’ or HF-group haemoplasmas found in wild 
carnivores, such as wolves and foxes (65). Our approach in the current study focused on 
phylogenetically defining the novel haemoplasma isolates derived in this study within the published 
16S rRNA gene and ITS sequences available from other rodent haemoplasmas from previous studies, 
which was especially true for the M. haemomuris isolates.  
The ITS region, between the 16S and 23S rRNA genes, is proposed to be unique to each bacterial 
strain (“ribotype”) and commonly used in clinical diagnostics to monitor outbreaks (284). The high 
variability of this region may provide a better means of defining new species than 16S rRNA gene 
phylogeny alone, and has been explored for Mycoplasmas (282). Based on ITS nucleotide sequence 
comparisons, isolate #6 (considered to be M. haemomuris) had 93% identity to ‘Ca. M. haemomuris 
subspecies ratti’ and 90% identity to ‘Ca. M. haemomuris subspecies musculi’. This compares to 99% 
identity to both of these proposed subspecies based on 16S rRNA gene sequences. It is difficult to 
determine whether our isolate defines a novel species or simply a novel strain from a geographically 
different location. Mycoplasma haemofelis and M. haemocanis are two distinct haemoplasma 
species that share 99% identity based on their 16S rRNA gene sequences (196) and 94% identity in 
the ITS. This 94% figure represents a marginally higher percentage identity than shown (93%) 
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between our study’s M. haemomuris isolate and its nearest phylogenetic neighbour ‘Ca. M. 
haemomuris subspecies ratti’. Thus our M. haemomuris isolate may represent a novel haemoplasma 
species.  Unfortunately, no ITS sequence data could be obtained for isolate #18 E. coccoides nor was 
it available for other E. coccoides isolates in the database nor its nearest phylogenetic neighbour ‘Ca. 
M. turicensis’. The relationships within this HF-group of haemoplasmas, that include rodent and non-
rodent (including feline) hosts, remains underexplored but might be crucial to understanding 
haemoplasma species-specificity (or lack thereof) amongst closely related isolates.  
More sequence data, ideally non-ribosomal gene sequences, will be required to further assess the 
phylogenetic relationships within the rodent haemoplasmas and determine if our novel M. 
haemomuris, E. coccoides and other isolates are indeed all members of their respective species, 
especially when they are isolated from different host species and different geographical locations. 
However, for the purpose of the current thesis and further studies described in later chapters, 
isolate #6 will be referred to as M. haemomuris, isolate #18 as E. coccoides and isolate #13 as M. 
haemomuris-like haemoplasma.  
2.4.2 Successful passage of wild-caught rodent haemoplasma isolates into laboratory mice 
Using quantitative methods of detection (qPCR), two of two inoculated mice successfully became 
infected with M. haemomuris as demonstrated by a rapid increase in haemoplasma genome copies 
per µl of blood over three days, from being undetectable on day 4 to over 1.00E+05 on day 3 post 
inoculation. Comparably rapid in vivo haemoplasma amplification was seen in two of two mice 
inoculated with M. haemomuris-like haemoplasma, although it was followed by an equally rapid 
decline in the observation period (Figure 11).  
The two mice inoculated with E. coccoides showed a different pattern of amplification with relative 
haemoplasma genome copies per µl of blood only reaching a maximum of 1.22E+04 and likely 
bordering the limit of detection of the PCR assay at other timepoints.  In brief, the limit of PCR assay 
detection of haemoplasmas can be explored by considering that DNA was extracted from a maximal 
volume of 10µl of blood, as no more than this could be collected safely once daily from the 
laboratory mice over a prolonged period of time. The DNA from this aliquot of blood was eluted into 
50µl of elution buffer during extraction and then only 5µl of this eluate included in each qPCR assay 
(2.2.1.2). Thus, effectively qPCR is being performed (assuming 100% efficiency of DNA extraction) on 
a sample equivalent to 1µl of blood. To reliably detect every haemoplasma copy in a blood sample, 
10 replicates (i.e. the entire eluate) would have been required. Low haemoplasma genome copy 
numbers (less than 1000 per ml of blood) have been reported in other studies using larger blood 
sample volumes (103, 120, 131, 149, 285) but were not feasible for us to report as laboratory mice 
are small (approximately 20g in the used age-range) and their blood volume is 58.6ml per kg, 
meaning there is approximately 1.16ml of blood in an average laboratory mouse. This illustrates the 
dilemma of being unable to reliably detect low haemoplasma copy numbers and explain the 
apparent fluctuation between non-detectable and relatively high (over 1000 per ml blood) copy 
numbers that was seen in infected mice. This low-level fluctuation does not necessarily reflect true 
haemoplasma copy cycling that is seen in cats or pigs when using much larger sample volumes and 
changes in haemoplasma copy numbers (107, 120). This might also explain a potential ‘lag-phase’ 
that could represent the presence of low copy numbers that remained undetected.  
Peaks and troughs of haemoplasma genome copies in the bloodstream could have been missed in 
the current study due to blood sampling being conducted at intervals of a few days apart. This blood 
sampling schedule was adopted primarily due to an inability to collect tiny blood volumes from mice 
more frequently initially, but practical experience derived in the current studies meant that daily 
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blood sampling was thought to be possible in subsequent studies. Potential peaks (or troughs) of 
blood haemoplasma copy numbers in the laboratory mice were also possibly missed by the killing of 
the M. haemomuris and M. haemomuris-like haemoplasma inoculated mice at day eight post 
inoculation, which was soon after amplification had been confirmed by increasing haemoplasma 
copies per µl of blood over time. Exsanguination of infected mice was, however, deemed the most 
effective way of securing cryopreserved inoculate for use in future studies, given that only one 
original sample was obtained from each individual field mouse (2.2.1.1.3.1).  
The successful amplification of rodent haemoplasmas in laboratory mice in our study was not 
entirely unexpected due to previous reports of successful passaging of haemoplasmas from sources 
similar to ours, such as M. haemomuris infection of Balb/C mice from samples of infected Apodemus 
argenteus specimens (197). However, as outlined in 2.4.1, confirmation of the species used in such 
passaging experiments was not extended beyond ribosomal gene phylogeny, so accurate predictions 
of host species and haemoplasma species specificity were not available.   
2.4.3 Failure to passage M. suis into laboratory mice 
In the two mice inoculated with porcine blood containing M. suis, hemoplasma genome copies were 
only detected in blood sampled on days four and seven post inoculation. Most importantly, the 
blood haemoplasma genome copies per µl blood (1 to 14 copies) at these time points stayed below 
the level that would have been expected through the dilution of the inoculum in the individual 
mouse’s blood volume alone of 7.43E+07 M. suis copies per µl blood. This figure is derived from 
knowing that the total blood volume of a 20g mouse is approximately 1.16ml and 8.69E+10 M. suis 
copies were inoculated into each mouse. Assuming complete uptake of the inoculated M. suis into 
the murine blood stream, there would be 7.43E+07 M. suis copies per µl blood detectable. Whilst 
this cannot fully explain the increase seen between days four and seven, one might speculate that 
uptake from the intraperitoneal injection site was delayed or, alternatively, that the haemoplasmas 
were able to briefly amplify before being eliminated by the murine immune system. However, it is 
probably more likely that the variation between days four and seven post inoculation is due to 
stochastic variation and may not have been apparent if more replicate qPCRs had been performed or 
a larger number of mice had been used. Our observation that M. suis could not establish infection in 
healthy laboratory mice concurs with observations by German research groups who were able to 
detect M. suis after intraperitoneal inoculation into four-week-old OF-1 mice (Oncins-France-1, an 
outbred strain) but were unable to establish infection or detect M. suis DNA after the first week 
(217). It can only be speculated how reliable the claims by Chinese research groups are that they 
have a mouse model of M. suis infection established in an outbred mouse strain; Kunming mice. 
(248, 249, 286). Full methodologies or nucleotide sequences for phylogenetic comparison are not 
available but using immunocompromisation (by the use of high doses of glucocorticoids) and 
repeated inoculation of M. suis (at least every three days) in combination with non-quantitative, gel-
based methods of PCR detection does question the reliability of their model (287). Currently we 
have found no evidence to support successful M. suis growth outside of their natural porcine hosts. 
Future research might involve different strains of mice, including genetically modified strains such as 
athymic mice, to assess species-specific infection of erythrocytes versus species-specific immune 
evasion of the organism.  
2.4.4 Successful passage of M. haemomuris and failure to passage E. coccoides and M. 
haemomuris-like haemoplasma into laboratory rats 
The M. haemomuris isolate #6 successfully established infection in a ten-week-old, SPF, female 
Wistar rat. No haemoplasma DNA was detected in the rats each inoculated with E. coccoides and M. 
haemomuris-like haemoplasma throughout the observation period. However, we did not perform 
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any qPCR on splenic tissue from the remaining two rats, which may have demonstrated latent 
infection at a later stage of the experiment, similar to what was seen in previous rat experiments on 
days ten and fifteen post inoculation of M. haemomuris-containing inocula (197).  
Whilst this report of M. haemomuris infection in a laboratory rat is limited by its demonstration in 
only one animal, it is the first time that haemoplasma genome copy numbers have been monitored 
in a rat over the course of experimental infection using qPCR. However, the M. haemomuris copies 
per µl of blood detected in the rat were much lower than those detected in the mice, with a 
maximum of 1.42E+04 copies per µl blood being reached two weeks post inoculation (Figure 12) in 
the rat compared to the mice which showed a 100-fold higher level of M. haemomuris copies per µl 
blood just one week post inoculation (Figure 11) with a potential peak still to be reached. It could be 
speculated that our M. haemomuris isolate underwent changes during its passaging in laboratory 
mice that subsequently compromised its ability to establish infection in rats. Another possibility is 
that the M. haemomuris isolate is able to evade the mouse immune system better than the rat 
immune system, as the infection kinetics seen in rats (short-lived bacteraemia) was compatible with 
that of an innate immune response clearing infection (288). Whilst rats would offer a larger 
laboratory model of haemoplasma infection compared to mice, the observed preliminary infection 
kinetics seen for M. haemomuris did not resemble the infection kinetics seen for the primary 
pathogenic haemoplasma species in either cats or pigs regarding magnitude of haemoplasma 
bacteraemia or duration of infection with pathogenic haemoplasmas (90, 107, 120). Additionally, the 
use of rats would be associated with higher costs and less well-established laboratory reagents being 
available compared to mice. Thus, mice were considered to be a more suitable host for a rodent 
model of haemoplasma infection and so inoculation of M. haemomuris into laboratory rats was not 
further explored in the current studies.  
2.4.5 Limitations of the current study and suggested future work using the novel haemoplasma 
isolates 
We have been unable to extend the phylogenetic classification and identification of our newly 
obtained haemoplasma isolates to subspecies-level, and we are currently unsure as to whether they 
represent novel strains or novel species of haemoplasmas when applying the most stringent criteria 
of classification. Future research should try to include sequencing of rnpB, DNAK and GAPDH for 
these isolates, as these genes have been successfully used for haemoplasma phylogeny in previous 
studies (216, 289). Ideally, however, future research would include derivation of whole genome 
sequences for our, and other rodent, haemoplasma isolates, to define phylogeny more accurately.  
Recently, cost reductions in bacterial genome sequencing have opened up this possibility to 
researchers working on less ‘funded’ pathogens, but the technique still requires adequate amounts 
of sufficiently pure template DNA to be available for sequencing. Currently, this DNA cannot easily 
be obtained for haemoplasmas that cannot be grown outside the murine host because if they are 
grown within the murine host, purification from host mouse DNA is difficult to achieve (94). Several 
hundred mice would also likely be required to provide sufficient haemoplasma DNA for purification 
attempts, and so this would be a significant undertaking and outside of the scope of the current 
experiments.  In the future whole rodent haemoplasma gene sequencing might become more 
feasible if sequencing methodology improves or if haemoplasma in vitro cultivation is successful.  An 
established mouse model of haemoplasma infection to act as a source of viable haemoplasmas for in 
vitro experiments will also be important.  
Due to the pilot nature of the in vivo infection experiments described in this chapter, a full rodent 
model of haemoplasma infection was not established in these studies, but the rodent experiments 
represented the foundations of such a model as we were able to successfully establish infection in 
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laboratory mice and rats and develop suitable means of cryopreservation, inoculation and 
monitoring of haemoplasma copies in inoculated rodents. Model selection and subsequent 
establishment of a repeatable model of infection are important. One should also consider the 
model’s analogy to M. haemofelis infection, as if the aim is to establish an animal model of disease, 
it ideally needs to represent its closest phylogenetic neighbour that is a primary pathogen with 
significant morbidity i.e. M. haemofelis.  
Future work will focus on repeating M. haemomuris and E. coccoides inoculations and infection in 
C57BL/6 mice and concentrate on the monitoring of infection kinetics. This will be achieved by more 
frequent sampling to evaluate more thoroughly the potential fluctuations of haemoplasma copies 
per µl blood, which represents an unexplained feature of M. haemofelis infection in cats. Ultimately, 
protection from haemoplasma reinfection and cross-protection can be evaluated in a mouse model 
that resembles M. haemofelis infection in cats as closely as possible.   
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3 ESTABLISHMENT AND INITIAL CHARACTERISATION OF A MOUSE MODEL 
OF HAEMOPLASMA INFECTION  
3.1 INTRODUCTION 
3.1.1 Known characteristics of rodent haemoplasma infection  
The kinetics of rodent haemoplasma infection are largely unknown. Similarities to feline or porcine 
haemoplasma infection (cats and pigs being the veterinary host species most investigated, and 
considered important, to suffer from clinical haemoplasmosis) would be required to successfully 
select a suitable mouse model of haemoplasma infection for further studies. Early studies following 
rodent haemoplasma infection over time were based on microscopy, and hence are likely to have 
missed low-level bacteraemia. Eliot (238) reported E. coccoides to appear two to four days post 
splenectomy in mice, with a dramatic increase in numbers of parasitized red blood cells over two to 
three days and less pronounced peaks of bacteraemia at intervals of several days afterwards, with 
the bacteraemia sometimes being still detectable three months after splenectomy. Similar 
observations of haemoplasmas becoming visible approximately three days post inoculation (dpi) or 
after splenectomy, with fluctuating levels and potentially deadly relapses over the first two to three 
weeks, were made by Ford and Eliot (237) in rats infected with M. haemomuris. These authors also 
reported a drop in viability of the organism following transfer into other healthy animals, once peak 
bacteraemia (at two to five days) had passed. Marmorston-Gottesman and Perla (240) reported that 
M. haemomuris (referred to as Bartonella muris) was detectable on red blood cells three to six days 
after infection of immunocompetent young white mice, with anaemia developing at around five dpi. 
Rikihisa, Kawahara (197) reported an increase in splenic weight at necropsy in mice experimentally 
infected with M. haemomuris (referred to as Haemobartonella muris) with a peak around five dpi 
that gradually decreased, but did not revert to normal, until the end of the experiment at 25 dpi. In 
this study, stained blood smears were said to be positive for haemoplasmas at ten dpi, but no 
further smears were taken. More recently, Cohen, Shemesh (34) monitored the infection dynamics 
of a ‘M. haemomuris-like haemoplasma’ in wild gerbils using the generic haemoplasma assays (185) 
described in Chapter 2 to monitor their successful passage into laboratory mice. Their findings 
included a peak in haemoplasma genome copies per µl blood occurring around 25 to 45 dpi, 
followed by a decline and plateau phase from 65 to 400 dpi (representing the end of the 
experiment) suggesting that persistent infection is common (34).  
3.1.2 Protective immunity against haemoplasma infection  
Haemoplasma infection can be chronic and difficult to eradicate from cats, pigs and mice (89, 120, 
136, 252). Until recently, no treatment protocol had been described that claimed to establish 
haemoplasma elimination (135), supporting the need for a vaccine if the aim is protection from 
infection and thus future relapses. However, despite promising immunoreactive M. suis antigens 
being investigated as vaccine candidates in pigs (120), no effective vaccine has been developed for 
any haemoplasma species to date. Protective immunity in animals that have recovered from 
haemoplasma infection would drive investigations into vaccine candidates, although it is not a strict 
requirement in vaccinology (290).  
In cats, protective immunity against re-infection with the same haemoplasma species has been 
demonstrated in small pilot studies for M. haemofelis and ‘Ca. M. turicensis’ (107, 124). In mice, 
Ford and Eliot (237) made a case against protective immunity as they documented relapses and 
anaemia in splenectomised rats previously ‘recovered’ from M. haemomuris infection; however they 
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were not aware of the role of the spleen in linking the innate and adaptive immune response (291) 
or more specifically, the role of splenic macrophages in clearing blood-borne pathogens such as 
haemoplasmas (292). Splenectomy has since been used to model more severe haemoplasmosis in 
piglets (120) and been suggested to be a risk factor in canine haemoplasmosis (293) but this 
observation regarding splenectomy does not rule out that protective immunity in non-
splenectomised animals to haemoplasmosis can occur. The fact that co-infections with different 
haemoplasma species can occur in the same host (98, 100, 294) suggests that cross-protection is 
very unlikely. There is some evidence in cats that previous exposure to different haemoplasma 
species, investigated with ‘Ca. M. turicensis’ and ‘Ca. M. haemominutum’, might even enhance 
clinical disease from subsequent M. haemofelis infection (180, 295). 
3.1.3 PCR detection and monitoring of infection kinetics of haemoplasmas 
Monitoring of infection kinetics requires quantitative methods to differentiate low-level chronic 
infection from fulminant bacteraemia, and to compare bacterial loads across timepoints and species 
as required for assessment of a rodent model of haemoplasma infection. The use of a generic 
haemoplasma qPCR assay for quantification can only be used with confidence when only a single 
haemoplasma species is present i.e. multiple-infections cannot be quantified by a generic qPCR as 
differentiation of species is not possible. Cohen, Shemesh (34) submitted 20% of their generic 
haemoplasma qPCR amplicons for Sanger sequencing to determine the haemoplasma species 
present, whilst monitoring ‘M. haemomuris-like haemoplasma’-infection dynamics, to help ensure 
the presence of only one haemoplasma species (the ‘M. haemomuris-like haemoplasma’ species). 
This method would not be suitable for experiments involving two or more haemoplasma species as 
sequencing of qPCR amplicons might still miss infection with more than one species. Amplification of 
one haemoplasma species with a significantly lower number of copies in the bloodstream is likely to 
be outcompeted by another species that is present at higher copies.  
In some host species, where co-infection with more than one haemoplasma species occurs, the 
problem of quantification of multiple infecting haemoplasma species has been solved by developing 
species-specific conventional PCR assays (296) and subsequently qPCR assays (187, 297, 298) 
designed to target regions of variance in the 16S rRNA gene, that otherwise exhibits a high degree of 
conservation across species. In cats, specific qPCR assays are available for M. haemofelis, ‘Ca. M. 
turicensis’ and ‘Ca. M. haemominutum’ (38, 297) with no observed cross-reactivity between the 
respective feline haemoplasma species at 1.0E+06 16S rRNA gene copies of the non-target 
haemoplasma species per reaction. In dogs, M. haemocanis and ‘Ca. M. haematoparvum’ can be 
detected by species-specific qPCR assays and no cross-reaction occurs up until a concentration of 
1.0E+05 16S rRNA copies of the non-target haemoplasma species per reaction (187).  
The 16S rRNA gene is used for species identification as it is highly conserved within, and in parts 
even across, species (299). The feline haemoplasma M. haemofelis is 84 % identical to ‘Ca. M. 
haemominutum’ and 88 % identical to ‘Ca. M. turicensis’ based on 16S rRNA gene sequencing (38). 
Interestingly, the M. haemofelis 16S rRNA gene sequence is identical to the corresponding sequence 
of the canine haemoplasma M. haemocanis, and ‘Ca. M. haemominutum’ shares 94% 16S rRNA gene 
identity with the canine haemoplasma ‘Ca. M. haematoparvum’, despite these organisms infecting 
different host species (298). The qPCR assays used for the detection of M. haemofelis and ‘Ca. M. 
haemominutum’ (297) have been successfully used to detect related haemoplasma species when 
used on a different host, i.e. detection of ‘Ca. M. haematoparvum’ in a dog using a feline ‘Ca. M. 
haemominutum’ qPCR assay (298), and detection of M. haemocanis in a dog using a feline M. 
haemofelis qPCR assay (148). Our two recently derived rodent haemoplasma isolates of M. 
haemomuris and E. coccoides (described in Chapter 2) are 89% identical based on 16S rRNA gene 
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sequencing and without significant insertions/deletions that could easily be used for sequence 
differentiation. High similarities with evenly spaced nucleotide polymorphisms pose a challenge to 
species-specific qPCR design that will not result in cross-reactions, as would be required for any 
experiments assessing cross-protection (i.e. infection with one haemoplasma species protecting 
against infection with another haemoplasma species).  
Quantitative PCR assays for the feline and canine haemoplasma species have been duplexed with a 
feline and canine internal control qPCR, respectively, to ensure the ability to detect amplifiable DNA 
and an absence of signficant qPCR inhibitors (100, 187). These multiplexed quantitative PCR assays 
also offer a means of haemoplasma copy number normalisation against the amount of host DNA 
present in a given blood sample (297).  
3.1.4 Objectives 
The first objective of this chapter was to develop qPCR assays specific to the two rodent 
haemoplasma species (M. haemomuris and E. coccoides) described in successful mouse inoculation 
studies in Chapter 2, and use them to monitor the infection kinetics of M. haemomuris and E. 
coccoides in C57BL/6 mice following experimental infection. The second objective was to further 
assess whether these two rodent haemoplasma species could be used to establish a suitable 
surrogate model of haemoplasma infection in cats (or other veterinary species) and assess whether 




3.2 MATERIALS AND METHODS 
3.2.1 Development of qPCR assays to specifically detect M. haemomuris and E. coccoides DNA in 
mouse blood samples 
3.2.1.1 Development of a M. haemomuris qPCR singleplex assay 
3.2.1.1.1 Origin of M. haemomuris 16S rRNA gene template DNA 
Template DNA for the M. haemomuris 16S rRNA gene qPCR assay development was generated from 
the pilot mouse infection experiments described previously (see 2.2.3). In brief, DNA was extracted 
using the NucleoSpin® Blood kit (Macherey-Nagel) and eluates stored at -20°C until use. As the M. 
haemomuris qPCR assay development overlapped with the first part of the experiment describing 
primary infection with E. coccoides and M. haemomuris (see 3.2.2), samples from these studies were 
also utilised. Where indicated, mouse DNA was used as a negative control or as ‘background’ DNA 
and was derived from pre-infection screenings from previous and ongoing mouse studies that had 
generated negative qPCR results following screening with a generic haemoplasma qPCR (2.2.3.3).  
As no concentrated genomic M. haemomuris 16S rRNA gene template DNA was available to use for 
studies requiring a high concentration of template DNA (i.e. to produce serial dilutions for standard 
curve generation) amplicons derived from primers 313-HBT-F and 680-HF-group-R (which amplified 
a section of 595 base pairs on the haemoplasma 16S rRNA gene) were generated as described in 
2.2.2.1.2 and diluted 1 in 1,000,000 with elution buffer (BE, Macherey-Nagel) prior to use, unless 
noted otherwise. For each experiment, amplicons were prepared and diluted individually.  
3.2.1.1.2 M. haemomuris qPCR primers and probe design 
Mycoplasma haemomuris qPCR primer pairs and TaqMan probe were designed to the partial 16S 
rRNA gene consensus sequence generated in 2.2.2.1.2. A multiple sequence alignment of the 16S 
rRNA gene sequences of the novel M. haemomuris and E. coccoides isolates Langford #6 and #18 and 
other closely related HF-group haemoplasmas was generated in Mega7 (268) and assessed for 
divergent regions. Other isolates included the ‘M. haemomuris-like haemoplasma’ isolate #13 and 
published sequences of E. coccoides (AY171918.1, EF175168.1, EF175169.1, EF175170.1), M. 
haemomuris (AB918692.1, AB758434.1, AB758435.1, AB758439.1, AB758440.1), ‘Ca. M. 
haemohominis’ (GU562823.1) and ‘Ca. M. turicensis’ (DQ464418.1, KR905459.1, KM275267.1). 
Primers and probes were designed using Primer3Plus (300) in “primer list” mode on the M. 
haemomuris 16S rRNA gene sequence to select primers spanning divergent regions, preferably being 
most divergent between species at the 3’ end and conserved within multiple isolates of the same 
species. Primer generation was achieved using the following settings:  
 
Primer size (base pairs): minimum 16; optimum 20; maximum 27 
Primer Tm (°C): min. 58.0; opt. 60.0; max. 62.0  
Primer G+C%: min. 40; max. 60  
Maximum self-complementarity: 4  
Maximum 3'-self-complementarity: 1  
Maximum poly-X: 4  
Mispriming (rodent and simple): 12 
Primer pairs were selected, aiming for amplicon sizes of 100 to 250 base pairs and subsequently 





Probe size (base pairs): minimum 18; maximum 27 
Probe Tm (°C): min. 68.0; opt. 70.0; max. 72.0  
Probe G+C%: min. 20; max. 80 
 
Predicted amplicons were assessed for secondary structure formation using the Mfold webserver 
(301) and primers discounted if secondary structure at the primer-binding site was predicted to have 
a melting temperature above the primer melting temperature, which would have interfered with 
primer annealing. The TaqMan probe was labelled with Texas Red (TEX) at the 5'-end and with black 
hole quencher 2 (BHQ2) at the 3'-end. All oligonucleotides (primers/probe) were ordered from 
Metabion, Germany.  
3.2.1.1.3 Optimisation of M. haemomuris qPCR conditions using SYBR Green 1 
3.2.1.1.3.1 QPCR conditions and dissociation curve analysis 
Six primer pairs (designed as above; shown later in 3.2.1.1.2 and 3.2.1.2.2) were assessed for their 
ability to amplify the M. haemomuris 16S rRNA gene. Each qPCR consisted of 2X GoTaq (Promega), 
4.5mM MgCl2, SYBR Green 1 (1 in 100,000; Sigma-Aldrich Ldt., Poole, UK) and forward and reverse 
primers, each at 200nM final concentration. Two microlitres of template DNA and water were added 
to a final volume of 25µl. Template DNA for the initial reactions was derived from pooling DNA 
samples from primary passages of novel rodent haemoplasmas (3.2.1.1.1) at a final concentration of 
approximately 2.5E+03 genome copies per µl. Each qPCR was run in duplicate and negative controls 
(water and mouse DNA) were included for each primer pair.  
All qPCRs were performed on a Mx3005 qPCR thermal cycling system (Agilent) under the following 
conditions: Initial incubation for 2 mins at 95°C followed by 40 cycles of denaturation at 95°C for 15 
seconds and annealing/extension at 60°C for 30 seconds. Fluorescence was detected at 516nm at 
the end of each annealing/extension phase. This was followed by a dissociation curve spanning 70°C 
to 90°C in 1°C increments.  
SYBR Green 1 reports the presence of double-stranded DNA as it fluoresces stronger when 
intercalated within double-stranded DNA. After initial detection (by reporting of the threshold cycle 
value) of amplifiable DNA, the melting temperature of the PCR amplicon (dependent on a number of 
factors including the length and GC-content) can be determined by a measuring fluorescence over a 
temperature gradient; the detection of a sudden drop in fluorescence signifies dissociation of 
double-stranded DNA and can be used to confirm the presence of a single amplicon (302).  
3.2.1.1.3.2 Assessment of M. haemomuris singleplex assay cross-reactivity to E. coccoides 
attributed to primers 
Initial assessment of cross-reactivity was carried out on two primer pairs that were tested against E. 
coccoides genomic DNA (Ct 26.06 when using the HF-assay described in 2.2.1.2.2; equivalent to 
1.62E+04 genome copies per reaction) in triplicate qPCRs. Positive (M. haemomuris genomic DNA) 
and negative (water) controls were included. Reaction conditions of each qPCR, including the 
subsequent generation of a dissociation curve, were identical to the ones described above 
(3.2.1.1.3.1).  
3.2.1.1.3.3 Reaction efficiency evaluation (standard curve generation)  
Reaction efficiency was assessed for two primer pairs, using a series of dilutions of target DNA 
consisting of M. haemomuris 16S rRNA gene PCR amplicons, spanning the target region. The 
amplicons were generated as described above (3.2.1.1.1) followed by a series of ten-fold dilutions in 
a mouse DNA background, comprising DNA from haemoplasma-free mice tested during the pre-
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infection screening process (2.2.3.3). The dilution series was prepared immediately prior to use and 
run in duplicate on the same qPCR plate, using the conditions described in 3.2.1.1.3.1.  
3.2.1.1.3.3.1 Calculating assay efficiency from the slope of the amplification curve 
A graph of Ct versus log10 of the copy number of the template was produced, and the slope of this 
graph was used to calculate qPCR efficiency using the MxPro™ v4.10 software package (Agilent) and 
the following formula: 
E = 10(-1/slope) – 1 
where E = qPCR efficiency and the slope being defined as the relative increase of Ct values over each 
10-fold dilution of template. 
As described earlier (2.2.1.2.2.2), PCR amplification follows an exponential curve that doubles the 
amount of product (amplification equal to 2Ct) with each cycle. As Ct values were plotted against 
log10 of the copy number (amplification being equal to 10-1/slope), a slope of -3.32 is considered ideal 
and equates to 100% efficiency, due to 10-1/-3.32 = 2 and 10-1/-3.32 – 1 = 1 (100%). 
3.2.1.1.4 Analysis of qPCR data 
Analysis was carried out using the MxPro™ v4.10 software package (Agilent). Threshold fluorescence 
was set at 300 relative fluorescence units (Rf) for all assays (M. haemomuris-specific, E. coccoides-
specific, and when in use, the host internal control qPCR assay). Data were compared using 
threshold cycle (Ct) values. For the purpose of assay development, no normalisation of Ct values was 
carried out. Where relative haemoplasma genome copy numbers are reported, these were 
calculated using the formula given in 2.2.1.2.2.2.  
3.2.1.2 Development of an E. coccoides qPCR singleplex assay 
3.2.1.2.1 Origin of E. coccoides 16S rRNA gene template DNA 
Template DNA for qPCR assay development was generated from the pilot mouse infection 
experiments (see 2.2.3) described previously and was extracted and stored as described for the M. 
haemomuris singleplex assay development (3.2.1.1) but using samples containing E. coccoides 
genomic DNA.   
As no concentrated E. coccoides genomic DNA was available, amplicons from primers 313-HBT-F and 
680-HF-group-R were generated as described in Chapter 2 and 3.2.1.1.1 and diluted 1 in 1,000,000 
with elution buffer (BE, Macherey-Nagel) prior to use, unless noted otherwise. Amplicon dilutions 
were prepared individually for each experiment and used for studies requiring a high concentration 
of template 16S rRNA gene DNA.  
3.2.1.2.2 E. coccoides qPCR primers and probe design 
Eperythrozoon coccoides qPCR primer pairs and a TaqMan probe were designed to the partial 16S 
rRNA gene consensus sequence generated in Chapter 2 in an identical approach as outlined for the 
M. haemomuris singleplex assay (3.2.1.1.2) using Primer3Plus (300). Primer pairs that produced 
predicted secondary structure by MFold (301) were excluded and all oligonucleotides 
(primers/probes) were ordered from Metabion, Germany. 
3.2.1.2.3 Optimisation of E. coccoides qPCR conditions using SYBR Green 1 
3.2.1.2.3.1 QPCR conditions and dissociation curve analysis 
Four primer pairs were assessed for their ability to amplify the E. coccoides 16S rRNA gene sequence. 
Reaction conditions for each qPCR were as described for M. haemomuris above (3.2.1.1.3.1) using 
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primers designed to the E. coccoides 16S rRNA gene. Template DNA for the initial reactions was 
derived from pooling DNA samples from primary passages of novel rodent haemoplasmas (3.2.1.2.1) 
at a concentration of approximately 3.0E+03 genome copies per µl. Negative controls (water and 
mouse background DNA) were included and qPCR conditions, including thermal cycling conditions 
and dissociation curve generation, were identical to the procedures outlined in 3.2.1.1.3.1.  
3.2.1.2.3.2 Assessment of E. coccoides singleplex assay cross-reactivity to M. haemomuris 
attributed to primers 
Initial assessment of cross-reactivity was carried out on three primer pairs, challenged with genomic 
M. haemomuris template DNA (Ct 16.30 when using the HF-assay described in 2.2.1.2.2; equivalent 
to 1.45E+07 genome copies per reaction) in triplicate qPCRs, with positive (E. coccoides) and 
negative (water) controls. Reaction conditions and generation of dissociation curves was identical to 
the method described for M. haemomuris above (3.2.1.1.3.1).  
3.2.1.2.3.3 Reaction efficiency evaluation (standard curve generation)  
Reaction efficiency was assessed for two primer pairs, using a series of dilutions of target DNA 
consisting of E. coccoides 16S rRNA gene PCR amplicons, spanning the target region. The amplicons 
were generated as described above (3.2.1.1.1) followed by a series of ten-fold dilutions in a mouse 
background DNA, comprising DNA from haemoplasma-free mice tested during the pre-infection 
screening process (2.2.3.3). The dilution series was prepared immediately prior to use and run in 
duplicate on the same qPCR plate, using the conditions described in 3.2.1.1.3.1.  
3.2.1.2.3.3.1 Calculating assay efficiency and slope of amplification curve 
Assay efficiency and slope of the amplification curve were calculated as described for 3.2.1.1.3.3.1. 
3.2.1.2.4 Analysis of qPCR data 
Data analysis was carried out as described in 3.2.1.1.4.  
3.2.1.3 Duplexing rodent haemoplasma and host DNA qPCR assays 
3.2.1.3.1 Novel rodent haemoplasma and internal mouse host control (GAPDH) qPCR primers and 
probe 
Mycoplasma haemomuris and E. coccoides-specific primers and probes, as designed in 3.2.1.1.2 and 
3.2.1.2.2, were used to develop haemoplasma species-specific qPCR singleplex assays using a 
TaqMan probe. Primers and probe from a previously published qPCR assay targeting the cat GAPDH 
gene (261) was used as an internal control as previously described under singleplex assay conditions, 
as the respective primer binding sites of the mouse GAPDH gene are identical to the cat GAPDH gene 
(2.2.1.2.2). The TaqMan probes specific to the M. haemomuris and E. coccoides 16S rRNA genes 
were labelled with Texas Red (TEX) at the 5’-end and a BHQ2 at the 3’-end and synthesized by 
Metabion. The TaqMan probe targeting the mouse GAPDH gene was labelled with 6-
carboxyflourescein (FAM) at the 5’-end and a black hole quencher 1 (BHQ1) at the 3’-end and 
synthesized by Invitrogen, UK.  
3.2.1.3.2 Optimisation of duplex qPCR conditions (M. haemomuris and E. coccoides) 
3.2.1.3.2.1 Singleplex qPCR conditions for the M. haemomuris and E. coccoides assays using a 
TaqMan probe 
Initial singleplex qPCR conditions consisted of 2X GoTaq (Promega), 4.5mM MgCl2, forward and 
reverse primers (specific to either M. haemomuris or E. coccoides 16S rRNA genes) each at 200nM 
and a TaqMan probe at 200nM final concentration. Probe concentration was subsequently varied at 
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200nM, 100nM and 50nM during optimisation. Water and template DNA were added to a final 
volume of 25µl. Initial singleplex reactions were tested with M. haemomuris and E. coccoides 16S 
rRNA gene amplicon dilutions (3.2.1.1 and 3.2.1.2.1) at three different concentrations (“low”, 
“medium” and “high”) in mouse genomic DNA generated from pre-infection screenings (2.2.3.3 and 
3.2.2.1.3) to create “mock infected samples”. Thermal cycling conditions were as follows: Initial 
incubation for 2 mins at 95°C followed by 40 cycles of denaturation at 95°C for 15 seconds and 
annealing/extension at 60°C for 30 seconds. Fluorescence was detected at 610nm (TEX) at the end of 
each annealing/extension phase.  
3.2.1.3.2.2 Initial duplex qPCR conditions for the M. haemomuris/GAPDH and E. coccoides/GAPDH 
assays 
Each initial duplex qPCR consisted of 2X GoTaq (Promega), 4.5mM MgCl2, forward and reverse 
primers (specific to either M. haemomuris or E. coccoides 16 S rRNA genes) each at 200nM and a 
TaqMan probe at 100nM final concentration. Primers for the host internal control (GAPDH) assay 
were added at 100nM each and the host internal control TaqMan probe at 50nM final 
concentration. Water and template DNA were added to a final volume of 25µl. Initial duplex 
reactions were tested with “mock infected samples” as outlined above (3.2.1.3.2.1). Each PCR was 
run in triplicate on the same plate. Thermal cycling was as above (3.2.1.3.2.1) and fluorescence was 
detected at 516nm (FAM) and 610nm (TEX) at the end of each annealing/extension phase. 
3.2.1.3.2.3 Optimisation GAPDH assay qPCR primer and probe concentrations 
The duplex qPCRs, specific to either M. haemomuris or E. coccoides 16S rRNA genes, were assessed 
for interference with the host internal control qPCR (targeting the mouse GAPDH gene) by repeating 
reactions with GAPDH primers/probe concentrations of 100nM/50nM, 50nM/25nM, and 
12.5nM/12.5nM per reaction in a final volume of 25µl. Template DNA comprised of three different 
haemoplasma 16S rRNA amplicon dilutions in a background of mouse genomic DNA, as outlined 
above (3.2.1.3.2.1). Thermal cycling conditions and detection of fluorescence was identical to the 
protocol outlined above (3.2.1.3.2.2).  
3.2.1.3.3 Murine haemoplasma duplex assay validation 
3.2.1.3.3.1 Reaction efficiency evaluation  
Reaction efficiency was assessed for the final assays by generating a standard curve, using a 10-fold 
dilution series of M. haemomuris and E. coccoides 16S rRNA gene amplicons in a background of 
mouse genomic DNA as described above (3.2.1.1.1 and 3.2.1.2.1). Dilution series were prepared 
immediately before use and added as 5µl template to make up 25µl duplex qPCRs comprising 
200nM forward and reverse primers for either the M. haemomuris or E. coccoides assay and 100nM 
of their shared probe (see below), 4.5mM MgCl2, 12.5nM of each internal control primer and probe.  
Standard curves were run in duplicate on the same qPCR plate under the conditions described in 
3.2.1.3.2.2.  
3.2.1.3.3.1.1 Calculating assay efficiency and slope of amplification curve 
Assay efficiency and slope of the amplification curve were calculated as described for 3.2.1.1.3.3.1. 
3.2.1.3.3.2 Assessment of final duplex assay cross-reactivity 
Cross-reactivity of the final M. haemomuris and E. coccoides-specific duplex assays was assessed by 
challenging the M. haemomuris-specific assay with a single dilution of E. coccoides 16S rRNA gene 
amplicon in mouse genomic DNA (approximately 1.79E+06 copies per reaction as used for standard 
curve generation in 3.2.1.2.3.3). Reactions were carried out in triplicate. The equivalent experiment, 
using a single dilution of M. haemomuris 16S rRNA gene amplicon in mouse genomic DNA 
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(approximately 1.17E+06 copies per reaction) was carried out in triplicate for the E. coccoides-
specific assay. Each qPCR consisted of reagents as described in 3.2.1.3.3.1 and cycling conditions and 
detection of fluorescence was identical to 3.2.1.3.2.2.  
3.2.1.3.3.3 Assessment of final duplex assay sensitivity (limit of detection) 
Template DNA amplicons were generated by conventional PCR (3.2.1.1.1 and 3.2.1.2.1).  
Molecular weights of template amplicons were calculated using the Sequence Manipulation Site 
(303) on www.bioinformatics.org/sms2/dna_mw.html and amplicon concentrations from the 
conventional PCRs measured using a Qubit® dsDNA HS assay with a Qubit® 2.0 fluorophotometer 
(Invitrogen, UK), according to the manufacturer’s instructions. The number of amplicons was 
calculated by dividing total DNA content by the calculated molecular weight of the amplicons.  
Ten-fold serial dilutions of the amplicons generated in the conventional PCR were made in elution 
buffer following an initial dilution of 160,000-fold. Samples were run in triplicate using either the M. 
haemomuris or E. coccoides duplex qPCR assay (3.2.1.3.3.1) and thermal cycling conditions described 
above (3.2.1.3.2.2) using a volume of 5µl of template DNA eluate per reaction. Fluorescence was 
detected at 610nm (TEX) at the end of each annealing/extension phase. Limit of detection (LoD) was 
defined as the last dilution that yielded one or more positive qPCR results.   
3.2.1.3.4 Analysis of qPCR data 
Analysis was carried out as described for 3.2.1.1.4.  
3.2.2 Application of the novel, species-specific duplex qPCR assays to monitor haemoplasma 
infection kinetics in mice 
3.2.2.1 Animals 
All mice were female, SPF C57BL/6 and sourced from Harlan Laboratories UK Ltd., Loughborough, 
UK. 
3.2.2.1.1 Ethical approval 
All studies involving laboratory rodents were subject to ethical review (Animal Welfare Ethical 
Review Body of the University of Bristol) and covered by a Home Office licence (PPL 30/2948).  
3.2.2.1.2 Housing conditions 
Mice were housed and monitored as previously described in 2.2.3.2. 
3.2.2.1.3 Screening mice for pre-existing M. haemomuris-infection  
One week prior to all inoculation experiments, mice were uniquely identified, allowed an 
acclimatisation period and had a 10µl blood sample withdrawn for generic haemoplasma qPCR 
analysis as outlined in 2.2.3.3.  
3.2.2.1.4 Haemoplasma Inoculation  
3.2.2.1.4.1 Inoculation schematic 




Figure 13 Inoculation schematic to outline experimental design for the rodent haemoplasma infection kinetic studies, 
assessing protection from re-infection with M. haemomuris and cross-protection from M. haemomuris following E. 
coccoides infection. In Phase 1 of the experiment, three groups of mice were either inoculated with cryopreserved M. 
haemomuris (re-inoculation group), inoculated with cryopreserved E. coccoides (cross-protection group) or were not 
inoculated and remained naïve (age-matched control group). The mice inoculated with haemoplasmas were subsequently 
monitored daily by qPCR for M. haemomuris and E. coccoides genome copies per µl blood. The control group was subject to 
the same procedures (blood sampling) and housed under the same conditions as the groups inoculated with 
haemoplasmas. Following recovery from infection in the Recovery phase, all three groups were inoculated with freshly 
collected M. haemomuris-containing mouse blood in Phase 2 of the experiment and monitored for M. haemomuris and E. 
coccoides infection by qPCR.  
In brief, mice (24) were split into three groups of eight mice and each group housed in two cages of 
four mice each. Randomisation was achieved at the level of mouse delivery from the supplier and 
information regarding the original litters the mice were in was not available to the researcher. One 
group of eight mice was used to assess naïve infection kinetics of M. haemomuris and a second 
group was used to assess naïve infection kinetics of E. coccoides. Both groups were later re-
inoculated with M. haemomuris-containing blood and an age-matched control group was inoculated 
at the same time with M. haemomuris-containing blood; this group was to control for age as well as 
any effects of blood sampling (including wound healing, associated stress) on immunity (see later). 
Phase 1 of the experiment (see Figure 13) represented primary infection with M. haemomuris of the 
re-inoculation group, and primary infection with E. coccoides of the cross-protection group. Phase 1 
also included the start of experiment for the age-matched control group. The period in-between 
Phase 1 and Phase 2 was named the ‘Recovery phase’ as it represented recovery from infection with 
M. haemomuris or E. coccoides of the groups that had been inoculated with these haemoplasmas in 
Phase 1. The age-matched control group underwent identical handling with blood sampling 
performed during the Recovery phase, but these blood samples did not undergo further testing 
except for samples taken immediately prior to Phase 2 inoculations. Phase 2 of the experiment 
comprised re-inoculation with M. haemomuris-containing blood of the mice previously inoculated 
with M. haemomuris or E. coccoides in Phase 1. It also included inoculation with M. haemomuris-
containing blood of the age-matched controls, representing primary infection with M. haemomuris 
of the age-matched control group.  
3.2.2.1.4.2 Inoculation procedure 
Inoculation procedures for all mice were identical to the procedure described in 2.2.3.4.  
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3.2.2.1.5 Generating inocula in amplifier mice 
The experiment was split into Phase 1 and Phase 2 and each phase had to be preceded by 
production of amplifier mice to generate the inocula for use in the three experimental groups in 
both phases 1 and 2 (Figure 13). The amplifier mice preceding Phase 1 of the experiment were 
produced by the inoculation of isolates that had undergone three previous serial passages in 
C57BL/6 mice since sourcing the original rodent haemoplasma isolates from field mice (Apodemus 
spp.) samples. The amplifier mice preceding Phase 2 of the experiment were produced by the 
inoculation of isolates that had undergone four serial passages in C57BL/6 mice since sourcing the 
original rodent haemoplasma isolates from field mice (2.2.1).  
3.2.2.1.5.1 Description of inocula used to inoculate the amplifier mice preceding Phase 1 
Two nine-week-old mice were inoculated with 0.1 ml cryopreserved blood containing M. 
haemomuris or E. coccoides. The origin and composition of the inocula used to inoculate these 
laboratory mice is given in Table 9. 
Mouse ID 
 
Organism Origin Cryopreservation Dilution ratio 
of inoculum in 
PBS 
Haemoplasma dose 







Blood from a 
C57BL/6 
mouse  






Blood from a 
C57BL/6 
mouse 
20% DMSO (v/v) 1:4 2.55E+06 
Table 9 Origin and composition of inocula used to inoculate the amplifier mice preceding Phase 1. These mice were 
subsequently used to generate further inocula for Phase 1 of the experiment as described in Figure 1. Inoculum 
haemoplasma doses were calculated as in 2.2.1.2.2.2. DMSO, dimethyl-sulfoxide. PBS, phosphate buffered saline. 
Inocula were allowed to defrost at room temperature for 10 minutes and were inoculated 
intraperitoneally as previously described (2.2.3.4.1). Following inoculation, amplifier mice were 
monitored daily for haemoplasma infection as described previously (2.2.3.6) and exsanguinated as 
described above (2.2.3.7) following confirmation of infection at four dpi (infection kinetics data not 
shown) to produce the inocula for Phase 1. The inocula for Phase 1 underwent cryopreservation as 
described before (2.2.3.7) and were stored at -80°C for 13 days prior to administration to the 
experimental groups. 
3.2.2.1.5.2 Description of inocula used to inoculate the amplifier mice preceding Phase 2 
Two 9-week-old mice were inoculated with 0.1ml cryopreserved blood containing M. haemomuris. 








dose in 0.1ml of 
inoculum per 
mouse 
Amplifier 3  




Blood from a 
C57BL/6 
mouse 
10% Glycerol (v/v) None  6.4E+05 
Table 10 Origin and composition of inocula used to inoculate the amplifier mice preceding Phase 2. These mice were 
subsequently used to generate further inocula for Phase 2 of the experiment as described in Figure 1. Haemoplasma doses 
were calculated as in 2.2.1.2.2.2. PBS, phosphate buffered saline. 
Following inoculation, amplifier mice were monitored for M. haemomuris infection as described 
previously (2.2.3.6) and exsanguinated as described above (2.2.3.7) on 45 dpi (infection kinetic data 
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not shown) to produce the inocula for Phase 2. The inocula for Phase 2 of the study were 
administered to the experimental groups without cryopreservation, within ten minutes of sample 
collection. 
3.2.2.1.6 Phase 1: Primary infection kinetics of M. haemomuris- and E. coccoides in naïve mice 
3.2.2.1.6.1 Re-inoculation group: Description of inoculum used for primary infection with M. 
haemomuris 
Eight eight-week-old mice were housed in two cages of four mice each; mice ‘1’ to ‘4’ in cage A and 
mice ‘5’ to ‘8’ in cage B. After an acclimatisation period of one week, each mouse was inoculated 
with 0.1ml of a M. haemomuris-containing inoculum that had been prepared by defrosting 0.1ml 
cryopreserved blood with 0.7ml of PBS at room temperature. The inoculum used for Phase 1 of the 
experiment had been generated in the amplifier mice preceding Phase 1 and the composition of the 
cryopreserved inoculum is given in Table 11. Mice were inoculated in sequential order of mouse ‘1’ 
to ‘8’ using the technique described in 2.2.3.4.1.  
Group 
inoculated 




































None n/a n/a n/a n/a n/a n/a 
Table 11 Origin and composition of inocula used to inoculate the mice in Phase 1 of the experiment. Amplifier mice (Table 
9) were killed at four days post inoculation. Inocula were cryopreserved and stored at -80 °C for 13 days until use. DMSO, 
dimethyl-sulfoxide. PBS, phosphate buffered saline. n/a, not applicable. 
3.2.2.1.6.2 Cross-protection group: Description of inoculum used for primary E. coccoides infection 
Eight eight-week-old mice were housed as described for the re-inoculation group (3.2.2.1.6.1). After 
acclimatisation, each mouse was inoculated with 0.1ml of an E. coccoides-containing inoculum that 
had been prepared by defrosting 0.1ml cryopreserved blood with 0.7ml of PBS at room temperature. 
The order and technique of inoculation was identical to the M. haemomuris-inoculated group 
described above (3.2.2.1.6.1). The inoculum used for Phase 1 of the experiment had been generated 
in the amplifier mice preceding Phase 1 and the composition of the cryopreserved inoculum is given 
in Table 11.  
3.2.2.1.6.3 Age-matched control group  
Eight eight-week-old mice were housed as described for the re-inoculation group (3.2.2.1.6.1). No 
mice in this group were subject to any haemoplasma inoculation in Phase 1 of the experiment. 
3.2.2.1.6.4 Monitoring of haemoplasma infection after Phase 1 inoculations 
Mice in the re-inoculation group and the cross-protection group were monitored for haemoplasma 
infection immediately following inoculation in Phase 1 by withdrawing 10µl of blood each day on 14 
consecutive days (up to 14 dpi); these blood samples underwent DNA extraction and subsequent 
generic haemoplasma qPCR as described in 2.2.3.6. The mice were also monitored for clinical signs 
of ill health at least once daily throughout the experiment.   
Mice in the age-matched control group also had 10µl of blood taken on the same days (up to 14 dpi) 
as the re-inoculation and cross-protection groups, but the blood samples were not further analysed.  
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This sampling was performed to control for the possible effects of blood sampling (including wound 
healing, associated stress) on immunity in Phase 2 of the experiment.   
3.2.2.1.7 Recovery phase in-between Phase 1 and Phase 2 
After 14 dpi (3.2.2.1.6.4), in the Recovery phase, the blood sampling frequency in all of the 
inoculated mice in the re-inoculation group and the cross-protection group was reduced from daily 
to every other day, and from 31 to 61 dpi further reduced to every three days. Thereafter blood 
sampling frequency dropped to once a week for 13 weeks. Blood samples were subject to a generic 
haemoplasma qPCR assay following DNA extraction as described before 2.2.3.6. The mice were also 
monitored for clinical signs of ill health at least once daily throughout the experiment.   
In the Recovery phase, the mice in the age-matched control group had 10µl of blood taken on the 
same days as the re-inoculation and cross-protection groups as described above, but the blood 
samples were not further analysed.  
3.2.2.1.8 Phase 2: M. haemomuris infection kinetics in mice previously infected with M. 
haemomuris (re-inoculation group) and E. coccoides (cross-protection group) and primary 
M. haemomuris infection of the age-matched control group 
3.2.2.1.8.1 Description of inocula used for the re-inoculation group, the cross-protection group and 
the age-matched control group 
One-hundred and fifty-three days after primary inoculation in Phase 1, all three groups (re-
inoculation group: recovered from M. haemomuris infection; cross-protection group: recovered 
from E. coccoides infection; age-matched control group: naive) were each inoculated with a M. 
haemomuris-containing inoculum. The inocula used for Phase 2 of the experiment had been 
generated in the amplifier mice preceding Phase 2 and the composition of the fresh, heparinised 
whole blood inocula is given in Table 12.  
Group 
inoculated 




































3.80E+02 None  1:1 1.90E+04 8 
Table 12 Origin and composition of inocula used to inoculate the mice in Phase 2 (re-inoculation with M. haemomuris of the 
mice previously inoculated with M. haemomuris or E. coccoides; primary M. haemomuris inoculation of the age-matched 
controls, see Figure 13) of the experiment. Amplifier mice (Table 10) were killed at 45 days post inoculation. Inocula were 
used fresh, without cryopreservation and at the minimal dilution to try and maximise successful inoculation of all 
experimental mice. PBS, phosphate buffered saline. 
Mice were inoculated in sequential order of mouse ‘1’ to ‘8’ in the re-inoculation group, followed by 
the same sequential order of the age-matched control group (using the same amplifier mouse to 
source inocula from; Amplifier 3, Table 12) and then mouse ‘1’ to ‘8’ in the cross-protection group 
(Amplifier 4, Table 12). The inocula (Table 12) were administered using the technique described in 
2.2.3.4.1 within ten minutes of exsanguination of the amplifier mice (Amplifiers 3 and 4, Table 12).  
3.2.2.1.8.2 Monitoring of haemoplasma infection after Phase 2 inoculations 
Mice in the re-inoculation group, the cross-protection group and the age-matched control group 
were monitored for M. haemomuris infection immediately following inoculation in Phase 2 by 
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withdrawing 10µl of blood each day on 14 consecutive days; these blood samples underwent DNA 
extraction and subsequent M. haemomuris-specific qPCR as described in 3.2.1.3.3.1. The DNA 
extracted from the blood samples taken from the mice in the cross-protection group additionally 
underwent E. coccoides-specific qPCR as described in 3.2.1.3.3.1. to monitor for any E. coccoides re-
emergence.  
3.2.2.2 Sample collection and processing of blood samples from laboratory mice  
3.2.2.2.1 Collection of inocula and post-mortem examination  
At the end of the whole experiment, 14 days after the Phase 2 inoculations, all mice were 
exsanguinated, and samples of the blood used to generate inocula for future use, using 
cryopreservation as described in 2.2.3.7. A subset of the blood samples underwent centrifugation at 
1000 x g for ten minutes at 4°C to derive plasma samples for storage for use in potential future 
serological studies; these samples were stored at -80°C. Post-mortem examinations were carried out 
on all mice and the spleens were weighed, with splenomegaly defined as a splenic weight of greater 
than 0.4% bodyweight (276) as no healthy control mice from the same population were available for 
comparison of splenic weight. 
3.2.2.2.2 Collection of blood samples for qPCR and development of the haemoplasma species-
specific qPCR assays 
Unless otherwise indicated, the method used for blood sampling for qPCR was identical to the 
procedure described in 2.2.3.3.2.1. Samples were stored at -20°C until DNA extraction and further 
use. 
3.2.2.2.3 DNA extraction for qPCR and development of the haemoplasma species-specific qPCR 
assays 
DNA was extracted manually using single-spin column silica membrane technology as previously 
described (2.2.1.2.1) up to and including 14 dpi of Phase 1. After 14 dpi (3.2.2.1.6) DNA extraction 
was streamlined to increase efficiency by replacing the single-spin columns with 8-well-strips 
(NucleoSpin® 8 Blood, Macherey-Nagel, UK). In brief, samples were defrosted, diluted with PBS to a 
final volume of 200µl and mixed with 25 µl of Proteinase K and 200µl of lysis buffer as described for 
the single-spin columns. This was followed by incubation for 30 minutes on a rocking platform. 
Ethanol was added to the mixture to a final volume of 410µl and the preparation loaded on the silica 
membrane strips, as for single-spin columns. The strips were mounted onto a 96-well rack/collection 
block, allowing for simultaneous processing of up to four 8-well-strips per block. After an initial spin 
at 1,600 x g for two minutes, the flow-through was discarded and washing steps were carried out as 
for the single-spin columns (2x 500µl of wash buffer 1, ‘BW’) but speed was adjusted to 3,000 x g for 
ten minutes. After the final wash (wash buffer 2, ‘B5’) and spinning at 3,000 x g for 10 minutes, 50µl 
of elution buffer (‘BE’) was added and incubated for ten minutes at room temperature. This was 
followed by spinning at 1,600 x g for two minutes into clean collection tubes. The flow-through was 
kept for subsequent qPCR and stored at -80°C until further use.  
3.2.2.3 Analysis of mouse blood samples for haemoplasma genome copies  
3.2.2.3.1 Conditions of the generic haemoplasma qPCR assay 
Samples from Phase 1 of the study (3.2.2.1.6) were analysed for haemoplasma genome copies per µl 
blood using the generic haemoplasma qPCR assay (HF-group) described previously (2.2.1.2.2). 
Negative (water) and positive controls of known M. haemofelis genome copy number and a 
separately run host control qPCR were used and were identical to the ones described for previous 
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studies (2.2.3.3.3). All qPCRs were performed on the same Mx3005P qPCR thermal cycling system 
(Agilent, UK). 
3.2.2.3.1.1 Analysis of qPCR data 
Analysis of data from the generic haemoplasma qPCR assay was carried out as described for 
2.2.1.2.2.2. Normalisation of Ct values and calculation of relative genome copies per µl blood was 
performed as described in 2.2.1.2.2.2.1 and 2.2.1.2.2.2.2. 
3.2.2.3.2 Conditions of the haemoplasma species-specific qPCR assays 
Samples from Phase 2 of the study (3.2.2.1.8) were analysed for haemoplasma genome copies per µl 
blood using the species-specific M. haemomuris and E. coccoides duplex qPCR assays described in 
3.2.1.3.3.1. Thermal cycling conditions were identical to 3.2.1.3.2.2. Positive control samples of 
known M. haemomuris and E. coccoides genome copy number and negative control samples (water) 
were included on each plate. All qPCRs were performed on the same Mx3005P qPCR thermal cycling 
system (Agilent, UK). 
3.2.2.3.2.1 Analysis of qPCR data 
Analysis of data from the haemoplasma species-specific qPCR assays was carried out as described for 
3.2.1.1.4. Normalisation of Ct values and calculation of relative genome copies per µl blood was 
performed as described in 2.2.1.2.2.2.1 and 2.2.1.2.2.2.2, using assay efficiencies of 0.980 for the M. 
haemomuris-specific qPCR assay and 0.998 for the E. coccoides-specific assay.   
3.2.2.4 Statistical analyses 
3.2.2.4.1 Power calculations 
No pilot data or previous research on protective immunity following M. haemomuris and E. 
coccoides infection were available to guide power calculations. Based on available data on feline 
haemoplasma infection with M. haemofelis (107, 295) or ‘Ca. M. turicensis’ (124), the required 
group sizes to detect significant differences in M. haemomuris infection kinetics were estimated 
using G*Power v3.1.9.2 (304). In brief, an a priori analysis was run on the difference between two 
independent means with two equal group sizes. Significance was defined as p<0.05 and statistical 
power set to 0.8. Based on full protection for feline M. haemofelis infection, effect size was 
estimated at 2.0 (meaning the difference between the group means had to be greater than two 
common standard deviations) using published M. haemofelis data at peak parasitaemia and the 
effect size calculator tool cNORM (305) and using the effect size classification by Cohen (306) and 
Hattie and Timperley (307). Required group sizes were calculated as six individuals per group and 
arbitrarily increased by two mice per group to account for unknown infection kinetics and a larger 
standard deviation due to smaller blood sampling volumes collected from mice compared to cats.  
3.2.2.4.2 Calculation of doubling time 




log(end haemoplasma genome copies/µl)/log(initial haemoplasma genome copies/µl)
 
where Dt = doubling time and log = logarithm to the base of 2 
3.2.2.4.3 Statistical assessment of protective immunity 
Area-under-the-curve (AUC) values were calculated for individual mice. Extraction failures or missed 
days (due to clinical concerns, n=1) were replaced by averages of preceding/following day for the 
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individual mouse. Due to the very small sample size (n=4 to n=8), and associated predicted lack of 
normal distribution, the data were treated as non-parametric in nature. The statistical software 
package SPSS v. 24 (IBM Corp. Released 2013. IBM SPSS Statistics for Windows, Version 24.0. 
Armonk, NY: IBM Corp.) was used to calculate Mann-Whitney-U statistics to compare groups. 





3.3.1 Haemoplasma species-specific duplex qPCR assays for two novel rodent haemoplasma 
isolates of M. haemomuris and E. coccoides  
3.3.1.1 Primers and probe for the M. haemomuris singleplex qPCR assay 
Six primer pairs and respective TaqMan probes designed to binding sites on the M. haemomuris 16S 
rRNA gene were selected for maximal sequence divergence to the E. coccoides 16S rRNA gene, and 
are shown in Table 13.  
Assay 
name 
Forward Primer 5’-3’ Probe 5’-3’ Reverse Primer 3’-5’ 
Mhm-1 GCGAAAGCCTGATGGAGTG AAAGCGAGCGCAGGCGGATT CGTTGAGCGGCTGCATT 
Mhm-2 GCGCAAGCCACTTGGAG CCACAATGGGCGAAAGCCTGA TACCATCATCATTTTCCCCAAT 
Mhm-3 AGCCACTTGGAGATTGGAGTATT CCACAATGGGCGAAAGCCTGA TACCATCATCATTTTCCCCAAT 
Mhm-4 GCGAAAGCCTGATGGAGT TGCCATGTGAACGATGAAGGTCTT TACCATCATCATTTTCCCCAAT 
Mhm-5 AGCCACTTGGAGATTGGAGTATT AAAGCGAGCGCAGGCGGATT CGTTGAGCGGCTGCATT 
Mhm-6 TGTATGCGCAGAATACTGTTTTTC AACACCAGAGGCGAAGGCGAAA GAGACTCAAGTCCCAACATCTAATATC 
Table 13 Primer and probe (oligonucleotide) sequences designed for species-specific quantitative detection of the M. 
haemomuris 16S rRNA gene.  
3.3.1.2 Results for initial M. haemomuris singleplex qPCR assays and cross-reactivity using SYBR 
Green 1 
The six primer pairs selected for M. haemomuris-specific qPCR detection (3.3.1.1) were subsequently 
assessed for reaction specificity at the primer level in a singleplex SYBR Green 1 qPCR. All samples, 
known to contain M. haemomuris DNA (3.2.1.1.3.1) gave positive results (Table 14).  
Assay 
name 
Ct results for M. 
haemomuris positive 
sample 
Ct results for mouse 
DNA positive sample 
Ct result for negative (water) samples 
Mhm-1 25.58 25.78 33.08 35.10 34.60 
Mhm-2 27.12 26.66 No Ct No Ct No Ct 
Mhm-3 25.56 25.84 33.06 33.11 34.61 
Mhm-4 26.28 25.79 33.28 No Ct No Ct 
Mhm-5 28.32 28.50 28.42 28.86 28.59 
Mhm-6 25.92 26.52 No Ct No Ct No Ct 
Table 14 Threshold cycle results (Ct) for the initial M. haemomuris singleplex qPCR assays using SYBR Green 1 as a reporter. 
All M. haemomuris-positive samples contained the same amount of M. haemomuris target DNA (same dilution of PCR 
amplicon).  
The peak dissociation temperatures of the products produced by primer pairs of assays Mhm-1, 
Mhm-2, Mhm-3 and Mhm-6 were approximately 86°C, suggesting similar PCR products. Primer pairs 
from assays Mhm-4 and Mhm-5 produced different peak dissociation temperatures of 
approximately 77°C and 80°C respectively, suggesting different products, possibly as a result of low 
specificity (Mhm-4, as this product also appeared with these primers when mouse DNA was used as 
template) or primer-dimer formation (Mhm-5, as the dissociation temperature was lower and was 
possibly at the primer-dimer dissociation temperature). The assays Mhm-2 and Mhm-6 resulted in 
no detected Ct value with E. coccoides genomic DNA as template (3.2.1.1.3.2), indicating a lack of 
cross-reactivity. Primer pairs from assays Mhm-2 and Mhm-6 were chosen for further evaluation in 
view of their apparent specificity to the target haemoplasma species. 
3.3.1.3 Reaction efficiencies of the M. haemomuris singleplex qPCR assay using SYBR Green 1  
Ten-fold dilutions of M. haemomuris target DNA (the 16S rRNA gene amplicons generated in 
3.2.1.1.1) were used to generate a standard curve for assays Mhm-2 and Mhm-6 using SYBR Green 1 
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as a reporter fluorophore. For assay Mhm-2, 1.0E+04-fold dilutions produced a correlation 
coefficient of 0.999, the slope of the standard curve was -3.523 and qPCR efficiency 92.2% (Figure 
14). For assay Mhm-6, 1.0E+04-fold dilutions produced a correlation coefficient of 0.997, the slope 




Figure 14  Amplification plot (Panel A) and standard curve (Panel B) for M. haemomuris singleplex qPCR assay Mhm-2 using 
SYBR Green 1.  
Panel A: Cycle numbers are plotted on the x-axis and relative fluorescence units are plotted on the y-axis with threshold 
fluorescence indicated by the green horizontal line and 40 cycle cut-off by the blue vertical line. Panel B: Standard curve as 
generated from duplicate dilutions over 10E+04-fold. Dilution from the starting quantity is plotted on the x-axis and 




Figure 15 Amplification plot (Panel A) and standard curve (Panel B) for M. haemomuris singleplex qPCR assay Mhm-6 using 
SYBR Green 1.  
Panel A: Cycle numbers are plotted on the x-axis and relative fluorescence units are plotted on the y-axis with threshold 
fluorescence indicated by the green horizontal line and 40 cycle cut-off by the blue vertical line. Panel B: Standard curve as 
generated from duplicate dilutions over 10E+04-fold. Dilution from the starting quantity is plotted on the x-axis and 
threshold cycles (Ct) are plotted on the y-axis.  
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Assay Mhm-6 was subsequently selected to be converted into a M. haemomuris-specific qPCR assay 
using a TaqMan probe, and duplexing with a mouse GAPDH internal control qPCR assay to confirm 
successful DNA extraction and lack of PCR inhibitors in the sample.  
3.3.1.4 Development of a M. haemomuris/mouse GAPDH duplex qPCR assay 
3.3.1.4.1 Performance and optimisation of the M. haemomuris TaqMan qPCR singleplex assay in 
mouse DNA background 
Under initial singleplex conditions, using a TEX-labelled TaqMan probe (3.2.1.3.2.1), the M. 
haemomuris assay Mhm-6 produced consistent Ct values when used with three different 
concentrations of M. haemomuris template DNA (16S rRNA gene amplicon dilutions) in a mouse 
DNA background (Table 15). 
M. haemomuris DNA 
template concentration  
Ct of singleplex assay, using a TEX-labelled 
TaqMan probe 
‘high’ 20.78     20.79     20.76 
‘medium’ 24.34     24.23     24.25 
‘low’ 28.18     28.01     28.26 
Table 15 Threshold cycle (Ct) results of the M. haemomuris singleplex qPCR assay Mhm-6 using a TEX-labelled TaqMan 
probe as a reporter. Mycoplasma haemomuris target DNA (M. haemomuris 16S rRNA gene amplicons) was evaluated at 
three different concentrations of M. haemomuris template DNA in a mouse DNA background.  
It was determined that the probe concentration could be lowered to 100nM per reaction without 
sacrificing adversely qPCR performance, using a threshold of 300 relative fluorescence units (Table 
16).  
Probe concentration (nM) Ct of singleplex assay, using a TEX-labelled 
TaqMan probe 
200 18.42     18.65     18.64 
100 19.27     19.08     19.04 
50 19.99     19.86     19.89 
Table 16 Threshold cycle (Ct) results of the M. haemomuris singleplex qPCR assay Mhm-6 using a TEX-labelled TaqMan 
probe as a reporter. The probe was used at three different concentrations. Mycoplasma haemomuris target DNA (M. 
haemomuris 16S rRNA gene) was used at the same concentration in a mouse DNA background. 
3.3.1.4.2 Optimising the M. haemomuris TaqMan duplex qPCR assay in mouse DNA background 
Under initial duplex conditions (3.2.1.3.2.2), addition of the GAPDH qPCR assay resulted in different 
Ct values for the Mhm-6 assay compared to singleplex Ct values at all three M. haemomuris 





Ct of singleplex assay 
(range, see Table 15) 
Ct of M. haemomuris/GAPDH 
duplex assay: GAPDH1 
concentration* 
Ct of M. haemomuris/GAPDH 
duplex assay: GAPDH2 
concentration* 
Ct of M. haemomuris/GAPDH 
duplex assay: GAPDH3 
concentration* 
‘high’ 20.76 - 20.79 21.77     21.63     21.63 20.99     20.65     20.67 21.06     21.00     20.79 
‘medium’ 24.23 - 24.34 25.85     25.64     25.66 24.45     24.45     24.47 24.19     24.14     24.51 
‘low’ 28.01 - 28.26 31.95     31.92     32.19 29.68     29.87     29.81 28.57     28.38     28.17 
Table 17 Threshold cycle (Ct) results of the M. haemomuris-specific duplex qPCR assay Mhm-6 using a TEX-labelled TaqMan 
probe as a reporter. Mycoplasma haemomuris template DNA (M. haemomuris 16S rRNA gene amplicons) was evaluated at 
three different concentrations in a mouse DNA background.  
*GAPDH1, primers and probe for GAPDH assay added at a final concentration of 100nM/50nM respectively; GAPDH2, 
primers and probe for GAPDH assay added at a final concentration of 50nM/25nM respectively; GAPDH3, primers and 
probe for GAPDH assay added at a final concentration of 12.5nM/12.5nM respectively; GAPDH, glyceraldehyde-3-
phosphate-dehydrogenase.  
Of the different combinations of GAPDH primer and probe concentrations, 12.5nM of each primer 
and 12.5nM of probe was found not to compete with the M. haemomuris qPCR assay at all three M. 
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haemomuris template DNA concentrations. Mouse DNA remained detectable with a Ct range of 
18.67 to 19.91 on the mouse GAPDH qPCR assay.  
3.3.1.4.3 Reaction efficiency of the final M. haemomuris duplex qPCR assay 
Ten-fold dilutions of M. haemomuris template DNA (16S rRNA gene amplicons, 3.2.1.1.1) in mouse 
genomic DNA background were used to generate a standard curve for assay Mhm-6 using a TEX-
labelled TaqMan probe as a reporter for the M. haemomuris 16S rRNA gene and a FAM-labelled 
TaqMan probe as a reporter for the mouse internal control GAPDH gene assay.  Final primers and 
probes and their respective concentrations following optimisation are shown in Table 18.  










200nM 100nM 200nM 







concentration (in 25 
µl) 
12.5nM 12.5nM 12.5nM 
Table 18 Primers and probes (oligonucleotide) sequences used for quantitative detection of the M. haemomuris 16S rRNA 
gene and of host genomic DNA for the GAPDH gene. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; FAM, 6-
carboxyfluorescein; TEX, Texas Red; BHQ1, Black Hole Quencher 1; BHQ2, Black Hole Quencher 2. Nucleotide-sequence 
mismatches to E. coccoides are shown in bold and shaded text.  
Over 1.0E+06-fold dilutions the correlation coefficient was 0.999, the slope of the standard curve 




Figure 16 Amplification plot (Panel A) and standard curve (Panel B) for the M. haemomuris singleplex qPCR assay Mhm-6 
using a TEX-labelled TaqMan probe.  
Panel A: Cycle numbers are plotted on the x-axis and relative fluorescence units are plotted on the y-axis with threshold 
fluorescence indicated by the red horizontal line and 40 cycle cut-off by the blue vertical line. Panel B: Standard curve as 
generated from duplicate dilutions over 1.0E+06-fold. Dilution from starting quantity is plotted on the x-axis and threshold 
cycles (Ct) are plotted on the y-axis.  
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3.3.1.5 Primers and probe for the E. coccoides singleplex qPCR assay 
Four primer pairs and respective TaqMan probes designed to binding sites on the E. coccoides 16S 
rRNA gene were selected for sequence divergence to the M. haemomuris 16S rRNA gene are shown 
in Table 19.  
Assay name Forward Primer 5’-3’ Probe 5’-3’ Reverse Primer 3’-5’ 
Ecoc-7 GACGAAAGTCTGATGGAGCAA AAAGCAAGCGCAGGCGGATG ACTTCCTACCACATTCTAGACGAATA 
Ecoc-8 ACAGTTGTTTGCACCGAATACTA AACACCAGAGGCGAAGGCGAAA* ACAGCACCGAAGCTCTAACC 
Ecoc-9 AATACTATTCGTCTAGAATGTGGTAGG GAACACCAGAGGCGAAGGCGA ACAGCACCGAAGCTCTAACC 
Ecoc-10 TGTGGTAGGAAGTTTTGGAATTAAATA AACACCAGAGGCGAAGGCGAAA* ACAGCACCGAAGCTCTAACC 
Table 19 Primer and probe (oligonucleotide) sequences designed for species-specific quantitative detection of the E. 
coccoides 16S rRNA gene. Asterisks (*) indicate an identical probe to assay Mhm-6 (Table 13). 
3.3.1.6 Results for initial E. coccoides singleplex qPCR assays and cross-reactivity using SYBR 
Geen 1 
The six primer pairs selected for E. coccoides-specific qPCR detection (3.3.1.5) were subsequently 
assessed for reaction specificity at the primer level in a singleplex SYBR Green 1 qPCR. All samples 
known to contain E. coccoides DNA (3.2.1.2.3.1) gave positive results (Table 20).  
Assay 
name 
Ct results for E. coccoides DNA positive 
sample 
Ct results for mouse DNA positive 
sample 
Ct result for negative (water) samples 
Ecoc-7 25.94 25.63 No Ct No Ct No Ct 
Ecoc-8 24.74 25.23 No Ct No Ct No Ct 
Ecoc-9 24.42 24.81 32.4 32.4 39.56 
Ecoc-10 25.52 25.41 No Ct No Ct No Ct 
Table 20 Threshold cycle results (Ct) for the initial E. coccoides singleplex qPCR assays using SYBR Green 1 as a reporter. All 
E. coccoides-positive samples were known to contain the same amount of E. coccoides target DNA.  
The peak dissociation temperatures of the products produced by the different primer pairs of the 
Ecoc-7, Ecoc-8 and Ecoc-10 assays were approximately 85°C, suggesting that similar PCR products 
had been amplified. Primer pairs from assay Ecoc-9 produced a different product (peak dissociation 
temperature approximately 82°C) with mouse DNA and no template (water), suggesting primer-
dimer formation. Assay Ecoc-9 was hence excluded from further evaluation. Amplification with the 
primer pairs from assays Ecoc-7, Ecoc-8 and Ecoc-10 with M. haemomuris genomic DNA (3.2.1.2.3.2) 
showed no cross-reactivity. Two primer pairs from assays Ecoc-8 and Ecoc-10 were chosen for 
further evaluation to develop an E. coccoides-specific qPCR assay (Table 20). 
3.3.1.7 Reaction efficiencies of the E. coccoides singleplex assay using SYBR green 
Ten-fold dilutions of E. coccoides template DNA (16S rRNA gene amplicons, 3.2.1.2.1) were used to 
generate a standard curve for assays Ecoc-8 and Ecoc-10 using SYBR Green 1 as a reporter 
fluorophore. For assay Ecoc-8, 1.0E+04-fold dilutions produced a correlation coefficient of 0.999, the 
slope of the standard curve was -3.608 and qPCR efficiency 89.3% (Figure 17). For assay Ecoc-10, 
1.0E+04-fold dilutions produced a correlation coefficient of 1.000, the slope of the standard curve 




Figure 17 Amplification plot (Panel A) and standard curve (Panel B) for the Ecoc-8 singleplex qPCR assay using SYBR Green 
1.  
Panel A: Cycle numbers are plotted on the x-axis and relative fluorescence units are plotted on the y-axis with threshold 
fluorescence indicated by the green horizontal line and 40 cycle cut-off by the blue vertical line. Panel B: Standard curve as 
generated from duplicate dilutions over 10E+04-fold. Dilution from starting quantity is plotted on the x-axis and threshold 





Figure 18 Amplification plot (Panel A) and standard curve (Panel B) for the Ecoc-10 singleplex qPCR assay using SYBR Green 
1.  
Panel A: Cycle numbers are plotted on the x-axis and relative fluorescence units are plotted on the y-axis with threshold 
fluorescence indicated by the green horizontal line and 40 cycle cut-off by the blue vertical line. Panel B: Standard curve as 
generated from duplicate dilutions over 10E+04-fold. Dilution from the starting quantity is plotted on the x-axis and 
threshold cycles (Ct) are plotted on the y-axis.  
Assay Ecoc-8 was subsequently selected to be converted into a E. coccoides-specific qPCR assay 
using a TaqMan probe, and duplexing with a mouse internal control GAPDH internal control qPCR 
assay to confirm successful DNA extraction and lack of PCR inhibitors in the sample. 
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3.3.1.8 Development of a. E. coccoides/mouse GAPDH duplex qPCR assay 
3.3.1.8.1 Performance and optimisation of the E. coccoides TaqMan singleplex qPCR assay in 
mouse DNA background 
Under initial singleplex conditions, using a TEX-labelled TaqMan probe (3.2.1.3.2.1) the E. coccoides-
specific qPCR assay Ecoc-8 produced consistent Ct values when used on different E. coccoides target 
amplicon dilutions in a mouse DNA background (Table 21). 
E. coccoides DNA template 
concentration 
Ct of singleplex assay, using a TEX-labelled 
TaqMan probe 
‘high’ 20.39     20.55     20.64 
‘medium’ 24.07     23.96     24.23 
‘low’ 27.38     28.13     27.84 
Table 21 Threshold cycle (Ct) results of the E. coccoides-specific singleplex qPCR assay Ecoc-8 using a TEX-labelled TaqMan 
probe to evaluate three different concentrations of E. coccoides template DNA amplicons in a mouse DNA background.  
It was determined that the probe concentration could be lowered to 100nM per reaction without 
sacrificing qPCR performance using a threshold of 300 relative fluorescence units (Table 22).  
Probe concentration (nM) Ct of singleplex assay, using a TEX-labelled 
TaqMan probe 
200 18.16     18.07     18.09 
100 18.89     18.67      18.69 
50 19.49     19.69      19.33 
Table 22 Threshold cycle (Ct) results of the E. coccoides-specific singleplex qPCR assay Ecoc-8 using a TEX-labelled TaqMan 
probe as a reporter. The probe was used at three different concentrations. Eperythrozoon coccoides target DNA (E. 
coccoides 16S rRNA gene) was used at the same concentrations in a mouse DNA background. 
3.3.1.8.2 Optimising the E. coccoides duplex assay in mouse DNA background 
Under initial duplex conditions (3.2.1.3.2.2), addition of the GAPDH qPCR assay resulted in different 
Ct values for the Ecoc-8 assay compared to singleplex Ct values at medium and low E. coccoides 





Ct of singleplex assay 
(range, see Table 21) 
Ct of M. 
haemomuris/GAPDH 
duplex assay: GAPDH1 
concentration* 
Ct of M. 
haemomuris/GAPDH 
duplex assay: GAPDH2 
concentration* 
Ct of M. 
haemomuris/GAPDH 
duplex assay: GAPDH3 
concentration* 
‘high’ 20.39 - 20.64 20.68     20.83     20.71 20.63     20.72     20.80 20.64     20.35     20.50 
‘medium’ 23.96 - 24.23 24.50     24.77     24.94 24.39     24.17     24.17 23.98     24.05     23.79 
‘low’ 27.38 - 27.84 No Ct     No Ct     No Ct 28.61     28.43     28.23 27.67     27.66     27.24 
Table 23 Threshold cycle (Ct) results of the E. coccoides-specific duplex qPCR assay Ecoc-8 using a TEX-labelled TaqMan 
probe as a reporter. Eperythrozoon coccoides template DNA (E. coccoides 16S rRNA gene amplicons) was evaluated at three 
different concentrations in a mouse DNA background.  
GAPDH1, primers and probe for GAPDH assay added at a final concentration of 100nM/50nM respectively; GAPDH2, 
primers and probe for GAPDH assay added at a final concentration of 50nM/25nM respectively; GAPDH3, primers and 
probe for GAPDH assay added at a final concentration of 12.5nM/12.5nM respectively; GAPDH, glyceraldehyde-3-
phosphate-dehydrogenase. 
Of the different combinations of GAPDH primer and probe concentrations, 12.5nM of each primer 
and 12.5nM of probe was found not to compete with the E. coccoides-specific qPCR assay at all three 
M. haemomuris template concentrations. Mouse DNA remained detectable with a Ct range of range 
17.86 to 18.97 on the mouse GAPDH qPCR assay.  
3.3.1.8.3 Reaction efficiency of the final E. coccoides duplex qPCR assay 
Ten-fold dilutions of E. coccoides template DNA (16S rRNA gene amplicons, 3.2.1.2.1) in mouse 
genomic DNA background were used to generate a standard curve for qPCR assay Ecoc-8 using a 
TEX-labelled TaqMan probe as a reporter for the E. coccoides 16S rRNA gene and a FAM-labelled 
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TaqMan probe as a reporter for the mouse internal control GAPDH gene assay.  Final primers and 
probes and their respective concentrations following optimisation are shown in Table 24. The probe 
used for the Ecoc-8 assay was identical to the probe used for the Mhm-6 assay (Table 18).  







concentration (in 25 
µl) 
200nM 100nM 200nM 
Host internal control 
(feline/mouse GAPDH) 
GCTGCCCAGAACATCATCC FAM-TCACTGGCATGGCCTTCCGT-BHQ1 CACAGGCAGCACCTAGACTG 
Final oligonucleotide 
concentration (in 25 
µl) 
12.5nM 12.5nM 12.5nM 
Table 24 Primers and probes (oligonucleotide) sequences used for quantitative detection of the M. haemomuris 16S rRNA 
gene and of host genomic DNA for the GAPDH gene. GAPDH, glyceraldehyde-3-phosphate dehydrogenase; FAM, 6-
carboxyfluorescein; TEX, Texas Red; BHQ, Black Hole Quencher; BHQ2, Black Hole Quencher 2. Nucleotide-sequence 
mismatches to the non-target species (E. coccoides) are shown in bold and shaded text.  
For assay Ecoc-8, over 1.0E+06-fold dilutions of E. coccoides template DNA produced a correlation 





Figure 19 Amplification plot (Panel A) and standard curve (Panel B) for the Ecoc-8 singleplex qPCR assay using a TEX-
labelled TaqMan probe.  
Panel A: Cycle numbers are plotted on the x-axis and relative fluorescence units are plotted on the y-axis with threshold 
fluorescence indicated by the red horizontal line and 40 cycle cut-off by the blue vertical line. Panel B: Standard curve as 
generated from duplicate dilutions over 10E+06-fold. Dilution from the starting quantity is plotted on the x-axis and 
threshold cycles (Ct) are plotted on the y-axis.  
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3.3.1.9 Cross-reactivity of the final M. haemomuris and E. coccoides duplex qPCR assays 
No cross-reactivity was detected when challenging the final M. haemomuris and E. coccoides-specific 
duplex qPCR assays (Mhm-6 and Ecoc-8) with over 1.0E+05 16S rRNA gene copies (3.2.1.3.3.2) of the 
respective non-target haemoplasma species (M. haemomuris for the E. coccoides assay Ecoc-8, and 
E. coccoides for the M. haemomuris assay Mhm-6). Positive controls, using 16S rRNA gene amplicon 
templates, for their respective species-specific duplex qPCR assay resulted in Ct values of 19.06 for 
M. haemomuris and 19.91 for E. coccoides.  
3.3.1.10 Limit of detection of the final M. haemomuris and E. coccoides duplex qPCR assays 
Using a series of ten-fold M. haemomuris and E. coccoides target DNA dilutions (16S rRNA gene 
amplicons) in elution buffer (3.2.1.3.3.3), the LoD of the final M. haemomuris and E. coccoides-
specific duplex qPCR assays was determined to be equivalent to one to ten copies per qPCR based 
on one positive Ct result being obtained out of three replicates (Table 25). All three replicates were 
positive at the one hundred times more concentrated sample, representing the equivalent of 79 M. 
haemomuris 16S rRNA gene copies for the M. haemomuris-specific assay and 72 E. coccoides 16S 
rRNA gene copies for the E. coccoides-specific assay.  
Assay Molecular weight 




to dilution (g/ml) 
Calculated amplicon 
copies per reaction 
prior to dilution  
Last detectable 
dilution of 
amplicon (>1 in 3 
replicates) 
Equivalent calculated limit 
of detection (amplicon 










5.50E-06 1.15E+11 1.6E+10 7.16 
Table 25 Determination of limit of detection (LoD) for the novel M. haemomuris and E. coccoides-specific qPCR assays. 
Amplicons of the target-species 16S rRNA gene were diluted 1:160,000 followed by a ten-fold dilution series and LoD 
defined as the last dilution that gave a positive qPCR result in at least one of three replicates.  
These haemoplasma species-specific duplex qPCR assays were subsequently used to monitor 
infection kinetics in laboratory mice infected with E. coccoides or M. haemomuris. 
3.3.2 Infection kinetics and protective immunity of murine haemoplasmas  
3.3.2.1 Clinical signs and post-mortem examinations 
No clinical signs of ill health were noted in the mice other than two showing mild lethargy for about 
30 minutes following blood sampling on 9 and 10 dpi after Phase 2 inoculations in the age-matched 
control group (3.2.2.1.8).  The lethargy was attributed to excessive blood loss during the sampling 
process, rather than parasitaemia, as blood sampling technique did lead to, comparable to other 
mice, deep incisions over the tail vein in the two affected individuals.  
Splenomegaly, defined as splenic weight over 0.4% bodyweight, was documented in all 20 mice at 
post-mortem examination i.e. in the re-inoculation group, the cross-protection group and aged-
matched control group, all killed on 14 dpi after Phase 2 inoculation of M. haemomuris-containing 







Group Number of mice 
examined 
Splenic weight range 
(% bodyweight) 
Splenic weight median 
(% bodyweight) 
Re-inoculation group 4 0.48 - 0.56  0.51  
Cross-protection group 8 0.66 - 0.89  0.73  
Age-matched control group 8 0.67 - 0.92  0.77  
Table 26 Splenic weights (as % bodyweight) in the mice killed 14 days post inoculation with M. haemomuris. Re-inoculation 
group: Previously infected and recovered from M. haemomuris-infection. Cross-protection group: Previously infected and 
recovered from E. coccoides infection. Age-matched control group: No previous infection but underwent the same blood 
sampling regimen as the other experimental groups to account for ongoing blood loss.  
Splenic weight was significantly increased in the cross-protection group (pMWU=0.06) and age-
matched control group (pMWU=0.07) (both of these groups had been naïve to M. haemomuris 
infection in Phase 2) compared to the re-inoculation group.  
3.3.2.2 Infection kinetics of primary M. haemomuris infection (Phase 1: re-inoculation group) 
None of the eight mice in the re-inoculation group had haemoplasma DNA detected by the generic 
haemoplasma assay on week before entering the experiment. 
Only four (all within the same cage) of the eight mice in the re-inoculation group became 
successfully infected with M. haemomuris in Phase 1 of the experiment, following inoculation in 
Phase 1 with cryopreserved M. haemomuris-containing blood (3.2.2.1.5.1), as shown by positive 
generic haemoplasma qPCR assay (3.2.2.3.1) results. The normalised relative M. haemomuris 
genome copies per µl blood in these four mice in the re-inoculation group are shown in Figure 20. 
An initial lag-phase was observed, followed by a growth phase with a doubling time (dt) of 8.2 hours 
(calculated from the median M. haemomuris genome copies per µl blood per day between 3 and 10 
dpi), a median peak of 1.95E+07 M. haemomuris copies per µl blood at 11 dpi, followed by a decline 
and plateau phase (Figure 20, lower panel). After around two months (60 dpi onwards, see Figure 
20, lower panel) the M. haemomuris genome copies per µl blood started to fluctuate, and this was 
interpreted as approaching the limits of the PCR detection, but M. haemomuris never became 









Figure 20 M. haemomuris genome copies in four of the eight mice in the re-inoculation group (Phase 1: upper panel, 
Recovery phase: lower panel) showing the infection kinetics of the four naïve mice successfully infected following 
inoculation with cryopreserved blood containing 2.52E+06 M. haemomuris copies per inoculum dose. Days post inoculation 
(dpi) are plotted on the x-axis and normalised relative M. haemomuris genome copies per µl of blood are plotted on the y-
axis. Lines represent individual mice (mice differentiated by colouring of the lines); blood sampling occurred once daily in 
Phase 1 (upper panel) and at longer intervals in the Recovery phase (lower panel). As zero values cannot be plotted on 
logarithmic scales, a value of one (1.00E+00) haemoplasma copy per µl blood (and qPCR reaction) is taken as being the 
equivalent of zero in this and subsequent graphs within this chapter.  
The remaining four mice in the re-inoculation group were monitored for 41 dpi but gave negative 
generic haemoplasma qPCR assay results at each sampling point, documenting failure of infection 
with M. haemomuris, and were omitted from the remainder of the experiment. However, they were 
re-inoculated with fresh mouse blood, containing a similar dose of M. haemomuris copies as part of 
a different experiment and showed similar infection kinetics curves as observed in the successfully 
infected mice of the re-inoculation group (data not shown), suggesting inoculum failure rather than 
immunological protection during the failed Phase 1 inoculation.  
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3.3.2.3 Infection kinetics of primary M. haemomuris infection (Phase 2: age-matched control 
group) 
None of the eight mice in the age-matched control group had haemoplasma DNA detected by the 
generic haemoplasma assay one week before entering the experiment and from blood samples 
taken immediately prior to Phase 2 inoculations (to ensure the separately housed mice had 
maintained haemoplasma-negative status). 
The eight mice in the age-matched control group became successfully infected with M. haemomuris 
in Phase 2 of the experiment, following inoculation in Phase 2 with freshly collected M. haemomuris-
containing blood (3.2.2.1.5.2), as shown by positive M. haemomuris-specific qPCR assay (3.2.2.3.2) 
results.  The normalised relative M. haemomuris genome copies per µl blood in the age-matched 
control group are shown in Figure 21. Compared to the primary M. haemomuris infection in the re-
inoculation group (3.3.2.2), the infection kinetics in the age-matched control group showed similar 
median peak values of 2.85E+07 M. haemomuris genome copies per µl blood at 10 dpi but 
demonstrated an early and prolonged growth phase with a dt of 16.6 hours calculated from the 
median M. haemomuris genome copies per µl blood per day between 3 and 10 dpi, but a dt of only 
7.7 hours between 0 and 7 dpi, and no detectable lag-phase.  
 
 
Figure 21 M. haemomuris genome copies in the eight mice in the aged-matched control group (Phase 2), showing the 
infection kinetics of eight naïve mice successfully infected following inoculation with freshly obtained blood containing 
1.90E+04 M. haemomuris copies per inoculum dose. Days post inoculation (dpi) are plotted on the x-axis and normalised 
relative M. haemomuris genome copies per µl blood are plotted on the y-axis. Lines represent individual mice (mice 
differentiated by colouring of the lines); blood sampling occurred once daily in Phase 2. 
The different infection kinetics of the primary M. haemomuris infection in the age-matched group in 
Phase 2 to the re-inoculation group in Phase 1 were assessed by modified comparative statistical 
analysis. To eliminate the effect of an absent lag-phase and synchronise infection kinetics curves 
based on the onset of bacteraemia, Mann-Whitney U statistics were performed on AUC values from 
0 to 14 dpi for the age-matched group in Phase 2 (that received fresh inocula, see Figure 21) and 
from 3 to 17 dpi for the re-inoculation group in Phase 1 (that received cryopreserved inocula, see 
Figure 20, upper panel). There was no significant difference in M. haemomuris genome copy AUC 
values over these two 14-day periods (pMWU=0.089). 
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3.3.2.4 Infection kinetics of primary E. coccoides infection (Phase 1: cross-protection group) 
None of the eight mice had haemoplasma DNA detected by the generic haemoplasma assay one 
week before entering the experiment. All eight mice successfully became infected with E. coccoides 
in Phase 1 of the experiment, following inoculation in Phase 1 with cryopreserved E. coccoides-
containing blood, as shown by positive generic haemoplasma qPCR assay (3.2.2.3.1) results. The 
normalised relative E. coccoides genome copies per µl blood in the eight mice in the cross-protection 
group are shown in Figure 22. There was a brief growth phase, a peak and then subsequent decline 
in E. coccoides genome copies per µl blood, and negative generic haemoplasma qPCR results started 
to occur as early as 10 dpi; thereafter the E. coccoides genome copies per µl blood continued to be 
low or were undetectable until cross-challenge with M. haemomuris occurred at 153 dpi (see later, 
not shown in Figure 22).  
 
 
Figure 22 E. coccoides genome copies in the eight mice in the cross-protection group (Phase 1: upper panel, Recovery phase: 
lower panel) showing the infection kinetics of the eight naïve mice successfully infected following inoculation with 
cryopreserved blood containing 4.25E+06 E. coccoides copies per inoculum dose. Days post inoculation (dpi) are plotted on 
the x-axis and normalised relative E. coccoides genome copies per µl blood are plotted on the y-axis. Lines represent 
individual mice (mice differentiated by colouring of the lines); blood sampling occurred once daily in Phase 1 (upper panel) 
and at longer intervals in the Recovery phase (lower panel) 
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Mann-Whitney U statistics were performed on AUC values from 0 to 14 dpi to show that the E. 
coccoides genome copies per µl blood in this primary E. coccoides infection in the cross-protection 
group in Phase 1 were significantly lower than both the M. haemomuris genome copies per µl blood 
seen during primary infection in the re-inoculation group in Phase 1 (pMWU=0.007) (3.2.2.1.6.1, 
kinetics given in Figure 20) and also the M. haemomuris genome copies per µl blood seen during 
primary infection in the age-matched control group in Phase 2 (pMWU=0.001) (3.2.2.1.8.1, kinetics 
given in Figure 21).  
No re-inoculation with E. coccoides was performed as it was not part of the experiment (3.2.2.1.4.1). 
3.3.2.5 Partial protection from re-infection with M. haemomuris following previous M. 
haemomuris infection (Phase 2: re-inoculation group) 
Normalised relative M. haemomuris genome copies per µl blood in the four mice in the re-
inoculation group, that had been previously infected and partially recovered from M. haemomuris 
infection inoculated in Phase 1, following repeat inoculation with M. haemomuris in Phase 2 on day 
153 dpi using freshly collected blood (from amplifier mice, 3.2.2.1.5.2) without cryopreservation, are 
shown in Figure 23; 153 dpi is represented as 0 dpi in the graph for simplicity. The mice were 
monitored for infection using the M. haemomuris-specific qPCR assay (3.2.2.3.2). The M. 
haemomuris genome copies per µl blood during the Recovery phase, between Phase 1 and Phase 2, 
are shown in Figure 20 above.  
 
Figure 23 M. haemomuris genome copies in the four mice in the re-inoculation group (Phase 2), showing the infection 
kinetics of four mice previously recovered from M. haemomuris following re-inoculation with freshly obtained blood 
containing 1.90E+04 M. haemomuris copies per inoculum dose. Days post inoculation (dpi) are plotted on the x-axis and 
normalised relative M. haemomuris genome copies per µl blood are plotted on the y-axis. Lines represent individual mice 
(mice differentiated by colouring of the lines); blood sampling occurred once daily in Phase 2. 
The four mice previously infected with M. haemomuris in the re-inoculation group demonstrated 
significantly lower (pMWU=0.007) M. haemomuris genome copy AUC values in the 14-day period of 
Phase 2 (Figure 23) than those in the eight mice in the age-matched control group in the 
corresponding period of Phase 2 (Figure 21); both these groups were infected with M. haemomuris 
using identical inocula. This suggests partial protection from re-infection with M. haemomuris in the 
re-inoculation group.  
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3.3.2.6 Lack of protection from M. haemomuris infection following previous E. coccoides 
infection (Phase 2: cross-protection group) 
Normalised relative M. haemomuris genome copies per µl blood in the eight mice in the cross-
protection group, that had been previously infected and partially recovered from E. coccoides 
infection inoculation in Phase 1, following inoculation with M. haemomuris in Phase 2 on day 153 dpi 
using freshly collected blood (from amplifier mice, 3.2.2.1.5.2) without cryopreservation, are shown 
in Figure 24; 153 dpi is represented as 0 dpi in the graph for simplicity. The mice were monitored for 
infection in Phase 2 using the M. haemomuris-specific qPCR assay (3.2.2.3.2) and the E. coccoides-
specific qPCR assay (3.2.2.3.2). The E. coccoides genome copies per µl blood during the Recovery 
phase, between Phase 1 and Phase 2, are shown in Figure 22, lower panel above.  
 
 
Figure 24 M. haemomuris genome copies in the eight mice in the cross-protection group (Phase 2), showing the infection 
kinetics of eight mice previously recovered from E. coccoides infection following inoculation with freshly obtained blood 
containing 1.20E+04 M. haemomuris copies per inoculum dose. Days post inoculation (dpi) are plotted on the x-axis and 
normalised relative M. haemomuris genome copies per µl blood are plotted on the y-axis. Lines represent individual mice 
(mice differentiated by colouring of the lines); blood sampling occurred once daily in Phase 2. 
The eight mice previously infected with E. coccoides in the cross-protection group showed M. 
haemomuris infection kinetics in Phase 2 (Figure 24) that included an initial median peak of 
6.99E+05 M. haemomuris genome copies per µl blood at 1 dpi, followed by a growth phase and 
further median peak of 5.35E+07 M. haemomuris genome copies per µl blood at 12 dpi. This peak 
was two days later than the 2.85E+07 10 dpi peak seen in the age-matched control group (Figure 
21).  
The eight mice previously infected with E. coccoides in the cross-protection group demonstrated 
significantly higher (pMWU=0.024) M. haemomuris genome copy AUC values in the 14-day period of 
Phase 2 (Figure 23) than those in the eight mice in the age-matched control group in the 
corresponding period in Phase 2 (Figure 21). The dt of M. haemomuris in the cross-protection group 
was 13.3 hours between 0 and 7 dpi, and 17.7 hours between 3 and 10 dpi. There was no apparent 
re-emergence of E. coccoides infection (i.e. negative results on the E. coccoides-specific qPCR assay) 





3.4.1 Successful development of qPCR assays specific to M. haemomuris and E. coccoides and 
duplexed with a murine GAPDH internal control 
We have, for the first time, developed and validated and duplexed (with a GAPDH internal control 
assay) qPCR assays for the detection of infection with M. haemomuris and E. coccoides in mice. 
These species-specific assays are essential when investigating possible cross-protection of E. 
coccoides to M. haemomuris infection, and when infection with both these haemoplasma species is 
possible in a host species. The inclusion of the GAPDH internal control was important to help rule 
out errors or variation in DNA extraction or PCR amplification to avoid false-negative results.  
As M. haemomuris and E. coccoides cannot be cultured in vitro, no samples of known colony forming 
units (CFU) could be generated to use as standards in qPCR to enable deduction of the exact number 
of haemoplasma copies present in samples. The use of 16S rRNA gene amplicons as an alternative 
target to allow calculation of haemoplasma copies in the samples assumes that only one 16S rRNA 
gene exists per haemoplasma genome; this has been demonstrated for all fully sequenced 
haemoplasmas (74-80, 82, 83) except for Mycoplasma ovis (81), in which two copies per genome 
were found. Another assumption that is made in these calculations when effectively equating one 
genome copy with one CFU is that there is 100% viability of the detected haemoplasma copies, 
which cannot be proven in the absence of in vitro cultivation. However, the use of plasmids 
containing the target region of a PCR assay is a widely accepted method to allow qPCR assay 
validation (308), and so we considered the use of PCR amplicons a suitable substitution for plasmids. 
However, the use of PCR amplicons is potentially less accurate than using actual CFUs or plasmids 
encoding the target region to determine a qPCR assay’s sensitivity due to the smaller size of PCR 
amplicons and thus errors that can result in measuring DNA content could contribute to large 
discrepancies in calculated amplicon copy numbers.  
The initial duplex conditions (3.2.1.3.2.2) in the qPCRs to amplify both the internal control GAPDH 
and specific rodent haemoplasma species resulted in higher Ct values for the haemoplasma 
amplification compared to the singleplex qPCR assay for the haemoplasma species alone, despite 
the use of the same conditions and dilution series. This was assumed to be due to competitive 
inhibition of the haemoplasma qPCR within the duplex qPCR by the internal control qPCR. The 
primer and probe concentrations of the internal control qPCR were subsequently reduced until 
inhibition was no longer seen. The reduction in primer and probe concentrations for the internal 
control qPCR resulted in flattening of the amplification curves and a small increase in Ct when 
compared to the original results (data not shown). This was deemed unimportant as quantification 
of mouse gDNA was not the purpose of the assay and normalisation of haemoplasma genome copies 
to mouse GAPDH gene copies is not affected by curve shape or higher Ct values, as long as detection 
is reliable and delivers repeatable results. Similar problems have been seen with other duplex qPCR 
assays that target an abundant internal control gene (e.g. GAPDH), Barker, Tasker (187) and Peters, 
Helps (100). 
Both duplex qPCR assays were able to detect between one and ten copies of either M. haemomuris 
or E. coccoides, which is of comparable sensitivity to the currently used qPCR assays for feline and 
canine haemoplasmas (100, 149, 187). In clinical laboratories, the last detectable dilution of 
template DNA is often reported as a qPCR assay’s sensitivity or LoD, although this definition can be 
misleading as the practical LoD for any qPCR assay is about three to four copies of template DNA per 
reaction (309). A more general definition, accounting for the number of replicates used to detect 
low-quantities of target DNA, and reporting a probability rather than a number of target DNA copies, 
83 
 
is given by the Clinical and Laboratory Standards Institute (310), and may better reflect the true LoD 
in a laboratory setting: the LoD is defined as the lowest amount of analyte in a sample that can be 
detected with a given probability. It is important to note that this definition does not include any 
information on the assay’s ability to quantify this detection. The limit of quantification (LoQ) is 
defined as the lowest amount of measurand in a sample that can be quantitatively determined with 
given acceptable precision and acceptable accuracy, under given experimental conditions (311). 
Whilst determination of LoQ was not attempted for the current study, our reported LoD of one to 
ten haemoplasma genome copies does need to be interpreted in conjunction with the fact that the 
assays were only able to detect one to ten haemoplasma genome copies in one out of three 
replicates. Guidelines for the determination of LoD in non-culturable targets call for at least six 
replicates to be performed over a ten-fold dilution series (308), so that the LoD could then be stated 
as the lowest genome copy equivalent (highest dilution) that yielded positive results over all six 
replicates. However, the same resource also reports any LoD lower than 20 genome equivalents per 
reaction to be ideal, which is close to what could be extrapolated from our dataset (Table 25). 
However, more replicates and assessment of target molecule copies per reaction that are less 
susceptible to error accumulation due to small amplicon size (i. e. using plasmids) would be required 
to report LoD in agreement with more stringent laboratory standards than currently applied to our 
research assays. Another limitation of our evaluation of assay sensitivity (defined as LoD) is that the 
dilution series was performed in elution buffer rather than in a background of mouse DNA, and 
background DNA could have interfered with assay performance at low target copies per reaction by 
unspecific product formation or competition of the mouse GAPDH assay for reaction substrates. 
However, no interference of the assays was demonstrated with the use of the optimised duplex 
conditions (using a background of mouse DNA) and no non-specific reactions with mouse DNA were 
demonstrated during the evaluation with SYBR Green 1, making it very unlikely that we would have 
encountered different LoD results when using a background of mouse DNA.  
No cross-reactivity was found between the E. coccoides and M. haemomuris species-specific qPCR 
assays when they were challenged with over 1.0E+05 target amplicon copies of the respective non-
target species. This is in full agreement with accepted guidelines that state that at least 1.0E+03 
genome copies of non-target species should not trigger cross-reactivity (308). However, cross-
reactivity to other non-target species was only assessed in silico and would need to be evaluated to 
further confirm specificity of these species-specific qPCR assays, especially if, for example, other 
haemoplasma species were found to infect mice. 
Validation guidelines (308) also exist for multiplex (i.e. duplex) qPCR assays and include having a 
linearity of dilution with a correlation coefficient of greater than 0.98 and a reaction efficiency of 80 
to 120 % or with a slope of -2.9 to 3.9; all of these criteria were met by our E. coccoides and M. 
haemomuris species-specific qPCR assays as they exhibited correlation coefficients and reaction 
efficiencies (E. coccoides assay: 0.999, E=99.6 %; M. haemomuris assay: 0.999, E=98.0 %) close to 
describing theoretical exponential amplification of target copies during the qPCR reaction. However, 
both the M. haemomuris and E. coccoides species-specific qPCR assays were only evaluated for use 
in blood. These assays would need to be re-evaluated before they can be used in different situations 
e.g. if being used to detect haemoplasma DNA in vector samples (e.g. tick, flea) or different tissues 
(e.g. spleen, liver) compared to blood.  
3.4.2 Monitoring of infection kinetics of M. haemomuris and E. coccoides in C57BL/6 mice under 
experimental conditions and protection from re-infection with M. haemomuris  
We have, for the first time, quantitatively monitored M. haemomuris and E. coccoides infection in 
mice, which is a crucially important step in the establishment of a laboratory mouse model of 
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haemoplasma infection. Cohen, Shemesh (34) have recently described the infection dynamics of a 
‘M. haemomuris-like haemoplasma’ in wild-caught, experimentally infected gerbils with a blood 
sampling interval of approximately two weeks. We observed a similar infection kinetics pattern to 
them, with a lag-, peak-, decline- and plateau-phase for M. haemomuris but not E. coccoides 
infection. The peak M. haemomuris genome copies per µl of blood seen in the current studies 
describing primary M. haemomuris infection (3.3.2.2 and 3.3.2.3) was approximately 100-fold higher 
than that observed by Cohen, Shemesh et al. in gerbils, but this could be due to the infrequent blood 
sampling in the gerbil study missing short-lived peaks in bacteraemia. In cats, a peak bacteraemia of 
approximately 1.0E+06 genome copies per µl blood occurs after M. haemofelis and ‘Ca. M. 
haemominutum’ infection, but levels do not significantly decline before entering a plateau-phase 
following naïve infection (89, 107, 136). Infection of cats with ‘Ca. M. turicensis’ results in a peak 
bacteraemia of 1.0E+03 per µl blood, with the organism becoming undetectable after approximately 
three months (124), which resembles the E. coccoides infection kinetics seen in the current study in 
mice, and may reflect the phylogenetical relationship between these two haemoplasmas, within the 
HF-group of haemoplasmas (see phylogeny presented in Chapter 2, Figure 5). Infection kinetics have 
only been described in one more of the veterinary relevant haemoplasmas, M. suis (120). Peak M. 
suis bacteraemia levels of over 1.0E+08 per µl blood have been described in experimental infection 
using splenectomised piglets, also showing a less pronounced decline prior to establishment of a 
plateau-phase as it is seen in feline haemoplasmas (89, 136).  
One major important finding in the current study is that partial protection from re-infection with M. 
haemomuris was observed in C57BL/6 mice; demonstrated by significantly lower levels of 
bacteraemia in mice that had been previous infected with M. haemomuris compared to those naïve 
to infection by undergoing M. haemomuris infection for the first time. Protective immunity to 
haemoplasma infection has previously been demonstrated for M. haemofelis (107) and ‘Ca. M. 
turicensis’ in cats (124), both species of which are able to induce anaemia in immunocompetent 
cats, although M. haemofelis (26) appears to be much more pathogenic than ‘Ca. M. turicensis’ (38). 
In the current study, we did not monitor haematological variables and so we are not able to 
document whether the observed protection from high levels of bacteraemia in M. haemomuris 
infection also protected the mice from developing anaemia or erythrocytic osmotic fragility, as is 
observed in M. haemofelis (123) and ‘Ca. M. turicensis’ (124) infection in cats. Although no obvious 
clinical signs of ill health were noted in the mice following M. haemomuris infection, which might 
have been expected if significant anaemia had resulted, we cannot rule out that anaemia or other 
changes in erythrocytic variables occurred as mild clinical signs, such as pallor or mild lethargy, are 
extremely easy to overlook in small rodents (312). One might speculate that the lethargy seen after 
the blood sampling procedure in two mice, as it occurred around peak bacteraemia in primary 
infection, could have represented such an occurrence, although increased bleeding from the 
sampling site was seen and attributed to the sampling procedure at the time.  
In the current study we used an inbred strain of mouse from the same supplier, of the same age, 
housed in the same facility and subjected to all the same experimental methods except for the 
haemoplasma species used for inoculation. Thus, we were able to minimise any effects of the source 
of the mice, their age, housing etc. on variation of the immune response. This has not been achieved 
in the same way in some of the published feline studies, e.g. in the study demonstrating protective 
immunity to M. haemofelis infection, the naïve cats inoculated with M. haemofelis were juvenile 
(seven months old) whereas the previously M. haemofelis-infected cats were much older, having 
been kept in the research establishment for seven years, and under different housing conditions 
(107). Variation such as this in the feline study demonstrates the need for a mouse model where 
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experimental conditions can be more easily closely controlled and allow investigations in a more 
cost-effective manner due to the lower price of purchase and maintenance costs of mice.  
We were able to show that no cross-protection from M. haemomuris infection occurs in mice 
previously infected with E. coccoides as M. haemomuris was still able to infect and establish ‘naïve-
like’ infection kinetics in mice that had previously recovered from E. coccoides infection. Lack of 
cross-protection between haemoplasma species has been experimentally demonstrated for M. 
haemofelis following previous recovery from ‘Ca. M. turicensis’ infection (295), and the concept of 
lack of cross-protection is supported in many host species due to the occurrence of multiple 
haemoplasma species infections in individual canine and feline hosts as commonly reported (for 
example, by Fujihara, Watanabe (294), Peters, Helps (100) or Filler (98)). However, co-infection with 
M. haemomuris and E. coccoides has not been demonstrated in rodents. This may be due to the lack 
of species-specific PCR assays available to enable detection of more than one haemoplasma species 
in a host (35, 36, 53). In fact, the current study demonstrated a higher number of M. haemomuris 
genome copies per µl blood in the cross-protection group, following E. coccoides infection, than in 
naïve infection with M. haemomuris in the re-inoculation and age-matched control groups. The 
latter corresponds to findings in cats (295), where signs of enhancement of M. haemofelis infection 
were seen in cats previously infected with ‘Ca. M. turicensis’.  And although different inocula 
(different donor mice and respective M. haemomuris inoculum dose) were used for inoculation of 
M. haemomuris in the cross-infection and the age-matched control groups, the M. haemomuris 
genome copies inoculated do not readily explain the greater increase in genome copies per ul of the 
cross-protection mice (who received 2.40E+02 M. haemomuris copies) compared to the age-
matched control mice (who received 3.80E+02 M. haemomuris copies).  
An even more pronounced difference between M. haemomuris genome copies was seen in naïve 
infection in the younger mice in Phase 1 (re-inoculation group) and naïve infection in the ‘aged’ mice 
in Phase 2 (age-matched control group), where the young mice exhibited a lag-phase that was not 
observed in primary infection of the ‘aged’ mice. The more rapid onset of infection in the ‘aged’ 
group (Phase 2, age-matched control group) was attributed to the difference in M. haemomuris 
inocula used (cryopreservation and dilution) although it is possible that age of inoculated mice might 
have been a contributing factor. The inoculum used for Phase 1 (re-inoculation group) was 
cryopreserved and it appeared to be less infective than expected as only four of the eight mice in the 
re-inoculation group became successfully infected with M. haemomuris initially. It was speculated 
that cryopreservation with 20% DMSO (v/v) and/or dilution in PBS may have reduced M. 
haemomuris viability significantly as the inoculum contained very high M. haemomuris genome copy 
numbers (2.52E+06). A similar complication was suspected in studies by Hicks, Willi (107) when using 
a low-dose M. haemofelis infection model following cryopreservation of inocula with 20% DMSO 
(v/v). In Phase 2 of the experiment, only fresh inocula were used and the age-matched control group 
received the same inocula and M. haemomuris doses as the re-inoculation group, hence ruling out 
reduced inoculum viability as a cause for the observed partial protection from re-infection with M. 
haemomuris.  
Following primary infection with E. coccoides, mice were not re-challenged with the same organism 
to see if prevention of re-infection occurred with E. coccoides, nor did we attempt to inoculate E. 
coccoides into mice previously infected with M. haemomuris to see if cross-protection to E. 
coccoides occurred. These studies would have been interesting to perform but were not carried out 
due to cost and ethical concerns.  Ultimately, our aim was to select and describe a laboratory animal 
model of haemoplasma infection in a veterinary relevant species, and our results suggested that the 
M. haemomuris model was most appropriate for this, as M. haemomuris showed prolonged and 
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high-level bacteraemia, and protection from re-infection, akin to the changes seen with the feline 
pathogenic haemoplasma M. haemofelis, suggesting its suitability for further investigations.  
We observed fluctuations of M. haemomuris and E. coccoides genome copies per µl blood at peak 
bacteraemia and at late stages of infection (around 80 dpi for M. haemomuris and as early as 10 dpi 
for E. coccoides). Dramatic fluctuations in haemoplasma genome copies per µl blood over periods of 
just a few days are a feature of M. haemofelis infection in cats around peak bacteraemia, but may 
also occur when the number of genome copies per µl blood are close to the LoD (89, 107). Cycling of 
haemoplasma copy numbers, e.g. a 1.0E+06-fold difference in haemoplasma copy number over just 
2 days, has been demonstrated during M. haemofelis infection (89) but was not seen during peak 
bacteraemia in mice in the current study. The observed low-level fluctuation of M. haemomuris and 
E. coccoides genome copies per µl blood were more likely due to stochastic effects during sample 
processing and might have disappeared if more replicate qPCRs per timepoint had been done, or 
higher blood volumes used for DNA extraction at each time point. This is an important consideration 
for the planning of studies evaluating clearance of infection or other applications where negative 
PCR results must be confirmed. Clearance from M. haemofelis in cats after consecutive antibiotic 
treatment was recently demonstrated using triplicate or quadruplicate qPCRs per negative sample 
(135). 
We noted splenomegaly in all mice in all groups at post-mortem examination, although splenic 
weight was significantly greater in mice that had undergone primary M. haemomuris infection than 
in mice that had undergone M. haemomuris re-infection. One possible explanation for this is that 
the spleens were not activated (for haemolysis, for example, or in immunological reactions to 
remove M. haemomuris) as much when lower M. haemomuris copy numbers were present in the 
blood. As no haematological variables or M. haemomuris copy numbers per mg of spleen were 
monitored in the current study, it is hard to speculate further on splenic activation. We did, 
however, account for the fact that splenomegaly could have been introduced by the effect of 
repeated blood loss during blood sampling, as the age-matched control group all underwent the 
same blood sampling protocol in Phase 1 and in the Recovery phase as the other groups. However, 
we did not include a healthy control group from within the same study population for the mice 
exsanguinated at the end of the experiment, 14 days after Phase 2 inoculations. Hence it remains 
unclear whether the lesser splenomegaly seen in the re-inoculated group was indeed clinically 
significant. We also did not assess the occurrence of splenomegaly during primary E. coccoides 
infection or at any other timepoint than 14 dpi with M. haemomuris, so further studies would be 
needed to further investigate splenomegaly over the course of rodent haemoplasma infections.   
3.4.3 Limitations of the current study and suggested future work using the mouse model of 
haemoplasma infection 
Limitations of the newly validated duplex qPCR assays targeting the M. haemomuris and E. coccoides 
16S rRNA genes have been mentioned above. Both assays were shown to have the required 
sensitivity and specificity for use in a mouse model of M. haemomuris and E. coccoides infection, but 
further work on inter- and intra-assay variability (robustness and LoQ), and their use in different 
types of samples, are ideally required.  
In the current study we have established a surrogate (see 1.5.2) mouse model of haemoplasma 
infection, using two different rodent haemoplasma species, M. haemomuris and E. coccoides, and 
the ‘fit-for-purpose’ scoring system of animal models as proposed by Denayer, Stöhr (313) that 
accounts for the research objective (i.e. monitor infection kinetics rather than assess therapy or 
measures of prevention) and the fact that our aim was to establish and monitor infection 
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irrespective of clinical disease. We did however, encounter problems with infecting mice using PBS-
diluted and DMSO-cryopreserved inocula. No comparative studies into haemoplasma 
cryopreservation have been carried out but DMSO is known to be cytotoxic during prolonged 
exposure at warmer temperatures (259). We thus subsequently adjusted our protocols to use 10% 
v/v glycerol, instead of DMSO as a cryopreservative, as glycerol is less likely to by cytotoxic at room 
temperature or above (259). We also changed our experimental protocols to use amplifier mice in 
order to generate larger numbers of viable haemoplasmas for standardised inoculation of 
experimental mice.  
We have used this surrogate mouse model of haemoplasma infection to demonstrate partial 
protection from M. haemomuris re-infection and the lack of cross-protection through previous E. 
coccoides infection. We have further selected M. haemomuris to be the most appropriate rodent 
haemoplasma pathogen to model M. haemofelis infection in cats based on their similar infection 
kinetics and induction of splenomegaly. However, before the use of this model in studies assessing 
therapy or vaccination, we will need to document the clinicopathological features of M. haemomuris 
infection in mice and establish their relatedness to haemoplasmosis in other veterinary species of 
social (e.g. cats) or economic (e.g. pigs) importance. Such a comparison of clinicopathological 
changes will help assess the model’s ‘face validity’ or the similarity in biology and symptoms 
between the animal model and the modelled disease (313) and is important in model validation, 
however, it may be adjusted to only include a subset of signs.  
Future studies will therefore aim to include the collection of some clinicopathological data, such as 
haematology, over the course of M. haemomuris infection, as this was not possible in the studies 
described in this chapter due to the limitation of quantity of blood that could be collected safely (up 
to a maximum of 10% total blood volume per day or 25% total blood volume per 4 consecutive 
weeks, accounting for 116µl per day or 290µl over 4 weeks) from the mice. Additionally, as we have 
demonstrated that partial protective immunity against M. haemomuris infection does occur in mice, 





4 FURTHER CHARACTERISATION OF THE MOUSE MODEL OF 
HAEMOPLASMA INFECTION  
4.1 INTRODUCTION 
4.1.1 Rationale for characterising the immune response to M. haemomuris infection in the 
mouse model of haemoplasma infection 
Following observations of protective immunity against re-infection with the same haemoplasma 
species in cats (107, 124) and mice (see Chapter 3), the development of a vaccine to protect from 
infection and/or clinical haemoplasmosis appears possible. The need for a vaccine is highlighted by 
the difficulty in being able to consistently clear haemoplasma infections from chronic carriers; only 
very recently has a possible protocol to achieve this been suggested in cats, and this comprised a 
long treatment protocol using two different antibiotics (135). In pigs, clearance of haemoplasma 
infection is economically challenging and has not focused on outcomes in individual pigs, but on 
removal of carrier pigs from the group and employment of sanitary methods that avoid iatrogenic 
transmission via shared needles etc. during husbandry measures (120). However, generally, further 
research into haemoplasma vaccine development is still hindered by the lack of an in vitro 
cultivation system for the haemoplasmas. Without the ability to grow haemoplasmas in vitro, our 
ability to investigate haemoplasma-host-interactions, including the molecular characterisation of 
protective immunity, is still greatly limited.  
Cytokines are small proteins that are biologically active as signalling molecules, either between 
leukocytes (interleukins; IL) or as chemotactic attractants (chemotactic cytokines; chemokines) of a 
variety of immunologically active cells (288). In a variety of host species and pathogens, certain 
cytokine profiles are known to be associated with a higher risk of infection (314) or a higher severity 
of disease or even death (315). Conversely other cytokine combinations have been identified to 
suggest protection from infection with a variety of extracellular (316) or intracellular pathogens 
(317).  
Knowledge of the nature of the immune response to a specific pathogen is required to guide 
decision making in preventative (i.e. vaccination) strategies against infection and to protect from 
clinical disease. Different branches of the immune system that are involved in the formation of 
protective immunity can potentially be addressed with vaccine design, e.g. by adding adjuvants that 
mimic or attract certain cytokines (318, 319) and hence induce a pronounced and lasting immune 
response. The general principles of the mammalian immune response (largely based on the mouse) 
and our current knowledge of immunological mechanisms involved in haemoplasma infection are 
outlined in the sections below.   
4.1.1.1 Patterns in immunology  
4.1.1.1.1 Innate and acquired response to infection 
Mammals have developed a variety of mechanisms to fight pathogens and prevent infection. 
Broadly, these can be split into innate and acquired immunity.  
Innate immunity comprises mechanisms encoded in the germline of the host, such as phagocytic 
cells, natural killer (NK) cells or the presence of substances in the blood to protect against infection, 
i.e. lysozyme, basic polypeptides and the complement complex (320). The cellular component of 
innate immunity (omitting mechanical barriers such as skin or gut lining) is mainly comprised of 
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granulocytic cells (neutrophils, eosinophils, basophils, monocytes, macrophages and specialised 
phagocytic cells) that proliferate in the presence of pathogen (e.g. bacterial) invasion and tissue 
injury and can also be monitored in the bloodstream to monitor clinical progression of disease (321). 
Phagocytic cells also produce cytokines to recruit further cells and guide the subsequent acquired 
immune response (322). Many of these innate defence mechanisms account for the species-
specificity of certain pathogens as they acquire specific ways to evade from or even invade the host’s 
defence (323).  
Acquired immunity is not directly encoded in the germline but based on constant variation of surface 
receptors to bind potential pathogens. This high variability, however, takes time to develop as it 
needs constant monitoring to eliminate self-reactiveness (324). Hence, an acquired immune 
response does not develop until exposure to an antigen, either naturally or via vaccination, and is 
primarily mediated by antigen-specific receptors expressed by lymphocytes (T-cell receptors and 
immunoglobulins). Antigens are typically proteins or large polysaccharides that are specific to the 
pathogen but cross-reactivity can occur (325). Acquired immunity can be split into two broad 
subtypes: humoral immunity, leading to production of circulating immunoglobulins by B-
lymphocytes that bind to pathogens or toxins, and cell-mediated immunity, requiring activated T-
lymphocytes to specifically attack pathogens (325).  
4.1.1.1.2 The innate immune response 
The innate immune system is defined by structures and mechanisms that are encoded in the host’s 
germline and subject to little variation (325).  Its receptors recognise shared antigen patterns or 
toxins and are located on cells that are most likely to encounter pathogens, such as antigen 
presenting cells (APC) or NK cells. The receptors of the innate immune system target antigens that 
have very limited variability, i.e. conserved metabolic proteins or carbohydrate structures that are 
vital to the pathogen itself (320). The generated innate immune response relies on a system of 
chemokines to control migration of phagocytic cells to affected tissues, e.g. macrophage 
inflammatory protein 1 (MIP1) that is secreted by epithelial cells. Chemokines also attract 
lymphocytes into the draining lymph nodes (e.g. RANTES; Regulated on Activation Normal T Cell 
Expressed and Secreted) to activate an adaptive response (322). Chemokines of the innate immune 
system are typically secreted locally by APC (mainly dendritic cells and macrophages) and other 
phagocytic cells but in fulminant inflammatory reactions, chemokines such as those secreted by 
macrophages (i.e. IL-1, IL-6, IL-12 and TNF-α), can also appear in the bloodstream (322).  
4.1.1.1.3 Th1/Th2/Th17 paradigm and formation of an acquired immune response 
The acquired immune system is defined by highly specific and variably receptors of T- and B-
lymphocytes. Upon activation (binding of presented antigen and costimulatory signals) these 
lymphocytes undergo clonal expansion and form memory cells to subsequently mount a more 
targeted immune response in case of re-infection. The type of acquired immune response, humoral 
(B-lymphocytes) or cell-mediated (T-lymphocytes), is dependent on the preceding innate response 
(320).  
T-helper (Th1 and Th2) cells are T-lymphocytes that help direct the acquired immune response by 
activation and down regulation of humoral or cellular pathways of immunity, sometimes in feedback 
loops, such as IL-10 limiting a Th1 response and hence dampening overall inflammation (326). The 
different cytokines most involved in their activation have traditionally been used to define Th1-type 
and Th2-type responses; IFN-γ for Th1-type/cell-mediated immunity and IL-4 for Th2-type/humoral 
immunity (327); but it is important to recognise that these cytokines are also produced by other cell 
90 
 
types and the resulting immune response is directed by combinations of cytokines rather than 
individual cytokines (328).  
An acquired, humoral immune response is best suited to deal with extracellular pathogens and can 
be triggered by IL-4 secretion by NK cells, or IL-10 secretion by macrophages and monocytes, leading 
to activation of Th2 helper cells that subsequently produce more IL-4 to stimulate B-cells to 
differentiate into plasma cells and secrete soluble immunoglobulins (i.e. B-cell receptors). Activated 
Th2 helper cells can also produce further proinflammatory cytokines such as IL-4, IL-5 or IL-9 as well 
as anti-inflammatory IL-13.  
An acquired, cellular immune response can be triggered by release of IL-12 from macrophages or 
secretion of IFN-γ from NK cells, leading to activation of Th1 helper cells, that produce more IFN-γ, 
TNF-α and mount an immune response best suited to deal with intracellular pathogens (322).  
Apart from Th1 cells directing cell-mediated immunity, by activation of cytotoxic T-cells and memory 
T-cells, and Th2 cells directing humoral immunity, by activation of B-cells into plasma cells and 
formation of memory B-cells, a third T-helper cell population, Th17, has recently been described. 
Th17 helper cells arise following stimulation with IL-6, IL-23 and transforming growth factor beta 
(TGF-β) and are inhibited by IL-4 and IFN-γ (329). They play an equally important role to Th1 and Th2 
helper cells in bridging the gap between the innate and acquired immune response (212). Th17 
helper cells promote inflammation by secretion of IL-17, TNF-α, GMCSF (granulocyote-macrophage 
colony stimulating factor), KC (keratinocyte chemoattractant, a pro-inflammatory, neutrophil-
recruiting chemokine) and IL-6, often leading to excess inflammation and autoimmunity (330). 
However, early release of IL-17 in infection might also upregulate defensive mechanisms until other 
T-helper cells are recruited for an acquired immune response, as Th17 pathways are thought to be 
evolutionary older than the formation of an acquired immune response (331). This early IL-17 
response is typically caused by innate release from γδ-T-cells; unusual T-cells that use their T-cell 
receptor for pattern recognition, thus acting as APC whilst allowing very early clonal expansion at 
sites of antigen exposure, such as the spleen or mucosa-associated tissues (332).  
Another subset of T-helper cells, T-regulatory cells (Tregs) arise from a combination of TGF-β and IL-10 
(333). An imbalance of Tregs and Th17 function is thought to be the underlying mechanism for many 
autoimmune diseases (330, 331). Accumulation of Tregs at the site of infection can sometimes favour 
pathogen persistence e.g. in leishmaniasis (334) or in Shistosoma mansoni infection (335). This 
mechanism of immune evasion has successfully been targeted in vaccination approaches to bacterial 
pathogens such as Mycobacterium bovis, where knowledge of the regulatory pathways can 
subsequently guide adjuvant selection and method of vaccine administration (336).  
The specific receptors of the acquired immune system only bind to microbial antigens that have 
been presented to the T-helper cells, which is followed by clonal expansion of specific cytotoxic T-
cells mediated by Th1 cells or B-cell proliferation and differentiation (leading to immunoglobulins 
being produced by plasma cells) mediated by Th2 cells (322). Whilst a Th17-mediated role in 
protection from infection is undisputed (331), their effects are less well defined and consist of 
neutrophil-recruiting, enhanced granulopoiesis as well as extramedullary haematopoiesis and a 
critical role in fighting extracellular pathogens that have escaped Th2 and Th1 effector mechanisms 
(337).  
Immunoglobulins bound to the surface of bacterial pathogens and can activate a cascade of proteins 
(complement reaction) leading to the elimination of pathogens from the host whereas cytotoxic T-
cells may directly attack their target, typically virus-infected cells (322). Subsets of these effector B- 
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and T-cells form memory cells that can persist for years and induce a longer, more specific (IgG 
versus IgM immunoglobulins) and more polarised (humoral versus cell-mediated), immune response 
upon re-encounter with the same antigen (288). A similar effect of polarisation of the immune 
response may be seen in chronic infection (338) and can be exploited for re-inoculation experiments 
(339).  
4.1.1.2 Detection of the immunological response to bacterial infection 
Detection of cytokines to reflect immunological responses is challenging due to their concentrations 
being low (pg/ml) and the biological substrate (plasma or other intercellular fluids) being highly 
complex and prone to causing assay interference (340). In the past, some cytokines, such as 
interferons, were measured in anti-viral assays, where their ability to block viral infection could be 
quantified in the number of living cells after incubation with virus particles and test substrate. 
Alternatively, cell migration was observed to assess for chemokines or competitive receptor binding 
used where capture antibodies were available to detect the molecule of question (341). More 
recently, ELISA-based immunoassays have been used to measure cytokines in clinical samples but 
development and validation of ELISA technology can be cumbersome and is not available for 
cytokines in less researched species, such as non-human, non-lagomorph and non-rodent mammals 
(342). Detection of messenger RNA (mRNA) by means of reverse-transcriptase quantitative PCR (RT-
qPCR) have been employed to measure cytokines at pre-expression level in less researched species 
such as cats (343). However, depending on the cytokine being measured, these were shown to have 
poor agreement with detection of the cytokine protein product by ELISA-based techniques (344). 
Similarly, ELISAs are time-consuming and not suited for detection of cytokines in small sample 
volumes. Thus these disadvantages of RT-qPCR and ELISA led to the development of bead-based 
techniques that allow simultaneous detection of multiple cytokines in a high-throughput, flow-
cytometry based format that utilise fluorescently labelled beads covered in detection antibodies 
(340). Performance of bead-based multiplex immunoassays has been comparable to the much 
slower and substrate-consuming ELISA technology (345), but is still significantly affected by sample 
handling (i.e. freeze-thaw cycles) and substrate (i.e. serum versus plasma), and these factors need to 
be evaluated before comparing actual data across studies detecting cytokines from different sources 
(346).   
The cellular immune response to bacterial infection can also be observed and roughly quantified by 
monitoring haematological parameters (i.e. counts of red and white blood cells) over the course of 
infection (347). Coagulation parameters, Coombs’ tests and osmotic fragility have also been included 
in routine monitoring of clinical haemoplasmosis in veterinary species (79, 90, 348) as they relate to 
the intensity of the immune response (349, 350), but may be difficult to perform on the very limited 
sample volumes that can be obtained from mice.  
4.1.2 Previous studies on the immune response to haemoplasma infection in non-rodent species 
Protective immunity after primary exposure and recovery from infection has been described in cats 
for infection with M. haemofelis and ‘Ca. M. turicensis’ (74, 107).  
When assessing protective immunity to re-infection with M. haemofelis, using RT-qPCR to feline 
cytokine mRNA, Hicks, Willi (107) did not find a clearly defined Th1/Th2 or Th17 differentiation 
between cats undergoing primary M. haemofelis infection and cats recovered from M. haemofelis 
infection after re-inoculation and re-infection. There was an increase in IL-10 mRNA (representing an 
anti-inflammatory, Th2 response) during peak bacteraemia in naïve infection but not in the re-
infection group, as well as a potential TNF-α mRNA and IL-6 mRNA increase in the re-infection group 
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that was not present in the naïve group, which was interpreted as a potential Th17 response, but 
this could not be confirmed with the employed methodology.  
In a similar study, assessing the occurrence of protective immunity and feline cytokine response to  
‘Ca. M. turicensis’ infection using RT-qPCR to feline cytokine mRNA, Novacco, Boretti (124) found an 
early IFN-γ mRNA (representing a Th1 response) increase in naïvely infected but not in re-inoculated 
re-infection cats, and an increase in IL-4 mRNA (representing a Th2 response) in re-infection cats as 
well as during the later stages of naïve infection. The authors concluded that Th1 responses play a 
role in protective immunity, but it must be noted that the infection kinetics investigated were 
shortlived (‘Ca. M. turicensis’ being undetectable after less than three months whilst M. haemofelis 
infection typically still shows a lasting plateau-phase at this point) and clinical changes were very 
mild following ‘Ca. M. turicensis’ naïve infection when compared to M. haemofelis. In line with the 
lack of a Th2 humoral response shown in the Novacco, Boretti (124) study with ‘Ca. M. turicensis’, 
another experiment showed a similar lack of humoral immunity in protection against M. haemofelis 
infection, when the transfusion of feline convalescent plasma from cats previously recovered from 
M. haemofelis infection to naïve cats did not prevent subsequent M. haemofelis infection (138).  
Earlier studies demonstrated an acute phase response in cats following infection with M. haemofelis 
and ‘Ca. M. haemominutum’ (108). A humoral immune response to a M. haemofelis heat-shock 
protein (DNAK) was demonstrated following M. haemofelis and ‘Ca. M. turicensis’ infection in cats 
(94, 351) but was not associated with protective immunity to either of these feline haemoplasmas.  
Studies on the porcine haemoplasma M. suis have concentrated on haematological outcomes of 
infection, such as anaemia (111), and documenting the humoral immune response to M. suis 
antigens such as the M. suis heat-shock protein HSP1 in search of vaccine candidates (142). 
Inoculation of HSP1 into naïve pigs was found to be immunogenic (91) but was not protective from 
subsequent M. suis infection (120).  
Other veterinary species and their immune response to haemoplasma infection have not yet been 
examined at molecular level.  
4.1.3 Previous studies on haemoplasmosis in rodents and the murine immune response to 
haemoplasma infection  
Anaemia (more specifically, approximately a 50% decrease in both red cell counts and haemoglobin 
concentrations) secondary to M. haemomuris (then named Bartonella muris) infection has been 
observed previously in young rats, rabbits, guinea pigs and mice, although no molecular 
characterisation of the used haemoplasma isolate could be attempted at the time to confirm its 
phylogeny (240). The authors also observed complement fixation at high dilutions of serum from 
infected rabbits when using bacterial haemoplasma suspensions from putative blood cultures in 
leptospira medium as antigen, suggesting that a Th2 humoral immune response was present (240). 
Complement binding was later also observed in infected mice (194).  
As has been observed in cats, pigs and other host species (see 1.2) infected with haemoplasmas, 
splenomegaly and peracute death have also been observed in M. haemomuris infection in rats (250) 
and mice (197). The study by Rikihisa, Kawahara (197) also describes probing of crude M. 
haemomuris antigen preparations with convalescent mouse sera by Western immunoblot, and 
found five major immunoreactive antigens ranging in size from 45 to 118kDa (Rikihisa, Kawahara et 
al. 1997). Identification of the antigens was not possible due to the whole genome sequence of M. 
haemomuris not being available to identify isolated proteins by mass spectroscopy. Similarly, as 
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there is a lack of an in vitro cultivation system, obtaining higher M. haemomuris protein quantities 
for purification of antigens was not feasible from mice.   
In mice, acute infection with E. coccoides appeared to have an interferon-lowering effect during 
ongoing viral infection experiments, potentially via interference with a Th1 immune response (253). 
The presence of a humoral immune response was confirmed by blocking infectivity of inocula by 
prior incubation with convalescent sera before inoculation via injection into susceptible mice (253). 
Iralu and Ganong (255) demonstrated hemagglutination of washed normal red blood cells of mice 
when incubated with washed E. coccoides infected red blood cells and concluded that infection 
occurs independently of humoral elements as they were not added to the in vitro experiment.  
4.1.4 Principal component analysis in immunology 
Immunological data are often analysed with simple tests, even when multiple relationships between 
the variables are possible or expected (352). These analyses often limit the statistical methods to 
non-parametric tests, as immunological data are rarely normally distributed between individuals 
(352). Often, there is a common underlying biological relationship to the observed changes that is 
hidden from direct observation of the data, such as ‘down-regulation’ or a ‘shift’ in immune 
response (353). Such relationships might also be subject to change depending on other variables, 
e.g. one cytokine might drive different effects in different environments, and the lack of knowledge 
about possible relationships in pilot studies must be accounted for (353). Multivariate analyses can 
account for such relationships amongst the variables if certain assumptions on the dataset, such as 
normality and homogeneity of variances, are met by the data. Principal component analysis (PCA) 
does not require such assumptions (354) and thus is better suited for use on highly structured data 
than multivariate analyses.  
Immunological studies often aim to identify clusters of immunological changes (profiles) based on 
previously described immunological changes, unless more specific questions on risk factors or known 
causative relationships can be asked (353). In the mouse model of haemoplasma infection, the 
desired clusters of immunological changes would ideally differentiate mice that show protection 
from re-infection with M. haemomuris from mice undergoing naïve M. haemomuris infection, 
despite the absence of other defined variables such as degree of anaemia, splenomegaly or possible 
other, as yet uncharacterised, laboratory changes associated with haemoplasma infection in mice in 
our model. Only when immunological changes reflecting protection from infection or 
haematological/clinical changes are better defined in the mouse model, can the model be used to 
identify risk factors for more severe clinical disease. Such knowledge of the immunological changes 
can also help investigate further research questions on transmission, therapy or vaccination against 
M. haemomuris infection.  
Principal component analysis identifies and investigates clusters within a dataset of correlated 
variables (such as cytokines) and subsequently guides further analyses without making assumptions 
about the underlying dataset (353). Principal component analysis reduces the dimensionality of the 
data by creating summary variables reflecting changes in two or more of the original variables. These 
summary variables are referred to as principal components or factors, depending on the conceptual 
assumptions made. The term factor is used when assuming that an underlying force (not included in 
the measurements) is driving the observed changes and associations. The term component reflects 
intrinsic relationships within the dataset of correlated variables that can be reduced in dimensions 
for a simpler form of analysis. Principal components are linear combinations of the underlying 
variables, although non-linear relationships may still be accounted for by transformation of the 
dataset (355). Each original datapoint is related to the new principal component by its ‘loading’, 
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reflecting the weight the original variable has on the extracted component; bigger loadings reflecting 
more influential variables. Loadings allow each datapoint to be assigned a new ‘component score’, 
that represents the original datapoint on the new component axis and can subsequently be used for 
analyses without reducing the information content (353). The clustering of component scores (e.g. 
reflecting cytokine concentrations on the extracted principal component) in reduced dimensions 
(e.g. data can now be plotted on three component axes instead of 30 cytokines by having all ‘high’ 
cytokines loading on a single component) and their relationship with other variables of infection can 
then be used to allow the dataset to better reflect the underlying immune response e.g. showing a 
Th1/Th2 bias (356).  
4.1.5 What does it take to validate mouse models? 
A validated mouse model is one in which there is significant overlap and analogies of the factors 
contributing to the model and the modelled disease (218). However, significance is a subjective 
measure and defined by a researcher and acceptance through the scientific community. However, it 
is generally assumed that there must be a large amount of overlapping data e.g. in response to 
infection, in the underlying biological phenomenon or the phylogenetic characteristics of a pathogen 
or model species. The data required for this overlap are directly dependent on the research 
objective, and some models might be better suited than others depending on the research objective 
(357).  
Research objectives must be clearly articulated to choose which animal model would be most 
suitable, or whether a single animal model or a combination or models would be more suitable for 
the infectious disease research (357). Different objectives e.g. investigating pathophysiology, or 
virulence factors versus the host immune response to infection, may require different animal 
models. Colby, Quenee (357) list several viral and bacterial infections which have mouse, guinea pig, 
ferret or non-human primate models available, each having different advantages depending on the 
research objective being investigated. For most measures to prevent infection with viral or bacterial 
pathogens, preference has been given to mouse models due to their small size allowing cost-
effective studies with relatively high animal numbers, even if they require a mouse-adapted strain of 
pathogen to be used and only few or no clinical signs are seen in mouse models e.g. for Ebola or 
Influenza virus (357). 
To select and validate the best model for a given research objective, Denayer, Stöhr (313) proposed 
a fit-for-purpose validation of animal models according to number of different criteria: 
• face validity, the similarity in the biology and symptoms between the model and disease 
• predictive validity, the similarity of clinical interventions (e.g. drugs) leading to similar effects 
• target validity, the similarity of the role of the target of investigation (e.g. receptor) in the 
model and disease.  
Although these criteria can be employed for general validation of an animal model, fit-for-purpose 
weighting of these criteria is suggested for individual objectives e.g. when studying pathological 
mechanisms of a disease, the face validity of the model is more important than other criteria.   
Using a similar but more detailed scoring system, Sams-Dodd (358) concluded that a model’s face 
validity is higher when more symptoms match. For our current surrogate mouse model of 
haemoplasma infection that has been established in Chapter 3, more clinical, pathological and 
laboratory data need to be collected to fully describe the biology and symptoms for face validity, 
which is difficult due to mice often hiding clinical signs (312) and their small size limiting collection of 
multiple blood samples over the course of M. haemomuris infection from the same animal. Scores of 
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model face validity (358) are also based on the phylogenetic relationship between the host species 
of model and disease, but are only established for human disease models. In human disease models 
a higher score is assigned to primates compared to other less related species for example, but this 
cannot be extrapolated to other veterinary species as they show a more distant phylogenetic 
relationship to mice than humans do (359). Ultimately, an animal model should only be used when 
the research question cannot be answered by other non-experimental animal means, typically 
shifting the use of models to pre-clinical drug testing and vaccine development, where repeatability 
cannot easily be achieved in human cohorts (360). However, as haemoplasmas remain unculturable 
in vitro, even basic questions regarding their pathogenic mechanisms cannot be studied outside of 
the host, thus adding an additional criterion of being able to investigate basic pathophysiology of 
haemoplasmosis to a fit-for-purpose definition of mouse model validation.  
The above considerations on model development and validation suggest that the current mouse 
model of haemoplasma infection described in Chapter 3 appears to lack a proof of repeatability due 
to the low mouse numbers used (group sizes of 8 mice to study infection kinetics after primary 
inoculation, cross-inoculation and protection from re-infection) and the high proportion of infection 
failures (4 out of 8 mice during primary inoculation) observed. However, protection from re-
infection with M. haemomuris was confirmed in mice, hence allowing us to use this mouse model to 
assess the immunological response to M. haemomuris infection and protection from-re-infection. 
Other research objectives to describe the pathophysiology of different haemoplasmas cannot be 
studied in our mouse model. There are no data currently available listing variables that are affected 
by haemoplasma infection yet alone determining whether M. haemomuris infection causes clinical 
signs of haemoplasmosis and associated laboratory changes in C57BL/6 mice.  
4.1.6 Objective 
This chapter explores the effect of M. haemomuris-infection and re-infection on murine 
haematology parameters, spleen size and plasma cytokine expression over two weeks following 
inoculation with M. haemomuris. Our aim was to define the pathological and laboratory changes 
associated with haemoplasmosis due to M. haemomuris in mice and use PCA to identify a cytokine 
signature of protection from re-infection compared to naïve infection with M. haemomuris. These 
studies will inform further studies that could provide possible insights into the immunisation against 




4.2 MATERIALS AND METHODS 
4.2.1 Animals 
All mice were female, SPF C57BL/6 and sourced from Harlan Laboratories UK Ltd., Loughborough, 
UK. The mice used for the studies described in this chapter were split into ‘haematology study’ and 
‘cytokine expression study’ animals due to limitations on analyses possible on each blood sample 
taken due to sample volume requirements and processing time. Both the haematology study and 
the cytokine expression study included samples collected over the first 14 days of naïve M. 
haemomuris infection, and the cytokine expression study also included samples collected over the 
first 14 days after re-inoculation with M. haemomuris.  
4.2.1.1 Ethical approval 
All studies involving laboratory rodents were subject to ethical review (Animal Welfare Ethical 
Review Body of the University of Bristol) and covered by a Home Office licence (PPL PCFCBE2EB). 
4.2.1.2 Housing conditions 
All mice were housed and monitored as previously described in 2.2.3.2. 
4.2.1.3 Screening mice for pre-existing M. haemomuris-infection  
Upon arrival at the facility, mice were allowed an acclimatisation period and one week before all 
experiments, mice were uniquely identified and had a 10µl blood sample withdrawn for generic 
haemoplasma qPCR analysis to screen for pre-existing M. haemomuris infection, as outlined in 
2.2.3.3.  
4.2.1.4 Haemoplasma inoculation  
4.2.1.4.1 Cryopreservation 
The cryopreservation of inocula for infecting mice was modified from previous studies (2.2.3.7) to 
account for potential DMSO toxicity. In brief, blood samples for cryopreservation were collected as 
previously described but mixed with 20% (v/v) glycerol (Sigma) instead of DMSO, and frozen at -80°C 
until use where cryopreservation was required. When uniform inocula needed to be generated to 
infect large groups of mice, blood was collected and used immediately, without cryopreservation, to 
try and allow for optimal M. haemomuris viability.  
4.2.1.4.2 Inoculation Procedure 
The inoculation procedures for the studies described in this chapter were as for the procedures 
described in 2.2.3.4.1, other than the handling of mice prior to inoculation was different as it 
required optimisation to accommodate the increased mouse number as outlined below in 
4.2.1.4.2.1. 
4.2.1.4.2.1 High-throughput inoculation 
Inoculation procedures were modified for use in the studies described in this chapter so that they 
could be completed by one person within a period of five minutes of obtaining the infected blood 
sample inoculum from an amplifier mouse. To minimise the time spent handling and identifying the 
mice, subsets of the experimental mice were separated into small plastic containers (containing 
litter and a cereal treat) prior to inoculation and placed back into their original cages upon 




Figure 25 Cages containing a subset of mice for the cytokine expression study, taken out and placed on the work surface 
before transferring the individual mice into the small plastic containers (pipette tip containers, shown with open lids, 
containing litter and a cereal treat) for easy and quick inoculation. Separating the mice using these pipette containers 
avoided time delays following inoculum collection and inoculation, as the mice could be identified ahead of inoculum 
collection. Mice were removed from the small plastic containers, inoculated with 0.1ml Mycoplasma haemomuris-
containing mouse blood inoculum intraperitoneally and placed back into their respective cages. Inoculation of all mice 
receiving the same inoculum could be completed in less than five minutes by a single researcher.   
4.2.1.5 Haematology study 
4.2.1.5.1 Inoculation schematic 
An overview of the inoculation schematic for the haematology study is given in Figure 26.  
 
 
Figure 26 Inoculation schematic to outline the experimental design for the haematology study. Sixteen mice were 
inoculated with freshly collected Mycoplasma haemomuris-containing mouse blood and four mice each were exsanguinated 
on days 3, 7, 10 and 14 post inoculation. Four mice, housed under identical conditions, were not inoculated but 
exsanguinated on day 0, the day of inoculation of the other groups, as controls. Dpi: days post inoculation. 
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Twenty mice were split into five groups of four mice and each group housed in the same cage. 
Randomisation was achieved at the level of mouse delivery from the supplier and information 
regarding the original litters the mice were from was not available to the researcher.  
At the start of the experiment, 16 mice were inoculated with M. haemomuris using inocula 
generated from freshly collected blood from amplifier mice. The four remaining mice were not 
inoculated and were exsanguinated under terminal anaesthesia as previously described (2.2.3.7) on 
day 0 of the experiment to act as uninfected controls. Further subsets of 4 mice each were 
exsanguinated on 3, 7, 10 and 14 days post-inoculation (dpi).  Anticoagulated blood collected at the 
time of exsanguination (see 4.2.2.1.3) underwent haematological analysis, as described below in 
4.2.4.   
4.2.1.5.2 Generating inocula in amplifier mice 
The haematology study was preceded by production of amplifier mice to generate the inocula for 
use in the haematology group (Figure 26). The amplifier mice preceding the haematology study were 
produced by the inoculation of a M. haemomuris isolate that had undergone seven serial passages in 
C57BL/6 mice since sourcing the original rodent haemoplasma isolates from field mice (2.2.1).  
4.2.1.5.2.1 Description of inocula used to inoculate the amplifier mice preceding the haematology 
study 
Three ten-week-old mice were inoculated with M. haemomuris-infected blood immediately 
following its collection from the tail vein of a M. haemomuris-infected mouse as previously 
described 2.2.3.4.1. The origin and composition of inocula used to inoculate the laboratory amplifier 
mice is given in Table 27.  
Mouse ID 
 
Organism Origin Cryopreservation Dilution ratio 
of inoculum in 
PBS 
M. haemomuris dose in 
0.1ml of inoculum per 
mouse 
Amplifier H1, 
Amplifier H2  
and Amplifier H3 
M. haemomuris Blood from a 
C57BL/6 
mouse 
None  1:4  6.91E+04 
Table 27 Origin and composition of inocula used to inoculate the amplifier mice preceding inoculation of the haematology 
group. These amplifier mice were subsequently used to generate inocula for the experiment as described in Figure 26. 
Inoculum haemoplasma doses were calculated as in2.2.1.2.2.2. PBS, phosphate buffered saline. 
Following inoculation, amplifier mice were monitored for M. haemomuris infection by taking blood 
samples of 10µl for qPCR analysis, using a M. haemomuris-specific qPCR assay, as described 
previously (3.2.2.3.2). At seven dpi (when harbouring 1.23E+07 M. haemomuris genome copies per 
µl blood), one mouse (‘Amplifier H1’, see Table 27) was exsanguinated under terminal anaesthesia, 
as previously described (2.2.3.7), to produce the inocula for the haematology group mice. The 
remaining two amplifier mice (‘Amplifier H2’ and ‘Amplifier H3’) remained unused but had been 
generated for contingency considerations (i.e. if less than the required blood volume could be 
collected from one or two of the amplifier mice) and were included in subsequent experiments for in 
vitro culture studies, as described in Chapter 5. 
4.2.1.5.3 Monitoring of haematological changes during primary M. haemomuris infection  
4.2.1.5.3.1 Description of inocula used for the haematology group 
Twenty ten-week-old mice were housed in five cages (A, B, C, D and E) of four mice each. After an 
acclimatisation period of two weeks, sixteen mice in cages B to E were each inoculated with 0.1ml of 
a M. haemomuris-containing inoculum that had been prepared from freshly collected, heparinised 
blood, generated in amplifier mice. The origin and composition of the inocula are given in Table 28. 
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The sixteen mice were inoculated in sequential order of mouse ‘1’ to ‘4’ from cages B to E using the 
technique described in 2.2.3.4.1. The four mice in cage “A” did not receive any inocula and acted as 
controls as described in 4.2.1.5.1.  
Mouse 
ID 
Cage Origin Cryopreservation Dilution ratio 
of inoculum 
in PBS 
M. haemomuris dose 





1, 2, 3, 4 A n/a n/a n/a n/a 0 
1, 2, 3, 4 B Amplifier H1 None 1:4 3.08E+08  3 
1, 2, 3, 4 C Amplifier H1 None 1:4 3.08E+08  7 
1, 2, 3, 4 D Amplifier H1 None 1:4 3.08E+08  10 
1, 2, 3, 4 E Amplifier H1 None 1:4 3.08E+08  14 
Table 28 Origin and composition of inocula used to inoculate the haematology group mice. One amplifier mouse (Table 1) 
was killed at seven days post inoculation (dpi) and inocula generated from its blood used without cryopreservation. On day 
0 of the experiment, all mice in cages B to E were inoculated with M. haemomuris-infected blood. Cage A mice were not 
inoculated and acted as controls. The mice in subgroup 0 were subsequently exsanguinated for collection of EDTA-
anticoagulated blood, followed by the same exsanguination procedure for each subgroup of four mice on 3, 7, 10 and 14 
dpi. PBS, phosphate buffered saline. n/a, not applicable. 
Following inoculation, mice were then exsanguinated in groups of 4 mice per day, at 0 (without prior 
inoculation) 3, 7, 10 and 14 dpi to collect EDTA-anticoagulated blood for haematological analysis.  
4.2.1.5.3.2 Monitoring of haemoplasma infection 
As repeated blood sampling may have interfered with haematological parameters, no daily sampling 
to monitor for M. haemomuris infection was attempted from the haematology group mice. Samples 
to determine M. haemomuris loads via qPCR were taken at post-mortem examination as will be 
described later in 4.2.2.1.2.  
4.2.1.6 Cytokine expression study 
4.2.1.6.1 Inoculation schematic 





Figure 27 Inoculation schematic to outline the experimental design of the cytokine expression study. In Phase 1 of the 
experiment, half of the mice (re-inoculation group and re-inoculation control group) were inoculated with M. haemomuris 
and subsequently monitored by qPCR for M. haemomuris genome copies per µl blood. The other half of the mice (naïve 
group and naïve control group) remained naïve to infection but was subjected to the same procedures (blood sampling: 
naïve group mice were sampled as the re-inoculation group mice and the naïve control group mice were sampled as the re-
inoculation control group mice) and housed under the same conditions as the mice inoculated with M. haemomuris. Control 
groups (re-inoculation control group and naïve control group) were used to allow more frequent blood sampling following 
inoculation without potentially interfering with cytokine expression in the main experimental groups that subsequently 
were not sampled following Phase 2 inoculations. Following recovery from infection of the inoculated mice in the Recovery 
phase, all mice were inoculated with M. haemomuris-containing blood In Phase 2 of the experiment. Naïve group mice and 
re-inoculation group mice were exsanguinated in subgroups of seven mice on days 0, 1, 2, 3, 7, 10 and 14 post Phase 2 
inoculations with M. haemomuris. Groups exsanguinated on 0 days post inoculation (dpi) were not inoculated in Phase 2 
before exsanguination for sample collection. Control mice (naïve control group and re-inoculation control group) were used 
to monitor naïve infection and re-infection following Phase 2 inoculations for 14 days as no consecutive sampling was 
attempted in the main experimental mice (naïve group and re-inoculation group). Two sets of amplifier mice (one for Phase 
1 and one for Phase 2) were used to generate inocula for all groups. Blood was pooled from two amplifier mice each to 
generate one inoculum in order to ensure comparable doses of M. haemomuris copies per mouse to be inoculated. 




Ninety-eight experimental mice were split into two groups of 49 mice each. These groups comprised 
seven subgroups of seven mice each and were housed in groups of four and three mice per cage as 
summarised later in Table 33. Randomisation was achieved at the level of mouse delivery from the 
supplier and information regarding the original litters the mice were in was not available to the 
researcher. Experimental groups were matched in age to address potential effects of ageing on 
cytokine expression and immunity. One group (naïve group) of 49 mice was inoculated with M. 
haemomuris to assess plasma cytokine expression in response to primary M. haemomuris infection 
and another one group (re-inoculation group) was inoculated with M. haemomuris, recovered from 
infection and re-inoculated with M. haemomuris to assess plasma cytokine expression associated 
with partial protection from re-infection as was described in the infection studies in Chapter 3. 
Frequent serial blood sampling of the 98 main experimental mice would likely have interfered with 
plasma cytokine expression, and so could not be performed, but daily monitoring of M. haemomuris 
genome copies per µl blood was required for confirmation of inoculum viability, to monitor recovery 
from infection and assessment of protective immunity. To resolve the problem of being unable to 
serially sample the mice to monitor M. haemomuris infection, two groups each of six control mice 
were inoculated using the same inoculum as the main experimental mice to be used for frequent 
monitoring of M. haemomuris genome copies within their blood; the naïve control group was 
inoculated the same as was the naïve group and the re-inoculation control group was inoculated the 
same as was the re-inoculation group. Two sets of amplifier animals were used to produce inocula 
with viable M. haemomuris preceding Phase 1 and Phase 2 of the experiment. 
Phase 1 of the experiment (see Figure 27) represents primary infection with M. haemomuris of the 
re-inoculation group and inoculation of the re-inoculation control group. Phase 1 also includes the 
start of the experiment for the naïve group and naïve control group. Infection with M. haemomuris 
was monitored at 0, 1, 2, 3, 7, 10 and 14 dpi in the re-inoculation group (samples from the naïve 
group were taken on the same days but did not undergo further testing) and daily for 14 dpi in the 
re-inoculation control group (samples from the naïve control group were taken on the same days but 
did not undergo further testing). 
The ‘Recovery phase’ between Phase 1 and Phase 2 represents the period when mice, previously 
inoculated with M. haemomuris ‘recovered’ from M. haemomuris infection. Recovery was 
monitored in the re-inoculation control group to avoid sampling of the re-inoculation group. The 
naïve control group was subject to the same blood sampling procedures as the re-inoculation control 
group, but samples did not undergo further testing. No samples were taken from the naïve group 
and the re-inoculation group during the Recovery phase. 
In Phase 2 of the experiment, the re-inoculation group (except subgroup 0) and re-inoculation 
control group were re-inoculated with M. haemomuris. Phase 1 also included the primary M. 
haemomuris inoculation of the naïve group mice (except subgroup 0) and naïve control group. 
Following Phase 2 inoculations, naïve group mice and re-inoculation group mice were exsanguinated 
in sets of seven mice per day and group on days 0, 1, 2, 3, 7, 10 and 14 dpi to collect EDTA-plasma 
for cytokine analysis. Subgroup names (see Figure 27) refer to the dpi of exsanguination. Naïve 
controls and re-inoculation controls were monitored for M. haemomuris infection for 14 dpi.
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4.2.1.6.2 Generating inocula in amplifier mice 
The experiment was split into Phase 1 and Phase 2 and each phase was preceded by production of 
amplifier mice to generate inocula for use in the two main experimental groups and two control 
groups (Figure 27). The amplifier mice preceding Phase 1 of the experiment were produced by the 
inoculation of isolates that had undergone seven serial passages in C57BL/6 mice since sourcing the 
original rodent haemoplasma isolates from field mice (Apodemus spp.) samples. The amplifier mice 
preceding Phase 2 of the experiment were produced by the inoculation of isolates that had 
undergone eight serial passages in C57BL/6 mice since isolation from field mice (2.2.1).  
4.2.1.6.2.1 Description of inocula used for the amplifier mice preceding Phase 1  
Eight nine-week-old mice were inoculated with 0.1 ml cryopreserved blood containing M. 
haemomuris. Origin and composition of inocula used to inoculate these laboratory mice is given in 
Table 29.  
Mouse ID 
 
Organism Origin Cryopreservation Dilution ratio 
of inoculum in 
PBS 
M. haemomuris dose in 








Amplifier C7  
and Amplifier C8 
M. haemomuris Blood from 
C57BL/6 
mouse 
20% v/v Glycerol None  2.63E+06 
Table 29 Origin and composition of inocula used to inoculate the amplifier mice preceding Phase 1 of the cytokine 
expression study. These mice were subsequently used to generate further inocula for the experiment as illustrated in Figure 
27. The donor mouse to generate inocula used in amplifier mice preceding Phase 1 had been exsanguinated by cardiac 
puncture at 14 dpi with M. haemomuris; eight samples were cryopreserved at – 80°C and stored for 28 days prior to use. M. 
haemomuris dose was calculated as in 2.2.1.2.2.2. PBS, phosphate buffered saline.  
Inocula were allowed to defrost at room temperature for 10 minutes and were inoculated 
intraperitoneally as previously described (2.2.3.4.1). Following inoculation, the eight amplifier mice 
preceding Phase 1 were monitored daily for M. haemomuris infection using a species-specific M. 
haemomuris qPCR assay as previously described (3.2.2.3.2).  
4.2.1.6.2.2 Inocula generated from amplifier mice preceding Phase 1  
Seven dpi sets of two amplifier mice each were exsanguinated through cardiac puncture and 
heparinised whole blood was gently mixed in a 5ml Sterilin tube (Thermo Fisher) to produce an 
inoculum aliquot (Table 30) to inoculate the re-inoculation group and re-inoculation control group in 
Phase 1 of the cytokine expression study (see Figure 27). Pooling of blood from two amplifier mice 
each was required to ensure volumes large enough to inoculate multiple subgroups of the main 
experimental mice from the same inoculum aliquot. The inocula for Phase 1 were used within ten 
minutes of exsanguinating the amplifier mice and did not undergo further storage or preservation. 
The remaining four amplifier mice (‘Amplifier C5’ to ‘Amplifier C8’) remained unused but had been 
generated for contingency considerations (i.e. if less than the required blood volume could be 
collected from one or two of the amplifier mice) and were included in subsequent experiments for in 





Inoculum aliquot ID Origin   Blood volume 
obtained from 
exsanguination (ml) 
M. haemomuris copies per 
µl blood 
Dilution ratio of 
inoculum in PBS 
Pool 1 Amplifier C1  0.6 6.02E+04 1:4  
Amplifier C2  0.6 3.04E+04  
Pool 2 Amplifier C3 0.5 7.91E+05 1:4 
 Amplifier C4 0.5 7.54E+04  
Table 30 Origin and composition for Phase 1 inoculum aliquots that were used to inoculate the re-inoculation group and re-
inoculation control group in Phase 1 of the cytokine expression study (Figure 27). M. haemomuris copies per µl blood were 
calculated as in 2.2.1.2.2.2. PBS, phosphate buffered saline. 
4.2.1.6.2.3 Description of inocula used for the amplifier mice preceding Phase 2  
Eighteen weeks after the Phase 1 inoculations, twelve nine-week old mice were inoculated with 
blood containing M. haemomuris. The origin and composition of inocula used to inoculate these 
laboratory mice is given in Table 31.  
Mouse ID 
 
Organism Origin Cryopreservation Dilution ratio 
of inoculum in 
PBS 
M. haemomuris dose in 














and Amplifier C21 
M. haemomuris Blood from 
C57BL/6 
mouse 
None  1:4 5.21E+06 
Table 31 Origin and composition of inocula used to inoculate the amplifier mice preceding Phase 2 of the cytokine 
expression study. These mice were subsequently used to generate further inocula for the experiment as illustrated in Figure 
27. The donor mouse to generate inocula used in amplifier mice preceding Phase 2 had been exsanguinated by cardiac 
puncture at 15 dpi with M. haemomuris and blood was used without further cryopreservation. M. haemomuris dose was 
calculated as in 2.2.1.2.2.2. PBS, phosphate buffered saline.  
Inocula were used without cryopreservation and inoculated intraperitoneally as previously described 
(2.2.3.4.1) within ten minutes of exsanguination of the donor mouse, used to collect M. 
haemomuris-infected blood. Following inoculation, the 12 amplifier mice preceding Phase 2, were 
monitored daily for M. haemomuris infection using a species-specific M. haemomuris qPCR assay as 
previously described (3.2.2.3.2).  
4.2.1.6.2.4 Inocula generated from amplifier mice preceding Phase 2  
Six days after inoculation, subsets of two amplifier mice each were exsanguinated through cardiac 
puncture and heparinised whole blood was gently mixed in a 5ml Sterilin tube (Thermo Fisher) to 
produce an inoculum aliquot (Table 32) to inoculate re-inoculation group, naïve group, re-
inoculation control group and naïve control group in Phase 2 of the cytokine expression study (see 
Figure 27). Pooling of blood was required to ensure volumes large enough to inoculate multiple 
subgroups of the main experimental mice from the same inoculum aliquot. Six amplifier mice 
remained unused due to contingency considerations (i.e. collecting less than the required blood 









M. haemomuris copies per 
µl blood 
Dilution ratio of 
inoculum in PBS 
Pool 3 Amplifier C9    0.4 5.65E+07 1:4  
Amplifier C10  0.6 5.50E+07  
Pool 4 Amplifier C11  0.5 4.86E+07 1:4  
Amplifier C12 0.4 3.43E+07  
Pool 5 Amplifier C13 0.5 2.91E+07 1:4  
Amplifier C14 0.6 5.53E+07  
Table 32 Origin and composition for Phase 2 inoculum aliquots that were used to inoculate the re-inoculation group, naïve 
group, re-inoculation control group and naïve control group in Phase 2 of the cytokine expression study (Figure 27). M. 
haemomuris copies per µl blood were calculated as in 2.2.1.2.2.2. PBS, phosphate buffered saline. 
4.2.1.6.3 Phase 1: Primary infection of re-inoculation group and re-inoculation controls 
4.2.1.6.3.1 Re-inoculation group: Description of inocula used for primary infection 
Forty-nine, nine-week-old mice were split into seven subgroups of seven mice each and housed in 
cages of four and three animals per subgroup. Mice ‘1’ to ‘4’ were housed in the first cage and mice 
‘4’ to ‘7’ were housed in the second cage of each group (see cage allocations in Table 33).  After an 
acclimatisation period of two weeks, mice were inoculated with 0.1ml of a M. haemomuris-
containing inoculum that had been generated in amplifier mice preceding Phase 1 of the experiment 
and prepared in aliquots by pooling freshly collected, heparinised blood and diluting it with PBS as 
described in 4.2.1.6.2.2. Origin and composition of inoculum aliquots has been given in Table 30 
above. Two inoculum aliquots were used as inocula for seven experimental groups of seven mice 
each. The origin (inoculation aliquot) and composition of the inocula used to inoculate the re-





Group inoculated Mouse ID Cage ID M. haemomuris 
dose in 0.1ml of 








Re-  1, 2, 3, 4 O 1.13E+07  Pool 1 0 
inoculation 5, 6, 7 P    
group 1, 2, 3, 4 Q 1.13E+07  Pool 1 1 
 5, 6, 7 R    
 1, 2, 3, 4 S 1.13E+07  Pool 1 2 
 5, 6, 7 T    
 1, 2, 3, 4 U 1.13E+07  Pool 1 3 
 5, 6, 7 V    
 1, 2, 3, 4 W 1.93E+07  Pool 2 7 
 5, 6, 7 X    
 1, 2, 3, 4 Y 1.93E+07  Pool 2 10 
 5, 6, 7 Z    
 1, 2, 3, 4 A2 1.93E+07  Pool 2 14 




Naïve group 1, 2, 3, 4 A n/a n/a 0 
 5, 6, 7 B    
 1, 2, 3, 4 C n/a n/a 1 
 5, 6, 7 D    
 1, 2, 3, 4 E n/a n/a 2 
 5, 6, 7 F    
 1, 2, 3, 4 G n/a n/a 3 
 5, 6, 7 H    
 1, 2, 3, 4 I n/a n/a 7 
 5, 6, 7 J    
 1, 2, 3, 4 K n/a n/a 10 
 5, 6, 7 L    
 1, 2, 3, 4 M n/a n/a 14 
 5, 6, 7 N    
Table 33 Origin and composition of inocula used to inoculate the mice in Phase 1 of the cytokine expression study. On day 0 
of Phase 1 the 49 re-inoculation group mice were inoculated with 0.1ml of an inoculum that had been produced in aliquots 
(Table 30) by pooling and diluting blood from amplifier mice (Table 29). Phase 1 represents the primary M. haemomuris 
infection of the re-inoculation group and Phase 2 represents the re-inoculation of the re-inoculation group and coinciding 
primary infection of the naïve group. No mice were exsanguinated during Phase 1. Dpi, days post (Phase 2) inoculation. N/a, 
not applicable. 
Mice were inoculated in sequential order of mouse ‘1’ to ‘7’ per subgroup and subgroups in the 
order of subgroups ‘0’ to ‘14’ using the technique described in 4.2.1.4.2. To ensure inoculum 
composition did not change within the same subgroup, the remaining inoculum aliquot was 
discarded if its volume dropped below 0.8ml. Exsanguination of amplifier mice to generate an 
inoculation aliquot and inoculation of the same aliquot into experimental mice was completed 
within ten minutes.  
4.2.1.6.3.2 Re-inoculation control group: Description of inocula used for primary infection 
After inoculation of the re-inoculation group (4.2.1.6.3.1) in Phase 1 of the experiment, another set 
of six, eight-week-old mice were housed in two cages of three mice each and inoculated with 0.1ml 
of a M. haemomuris-containing inoculum that had been generated in amplifier mice preceding Phase 
1 of the experiment and prepared as inoculum aliquots (Table 30). Each of the inoculum aliquots 
used for primary inoculation of the re-inoculation group (Table 33) was also used to inoculate three 
re-inoculation control group mice immediately after completing the inoculation procedure in the re-
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inoculation group. The re-inoculation control group was used to ensure inoculum viability 
throughout the inoculation procedure and monitor subsequent M. haemomuris infection and 
recovery from infection as frequent sampling of the re-inoculation group mice was avoided to 
minimise effects on cytokine expression. The origin (inoculum aliquot) and composition of the 
inocula used to inoculate the re-inoculation control group in Phase 1 is given in Table 34. 
Mouse ID 
(re-inoculation control group) 









D2 Pool 2 
 
 
Table 34 Re-inoculation control group mice as inoculated to monitor primary M. haemomuris infection in Phase 1 of the 
cytokine expression study. 
4.2.1.6.3.3 Monitoring of M. haemomuris infection after Phase 1 inoculations 
Following primary inoculation of the re-inoculation group (4.2.1.6.3.1), these mice were monitored 
for M. haemomuris infection at 0, 1, 2, 3, 7, 10 and 14 dpi by withdrawing 10µl of blood followed by 
M. haemomuris-specific qPCR as described above (3.2.2.3.2).  
Following primary inoculation of the re-inoculation control group (4.2.1.6.3.2), these mice were 
monitored for M. haemomuris infection once daily at 0 to 14 dpi by withdrawing 10µl of blood 
followed by M. haemomuris-specific qPCR as described above (3.2.2.3.2).  
Additionally, all inoculated mice were monitored for clinical signs at least once a day and three times 
daily around expected peak parasitaemia, approximately one to two weeks after inoculation (see 
infection kinetics described in Chapter 3; 3.3.2.2). 
4.2.1.6.3.4 Naïve group 
Forty-nine eight-week-old female mice were split into seven subgroups of seven mice each and 
housed in cages of four and three animals per subgroup. Mice ‘1’ to ‘4’ were housed in the first cage 
and mice ‘4’ to ‘7’ were housed in the second cage of each group (see cage allocations in Table 33). 
After an acclimatisation period of two weeks and coinciding with the primary M. haemomuris 
infection of the re-inoculation group (4.2.1.6.3.1), mice had 10µl of blood taken on days 0, 1, 2, 3, 7, 
10 and 14 of the experiment, equivalent to dpi of the re-inoculation group, 4.2.1.6.3.1. Collected 
samples did not undergo further testing except for samples taken immediately prior to Phase 2 
inoculations (presented later in 4.2.1.6.5). This sampling was performed to control for the possible 
effects of blood sampling (including wound healing, associated stress) on immunity in Phase 2 of the 
experiment.   
4.2.1.6.3.5 Naïve control mice 
Another set of six, eight-week-old mice were housed in cages of three mice each and subject to the 
same blood sampling regiment as the re-inoculation control group (once daily for 14 dpi, see 
4.2.1.6.3.3). Collected samples did not undergo further testing except for samples taken immediately 
prior to Phase 2 inoculations (presented later in 4.2.1.6.4). The naive control group was used to 
monitor primary M. haemomuris infection in Phase 2 of the experiment (presented later in 
4.2.1.6.5.2). 
4.2.1.6.4 Recovery phase in-between Phase 1 and Phase 2 
Fourteen days after Phase 1 inoculations (4.2.1.6.3.1 and 4.2.1.6.3.2), in the Recovery phase, the 
blood sampling frequency in the re-inoculation control group and naïve control group was reduced 
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and these mice were only sampled on days 21, 35, 42, 56, 98, 119 and 126 post Phase 1 inoculations. 
Samples from the re-inoculation control group were monitored for M. haemomuris infection using 
M. haemomuris-specific qPCR as described before (3.2.2.3.2) and samples from the naïve control 
group were not further analysed except samples taken 126 days post Phase 1 inoculations, to ensure 
M. haemomuris-negative status. The re-inoculation group and naïve group were not subject to any 
blood sampling during the Recovery phase.  
4.2.1.6.5 Phase 2: Plasma cytokine expression in mice previously infected with M. haemomuris 
after re-inoculation with M. haemomuris (re-inoculation group) and naïve mice after 
primary M. haemomuris infection (naïve group) 
4.2.1.6.5.1 Description of inocula used for re-inoculation of the re-inoculation group and primary 
infection of the naïve group 
One-hundred and thirty-one days after primary inoculations in Phase 1 (4.2.1.6.3.1), six out of seven 
subgroups of the re-inoculation group were inoculated with 0.1ml of a M. haemomuris-containing 
inoculum that had been generated in amplifier mice preceding Phase 2 of the experiment and 
prepared in aliquots by pooling freshly collected, heparinised blood and diluting it with PBS as 
described in 4.2.1.6.2.4. The origin and composition of inoculation aliquots has been given in Table 
32 above. Re-inoculation of the re-inoculation group coincided with primary infection of the 49 naïve 
group mice (see Figure 27). At the day of re-inoculation of the re-inoculation group, six out of seven 
subgroups of the naïve group were inoculated with 0.1ml of the same M. haemomuris-containing 
inoculum aliquot that was used to inoculate the corresponding subgroups of the re-inoculation 
group. Three inoculation aliquots were used as inoculum during Phase 2 inoculations. The origin 
(inoculation aliquot) and composition of the inocula used to inoculate the re-inoculation group and 





Group inoculated Mouse ID Cage ID M. haemomuris 
dose in 0.1ml of 







Phase 2  
Re-  1, 2, 3, 4 A - - 0 
inoculation 5, 6, 7 B    
group 1, 2, 3, 4 C 1.39E+09  Pool 3 1 
 5, 6, 7 D    
 1, 2, 3, 4 E 1.39E+09  Pool 3 2 
 5, 6, 7 F    
 1, 2, 3, 4 G 1.06E+09  Pool 4 3 
 5, 6, 7 H    
 1, 2, 3, 4 I 1.06E+09  Pool 4 7 
 5, 6, 7 J    
 1, 2, 3, 4 K 1.08E+09  Pool 5 10 
 5, 6, 7 L    
 1, 2, 3, 4 M 1.08E+09  Pool 5 14 
 5, 6, 7 N    
  
 
Phase 2  
Naïve group 1, 2, 3, 4 O - - 0 
 5, 6, 7 P    
 1, 2, 3, 4 Q 1.39E+09  Pool 3 1 
 5, 6, 7 R    
 1, 2, 3, 4 S 1.39E+09  Pool 3 2 
 5, 6, 7 T    
 1, 2, 3, 4 U 1.06E+09  Pool 4 3 
 5, 6, 7 V    
 1, 2, 3, 4 W 1.06E+09  Pool 4 7 
 5, 6, 7 X    
 1, 2, 3, 4 Y 1.08E+09  Pool 5 10 
 5, 6, 7 Z    
 1, 2, 3, 4 A2 1.08E+09  Pool 5 14 
 5, 6, 7 B2    
Table 35 Origin and composition of inocula used to inoculate the mice in Phase 2 of the cytokine expression study. On day 0 
of Phase 2 (corresponding to 131 days after Phase 1 inoculations) the re-inoculation group mice and naïve group mice were 
inoculated with 0.1 ml of an inoculum that had been produced in aliquots (Table 32) by pooling and diluting blood from 
amplifier mice (Table 31). The experiment was split in two parts, Phase 1 and Phase 2 (inocula presented here) with an 
interspersed Recovery phase (see Figure 27). Phase 1 represents the primary M. haemomuris infection of the re-inoculation 
group and Phase 2 represents the re-inoculation of the re-inoculation group and coinciding primary infection of the naïve 
group. No mice were exsanguinated during Phase 1. In Phase 2, all mice from the re-inoculation group and naïve group 
were exsanguinated for collection of EDTA-plasma in groups of seven mice (equivalent to one subgroup) per day at 0, 1, 2, 
3, 7, 10 and 14 dpi. Dpi, days post (Phase 2) inoculation. 
Mice were inoculated in sequential order of mouse ‘1’ to ‘7’ per subgroup and subgroups in the 
order of ‘1’ to ‘14’ using the technique described in 4.2.1.4.2. The order of inoculation of subgroups 
was matched across the main experimental groups; the identical subgroup was first inoculated in the 
re-inoculation group, then in the naïve group (i.e.  subgroup ‘1’ of the re-inoculation group was first 
inoculated, then subgroup ‘1’ of the naïve group followed by subgroup ‘2’ of the re-inoculation 
group, then subgroup ‘2’ of the naïve group, etc.). Subgroups ‘0’ did not receive any inocula during 
Phase 2. To ensure, inoculation aliquots did not change within the identical subgroups, the 
remaining inoculum was discarded if its volume dropped below 1.6ml. The higher volume cut-off 
compared to Phase 1 inoculations (0.8ml) was required to ensure subgroups of re-inoculation group 
mice and naïve group mice could be matched for inoculations as shown in Table 35 above. 
Exsanguination of amplifier mice to generate an inoculation aliquot and inoculation of the same 
aliquot into experimental mice was completed within ten minutes.  
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4.2.1.6.5.2 Re-inoculation control group and naive control group: Description of inocula used for re-
inoculation of the re-inoculation control group and primary infection of the naïve control 
group   
After re-inoculation of the re-inoculation group and primary inoculation of the naïve group 
(4.2.1.6.5.1) in Phase 2 of the experiment, the six previously inoculated re-inoculation control group 
mice (4.2.1.6.3.2) and the six naïve control group mice (4.2.1.6.3.5) were inoculated with 0.1ml of a 
M. haemomuris-containing inoculum that had been generated in amplifier mice preceding Phase 2 
of the experiment and prepared as inoculum aliquots (Table 32). Each of the inoculum aliquots used 
for Phase 2 inoculations (Table 33) was also used to inoculate one to three re-inoculation control 
group mice and one to three naïve control group mice immediately after completing the inoculation 
procedure in the main experimental groups. The varying number of inoculated mice was due to 
varying residual volumes of inoculation aliquots. The control groups were used to ensure inoculum 
viability throughout the inoculation procedure and monitor primary M. haemomuris infection in the 
naïve control group and protection from re-infection in the re-inoculation control group as sampling 
of the main experimental mice (re-inoculation group and naïve group) was avoided to minimise 
effects on cytokine expression. Origin (inoculation aliquot) and composition of inocula used to 




Cage ID Mouse ID 
(re-inoculation control 
group) 
Cage ID Origin 
(inoculation aliquot) 
Control 7 E2  Control 1 C2 Pool 3 
Control 8 
Control 9 
E2 Control 2 
Control 3 





F2 Control 4 
Control 5 
Control 6 
D2 Pool 5 
 
 
Table 36 Re-inoculation control group mice and naïve control group mice as inoculated to monitor M. haemomuris infection 
in Phase 2 of the cytokine expression study. Control mice ‘1’ to ‘6’ had previously been inoculated with M. haemomuris as 
shown in Table 34. 
Inoculum aliquots were used in the order given by their use in the main experimental mice 
(4.2.1.6.5.1) whilst inoculating the re-inoculation control group mice prior to the naïve control group 
mice from the same inoculum aliquot to ensure optimal inoculum viability in the re-inoculation 
control group mice and avoid attributing protection from re-infection to reduced inoculum viability.  
4.2.1.6.5.3 Monitoring of haemoplasma infection after Phase 2 inoculations 
As blood sampling may have interfered with plasma cytokine expression, no daily sampling to 
monitor M. haemomuris infection was attempted from the re-inoculation group and naïve group 
mice (4.2.1.6.5.1 and Figure 27). Samples to determine M. haemomuris genome copies per µl blood 
by M. haemomuris-specific qPCR were obtained post-mortem from the main experimental mice, as 
will be described later in 4.2.2.2.2.  
Mice from these two main experimental groups (re-inoculation group and naïve group) were 
subsequently killed in groups of seven mice per day on days 0, 1, 2, 3, 7, 10 and 14 after Phase 2 
inoculations to collect EDTA-plasma for cytokine analysis as described later in 4.2.2.2.4 and 4.2.5. 
Re-inoculation control group mice and naïve control group mice were monitored for M. haemomuris 
infection on days 1 to 14 post (Phase 2) inoculations (4.2.1.6.5.2) by M. haemomuris-specific qPCR. 
Additionally, they were monitored for clinical signs at least once a day and three times daily over 
expected peak parasitaemia approximately one to two weeks post inoculation (see infection kinetics 
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described in Chapter 3; 3.3.2.2). All mice from both control groups were exsanguinated under 
terminal anaesthesia at the end of the experiment, 14 days post Phase 2 inoculations.  
4.2.2 Sample collection and processing of blood samples from laboratory mice 
4.2.2.1 Sample collection during the haematology study 
4.2.2.1.1 Collection of blood samples for qPCR from the amplifier mice 
Samples from the amplifier mice preceding the haematology study (4.2.1.5.2) were collected once a 
day by venepuncture of the tail via a heparin-coated microcapillary tube and diluted in PBS as 
described previously (2.2.3.3.2.1). Samples were stored at -80°C until DNA extraction and qPCR. 
4.2.2.1.2 Collection of blood samples for qPCR from the haematology study mice 
Samples were collected by dipping an uncoated capillary tube (Hawskley & Sons) into the hub of the 
needle used for cardiac puncture (collected blood containing approximately 2.5mM EDTA) and 
allowing the tube to fill up to a pre-placed mark at 10µl. The capillary tube was then emptied into 
90µl of PBS as described previously (2.2.3.3.2.1). Samples were stored at -80°C until DNA extraction 
and qPCR. 
4.2.2.1.3 Collection of EDTA-anticoagulated whole blood for haematological analysis from the 
haematology group mice  
Syringes (1ml; Becton Dickinson) were equipped with 5/8-inch 23G needles (Terumo) and preloaded 
with EDTA by drawing up a 25µl droplet of 50mM EDTA (Sigma-Aldrich) from a water-repellent 
surface. This procedure was completed on each day of EDTA-plasma collection, immediately prior to 
anaesthesia. Four mice were anaesthetised on days 0, 3, 7, 10 and 14 after inoculation of the 
haematology group mice and blood was collected by cardiac puncture as previously described 
(2.2.3.7), replacing heparinised syringes with the EDTA-preloaded syringes produced prior to 
anaesthesia. EDTA-anticoagulated whole blood samples were returned to the laboratory and stored 
at 4°C until analysis. Storage time was kept to a minimum to prevent reported changes in 
haematological parameters (361) and analysis was completed within a four-hour time window 
following sample collection on each study day. 
4.2.2.2 Sample collection during the cytokine expression study 
4.2.2.2.1 Collection of blood samples for qPCR from the amplifier mice 
Samples from the amplifier mice preceding Phase 1 and Phase 2 of the experiment (4.2.1.6.2) were 
collected once a day by venepuncture of the tail via a heparin-coated microcapillary tube and diluted 
in PBS as described previously (2.2.3.3.2.1). Samples were stored at 4°C until DNA extraction and 
qPCR. 
4.2.2.2.2 Collection of post-mortem blood samples for qPCR from the re-inoculation group and 
naïve group of the cytokine expression study on respective exsanguination days 
Samples from the re-inoculation group and naïve group of the cytokine expression study were 
obtained during Phase 2 of the experiment (4.2.1.6.5) from seven mice per group on 0, 1, 2, 3, 7, 10 
and 14 dpi. Blood was collected by dipping an uncoated capillary tube into the hub of the needle 
used for cardiac puncture (collected blood containing approximately 2.5mM EDTA) and allowing the 
tube to fill up to a pre-placed mark at 10µl. The capillary tube was then emptied into 90µl of PBS as 
described previously (2.2.3.3.2.1). Samples were frozen at -80°C until DNA extraction and qPCR. 
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4.2.2.2.3 Collection of blood samples for qPCR from the re-inoculation control group and the naïve 
control group (and sample collection during primary infection of the re-inoculation group 
in Phase 1) 
Samples from the re-inoculation controls and naïve controls of the cytokine expression study were 
obtained once a day for 14 days following Phase 1 and Phase 2 inoculations. Additionally, samples 
were collected from the re-inoculation group during primary M. haemomuris infection on 0, 1, 2, 3, 
7, 10 and 14 dpi. Blood samples were collected by venepuncture of the tail as described previously 
(2.2.3.6.1.1) but using uncoated capillary tubes that were allowed to draw up 1µl of 50mM EDTA 
(Sigma-Aldrich) immediately prior to the sampling procedure. Blood samples were then emptied into 
90µl of PBS as previously described (2.2.3.3.2.1). Samples were then returned to the laboratory, 
transferred into 96-well plates and then frozen at -80°C until DNA extraction and qPCR.  
4.2.2.2.4 Collection of EDTA-plasma from the re-inoculation group and naïve group of the cytokine 
expression study on respective exsanguination days 
Syringes (1 ml; Becton Dickinson) were equipped with 5/8-inch 23G needles (Terumo) and preloaded 
with EDTA by drawing up a 25µl droplet of 50mM EDTA (Sigma-Aldrich) from a water-repellent 
surface. This procedure was completed on each day of EDTA-plasma collection, immediately prior to 
anaesthesia. Seven mice per group (re-inoculation group and naïve group) were anaesthetised on 
days 0, 1, 2, 3, 7, 10 and 14 post Phase 2 inoculations (4.2.1.6.5.1 and Figure 27) and blood was 
collected by cardiac puncture as described (31), replacing heparinised syringes with the EDTA-
preloaded syringes produced prior to anaesthesia. EDTA-anticoagulated whole blood samples were 
returned to the laboratory and spun at 1000 x g for 10 min at 4°C. The plasma was removed carefully 
not to disturb the pellet. Samples were then returned to the laboratory and frozen at -80°C until 
cytokine analysis. 
4.2.2.3 DNA Extraction of mouse blood samples for qPCR 
4.2.2.3.1 DNA extraction from blood samples from amplifier mice  
Diluted blood samples from all amplifier mice used in the haematology and cytokine expression 
studies (4.2.2.1.1 and 4.2.2.2.1) were always subject to qPCR analysis on the day of sample 
collection. DNA was extracted using single spin columns (Macherey-Nagel, UK) on each blood 
sampling day as previously described (2.2.1.2.1).  
4.2.2.3.2 DNA extraction from blood samples from the re-inoculated group and naïve group of the 
cytokine expression study and blood samples from the haematology group of the 
haematology study 
Diluted blood samples obtained post-mortem from the haematology group of the haematology 
study, the re-inoculation and naïve groups as well as samples obtained during the primary infection 
of the re-inoculation group of the cytokine study (4.2.2.1.2, 4.2.2.2.2 and 4.2.2.2.3) were kept frozen 
at -80°C until addition of lysis buffer was added during the DNA extraction process. Total nucleic acid 
(TNA) was extracted using an automated, magnetic bead system (Chemagic, Chemagen, UK). In brief, 
samples were diluted with PBS to a final volume of 200µl and incubated for 20 min at room 
temperature with protease (Chemagen) and lysis buffer (Chemagen). After incubation, the Chemagic 
instrument was used to add magnetic beads (Chemagen) to bind nucleic acids. Using the magnetic 
separator and two washing steps, the instrument eluted TNA in a final volume of 50µl elution buffer 
(Chemagen) and removed the magnetic beads. TNA samples were stored at -80°C until further use.  
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4.2.2.3.3 DNA extraction from blood samples from re-inoculation control group and naïve control 
group of the cytokine expression study 
Diluted blood samples from the re-inoculation controls and naïve controls of the cytokine study 
(4.2.2.2.3) were processed as described for the mice comprising the main cytokine expression 
experiment (4.2.2.3.2), however half of the samples (0 to 7 dpi) were extracted on an earlier, 
separate occasion to allow for mid-experiment monitoring of successful M. haemomuris infection 
using the different inocula listed in 4.2.1.6.2. 
4.2.3 Analysis of mouse blood samples for M. haemomuris genome copies  
4.2.3.1 Conditions of the M. haemomuris-specific qPCR assay 
Conditions of the M. haemomuris-specific duplex qPCR assay were identical to the conditions 
described in 3.2.2.3.2 using primer/probe combinations described in 3.3.1.4.3. 
4.2.3.2 Analysis of qPCR data 
Analysis of qPCR data, including normalisation and calculation of relative M. haemomuris genome 
copies per µl blood, was carried out as described for 3.2.2.3.2.1.  
4.2.3.3 Statistical analysis of M. haemomuris genome copies in mouse blood samples  
Mann-Whitney-U statistics were calculated to compare M. haemomuris genome copies per µl blood 
across groups, i.e. to compare M. haemomuris genome copies on individual days during primary M. 
haemomuris infection as needed to compare post-mortem qPCR results of the re-inoculation group 
or naïve group mice to their respective control groups.  
Similarly, Mann-Whitney-U statistics were calculated on AUC values of individual mice to compare 
M. haemomuris genome copies per µl blood over the course of the first 14 dpi, i.e. to assess 
protective immunity as described in Chapter 3 (3.2.2.4.3) by using data from the re-inoculation 
control group and naïve control group. No AUC values were calculated for the haematology group of 
the haematology study, the re-inoculation group or the naïve group of the cytokine expression study 
as mice were only sampled once, at the time of exsanguination. SPSS v. 24 (IBM) was used for 
statistical analyses and significance was defined as p<0.05. 
4.2.4 Haematological analysis 
4.2.4.1 Sample preparation for haematology 
EDTA-anticoagulated blood samples (4.2.2.1.3) were allowed to reach room temperature on a roller 
shaker at 40rpm prior to analysis.  
4.2.4.2 Laboratory haematological analysis 
Blood samples were subject to haematological analysis using the ADVIA 120 system (Siemens 
Healthcare GmbH, Erlangen, Germany) and its pre-configured software package (v. 1.2) with settings 
set to ‘mouse’. Haematologic parameters were either measured directly or calculated. Directly 
measured analytes were red blood cell count (RBC), haemoglobin concentration (Hb), platelet count 
(PLT), total nucleated cell count (WBC) and absolute counts of reticulocytes, neutrophils, 
lymphocytes, monocytes, eosinophils, basophils, and large unstained cells. Mean platelet volume 
(MPV), mean corpuscular volume (MCV), plateletcrit (PCT), haematocrit (HCT), mean corpuscular 
haemoglobin (MCH), mean corpuscular haemoglobin concentration (MCHC), cell haemoglobin 
concentration mean (CHCM), cell haemoglobin content (CH), haemoglobin concentration 
distribution width (HDW), red cell distribution width (RDW), platelet distribution width (PDW), 
lobularity index (LI), myeloperoxidase index (MPXI), white blood cell count by peroxidase (WBCP), 
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mean platelet component (MPC), mean platelet mass (MPM) and the percentages of reticulocytes, 
neutrophils, lymphocytes, monocytes, eosinophils, basophils, and large unstained cells were 
calculated using the inbuilt software package.  
4.2.4.3 Analysis of haematological data 
As the haematology study (4.2.1.5) was a pilot study by design, descriptive statistics were used, and 
results were described as medians and ranges. Obtained values were compared to published normal 
values (95% confidence interval, CI) for adult, female C57BL/6 mice (362) and to the ranges of the 
samples obtained on day 0 of the experiment as an in-house, pre-infection control.  
4.2.5 Cytokine analysis 
4.2.5.1 Preparation of EDTA plasma samples 
Samples were collected and processed as described in 4.2.2.2.4. Upon completion of the 
experiment, and after qPCR data from simultaneously collected blood samples was obtained to 
confirm M. haemomuris infection had been successful, EDTA-plasma samples were transported to 
the flow cytometry facility on dry ice, then allowed to defrost at 4°C and spun at 1000 x g for 10 
minutes to pellet any remaining platelets and debris.  
4.2.5.2 Selection of EDTA plasma samples for analysis with the cytokine immunoassay  
One 96-well plate was available for cytokine analysis. Twelve wells were required for the assay 
standards and 84 wells were available for experimental plasma samples. Sample numbers per group 
were reduced to 6 mice per experimental day in the naïve group and 5 mice per experimental day in 
the re-inoculation group except for the day 0 subgroup that still comprised 6 samples. Sample 
selection was achieved semi-randomly, by excluding samples from mice that were known to have 
had increased haemolysis due to suboptimal sample collection (e.g. having to use a second syringe) 
and preferring samples of higher volume. A final list of included samples is given in Table 37.  
Mouse ID Cage ID  Mouse ID  Cage ID Exsanguination group (dpi) 
Re- inoculation group   Naïve group  
1, 2, 3 O  1, 2, 3, 4 A 0 
5, 6, 7 P  5, 6 B  
1, 2, 4 Q  1, 2, 3, 4 C 1 
5, 6, 7 R   7 D  
1, 2, 3 S  1, 3, 4 E 2 
5, 6, 7 T  5, 6 F  
1, 2, 4 U  1, 2, 3 G 3 
5, 6, 7 V   6, 7 H  
1, 2, 4 W  1, 2, 3, 4 I 7 
5, 6, 7 X   6 J  
1, 3, 4 Y  1, 2, 4 K 10 
5, 6, 7 Z  5, 6 L  
1, 2, 3, 4 A2  1, 3, 4 M 14 
5, 7 B2   6, 7 N  
Table 37 EDTA plasma samples included for cytokine analysis based on the experimental outline and inoculation schematic 
given in Table 33. Six mice per exsanguination group (defined by Phase 2 dpi) were included from the naïve group and the 
day 0 subgroup of the re-inoculation group. Five mice per exsanguination day were selected from remaining re-inoculation 
group mice. Dpi: days post (Phase 2) inoculation. 
114 
 
4.2.5.3 Measuring cytokine concentrations using the Bio-Plex ProTM 23-plex mouse cytokine 
immunoassay 
4.2.5.3.1 Assay principle  
The Bio-Plex ProTM 23-plex cytokine immunoassay (Bio-Rad Laboratories Ltd., Watford, UK) detects 
and allows simultaneous detection and quantification of 23 mouse/rat cytokines from 12.5µl to 50µl 
of serum, plasma or culture supernatant. Magnetic beads, measuring 6.5µm are used to detect each 
cytokine. The beads are coupled with specific anti-cytokine antibodies and a specific fluorescent dye 
that allows assay (cytokine) identification. Beads are allowed to react with the sample and after 
removal of unbound protein (using the magnetic property of the beads to hold them in the wells) a 
biotinylated detection antibody is added to bind to a different epitope on the cytokine. Streptavidin-
phycoerythrin (streptavidin-PE) is added to bind the biotin on the detection antibody and allow 
fluorescent identification. After washing, the reaction is measured in a flow-based bead suspension 
assay system and analytes are identified and quantified by bead colour and fluorescence intensity. 
All technical procedures were carried out in accordance with the manufacturer’s instructions and are 
briefly outlined below.  
4.2.5.3.2 Preparation of beads, standards and samples 
In brief, antibody-coupled beads were carefully vortexed and diluted 1:10 to a total volume of 5.7ml. 
A four-fold dilution series of standards (6 dilutions and one blank) was prepared with standard 
diluent. Experimental EDTA-plasma samples were diluted 1:4 with standard diluent prior to analysis.  
4.2.5.3.3 Preparation of detection antibody and streptavidin-PE 
Detection antibodies were prepared 15 min prior to use by careful resuspension and diluting 1:10 
with detection antibody diluent to a final volume of 3ml. Streptavidin-PE was prepared 10 minutes 
prior to use to a final volume of 6ml and vials were covered in aluminium foil to protect it from light. 
4.2.5.3.4 Incubating magnetic beads, samples and standards 
Magnetic beads were added to the plate and the plate washed twice with 100µl of wash buffer per 
well using a magnetic wash station to keep the beads in the wells. Experimental samples (equivalent 
to 12.5µl of EDTA-plasma) were added to the plate and standards were added in duplicate. No 
positive controls were included. This was followed by an incubation step of 30 minutes at room 
temperature on an orbital shaker at 850rpm.  
4.2.5.3.5 Incubation of detection antibody  
After bead incubation, the plate was washed three times with 100µl of wash buffer per well. 
Detection antibodies were added and allowed to incubate for 30 minutes at room temperature on 
an orbital shaker at 850rpm.  
4.2.5.3.6 SA-PE incubation 
After detection antibody incubation, the plate was washed three times with 100µl of wash buffer 
per well. Streptavidin-PE was added and allowed to incubate for 30 minutes at room temperature on 
an orbital shaker at 850rpm. This was followed by another wash step consisting of 3 x 100µl of wash 
buffer per well. Beads were subsequently resuspended with 125µl of assay buffer.  
4.2.5.3.7 Detection of fluorescence  
Fluorescence was detected using a Luminex® MAGPIX® platform (Luminex Corp, Austin, USA) 
measuring fluorescence, specific to the bead as excited by a laser at 621nm and the fluorescent 
streptavidin-PE (excited at 511nm) to report the amount of bound cytokine per bead.  
115 
 
4.2.5.4 Analysis of cytokine data 
4.2.5.4.1 Evaluation of quantification (generation of optimised standard curve) 
Multiplex assay performance was assessed using the Bio-Plex ManagerTM v. 6.1 software package 
(Bio-Rad). Recovery of standards (observed concentration/expected concentration x 100) was 
assessed for fitting within the expected recovery percentage. Outliers were identified as <10% CV 
(intraassay coefficient of variation, using standard duplicates) and excluded from generating an 
optimised standard curve for each cytokine. Five-parameter logistic regression (5PL) plots were 
generated using the five-parameter logistic equation to fit the standard data to a non-linear 
(sigmoid) regression model. Plots were assessed for location of sample values within the range of 
the standard curve and calculated values outside the standard curve marked for later analysis. 
Residual variance and probability of fit was assessed for each cytokine. Standard recovery was used 
as the primary measure as measurement quality as specified by the manufacturer.  
4.2.5.4.2 Statistical analysis of cytokine multiplex data 
Subsequent data analysis was performed using SPSS Statistics 24 (IBM). Analysis was performed in 
two stages, firstly, principal component analysis was performed to assess the intrinsic variation 
within the dataset across the 23 variables then reduce the dimensionality of the dataset based on 
extracted principal components. Secondly, univariate analyses of variance were conducted to assess 
the newly obtained variables (component scores) over time and between groups. Additionally, 
general linear models were built to better assess individual behaviours of cytokines, previously 
identified to be highly influential to the derived principal components.  
4.2.5.4.2.1 Power calculations  
No previous data were available to guide power calculations, so group sizes were based on 
maximum effect sizes as previously described (3.2.2.4.1), leaving the pilot nature of the study 
unchanged.  
4.2.5.4.2.2 Pre-analytical considerations 
Cytokine concentrations were recorded as pg/ml as converted from fluorescence values using the 
optimised standard curve (4.2.5.4.1). For cytokines whose values unexpectedly dropped below the 
limit of detection (i.e. when group medians were located well away from the limit of detection) the 
value was treated as an outlier and removed from analysis. However, to assess the potential 
introduction of bias, analysis was repeated, assuming ‘0pg/ml’ for these outliers at the end of data 
analysis. Values located outside of the optimised standard curve were visually assessed and if found 
to be located within the well-defined linear part of the curve, included in analysis.  
4.2.5.4.2.3 Calculation of percentage of change 
Percentage of change over time was calculated for each absolute cytokine concentration, using the 
following formula: 
Percentage of change from baseline = (Cconc – Md0)/Md0 x 100 
(Cconc = cytokine concentration of individual mouse, Md0 = Median of cytokine concentrations on day 
0; the day 0 subgroup of the re-inoculation group was used for re-inoculation data and the day 0 
subgroup of the naïve group was used for naïve group data respectively)  
Subsequent analysis was performed on two datasets, comprising absolute values and percentage of 
change values respectively.  
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4.2.5.4.2.4 Principal component analysis (PCA) 
A PCA was run for unsupervised clustering of data and hence unbiased identification of the main 
contributors to total variation in the multidimensional dataset of 23 cytokines in plasma and M. 
haemomuris genome copies in blood over time. This dataset was subsequently reduced to principal 
components which represent linear combinations of the original variables but aim to combine as 
much variation as possible within a single component, without necessarily reducing the information 
content. The first four extracted principal components were then further analysed in univariate 
analyses, aiming to define differences over time and across experimental groups. Univariate analysis 
hence was based on component scores, as they represent each individual cytokine result as it is 
plotted on the extracted component axis in the new dataset with reduced dimensions as described 
by DiStefano, Zhu (363). Cytokine concentrations and percentage of change from baseline 
(4.2.5.4.2.3) were analysed as two separate sets of variables and components were extracted from 
each set via PCA.  
At this stage, the output of component loadings (describing the relationship between each 
measurement and the extracted component) is considered unrotated as it forces the reduced 
dimensions (principal components) to be orthogonal to each other. In other words, a dataset 
comprising three principal components would easily be visualised in a Cartesian coordinate system. 
Traditionally, rotation is performed on the component loading matrix to help interpretability. On a 
Cartesian coordinate system this means optimising the axes, so the components load in a more 
meaningful pattern. After rotation, dimensions may, but do not need to be orthogonal to each other 
which accounts for correlations between components. An unrotated component loading matrix was 
selected for initial interpretation and interpretability based on shared conceptual (immunological) 
meaning within and in-between components. Component loadings were then subject to Promax 
rotation to assess optimisation of interpretability by placing non-orthogonal axes to maximise 
component loadings on all extracted components. Extracted component scores, measuring each 
observation (i.e. cytokine concentration) on each of the four extracted components were saved for 
regression analysis.  
Scree plots (which show the percentage of variance within the dataset that is explained by each 
extracted component) were generated to assess the number of meaningful components extracted. 
Components with an eigenvector >1 were extracted. The eigenvector reflects the direction of the 
extracted component with a dimensionless length that reflects the magnitude of the observed 
variation of the dataset it accounts for. Eigenvalues close to zero do not account for any significant 
variation within the dataset. 
Appropriateness of PCA was assessed based on continuity and linear relationships between the 
measurements. Sampling adequacy was assessed using the Kaiser-Meyer-Olkin (KMO) measure of 
sampling adequacy as described by Kaiser (364). Sphericity of the data was tested using Bartlett's 
test of sphericity (365) which assesses adequate linear correlations between the variables and hence 
suitability of the dataset for reduction. Means and standard deviations were calculated for each of 
the extracted components and outliers were identified by component scores greater than three 
standard deviations from the mean if not already removed at pre-analytical stage (see 4.2.5.4.2.2). 
Scores for each component (akin to individual cytokine measurements in reduced dimensions) were 
plotted against each other to assess obvious clustering or divisions within the data.  
4.2.5.4.2.5 Univariate analyses of variance 
To further assess PCA results, general linear models were constructed, entering component scores 
as the dependent variable and experimental groups (re-inoculated and naïve) as well as dpi as fixed 
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factors. Significance was defined as p<0.05. Where significant effects between experimental groups 
were found, the analysis was repeated with the model allowing for linear interactions of 
experimental group and the dpi.  
Additionally, general linear models were constructed for individual cytokines that were found to be 
loading on extracted components using the same approach as outlined for PCA factor scores.  
4.2.5.4.2.5.1 Assessment of normality and residuals 
For all univariate analyses, residuals (distance of observed datapoints to the value predicted by the 
linear model) were calculated and plotted against each other. Normality of errors and homogeneity 
of variance was assessed visually.  
4.2.5.4.2.6 Comparison of individual days 
Where appropriate, observed peaks in cytokine concentrations on individual days were assessed for 
significant differences against baseline concentrations using Mann-Whitney-U statistics. Significance 
was defined as PMWU<0.05. 
4.2.6 Post-mortem examinations 
All mice killed in the experiments outlined above underwent a basic post-mortem examination. 
Splenomegaly was defined as >0.4% bodyweight (see 3.2.2.2.1). Spleens were removed and frozen 
separate to the carcasses at -80°C for potential future use.  
4.2.6.1 Analysis of post-mortem data 
Splenic weights at the time of post-mortem examination (0, 1, 2, 3, 7, 10 and 14 dpi) were calculated 
as % bodyweight and expressed as medians and ranges for each study group and dpi. Mann-
Whitney-U statistics were calculated to compare splenic weights (as % bodyweight) between the 
naïve group and the re-inoculation group. Spearman’s rank-order correlation coefficient (rs) was 
calculated for observed splenic weight and M. haemomuris copies per µl blood using SPSS Statistics 
24 (IBM SPSS Statistics for Windows, 24.0, IBM Corp., USA). 
4.3 RESULTS 
4.3.1 Clinical signs, deaths and post-mortem examinations 
4.3.1.1 Haematology study 
No clinical signs of ill health were noted in any of the mice throughout the experiment. 
Splenomegaly was documented in all 20 mice at post-mortem examination after being killed at 0, 3, 
7, 10 and 14 dpi when using a 0.4% bodyweight cut-off to define splenomegaly. However, 
splenomegaly was only apparent in the second week post inoculation (mice killed at 7, 10 and 14 
dpi) when splenic weights were compared to pre-inoculation weights, defined as the range of the 








Number of mice 
examined 
Splenic weight range (% 
bodyweight) 
Splenic weight median (% 
bodyweight) 
0  4 0.40 - 0.47 0.43 
3  4 0.34 - 0.50 0.43 
7  4 1.65 - 1.90 1.85 
10  4 0.79 - 1.12 0.88 
14  4 0.66 - 1.56 0.84 
Table 38 Splenic weights (as % bodyweight) in the mice killed at 0 (no inoculation), 3, 7, 10 and 14 days post inoculation 
with M. haemomuris in the haematology study. Four mice were killed at each study day. Values above normal (defined as 
the range of the mice killed at 0 dpi, without prior inoculation) are indicated by shaded cells. Bolded text indicates 
deviations based on a 0.4% bodyweight cut-off as defined by published confidence intervals for splenic size in female 
C57BL/6 mice (276). Dpi, days post inoculation. 
4.3.1.2 Cytokine expression study 
No clinical signs of ill health were noted throughout the experiment. However, two mice, used as 
amplifiers preceding Phase 2 of the experiment (see 4.2.1.6.2.3 and Figure 27) were found dead at 8 
and 10 dpi without any prior clinical signs being noted on monitoring that occurred three times per 
day. Post-mortem examinations of these mice revealed no abnormal finding other than 
splenomegaly with splenic weights of 1.98% bodyweight for the mouse found dead at 8 dpi and 
1.65% for the mouse found dead at 10 dpi; the two mice had full stomachs, indicating the mice had 
not been inappetent prior to death.  
During the main experiment (inoculation of re-inoculation group and naïve group and their 
respective control groups, see Figure 27) one mouse was found dead at 7 dpi (primary infection of 
the re-inoculation group, Phase 1, 4.2.1.6.3.1) before sample collection could be completed and a 
second mouse died peracutely at 8 dpi (primary infection of the naïve control group, Phase 2, 
4.2.1.6.5.2). Post-mortem examinations of these mice revealed no abnormal findings other than 
splenomegaly with splenic weights comprising 1.95% bodyweight for the mouse found dead at 7 dpi 
and 2.04% bodyweight for the mouse found dead at 8 dpi) and some damage of the corpse by the 
remaining mice within the cage. These two mice were infected with M. haemomuris at different 
phases of the experiment and did not receive doses of the same inoculum. Splenic weights of the 
remaining mice of the cytokine expression study (including control groups killed 14 days after Phase 































  Re-inoculation group    Naïve group 
0  7 0.41 – 0.65 0.46  0  7 0.35 – 0.46 0.41 
1  7 0.45 – 0.60 0.50  1  7 0.34 – 0.49 0.42 
2  7 0.40 – 0.57 0.52  2  7 0.35 – 0.47 0.40 
3  7 0.42 – 0.59 0.47  3  7 0.42 – 0.52 0.50 
7  6* 0.41 – 0.54 0.44  7 7 0.43 – 2.12 1.65 
10  7 0.41 – 0.49 0.45  10  7 1.10 – 1.50 1.33 
14  7 0.40 – 0.60 0.47  14  7  0.67 – 0.85 0.77 
  Re-inoculation control group    Naïve control group 
14  6 0.41 – 0.57 0.54  14  5* 0.71 – 0.98 0.78 
Table 39 Splenic weights (as % bodyweight) in the mice killed in the cytokine expression experiment killed at 0 (no 
inoculation), 1, 2, 3, 7, 10 and 14 days post inoculation with M. haemomuris in Phase 2 of the cytokine expression study. 
Seven mice of each subgroup of the re-inoculation group and naïve group were killed on each study day except for subgroup 
‘7’ of the re-inoculation group where one mouse had died in Phase 1 of the experiment. Six mice were killed at 14 dpi from 
the re-inoculation control group and five mice (after one mouse had died at 8 dpi) were killed at 14 dpi from the naïve 
control group. Subgroups/groups with reduced mouse numbers due to death are indicated with an asterisk (*). The five 
naïve control group mice and six re-inoculation control group mice are presented separately as serial blood sampling may 
have influenced spleen size through extramedullary haematopoiesis. Values above normal (defined as the range of the mice 
killed at 0 dpi, without prior inoculation) are indicated by shaded cells. Bolded text indicates deviations based on a 0.4 % 
bodyweight cut-off as defined by published confidence intervals for splenic size in female C57BL/6 mice (276). Dpi, days post 
inoculation. 
Using Mann-Whitney-U statistics to compare splenic weights (as % bodyweight) between the naïve 
group and the re-inoculation group, splenic weights were not significantly different at 0 dpi 
(pMWU=0.085). Following inoculation with M. haemomuris, using the same inoculum aliquot (see 
Table 33), splenic weight was significantly increased in the re-inoculation group at 1 dpi 
(pMWU=0.004) and 2 dpi (pMWU=0.006). There was no significant difference in splenic weights between 
groups at 3 dpi (pMWU=0.565). Splenic weights were significantly increased in the naïve group at 7 dpi 
(pMWU=0.010), 10 dpi (pMWU=0.002) and 14 dpi (pMWU=0.002). 
4.3.2 Infection kinetics and protection from re-infection with M. haemomuris   
4.3.2.1 Haematology study 
4.3.2.1.1 Amplifier mice 
None of the three amplifier mice preceding inoculation of the haematology group (see Figure 26) 
had haemoplasma DNA detected by the generic haemoplasma assay one week before entering the 
experiment. All three amplifier mice became successfully infected with M. haemomuris and showed 
infection kinetics similar to previous observations (see Chapter 3). Normalised relative M. 
haemomuris genome copies per µl blood in these amplifier mice, monitored using a M. haemomuris-




Figure 28 M. haemomuris genome copies in the three amplifier mice preceding inoculation of the haematology group mice, 
following inoculation with fresh blood containing 6.91E+04 M. haemomuris copies per inoculum dose. Days post inoculation 
(dpi) are plotted on the x-axis and M. haemomuris genome copies per µl of blood are plotted on the y-axis. Lines represent 
individual mice (mice differentiated by colouring of the lines); blood sampling occurred once daily. One mouse (light blue 
line) was killed at 7 dpi and the two remaining mice not subject to daily blood sampling after 7 dpi. As zero values cannot be 
plotted on logarithmic scales, values of one (1.00E+00) haemoplasma copy per µl blood (and qPCR reaction) are treated as 
the equivalent of zero on this and on subsequent graphs within this chapter. 
4.3.2.1.2 Haematology group: Infection kinetics of primary M. haemomuris infection 
None of the 20 haematology group mice had haemoplasma DNA detected by the generic 
haemoplasma assay one week before entering the experiment.  All 20 mice successfully became 
infected with M. haemomuris. Normalised relative M. haemomuris genome copies per µl blood in 
the haematology group mice, monitored using a M. haemomuris-specific qPCR assay are shown in 
Figure 29.  
 
Figure 29 M. haemomuris genome copies in the 20 haematology group mice undergoing primary M. haemomuris infection, 
following inoculation with freshly obtained blood containing 3.08E+08 M. haemomuris copies per inoculum dose. Days post 
inoculation (dpi) are plotted on the x-axis and M. haemomuris genome copies per µl of blood are plotted on the y-axis. Dots 
represent individual mice exsanguinated for haematological analysis on that day (one dot equals one mouse).  
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The M. haemomuris genome copies per µl blood at the time of exsanguination agreed with previous 
observations of infection kinetics in mice naïve to M. haemomuris infection as described in Chapter 3 
but no control group was monitored over the course of infection after inoculation from the same 
inoculum. However, observed M. haemomuris genome copies per µl blood in the 16 M. 
haemomuris-infected mice of the haematology group did not differ from age-matched, mice naïve to 
M. haemomuris infection that were inoculated as part of the cytokine expression experiment on 
respective sampling days of 0, 3, 7, 10 and 14 dpi (kinetics shown in Figure 32 below). Mann Whitney 
U statistics comparing the M. haemomuris genome copies per µl blood on individual days for the 
haematology group and the naïve infection of the re-inoculation group of the cytokine expression 
study (4.2.1.6.3.1) showed no significant differences for day 0 (pMWU=1.000), day 3 (pMWU=0.055), day 
7 (pMWU=0.201), day 10 (pMWU=0.806) and day 14 (pMWU=0.327).  
4.3.2.2 Cytokine expression study 
4.3.2.2.1 Infection kinetics in amplifier mice preceding Phase 1  
None of the eight amplifier mice preceding Phase 1 of the cytokine expression study (see Figure 27) 
had haemoplasma DNA detected by the generic haemoplasma assay one week before entering the 
experiment. All eight amplifier mice preceding Phase 1 of the cytokine expression study successfully 
became infected with M. haemomuris and showed infection kinetics similar to previous observations 
made in Chapter 3. Normalised relative M. haemomuris genome copies per µl blood in these eight 
amplifier mice, monitored using a M. haemomuris-specific qPCR assay are shown in Figure 30.  
 
Figure 30 M. haemomuris genome copies in the 8 amplifier mice preceding Phase1 of the cytokine expression study 
following inoculation with cryopreserved blood containing 2.63E+06 M. haemomuris copies per inoculum dose. Days post 
inoculation (dpi) are plotted on the x-axis and M. haemomuris genome copies per µl of blood are plotted on the y-axis. The 
individual mice are indicated by the colouring of the lines and represent individual mice sampled once daily. Six mice were 
killed 7 dpi and the two remaining mice not subject to daily blood sampling after 7 dpi.  
4.3.2.2.2 Infection kinetics in amplifier mice preceding Phase 2 
None of the twelve amplifier mice preceding Phase 2 of the cytokine expression study (see Figure 
27) had haemoplasma DNA detected by the generic haemoplasma assay one week before entering 
the experiment. All amplifier mice preceding Phase 2 successfully became infected with M. 
haemomuris. Normalised relative M. haemomuris genome copies per µl blood in these twelve 




Figure 31 M. haemomuris genome copies in the 12 amplifier mice preceding Phase 2 of the cytokine expression study 
following inoculation with freshly obtained blood containing 5.21E+06 M. haemomuris copies per inoculum dose. Days post 
inoculation (dpi) are plotted on the x-axis and M. haemomuris genome copies per µl of blood are plotted on the y-axis. The 
individual mice are indicated by the colouring of the lines and represent individual mice sampled once daily. Dashed lines 
indicated the two mice found dead 8 and 10 dpi. Eight mice were killed 6 dpi (indicated by ending lines) and the remaining 
mice were killed on 10 dpi. 
Infection kinetics showed cycling of M. haemomuris genome copies in the bloodstream of four mice 
that had not previously been observed in M. haemomuris infection kinetics. The internal control 
(GAPDH) assay for the unexpectedly low or undetectable M. haemomuris genome copies fell within 
the expected range, ruling out extraction failure or qPCR inhibitors as a cause of the unusual cycling 
pattern (data not shown). The two amplifier mice found dead 8 and 10 dpi (dashed blue and grey 
lines in Figure 31) had 1.40E+08 and 1.43E+07 M. haemomuris copies per µl blood measured one 
day prior to death. 
4.3.2.2.3 Infection kinetics of primary M. haemomuris infection (Phase 1: re-inoculation group and 
re-inoculation control group) 
None of the 49 re-inoculation group mice and six re-inoculation control group mice had 
haemoplasma DNA detected by the generic haemoplasma assay one week before entering the 
experiment. All 49 re-inoculation group mice and six re-inoculation control group mice became 
infected with M. haemomuris and showed infection kinetics curves similar to previous observations 
in Chapter 3 (see 3.3.2.5). Normalised relative M. haemomuris genome copies per µl blood in the 49 
re-inoculation group mice, monitored using a M. haemomuris-specific qPCR assay are shown in 
Figure 32, upper panel and M. haemomuris genome copies per µl blood in the six re-inoculation 





Figure 32 M. haemomuris genome copies in the 49 re-inoculation group mice (upper panel) and the respective 6 re-
inoculation control group mice (lower panel) showing the infection kinetics following primary inoculation with M. 
haemomuris in Phase 1 of the cytokine expression study after inoculation from the same inoculum aliquots as described in 
4.2.1.6.3.1 and 4.2.1.6.3.2. The individual mice are indicated by the colouring of the lines and represent individual mice 
sampled at 0, 1, 2, 3, 7, 10 and 14 dpi (upper panel) and once daily (lower panel). The black dashed line (upper panel) 
indicates the mouse found dead at 7 dpi. Days post inoculation (dpi) are plotted on the x-axis and M. haemomuris genome 
copy numbers per µl of blood are plotted on the y-axis.  
The mouse found dead at 7 dpi (indicated by the black dashed line in Figure 32, upper panel 
harboured 1.77E+05 M. haemomuris genome copies per µl blood on the last blood sample taken 
four days prior to death. As blood samples from the re-inoculation group were taken at 0, 1, 2, 3, 7, 
10 and 14 dpi in Phase 1, no sample could be obtained ante mortem at 7 dpi.  
The M. haemomuris genome copies per µl blood in the 49 re-inoculation group mice used for 
cytokine measurements (only sampled at 0, 1, 2, 3, 7, 10 and 14 post dpi in Phase 1) did not greatly 
differ from the genome copies measured in the six re-inoculation control group mice on the 
respective days of blood sampling.  Mann-Whitney U statistics to compare M. haemomuris genome 
copies per µl blood between the re-inoculation group and the re-inoculation control group per 
sampling day showed no significant difference for day 0 (pMWU=1.000, all negative), day 1 
(pMWU=0.345) , day 3 (pMWU=0.409), day 7(pMWU=0.065) day 10 (pMWU=) and day 14 (pMWU=0.085) post 
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inoculation but were significantly higher in the re-inoculation control group on day 2 (pMWU=0.030) 
post inoculation.  
Mycoplasma haemomuris genome copies per µl blood from the six re-inoculation control group mice 
during the Recovery phase in-between Phase 1 and Phase 2 of the experiment are shown in Figure 
33.  
 
Figure 33 M. haemomuris genome copies in the six re-inoculation control group mice during the Recovery phase following 
primary inoculation in Phase 1 of the cytokine expression study. The first 14 days of the infection kinetics curves have been 
shown in Figure 32 above. The individual mice are indicated by the colouring of the lines and represent individual mice 
sampled at 21, 35, 42, 56, 98, 119 and 126 dpi. Days post inoculation (dpi) are plotted on the x-axis and M. haemomuris 
genome copy numbers per µl of blood are plotted on the y-axis. 
During the Recovery phase, the re-inoculation control group showed low levels of M. haemomuris 
genome copies in their blood, but did not fully recover from infection, confirming previous 
observations made in Chapter 3. 
4.3.2.2.4 Infection kinetics of primary M. haemomuris infection (Phase 2: naive group and naive 
control group) 
None of the 49 naïve group mice and six naïve control group mice had haemoplasma DNA detected 
by the generic haemoplasma assay one week before entering the experiment. All mice successfully 
became infected with M. haemomuris and showed infection kinetics similar to previous observations 
in Chapter 3 (3.3.2.2). Normalised relative M. haemomuris genome copies per µl blood in the 49 
naive group mice, monitored using a M. haemomuris-specific qPCR assay are shown in Figure 34, 
upper panel. In Phase 2 of the cytokine expression study, blood samples from the naïve group were 
only collected at the time of exsanguination (4.2.1.6.5.3), meaning that individual dots (Figure 34, 
upper panel) represent individual mice and no lines were constructed. Normalised relative M. 
haemomuris genome copies per µl blood in the six naive control group mice, receiving doses of the 
same inoculum aliquots as the naïve group mice followed by daily blood sampling are shown in 





Figure 34 M. haemomuris genome copies in the 49 naïve group mice (upper panel) and their respective six naïve control 
group mice (lower panel) showing the infection kinetics following primary inoculation with M. haemomuris   in Phase 2 of 
the cytokine expression study after inoculation from the same inoculum aliquots as described in 4.2.1.6.5.1 and 4.2.1.6.5.2. 
Upper Panel: Individual dots represent individual mice at the time of exsanguination at 0, 1, 2, 3, 7, 10 and 14 dpi and no 
line charts were constructed. Lower panel: The individual mice are indicated by the colouring of the lines and represent 
individual mice sampled once daily. The dark blue dashed line (lower panel) indicates the mouse found dead at 8 dpi. Days 
post inoculation (dpi) are plotted on the x-axis and M. haemomuris genome copy numbers per µl of blood are plotted on the 
y-axis. 
The M. haemomuris genome copies per µl blood in the 49 naïve group mice used for cytokine 
measurements (only sampled on the day of exsanguination) did not differ greatly from the six naïve 
controls on respective blood sampling days. Mann-Whitney-U statistics to compare M. haemomuris 
genome copies between the naïve group and the naïve control group per sampling day showed no 
significant difference for day 0 (pMWU=1.000, all negative), day 2 (pMWU=0.749), day 3 (pMWU=0.631), 
day 7 (pMWU=0.200) and day 14: pMWU=0.715) but was significantly lower in the naïve control group 
on day 1 (pMWU=0.037) and higher in the naïve control group on day 10 (pMWU=0.035).  
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4.3.2.2.5 Infection kinetics of partial protection from M. haemomuris re-infection (Phase 2: re-
inoculation group and re-inoculation control group) 
Normalised relative M. haemomuris genome copies per µl blood in the 48 (following one death in 
Phase 1) re-inoculation group mice, following re-inoculation with M. haemomuris in Phase 2 of the 
cytokine expression study and monitored using a M. haemomuris-specific qPCR assay are shown in 
Figure 35, upper panel; 0 dpi in Phase 2 is represented as 131 dpi in the graph for continuity. In 
Phase 2 of the cytokine expression study, blood samples from the re-inoculation group were only 
collected at the time of exsanguination (4.2.1.6.5.3), meaning that individual dots (Figure 35, upper 
panel) represent individual mice and no line charts could be constructed. Normalised relative M. 
haemomuris genome copies per µl blood in the six re-inoculation control group mice, receiving 
doses of the same inoculum aliquots as the re-inoculation group mice followed by daily blood 
sampling are shown in Figure 35, lower panel.  
 
 
Figure 35 M. haemomuris genome copies in the 48 re-inoculation group mice (upper panel) and their respective six re-
inoculation control group mice (lower panel) showing the infection kinetics following re-inoculation with M. haemomuris in 
Phase 2 of the cytokine expression study after inoculation from the same inoculum aliquots as described in 4.2.1.6.5.1 and 
4.2.1.6.5.2. Upper Panel: Individual dots represent individual mice at the time of exsanguination at 0, 1, 2, 3, 7, 10 and 14 
dpi and no line charts could be constructed. Lower panel: The individual mice are indicated by the colouring of the lines and 
represent individual mice sampled once daily. Days post inoculation (dpi) are plotted on the x-axis. M. haemomuris genome 
copy numbers per µl of blood are plotted on the y-axis. 
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The M. haemomuris genome copies in the 48 re-inoculation group mice used for cytokine 
measurements (only sampled at 0, 1, 2, 3, 7, 10 and 14 post dpi in Phase 2 where 0 dpi corresponds 
to 131 days post primary inoculation in Phase 1) did not greatly differ from the genome copies 
measured in the six naive control group mice on the respective days of blood sampling. Mann-
Whitney-U statistics to compare M. haemomuris genome copies between the re-inoculation group 
and the re-inoculation control group per sampling day showed no significant difference for day 0 
(pMWU=0.514), day 1 (pMWU=0.253) , day 2 (pMWU=0.153), day 3 (pMWU=0.886), day 10 (pMWU=0.317) 
and day 14: pMWU=0.775) but was significantly lower in the re-inoculation control group mice on day 
7 (pMWU=0.046).  
The six re-inoculation control group mice (used to monitor infection kinetics by daily sampling whilst 
avoiding sampling of the re-inoculation group) demonstrated partial protection from re-infection, 
indicated as significantly lower M. haemomuris genome copies per µl blood (pMWU=0.004, comparing 
AUC values over 14 dpi) than the six naïve control group mice (kinetics shown in Figure 34, lower 
panel) confirming previous results (3.3.2.5). No comparative statistics on protection from re-
infection were performed on the main experimental mice, comparing the re-inoculation group and 
naïve group as these mice were used for cytokine measurements were only sampled on the day of 
exsanguination, delivering only single measurements, hence not allowing calculation of AUC values.  
4.3.2.2.6 Correlation of splenomegaly and M. haemomuris genome copies  
A Spearman’s rank-order correlation was run between splenic weights at 14 dpi (as % bodyweight) 
and normalised relative M. haemomuris genome copies per µl blood at the time of exsanguination. 
There was a low but statistically significant positive correlation between splenic weight and M. 
haemomuris genome copies (rs=0.412, p<0.001).  
4.3.3 Haematological response to M. haemomuris infection  
Problems with sample processing (clotting, n=1; machine repairs, n=2) led to three samples being 
lost for haematological analysis. This affected one sample, collected at 3 dpi and two samples 
collected at 14 dpi. Analysis of haematological parameters by comparing obtained values to 
published 95 % CI (362) yielded an unacceptable number of deviations in the 0 dpi group (which 
were considered a healthy, in-house control group) and a lack of sensitivity for changes over time. 
Preference was given to analysing the data by comparing group medians to ranges of the day 0 
group to serve as a reference interval for each parameter within the experiment.  
4.3.3.1 Haematocrit, haemoglobin and RBC 
Red blood cell parameters over the course of naïve M. haemomuris infection as measured in four 






































































































































Table 40 Red blood cell parameters over the course of primary M. haemomuris infection measured from 2 to 4 mice 
exsanguinated 0, 3, 7, 10 and 14 days after primary inoculation with M. haemomuris. M. haemomuris infection kinetics 
curves have been presented in Figure 29 above. Values are given as median (range) and derived from four mice per dpi, 
except 3 dpi (3 mice) and 14 dpi (2 mice). Values above or below normal (defined as the range of the mice killed at 0 dpi for 
each parameter) are indicated by ↑ or ↓ in shaded cells. Bolded text indicates deviations based on published confidence 
intervals for healthy, female C57BL/6. Asterisks (*) note parameters with no CI published by Charles River Laboratories 
(362). Abbreviations: RBC, red blood cells; HGB, haemoglobin; HCT, haematocrit; MCV, mean corpuscular volume; MCH, 
mean corpuscular haemoglobin; MCHC, mean corpuscular haemoglobin concentration; CHCM, cell haemoglobin 
concentration mean; CH, cellular haemoglobin content (mean of RBC cellular haemoglobin histogram); RDW, red cell 
distribution width; HDW, haemoglobin distribution width; Dpi, days post inoculation.  
There was a marked drop in RBC, HGB and HCT (all consistent with anaemia) at 7 dpi that coincided 
with peak parasitaemia (see Figure 29 above). Erythrocyte indices were consistent with regeneration 
(i.e. decreased MCHC, increased MCH, MCV, RDW and HDW) following the onset of anaemia that 
were not fully resolved until the end of the experiment at 14 dpi. Erythrocyte morphology flags also 
agreed with a regenerative response indicated by variable levels of haemoglobin in variably sized 
cells. Haematological analysis based on laboratory CIs did reflect anaemia at 7 dpi but failed to 
indicate signs of regeneration as erythrocyte indices stayed within CIs despite a rather drastic 
increase in RDW – attributed to mice at 0 dpi all having values below published CIs, hence 
highlighting the increase over time.  
4.3.3.2 Leucocyte parameters 
Leucocyte parameters over the course of naïve M. haemomuris infection as measured in four mice 



















































































































Table 41 Leukocyte parameters over the course of primary M. haemomuris infection measured from 2 to 4 mice 
exsanguinated 0, 3, 7, 10 and 14 days after primary inoculation with M. haemomuris. M. haemomuris infection kinetics 
curves have been presented in Figure 29 above. Values are given as median (range) and derived from four mice per dpi, 
except 3 dpi (3 mice) and 14 dpi (2 mice). Values above or below normal (defined as the range of the mice killed at 0 dpi for 
each parameter) are indicated by ↑ or ↓ in shaded cells. Bolded text indicates deviations based on published confidence 
intervals for healthy, female C57BL/6. Asterisks (*) note parameters with no CI as per Charlesriver laboratories. 
Abbreviations: WBC, white blood cells; Neut, neutrophils; Lymp, lymphocytes; Mono, monocytes; Eos, eosinophils; Baso, 
basophils; LUC, large unstained cells; LI, lobularity index; MPXI, myeloperoxidase index; WBCP, white blood cell count by 
peroxidase; Dpi, days post inoculation.  
There was an increase in white blood cells (lymphocytes and neutrophils) suggesting an 
inflammatory response to infection and antigenic stimulation of lymphocytes. The preceding 
lymphopenia at 3 dpi is consistent with corticosteroid release, either mediated by the start of the 
experiment or acute onset of infection as increasing M. haemomuris genome copies per µl blood at 




Figure 29). A similar reaction pattern was observed for eosinophils in a later stage of the infection. A 
drop in neutrophil MPXI is consistent with bacterial sepsis at day 7 post inoculation. Peroxidase-
derived white blood cell counts (WBCP) were similar to WBC, indicating no major morphologic 
abnormalities but due to low sample numbers no statistical comparisons were attempted.  
Haematological analysis based on laboratory CIs did not reflect changes in leucocyte parameters as 
mice at 0 dpi had below-normal neutrophil counts that only rose to remain within CI. All mice were 





4.3.3.3 Platelet parameters 
Platelet counts and indices over the course of naïve M. haemomuris infection as measured in four 
mice on 0, 7, 10 dpi, three mice on 3 dpi and two mice on 14 dpi are given in Table 42. 
























































































Table 42 Platelet parameters over the course of primary M. haemomuris infection measured from 2 to 4 mice 
exsanguinated 0, 3, 7, 10 and 14 days after primary inoculation with M. haemomuris. M. haemomuris infection kinetics 
curves have been presented in Figure 29 above. Values are given as median (range) and derived from four mice per dpi, 
except 3 dpi (3 mice) and 14 dpi (2 mice). Values above or below normal (defined as the range of the mice killed at 0 dpi for 
each parameter) are indicated by ↑ or ↓ in shaded cells. Bolded text indicates deviations based on published confidence 
intervals for healthy, female C57BL/6. Asterisks (*) note parameters with no CI as per Charlesriver laboratories. 
Abbreviations: PLT, platelets; MPV, mean platelet volume; PDW, platelet distribution width; PCT, plateletcrit; MPC, mean 
platelet component (measure of activation); MPM, mean platelet mass; Dpi, days post inoculation.  
Platelet counts stayed within the range observed at 0 dpi and published normal values throughout 
the experiment. There was an elevation in platelet volume (MPV) and mass (MPM) following 7 dpi, 
with a marked increase in large platelets at the last day of the experiment (14 dpi).  
Haematological analysis based on laboratory CIs consistently reported elevated MPVs but no 





4.3.4 Plasma cytokine expression in response to primary M. haemomuris infection and re-
inoculation with M. haemomuris (occurring with partial protection from re-infection) 
Forty-two EDTA plasma samples were analysed from the naïve group (six samples from each 
exsanguination day; 0, 1, 2, 3, 7, 10 and 14 dpi) during the first two weeks following primary M. 
haemomuris inoculation and 36 EDTA plasma samples were analysed from the re-inoculation group 
(six samples collected at 0 dpi and five samples collected 1, 2, 3, 7, 10 and 14 dpi) during the first 
two weeks following re-inoculation with M. haemomuris. All plasma samples were collected during 
Phase 2 of the cytokine expression experiment (see Figure 27).  
4.3.4.1 Evaluation of quantification 
Quantification of cytokines was evaluated according to the manufacturer’s instructions (Bio-Rad 
Laboratories). Recovery of standards fell within the acceptable 70-130% range for all but the most 
dilute standard for GM-CSF which was still included for analysis. Thirteen standard values were 
classified as outliers and excluded from the standard curve generation for each cytokine: Standard 1 
(highest concentration) was excluded for GM-CSF, IL-9, MCP-1, MIP-1a and RANTES. Standard 2 was 
excluded for GM-CSF. Standard 8 (lowest concentration) was excluded for IL-12(p70), IL-13, KC, 





4.3.4.2 Principal Component Analysis 
4.3.4.2.1 Suitability of data 
The dataset was found suitable for PCA. The KMO measure of sampling adequacy was 0.825 (values 
closer to 1 mean better fit) and Bartlett’s test demonstrated sphericity of the data with p<0.001.  
4.3.4.2.2 Extraction of principal components and component scores 
The first four components displayed eigenvalues of >1 which was consistent with the interpretation 
of the Scree plot (Appendix C, Figure C-1), suggesting only the first four components were 
meaningful to the analysis. Components 1 to 4 accounted for 77.9% of the observed variance within 
the dataset as shown in Table 43. 
Component Eigenvalue % of Variance 
explained 
Cumulative % of 
Variance explained 
1 11.042 48.009 48.009 
2 3.694 16.062 64.070 
3 1.866 8.112 72.182 
4 1.315 5.718 77.900 
Table 43 Total variance of the dataset of 23 cytokines from 42 mice undergoing naïve M. haemomuris infection and 36 mice 
undergoing re-infection with M. haemomuris as variance is explained by principal component 1 - 4, using the eigenvalue > 1 
criterion of selection. Eigenvalues represent the (dimensionless) length of the eigenvector. Eigenvectors are used to define 
the direction of the variation within the data after dimension reduction. Similar eigenvalues do not need to represent similar 
variance as they represent a different dimension, orthogonal to the other components. Eigenvalues close to zero do not 
account for any significant variation within the data respectively.  
Four principal components were extracted and respective component loadings (representing the 
relationship of the underlying variable i.e. cytokine concentration to the extracted component) are 




Cytokine Component loadings 
 Component 1 Component 2 Component 3 Component 4 
IL-1a 0.558 0.428 0.363 0.157 
IL-1b 0.803 -0.482 0.159 0.002 
IL-2 0.216 0.774 0.375 -0.109 
IL-3 0.905 -0.165 -0.048 0.299 
IL-4 0.900 0.094 0.126 0.110 
IL-5 0.815 -0.337 -0.039 0.026 
IL-6 0.738 -0.107 -0.110 0.443 
IL-9 0.919 -0.142 0.214 -0.037 
IL-10 0.563 0.310 -0.382 -0.504 
IL-12p40 0.486 0.553 -0.390 -0.156 
IL-12p70 0.810 -0.031 0.205 -0.139 
IL-13 0.493 -0.294 0.454 -0.161 
IL-17 -0.074 0.882 0.145 0.094 
Eotaxin -0.487 0.370 0.338 0.310 
GCSF 0.552 0.294 -0.406 0.223 
GMCSF 0.875 -0.222 -0.095 0.094 
IFN-γ 0.912 0.080 0.238 0.002 
KC 0.465 -0.096 0.670 -0.364 
MCP1 0.694 0.146 -0.059 -0.295 
MIP1a 0.788 0.220 -0.300 -0.342 
MIP1b 0.820 0.309 -0.297 0.102 
RANTES -0.075 0.881 0.163 0.103 
TNF-α 0.873 0.050 -0.039 0.367 
Table 44 Component matrix of component loadings from individual cytokine variables as extracted by principal component 
analysis (PCA) for components with eigenvalues > 1. Component loadings represent the relationship between the original 
variable and the extracted component. (Squared component loadings give the percentage of variance that is explained by 
the original variable prior to dimension reduction.) Component loadings were considered significant for their respective 
components if they exhibited a loading greater than 0.5 for that component and less than 0.5 for all other components. 
These are indicated by shaded cells and bolded text. Component 4 was included in PCA interpretation to guide further 
analysis of individual cytokine responses. IL-1a, Interleukin-1a; IL-1b, Interleukin-1b; IL-2, Interleukin-2; IL-3, Interleukin-3; 
IL-4, Interleukin-4; IL-5, Interleukin-5; IL-6, Interleukin-6; IL-9, Interleukin-9; IL-10, Interleukin-10; IL-12p40, Interleukin-12 
Subunit p40; IL-12p70, Interleukin-12 Subunit p70; IL-13, Interleukin-13; IL-17, Interleukin-17; GCSF, Granulocyte Colony 
Stimulating Factor; GMCSF, Granulocyte-Macrophage Colony Stimulating Factor; IFN-γ, Interferon Gamma; KC, 
Keratinocyte Chemoattractant (CXCL1); MCP1, Mast Cell Protease 1 (CCL2); MIP1a, Macrophage Inflammatory Protein 1a; 
MIP1b, Macrophage Inflammatory Protein 1b; RANTES, Chemokine 'Regulated on Activation, Normal T cell Expressed and 
Secreted', (CCL5); TNF-α, Tumour Necrosis Factor Alpha. 
In interpreting the (unrotated) component matrix (Table 44), a cytokine was interpreted to load on a 
given component if the component loading was greater than an arbitrarily chosen value of 0.5 for 
that component and less than 0.5 for the remaining components. Employing these criteria, 16 
cytokines were found to load on component 1, four cytokines were found to load on component 2, 
one cytokine loaded on component 3 and none on component 4. Component loadings, derived from 
percentage of change from baseline instead of absolute values of cytokine concentration did not 
exhibit a pattern different to the presented loadings from absolute values and were not further 




4.3.4.2.3 Univariate analyses of unrotated component scores  
Unrotated component scores, representing each measurement on the extracted component from 
the unrotated solution were calculated for each individual cytokine measurement for further 
investigation of the dataset. The distribution of errors and homogeneity of variance was consistent 
with normal distribution and homogeneity as assessed visually (data not shown). Results of 
univariate analyses on the first four unrotated component scores (assigning each individual cytokine 
value a score on a given component) and experimental groups (re-inoculation group versus naïve 
group), time (dpi) and interactions between the experimental group and dpi are presented in Table 




Dependent variable: Component scores on principal component 1 
Source Type III sum of squares Df Mean square F Significance 
Corrected model 26.824 13 2.063 2.978 0.003 
Intercept 0.542 1 0.542 0.782 0.381 
Group 9.855 1 9.855 14.225 0.000 
Dpi 9.604 6 1.601 2.310 0.050 
Group * Dpi 7.017 6 1.169 1.688 0.146 
Error 31.176 45 0.693   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .462 (Adjusted R Squared = .307)  
Dependent variable: Component scores on principal component 2 
Source Type III sum of squares Df Mean square F Significance 
Corrected model 21.205 13 1.631 1.995 0.044 
Intercept 0.011 1 0.011 0.014 0.908 
Group 11.983 1 11.983 14.655 0.000 
Dpi 4.621 6 0.770 0.942 0.475 
Group * Dpi 3.607 6 0.601 0.735 0.624 
Error 36.795 45 0.818   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .366 (Adjusted R Squared = .182)     
Dependent variable: Component scores on principal component 3 
Source Type III sum of squares Df Mean square F Significance 
Corrected model 33.088 13 2.545 4.597 0.000 
Intercept 0.394 1 0.394 0.711 0.403 
Group 1.289 1 1.289 2.328 0.134 
Dpi 17.522 6 2.920 5.275 0.000 
Group * Dpi 11.703 6 1.951 3.523 0.006 
Error 24.912 45 0.554   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .570 (Adjusted R Squared = .446)  
Dependent variable: Component scores on principal component 4 
Source Type III sum of squares Df Mean square F Significance 
Corrected model 24.572 13 1.890 2.544 0.010 
Intercept 0.006 1 0.006 0.008 0.929 
Group 1.346 1 1.346 1.812 0.185 
Dpi 2.567 6 0.428 0.576 0.747 
Group * Dpi 22.147 6 3.691 4.969 0.001 
Error 33.428 45 0.743   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .424 (Adjusted R Squared = .257) 
Table 45 Univariate analyses of component scores (dependent variable) and experimental groups (naïve group versus re-
inoculation group) and dpi (dpi in Phase 2 of the cytokine expression study, see Figure 27). Significance was defined as 
p<0.05 and significant results are indicated by shaded cells and bolded text, results that became significant due to the 
interaction effect are indicated by bolded text alone. Component scores 1 and component scores 2 were significantly 
different between the groups and bordered significance levels for dpi on component scores 2. Significant linear interactions 
(Group * Dpi) were found for component scores 3 and component scores 4. A visualisation of the component scores on all 
four principal components the 14-day observation period is given in Figure 36. Note, that component scores reflect cytokine 
concentrations but cannot be interpreted as such. Group, experimental group (naïve group versus re-inoculated group); df, 




Component scores on principal component 1 (see interpolation lines in Figure 36, top left panel too) 
were found to be significantly higher in the re-inoculation group (p<0.001) and approaching 
significance levels (p=0.050) for a difference over time, defined as days post inoculation (dpi). 
However, the chronological order of changes in cytokine concentrations was not assessed by the 
current statistical analysis. No linear interaction effect was found (p=0.146), meaning that the 
difference over time was not significantly difference between groups. Component scores on 
principal component 2 (see interpolation lines in Figure 36, top right panel) were significantly higher 
in the naïve group (p<0.001) with no linear interaction effect with dpi (p=0.624), meaning that the 
difference stayed the same over the observation period when both groups were assessed. 
Component scores on principal component 3 (see interpolation lines in Figure 36, middle left panel) 
were significantly different over time (p<0.001) and dependent on the experimental group with 
p=0.006 for the interaction effect of group and dpi, meaning that component scores changed in 
different directions in the re-inoculated group at different time points. Component scores on 
principal component 4 (see interpolation lines in Figure 36, middle right panel) displayed a 
significant interaction effect (p=0.001). 
Adding normalised, relative M. haemomuris genome copies per µl blood as a covariate in the linear 
models of component scores (see bottom panel in Figure 36) resulted in no significant differences in 
component scores for increased M. haemomuris genome copies for principal component 1 (p=0.604) 
and principal component 3 (p=0.970). Component scores for principal component 2 were 
significantly lower with increased M. haemomuris genome copies (p=0.009) and significantly lower 
for component scores for principal component 4 (p=0.025) that were due to lower component 
scores in the naïve group alone (p<0.001).  
A visualisation of the component scores on all four principal components and normalised relative M. 





Figure 36 Component scores (unrotated solution) spanning cytokine data of 14 consecutive days post inoculation (dpi) in 
Phase 2 of the cytokine expression experiment including a (linear) representation of normalised, relative M. haemomuris 
genome copies per µl blood over the same period. Calculated component scores for each of the four principal components 
(circles represent scores calculated for individual cytokine measurements) are plotted on the y-axis and dpi are plotted on 
the x-axis. Green circles represent component scores of the naïve group. Blue circles represent component scores for the re-
inoculation group. Dotted black lines are linear interpolation lines (based on group medians) and labelled for both groups. 
Note, that component scores reflect cytokine concentrations but cannot be interpreted as such. Normalised relative M. 
haemomuris genome copies per µl blood have been added for comparison on a linear (not logarithmic) chart. Component 
scores 1, component scores on principal component 1; component scores 2, component scores on principal component 2; 
component scores 3, component scores on principal component 3; component scores 4, component scores 4 on principal 
component 4; Group, experimental group (naïve group versus re-inoculated group), Dpi, days post inoculation. 
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The univariate analyses (Table 45) of component scores and experimental groups over time did not 
account for all variability within the dataset as observed in the 14-day observation period (see linear 
interpolation lines in Figure 36) especially variations of component scores around peak parasitaemia 
(7 dpi) for both experimental groups. The model was subsequently restricted to chronological 
changes (defining dpi as covariate to allow plotting of linear regression lines) and re-calculated for 
non-linear (quadratic) interactions but did not yield a better representation of the data apart from 
component 3, that was better described by a quadratic interaction of dpi and component scores 
with p=0.002. The univariate analyses of component scores in chronological order and allowing for 
quadratic interactions are presented in Appendix C, Table A-C2 and A-C3.  
4.3.4.2.4 Assessment of structure within the unrotated PCA dataset 
Unrotated component loadings (reflecting the relationship between each datapoint and the 
extracted component) are optimised for maximal explanation of data variance but not necessarily 
structure within the dataset (see 4.2.5.4.2.4). Univariate analyses (Table 45) suggested principal 
components 1 and 2 should be able to identify a difference between groups. To visualise this 
relationship a scatterplot matrix was created, plotting component scores of all four principal 
components against each other. The scatterplot matrix of component scores is shown in Figure 37. 
 
Figure 37 Scatterplot matrix of unrotated component scores plotted against each other illustrating the relationships 
between the extracted components and clustering of the underlying dataset. As expected from univariate analyses (see 
Table 45), components 1 and 2 exhibited rough clustering that suggests a linear relationship between the two components. 
Green circles represent component scores of the naïve group and blue circles represent component scores for the re-
inoculation group. Component scores 1, component scores on principal component 1; component scores 2, component 
scores on principal component 2; component scores 3, component scores on principal component 3; component scores 4, 
component scores 4 on principal component 4; Dpi, days post inoculation. 
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Component scores on principal component 1 and 2 exhibited clustering, thus suggesting and roughly 
illustrating a linear relationship between the two components but without suggesting discriminative 
power to differentiate groups in two dimensions.  
4.3.4.2.5 Consequences of component rotation on data structure and univariate analyses 
To further analyse the data structure, component loadings were subject to Promax rotation which 
places the axes of principal components to maximise structure and allows for correlations between 
components as component axes are no longer required to be orthogonal to each other (see 
4.2.5.4.2.4).  
Solutions for the rotated principal component analysis are presented in Appendix C but will briefly 
be summarised here. Promax rotation of principal component loadings resulted in a change in 
cytokine composition loading on the extracted components. Rotated components will be referred to 
as ‘rotated component 1’ to ‘rotated component 4’ as they are not identical to the unrotated 
components described earlier in this chapter. After Promax rotation, 10 cytokines (IL-1b, IL-3, IL-4, 
IL-5, IL-6, GCSF, GMCSF, IFN-γ, MIP1b and TNF-α) were found to be loading on component 1, 4 
cytokines (IL-9, IL-12p70, IL-13 and KC) loaded on component 2, 4 cytokines (IL-10, IL-12p40, MCP1 
and MIP1a) loaded on component 3 and 5 cytokines (IL-1a, IL-2, IL-17, Eotaxin and RANTES) loaded 
on component 4 when using the same criteria for interpretation as described for the unrotated 
solution (4.3.4.2.2).  
A revised component matrix is given in Appendix C, Table A-C4. The component scores on the 
rotated principal components were subject to univariate analyses as described for the rotated 
solution above (4.3.4.2.3) and summarised in Appendix C Table A-C5. Component scores for rotated 
components were significantly different for groups and dpi: Component scores for rotated 
component 1 were significantly higher in the re-inoculation group (p<0.001). Component scores for 
rotated component 2 were significantly higher in the re-inoculation group (p<0.001) compared to 
the naïve group and also significantly increased over time (p=0.010). There was a significant 
interaction between experimental groups and dpi (p=0.002), meaning that re-inoculated mice 
demonstrated a steep increase in component scores whilst naïve mice stayed low. Component 
scores on rotated component 3 were significantly different (p=0.003) over time but varied with 
group as the increase was more pronounced in the naïve group (p=0.011). Component scores on 
rotated component 4 were significantly higher in the naïve group (p=0.019) and did not significantly 
change over time for either experimental group (p=0.981). 
Similar to the unrotated solution (4.3.4.2.3), allowing normalised relative M. haemomuris genome 
copies per µl blood as a covariate in the linear model resulted in significantly increased component 
scores with increased M. haemomuris genome copies (p=0.019) for the rotated component 3, 
reflecting a peak of scores over peak parasitaemia in the naïve group. A scatterplot matrix of the 
rotated solution is shown in Appendix C, Figure A-C2. As discriminative data clustering was not the 
aim of the current study and interpretability (based on immunological relationships between the 
cytokines) was not improved when using rotated component scores, the rotated solution to the PCA 
was not used to guide interpretation of PCA results.  
4.3.4.3 Concentrations and univariate analyses of individual cytokines 
Individual cytokine concentrations of the naïve and re-inoculated group mice, exsanguinated at 0, 1, 
2, 3, 7, 10 and 14 dpi are given as absolute values (pg/ml) in Figure 38 to Figure 40 and presented as 





Figure 38 Cytokines loading on component 1. Cytokine concentrations are plotted in absolute values (pg/ml) on the y-axis and days post inoculation (dpi) are plotted on the x-axis. Bars 
represent the interquartile range, medians are highlighted. Whiskers represent total variation and outliers (more than 1.5 times the interquartile range from the median) are indicated as 
circles and dots. Experimental groups are indicated by the colouring of the bars: blue, re-inoculated group and green, naïve group. IL-3, Interleukin-3; IL-4, Interleukin-4; IL-5, Interleukin-5; IL-9, 




Figure 39 Cytokines loading on component 1 (continued). Cytokine concentrations are plotted in absolute values (pg/ml) on the y-axis and days post inoculation (dpi) are plotted on the x-axis. 
Bars represent the interquartile range, medians are highlighted. Whiskers represent total variation and outliers (more than 1.5 times the interquartile range from the median) are indicated as 
circles and dots. Experimental groups are indicated by the colouring of the bars: blue, re-inoculated group and green, naïve group. IL-1a, Interleukin-1a; IL-1b, Interleukin-1b; IL-6, Interleukin-6; 





Figure 40 Cytokines loading on Component 2 (top row) and 3 (KC, bottom row) as well as cytokines not significantly loading on any of the four principal components (Eotaxin and IL-13, bottom 
row). Cytokine concentrations are plotted in absolute values (pg/ml) on the y-axis and days post inoculation (dpi) are plotted on the x-axis. Bars represent the interquartile range, medians are 
highlighted. Whiskers represent total variation and outliers (more than 1.5 times the interquartile range from the median) are indicated as circles and dots. Experimental groups are indicated 
by the colouring of the bars: blue, re-inoculated group and green, naïve group. IL-13, Interleukin-13; IL-17, Interleukin-17; KC, Keratinocyte Chemoattractant (CXCL1); RANTES, Chemokine 
'Regulated on Activation, Normal T cell Expressed and Secreted', (CCL5), IL-12p40, Interleukin-12 Subunit p40; IL-1, Interleukin-1.
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As suggested by the linear model in the univariate analysis of component scores presented above in 
4.3.4.2.3 and the loading of different groups of cytokines on the four principal components (Table 
44), most cytokines loading on component 1 (Figure 38 and Figure 39) showed a tendency towards 
higher and increasing cytokine concentrations in the re-inoculation group (e.g. IL-9, IFN-γ, IL-3, IL-4, 
GMCSF, TNF-α, IL-5, IL-12p70, IL-1b, IL-6 and MCP1). There was an apparent ‘peak’ at 7 dpi in the re-
inoculation group for IL-3, TNF- α, MIP1b (including naïve group cytokine concentrations) and IL-6. A 
‘peak’ appeared at 7 dpi in the naïve group for MIP1b (including re-inoculation group cytokine 
concentrations), MIP1a, GCSF and IL-10.  
The cytokines, loading on component 2 (IL-17, RANTES, IL-2 and IL-12p40) demonstrated higher 
concentrations in the naïve group of the experiment, most pronounced at 7 dpi whilst cytokine 
concentrations in the re-inoculation group remained steady over the observation period.  
Only KC was found to load on component 3 using the selected criteria and showed little variation, 
but a mild increase over time, in the re-inoculation group.  
The cytokines not significantly loading on the four extracted components in the unrotated PCA 
interpretation showed a tendency to decrease over time from pre-inoculation levels (Eotaxin) and an 
increase over time in the re-inoculation group/decrease in the naïve group from pre-inoculation 
levels (IL-13).  
General linear models for all cytokines, separated by groups, were calculated as well as isolated 
‘peaks’ assessed for significant differences across groups and from pre-inoculation levels (data not 
shown). However, such analysis was not considered helpful in the interpretation of the current pilot 
study that aimed to identify a cytokine signature suggesting protection from re-infection and not 





4.4.1 Clinical signs and haematological changes during primary M. haemomuris infection 
Due to the pilot nature of the haematology study, no statistical analysis was attempted. However, 
we have, for the first time, demonstrated the development of haematological changes including 
anaemia subsequent to M. haemomuris infection in C57BL/6 mice. The degree of anaemia roughly 
agreed with observations of M. haemofelis infection in cats (89) and extrapolating from feline data, 
some individuals could reach much lower (<10 % HCT) values than the observed range in our studies 
of 20.8-24.3 % HCT (see Table 40). Such individual lower responses could have been missed in our 
studies by sampling on a fixed set of days, but this limitation is not easily alleviated as repeated 
sampling from mice is likely to cause haematological disturbances on its own (366, 367). Another 
limitation of the haematology study is that there were no control mice to demonstrate a typical 
course of infection. However, as differences in inoculum dose were deemed negligible, very similar 
infection kinetics may be assumed.  
4.4.2 Cycling of M. haemomuris genome copies per µl blood and peracute death of mice 
Cycling of M. haemomuris genome copies over the course of infection has not previously been 
observed but is a feature of M. haemofelis infection (89). Interestingly, the cycling of M. haemomuris 
genome copies appeared at the same number of passages from the original Apodemus spp. isolate 
as did more frequently occurring peracute deaths at peak parasitaemia. Fatal outcomes following 
primary M. haemomuris infection had been observed (data not shown) previously but were isolated 
rare events and attributed to secondary complications such as lymphatic neoplasia in old animals or 
excessive bleeding from the sampling site. This raises the question of whether obtaining inocula 
during exponential expansion of M. haemomuris increases pathogenicity and whether serial 
passaging of our isolate had a pathogenicity-enhancing effect. Although typical infection kinetics 
have now been described for 14 days following naïve infection with M. haemomuris, future studies 
should include daily sampling on larger groups of mice to further elucidate the effect of cycling 
genome copies and a potential correlation with more severe outcomes. The current dataset does 
not include enough cases (5 mice with observed cycling and 4 peracute deaths, one mouse that died 
following cycling genome copies) to either support or refute this hypothesis.  
4.4.3 Principal component analysis suggests Th17-driven immune response in naïve M. 
haemomuris infection 
We have successfully extracted four principal components to identify the cytokine expression 
signatures following naïve inoculation with M. haemomuris and re-inoculation (akin to protection 
from re-infection) with the same organism. The first two components were considered meaningful in 
analysis although different ways of clustering the dataset (i.e. Promax rotation as briefly summarised 
in 4.3.4.2.5) or employing different criteria of defining meaningful component loading (see 4.3.4.2.2) 
were left underexplored.  
Principal component 1 comprised a pleiotropic immune response consisting of Th1 (i.e. IFN-γ, TNF-α 
and IL-12p70), Th2 (i.e. IL-4, IL-5, IL-9 and IL-13) and Th17 (i.e. IL-6, GMCSF) components as well as 
various chemokines activating these pathways (i.e. MIP1a, MIP1b, IL-1a and IL-1b). These cytokines 
were found to be expressed more in the re-inoculation group when compared to the naïve group 
and subject to an increase over time as shown in Figure 38 and Figure 39 and reflected in 
component scores on principal component 1 (see Figure 36, top left panel).  
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Looking at individual cytokines loading on component 1 (Figure 38 and Figure 39), the observed 
‘peaks’ at 7 dpi occurred in the re-inoculation group for the proinflammatory cytokines TNF-α and IL-
6 that act as endogenous pyrogens (368) and IL-3 that mediates allergic and eosinophilic 
inflammation (369) as well as the chemokine MIP1b that mediates granulocytic inflammation by 
further inducing TNF-α, IL-6 and other proinflammatory mediators (370). Both Th1 and Th2 
pathways appear to be active during protection from re-infection with M. haemomuris, which 
includes the cytokine ‘peak’ seen at 7 dpi for IL-3, TNF-α and MIP1b that did not have a 
corresponding peak in M. haemomuris genome copies per µl blood in the re-inoculation group. 
However, these cytokine peaks did correspond to peak bacteraemia in the naïve group at the same 
time after inoculation (see Figure 32 and Figure 35). Interleukin-6, IL-3 and TNF- α are all commonly 
associated with chronic inflammatory disease (369, 371, 372), however these cytokines did not 
remain elevated throughout the study period, suggesting successful dampening of pro-inflammatory 
stimuli after controlling excessive M. haemomuris proliferation. The ‘peak’ in cytokine 
concentrations as seen in cytokines loading on principal component 1 (Figure 38 and Figure 39) was 
also present in the naïve group but occurred in IL-10, GCSF and MIP1b (that also increased in the re-
inoculation group). Whilst MIP1b as mentioned above and GCSF have primarily proinflammatory 
roles, especially GCSF that drives neutrophilic inflammation and potentially aggravates tissue 
destruction (373), IL-10 has evolved to regulate inflammation and protect from excessive tissue 
damage, especially in allergic and auto-immune disease (374). This increase of IL-10 at peak 
bacteraemia agrees with current therapeutic strategies in haemoplasmosis in cats that do not 
involve corticosteroids unless in rare, extreme cases, although translatability of these mouse model 
findings to feline haemoplasmosis has not yet been assessed. Unfortunately, no cytokine data were 
available from the mice that died at the time of peak bacteraemia (4.3.1.2) to correspond potential 
dysregulation of inflammation to mortality. The increase of IL-6 and TNF-α that was more 
pronounced in the re-inoculated group and the peak of IL-10 coinciding with peak bacteraemia 
agrees with previous findings in cytokine mRNA levels in response to infection/re-infection with M. 
haemofelis (107).  
Principal component 2 indicated the presence of Th17 pathway cytokines (IL-17, IL12p40 and IL-2), 
that are thought to clear extracellular pathogens not effectively handled by Th1 and Th2 pathways 
(375). The component scores on component 2 were found to significantly differentiate between the 
naïve and re-inoculated groups, especially at the time of peak bacteraemia at 7 dpi (Figure 36, top 
right panel). 
The difference in component scores on principal component 2 between experimental groups was 
reflecting rising and elevated plasma cytokine concentrations in the naïve group (Figure 40, top 
row). Interleukin-17 is the hallmark of the pro-inflammatory Th17 response as discussed above in 
4.1.1.1.3. Interleukin-12p40 is a subunit of IL-23 (shared between IL-12 and IL-23) that is involved in 
maintaining a Th17 response (376). Interleukin-12 however, has a different function, and drives a 
Th1 response and secretion of IFN-γ, which inhibits Th17 proliferation (377). As IL-23 was not 
measured in the current study, confirmatory measurement of IL-23 would be required to rule out 
other sources of IL-12p40 in primary M. haemomuris infection. Interleukin-2 and IL-1b convert Tregs 
into Th17 cells, promoting an inflammatory response (378). RANTES is a granulocyte and lymphocyte 
chemoattractant, associated with inflammatory disease and autoimmune disorders but also plays a 
vital role in immune response to viral infection (379). In contrast to other pro-inflammatory 
chemokines, IL-17 seems to have a suppressive effect on RANTES in most environments, limiting 
further lymphocyte infiltration (380) whilst Th17 cells themselves are strongly attracted by RANTES 
to sites of inflammation (381). Receptors for RANTES are also expressed on NK-cells and play a role 
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in homing NK cells and Th17 cells to the red pulp of the spleen (382); RANTES has been shown to 
promote resistance to infection with Leishmania major (383).  
The differential clustering of the cytokines on principal components 2 and 1 (see Figure 37) suggests 
that Th17 pathways play a vital role in naïve M. haemomuris infection but not in protection from-
reinfection, as the re-inoculation group exhibited higher concentrations of cytokines associated with 
Th1, Th2 and Th17 pathways. A subjective favouring of Th1 cytokines (i.e. IFN-γ, TNF-α, as shown in 
Figure 38) early in the re-inoculation group would have to be explored further in more targeted 
studies. Cytokine ratios, that have traditionally been used to define cytokine expression patterns in 
infections, allergic diseases (384, 385) or haemoplasma infection (107) were not explored in the 
current study in favour of the PCA. Further studies could consolidate our current findings and design 
experiments to look at a limited number of cytokines, their progression over time and try to identify 
risk factors for more severe clinical disease or lack of protection by the use of higher mouse numbers 
in pre-defined experimental settings.  
Measuring other Th17-type cytokines not included in the current assay (e.g. IL-21 or IL-22) would 
help consolidate the hypothesis that Th17 cells play a vital role in primary infection with M. 
haemomuris. For instance IL-22 is another effector cytokine produced by Th17 cells and regulates 
epithelial barrier function during infection but can also promote autoimmunity (337). Interleukin-21 
is also produced by Th17 cells and amplifies Th17 responses in an autocrine loop, hence favouring 
Th17 over Treg differentiation (337). 
Principal component 3 was found to mainly represent KC as found in wound healing and other 
cytokines (like IL-13, although it was not included in the analysis due to its low component loading) 
that exhibited a decrease at peak parasitaemia in the naïve group and an increase in early recovery 
in the re-infected group (Figure 40, bottom row). As a result, this component was able to 
differentiate between the groups as an interaction with dpi (see 4.3.4.2.3). The chemokine KC has 
been shown to be critical for neutrophil migration and clearing of septicaemia (386), and appears to 
share regulatory pathways with IL-17 (387, 388). Interleukin-13 is a Th2 type cytokine, playing a role 
in chronic infection, allergic airway disease and is associated with protective immunity against 
nematodes (389). 
Principal component 4 was found to be less meaningful than the previous components but was 
retained for analysis as an additional dimension. Similar to principal component 3, it appeared 
influenced by cytokines/chemokines that had a distinct but less pronounced ‘peak’ in one of the 
groups over the course of infection (Figure 40, bottom row), however further analysis was not 
attempted.  
When assessing component scores over time (Table 45), the observed changes in component scores 
were primarily analysed as a general linear model and not restricted to chronological order (as the 
variable of dpi was entered as a fixed factor rather than a covariate into the univariate analyses 
allowing for 6 degrees of freedom). Hence, the statistical significances listed in Table 45 only refer to 
any changes over time but not the exact development of those changes. A better fitted model could 
not be achieved by restricting the degrees of freedom (equivalent to ordering the dpi chronologically 
by rendering dpi as a covariate) and allowing for non-linear (i.e. quadratic) interactions. The lack of 
significant differences described by a quadratic curve over time could have been caused by the 
scattering of the data and the observed ‘peaks’ at 7 dpi that were not preceded by gradual increases 
or decreases over time. The significance of the ‘peaks’ at 7 dpi was already assessed in the linear 
model summarised in Table 45. It was, however, not the purpose of this study to fit a perfect model 
of component scores over time but to describe a broader level of variability and clustering within the 
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dataset. Hence no linear regression lines were plotted in Figure 36 as they could be interpreted for 
significance (Table 45) and dotted interpolation lines are given to point towards potential non-linear 
relationships that could guide further studies and cytokine changes of interest over the course of 
infection with M. haemomuris.  
Changes in cytokine concentrations over time (Figure 38 to Figure 40) were presented as box plots 
without further statistical analyses. Such analyses (e.g. general linear models to look at time courses 
or Mann-Whitney-U statistics to compare individual days between groups) were performed but 
were not presented within this chapter as such “cherry picking” would undoubtedly have produced a 
high number of significant results without adding to the overall interpretability of the findings. 
Additionally, in the current pilot study, the effect size was undoubtedly close to individual variation, 
hence selecting out individual ‘peaks’ between days and groups would not have been appropriate 
without defining a biologically meaningful question and addressing it further with a suitably 
powered study.  
4.4.4 Limitations of the current mouse model and further work 
The studies described in this chapter have successfully demonstrated the development of 
haemoplasmosis in C57BL/6 mice after infection with M. haemomuris based on haematology, 
splenomegaly, bacteraemia-associated deaths and an inflammatory cytokine response over 14 days 
following primary infection. Although the described haematology- and cytokine expression studies 
were pilot in nature, the newly established mouse model can now be used to investigate clinical and 
laboratory changes that occur in host animals infected with haemoplasmas. The use of the mouse 
model is not limited by focusing on infection kinetics alone. Full validation for subsequent research 
purposes will still require further studies to define confidence intervals for defined changes before 
further conclusions can be drawn. The translatability of findings from mouse to cats or other host 
species has not been determined for haematology, splenomegaly, risk of death or cytokine 
expression. However, we now have a surrogate mouse model of haemoplasma infection and 
haemoplasmosis that allows for the design of more targeted studies. We have also demonstrated 
that the use of amplifier mice (4.2.1.5.2 and 4.2.1.6.2) appears to eliminate the problem of loss of 
inoculum viability that was seen in the work described previously in Chapter 3.  
In the cytokine expression study, cytokine levels were measured in plasma. Whilst their role is to 
recruit cells of the immune system to the site of infection (blood), they typically act on their 
paracrine environment, only reaching cells in immediate proximity (322). The spleen is the specialist 
organ that usually deals with blood borne pathogens and as such, could be more likely to pick up 
paracrine cytokine signals (322). Whilst spleens from all mice exsanguinated as part of the cytokine 
expression study and haematology study were cryopreserved at -80°C, splenic cytokine expression 
was not addressed by our methods, potentially missing detection of a more polarised immune 
response over the course of infection. Whilst splenic cell suspensions might not be comparable to 
plasma cytokine expression, due to required sample preparation and tissue lysis (346), future 
experiments could involve measuring splenic cytokine expression in vitro, with or without prior 
extraction of lymphocyte populations.  
A statistical limitation of the cytokine expression study that has not yet been mentioned for the 
plasma cytokine measurements discussed above, is the possible introduction of a type-1 error 
(rejection of a true null hypothesis or ‘false positive’ finding). Although the naïve and re-inoculation 
groups and their respective control groups (see Figure 27) were matched in age and procedures, 
some cytokines could still reflect an effect on the subgroups exsanguinated on a given day, or at 
least be influenced by it. As the precision and repeatability of the assay under the employed 
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conditions was found to be acceptable (see ‘evaluation of quantitation’, 4.3.4.1) we did not run our 
samples in duplicate or triplicate due to the financial considerations of a pilot study. It is unlikely, but 
possible, that some of the scattering of absolute cytokine measurements (Figure 38 to Figure 40) 
was due to assay variation rather than individual variation within the experimental groups and 
would have been greatly reduced if sufficient replicate measurements were used.  
The interpretation of the reduced dimensions of a dataset obtained through PCA is inherently 
subjective as it is based on the current understanding of biological phenomena that might be subject 
to change over time. Even though PCA is one of the most commonly used methods to reduce data 
dimensions and extract features in the medical field, as it plots the variability of the data on a lower 
number of axes (components), it can introduce discriminatory features that lack biological meaning 
(390). This is especially true for rotation of components to maximise discriminatory power at the 
cost of displaying the maximum variability within a dataset (391), which is why further rotations or 
other constraints, such as making a component sparse (392), were not explored in the current study. 
Future studies should concentrate on asking more defined questions (i.e. better defining the IL-
17/IL-23 axis or following IFN-γ and TNF-α over the recovery time, prior to re-inoculation) in pre-
defined environments and use the current dataset as guidance rather than directly inform decision 
on preventative strategies. Such strategies could ultimately identify predictors of more severe 
outcomes or less effective development of protective immunity, which in turn will guide 





5 IN VITRO CULTIVATION OF MYCOPLASMA HAEMOMURIS 
5.1 INTRODUCTION 
5.1.1 Haemoplasma whole genome sequence data and metabolic capacities 
Haemoplasmas are currently unculturable in vitro (11). Due to their narrow biological niche in the 
bloodstream of their hosts, they have likely undergone metabolic reduction further than other 
Mycoplasma species (72). The lack of certain metabolic core enzymes and the presence of a variety 
of transporter proteins is an indication that haemoplasmas are fully equipped to scavenge vital 
substrates off their hosts and utilise nutrients they find in abundance within the bloodstream (72). 
Similar to the erythrocytes they adhere to, haemoplasmas use glycolysis as their primary source of 
energy, but in contrast to erythrocytes they have lost their pentose-phosphate pathway that 
generates NADPH to prevent oxidative stress, and require importation of nicotinamide for NADPH 
generation (72, 196). Having lost the ability to synthesise purine and pyrimidine nucleotides 
(substrates for RNA and DNA synthesis), these must also be imported alongside nine essential 
vitamins and other substrates to enable haemoplasmas to replicate (393). The feline haemoplasma, 
M. haemofelis, requires hypoxanthine, adenine, guanine, uracil and cytidine monophosphate to 
maintain its nucleotide metabolism, based on whole genome sequence analysis (393), but the 
concentrations required and any potentially inhibitory effects cannot be directly inferred from 
genomic data. Hypoxanthine is a by-product of purine nucleotide metabolism in erythrocytes, and is 
also required for growth of other pathogens inhabiting a similar biological niche, such as 
Plasmodium falciparum (394). Hypoxanthine is also released from erythrocytes, particularly during 
oxidative stress as expected during haemoplasmosis and suboptimal in vitro cultivation conditions 
(395). Adenine is a purine nucleobase required for the growth and spore formation of Clostridium 
spp. and Bacillus spp., which are phylogenetically close to Mycoplasma spp. (396, 397). Other purine 
nucleobases, such as guanine or the pyrimidine derivatives cytosine and cytosine monophosphate, 
have similar effects on Bacillus spp. growth when in high concentrations, although they can 
sometimes have inhibitory growth effects (398). The uptake of nucleotides and their precursors has 
been demonstrated for several Mollicutes (399, 400) but they are generally less studied in their 
metabolic activities than other Tenericutes due to their fastidious nature and difficulties in culturing 
them.  
5.1.2 Recent attempts of in vitro cultivation using data from whole genome sequencing 
Recent attempts to cultivate M. suis outside of the porcine host, informed by whole genome 
sequence data, resulted in nanotransformation, but not specific growth in the mycoplasma media 
SP-4 and Hayflick’s medium (242). Nanotransformation represents organisms with a reduced size, 
which are putatively metabolically inactive, and can be detected and differentiated from their 
normal state by electron microscopy. Quantification by qPCR of the nanotransformed organisms 
showed a stationary level of genome copies per ml of medium over two to three weeks of in vitro 
cultivation in media supplemented with haemin, haemoglobin and transferrin, but not in media 
devoid of these iron-binding proteins where drastic decreases in copies per ml occurred (242). 
Unfortunately in the latter study, Schreiner, Hoelzle (242) could not assess the viability of the 
nanotransformed M. suis, so the nature of the nanotransformed organisms that resulted from this 
growth experiment is unknown.  
More recently, Hicks (216) attempted to cultivate M. haemofelis outside of the feline host and 
produced promising, but not reproducible, results when supplementing MEXp (243) medium with 
120µM hypoxanthine over 4 days. Unfortunately, due to patent restrictions, the exact composition 
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of the medium could not be disclosed. Inoculation of other media, such as RPMI-1640, produced 
fluctuations of M. haemofelis genome copies per ml over the first hour post inoculation (which was 
not assessed for the MEXp studies), but did not result in sustained growth when incubated for a 
longer time period (216). Cultivation with Dulbecco’s modified Eagle’s medium (DMEM) or co-
cultivation with cell lines such as Crandell Rees feline kidney (CRFK) or the armyworm ovarian cell 
line SF-9 also did not result in M. haemofelis growth (216).  
5.1.3 Rationale of using intact cells in cultivation experiments 
Very early observations of E. coccoides by light microscopy (203, 238) reported them to exist in a 
form that was not attached to erythrocytes. The porcine haemoplasma M. suis was also visualised 
‘free’ on blood smears as part of studies of erythrocyte-membrane alterations during M. suis 
infection (116). However, haemoplasmas have not generally been found ‘cell-free’ in the plasma 
fraction (that is not associated with erythrocytes) from infected animals nor in tissues (11, 99, 285) 
by molecular techniques. Additionally, in recent experiments cultivating M. suis (241, 242) and M. 
haemofelis (216), no sign of free growth following erythrocyte detachment of the haemoplasmas 
was detected. Thus, these studies suggested that future cultivation studies may benefit from the use 
of intact erythrocytes. Erythrocytes have a limited life-span of about 40 days in mice (401) and are 
not the only erythroid cells found in the mammalian/murine bloodstream (402), so additionally the 
use of erythroid progenitor cells seemed logical to use in long-term in vitro cultivation experiments. 
Furthermore, the only reports of in vitro propagation of a haemoplasma species, E. coccoides, used 
chicken embryos (9), and the yolk sac is a source of erythroid progenitor cells in chicken, murine and 
human embryological development (403). Immortalised erythroid progenitor cell lines are not 
available for cats or pigs, but their murine counterparts have played an important role in the 
development of laboratory-grown blood transfusions (404), and are available for use in culture 
experiments.  
5.1.4 Rationale for using amplifier mice to generate viable M. haemomuris  
The studies by Nonaka, Thacker (241) and Hicks (216) that failed to produce significant 
haemoplasma growth, used cryopreserved blood (containing polyvinylpyrrolidone, glycerol or 
DMSO). Cryopreservation could have affected haemoplasma viability, and viability may also have 
been affected by prolonged storage in liquid nitrogen or at -80°C. A possible negative effect of 
cryopreservation on haemoplasma viability is supported by our failed infection attempts in Chapter 
3; 3.3.2.2, using cryopreserved blood samples. Additionally, cryopreserved samples used by Hicks 
(216) to inoculate cats according to the low-dose M. haemofelis infection model described by 
Baumann, Novacco (189) were not effective. By having a rapidly available source of viable M. 
haemomuris organisms through our recently established mouse model, we were given the 
opportunity to perform cultivation experiments using freshly sourced, and thus likely viable, 
haemoplasmas in a reasonably cost-effective way.  
5.1.5 Rationale for using sentinel mice to detect M. haemomuris viability 
As discussed above in 5.1.2, haemoplasma viability could not be assessed in previous cultivation 
attempts likely due to costs and ethical concerns of housing host animals for the sole purpose of 
infecting them with cultivated haemoplasmas to assess viability. However, failure to do this viability 
confirmation conflicts with Koch’s third postulate, which states that the disease must be reproduced 
when a specific bacteria is re-introduced into a susceptible host (405). Using live animals as a binary 
assay (infected vs. uninfected) to detect haemoplasmas has been suggested to identify more or less 
favourable haemoplasma culture conditions, but has not been used in subsequent studies (242). A 
mouse model would enable us to assess viability, although ethical concerns with the use of live 
animals remain. The mouse model would allow inoculation of sentinel mice to indicate the presence 
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of viable haemoplasma organisms (M. haemomuris) in cultivation attempts independently of in vitro 
maintenance or growth.  
5.1.6 Objectives 
The aim of this study was to define the maintenance and growth requirements for the haemoplasma 
species M. haemomuris using the mouse model of infection to assess viability after in vitro 
propagation. The growth of M. haemomuris in liquid culture was studied, with culture conditions 
optimised to support growth of murine erythroblast progenitor cells and their differentiation into 
mature erythroblasts, to provide an alternative cellular substrate to erythrocytes. Essential 
metabolic substrates not usually included in the base medium composition, such as hypoxanthine or 
nucleotide precursors, were added to try and define media compositions that were favourable for 
M. haemomuris viability and growth. The viability of cultivated M. haemomuris was defined by the 
inoculation of naïve sentinel mice with cultivated M. haemomuris, using them as a binary detection 
mechanism where successfully infected mice detect viable M. haemomuris organisms compared to 
not successfully infected mice detecting non-viable M. haemomuris, respectively. Under in vitro 
conditions, M. haemomuris growth was detected by comparison of repeated samples from in vitro 
cultures followed by DNA extraction and qPCR for M. haemomuris.  
5.2 MATERIALS AND METHODS 
5.2.1 Assessment of M. haemomuris assay variability 
In order to reliably differentiate M. haemomuris growth during in vitro cultivation studies from qPCR 
data, the intra-assay and inter-assay variations of the M. haemomuris-specific assay (3.3.1.4) needed 
to be determined. 
5.2.1.1 Origin of samples  
Dilutions of PCR amplicons, spanning the qPCR assay’s target sequence (see 3.3.1.4) were prepared 
in mouse gDNA. Background gDNA was sourced from M. haemomuris-negative mice during pre-
infection screening from earlier studies as previously described in 4.2.1.3. Extracted DNA samples 
were stored at -20°C until use.  
5.2.1.2 Intra-assay and inter-assay variation determination 
A dilution series of four sequential ten-fold dilutions was prepared, and each dilution was run in ten 
replicates on the same qPCR plate to determine intra-assay variation for each dilution. Ten threshold 
cycle values and ten calculated relative M. haemomuris genome copies per reaction (calculated as in 
2.2.1.2.2.2.2) were recorded for each dilution. The dilution series was stored at 4°C over-night and 
the experiment repeated the next day with freshly prepared qPCR reagents to determine inter-assay 
variation. All reactions were carried out on the same thermal cycler (Mx3005P; Agilent) and plates 
assembled by manual pipetting rather than pre-mixing of master mix and DNA template to mimic 
actual experimental conditions to be used in the cultivation experiments.  
5.2.1.3 Calculation of coefficients of variation 
Results of the intra-assay and inter-assay variation studies were expressed as means and standard 
deviations (stdev) of all replicates for each dilution on each qPCR plate on both experimental days. 
Means and stdevs were calculated for threshold cycle values and relative M. haemomuris genome 
copies per reaction. Coefficients of variation (%CV) were calculated using Excel (Microsoft® 2013). 
The intra-assay % CV was calculated for each dilution as (stdev/mean)*100 using values from 
replicates obtained on the first day. The inter-assay %CV was calculated as (stdev/mean)*100 using 
values from all 20 replicates per dilution obtained on both days.  
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5.2.2 In vitro cultivation studies 
5.2.2.1 Animals 
All mice were female, SPF C57BL/6 and sourced from Harlan Laboratories UK Ltd., Loughborough, 
UK.  
5.2.2.1.1 Ethical approval 
All studies involving laboratory rodents were subject to ethical review (Animal Welfare Ethical 
Review Body of the University of Bristol) and covered by a Home Office licence (PPL PCFCBE2EB). 
5.2.2.1.2 Housing conditions 
Mice were housed under conditions and monitored as previously described in 2.2.3.2 but separated 
into individual cages after inoculation.  
5.2.2.1.3 Screening mice for pre-existing M. haemomuris-infection  
Mice were allowed an acclimatisation period of three to ten days. One week prior to all experiments, 
mice were uniquely identified, and had a 10µl blood sample withdrawn for generic haemoplasma 
qPCR analysis as outlined in 2.2.3.3.  
5.2.2.1.4 Amplifier mice to generate viable inocula for in vitro cultivation studies 
Due to concerns over cryopreservation of M. haemomuris, amplifier mice were used to generate 
viable M. haemomuris inocula to inoculate culture media preparations for in vitro culture 
experiments.  
5.2.2.1.4.1 Inoculation and monitoring of infection in amplifier mice 
Inoculation procedures for the studies described within this chapter did not vary from the procedure 
described in 2.2.3.4.1. Infection with M. haemomuris was monitored by daily blood sampling of 10 µl 
followed by DNA extraction from the blood sample and M. haemomuris-specific qPCR as described 
previously in 3.2.2.3.2. 
5.2.2.1.4.2 Collection of M. haemomuris-infected blood from amplifier mice 
Collection of blood for inoculation of culture media preparations was performed using the technique 
outlined in 2.2.3.7. However, no cryopreservative was added to the blood at any point and 
aseptically collected samples were transported to the laboratory for use in cultivation experiments 
within 5 minutes of collection under isothermal conditions. 
5.2.2.1.5 Sentinel mice to monitor M. haemomuris viability after in vitro cultivation experiments  
5.2.2.1.5.1 Inoculation of sentinel mice with M. haemomuris after in vitro propagation 
As specified in the individual experiments, aliquots of M. haemomuris in culture media suspension 
were inoculated into 9 to 15-week-old mice using the technique described in 2.2.3.4.1. Total 
inoculation volume was 200µl per mouse, and inocula were prepared by allowing the cultured cells 
(typically 500µl) to sediment, removing the supernatant, and resuspending the cells in 200µl of fresh 
culture medium of the previously used composition to generate an inoculum.  The total volume of 
culture wells (typically 500µl) could not be used for inoculation as this would have been too great a 
volume to inoculate intra-peritoneally into each mouse (as stipulated by regulated procedures 
covered by the Home Office licence).  
5.2.2.1.5.2 Monitoring of sentinel mice after inoculation with in vitro propagated M. haemomuris  
Infection with M. haemomuris was monitored by daily blood sampling of 10µl followed by DNA 
extraction from the blood sample and M. haemomuris-specific qPCR as described previously in 
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3.2.2.3.2. Mice were monitored for 16 consecutive days following inoculation unless specified 
otherwise.  
5.2.2.2 Preparation of culture media and stock additives 
5.2.2.2.1 Preparation of StemPro™-34 culture medium 
StemPro™-34 serum-free stem cell medium (Life Technologies, Gibco, UK) was mixed with frozen 
supplement (StemPro™-34 Nutrient Supplement) prior to use and stored at 4°C. After six months of 
use (duration of experiment was longer than anticipated due to overlap with the studies described in 
Chapter 4) culture medium was discarded and replaced by a freshly prepared batch. StemPro™-34 is 
a specialist medium optimised to support the growth of human haematopoietic stem cells and was 
chosen as a base medium to try and co-cultivate murine erythroblast progenitor cells (stem cells) as 
described by von Lindern, Deiner (406) with M. haemomuris.  
5.2.2.2.2 Preparation of hypoxanthine 
A stock solution of hypoxanthine (Gibco) of 0.1M was prepared in 0.1N NaOH and filtered through a 
sterile 0.2μm filter (Nalgene, Thermo Fisher, UK) and stored at 4°C until use.  
5.2.2.2.3 Preparation of CaCl2 and MgCl2 
To determine if CaCl2 or MgCl2 concentrations in the base media, optimised to grow non-adherent 
cell lines, required adjustment to mirror mouse plasma levels and favour adherence of cells, the 
concentrations of ionised calcium and magnesium in StemPro™-34 were increased by 25%; adding 
41µl/ml CaCl2 and 25µl/ml MgCl2. Stock solutions of CaCl2 and MgCl2 (10mg/ml) were prepared from 
anhydrous electrolyte preparations (Gibco) and filtered through a sterile 0.2μm filter (Nalgene) and 
stored at 4°C until use. Electrolytes are recognised co-factors in cell-adhesion and may play a role in 
pathogen adhesion (407, 408). 
5.2.2.2.4 Preparation of nucleobases, nucleosides and nucleotides 
Mycoplasma haemofelis was used as an example of a phylogenetically related haemoplasma that 
has full genome sequencing data available for exploration of metabolic capacities for use in the 
cultivation studies of M. haemomuris.  
Stock solutions of 20mg/ml were prepared as follows: 
Nucleobases: Adenine (Sigma) was dissolved in 0.5M HCl, Guanine (Sigma) was dissolved in 1N 
NaOH, Thymine (Sigma) was dissolved in 0.5N NaOH, Uracil (Sigma) was dissolved in 0.5N NaOH, 
Cytosine (Sigma) was dissolved in 0.5M HCl.  
Nucleosides: Cytidine (Sigma) was dissolved in distilled water. 
Nucleotides: Cytidine monophosphate (CMP; Sigma) was dissolved in distilled water. 
Reagents were filtered through a sterile 0.2μm filter (Nalgene) and were stored at 4°C until use.  
5.2.2.2.5 Preparation of salmon sperm DNA 
Single-stranded salmon sperm DNA (0.1mg/ml; Sigma) was defrosted immediately prior to addition 
to culture media and stored at –20°C. Single-stranded DNA is a by-product of late-stage erythrocyte 
maturation (409) and was added in an attempt to provide a possible substrate for direct nucleotide-
importation, as would be possible in vivo from within the host’s bloodstream and splenic pulp (409).  
5.2.2.2.6 Preparation of splenocyte suspensions 
The spleen was extracted aseptically from a 9-week-old mouse (killed under terminal anaesthesia as 
described in 2.2.3.7) and placed in a sterile tissue culture dish, containing 2ml StemPro™-34 
medium. The pulp was removed by applying blunt pressure to the capsule and the capsule 
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subsequently removed from the dish. The suspension was passed through a series of needles in 
decreasing diameters (18G, 20G, 23G; Terumo) and the suspension centrifuged at 1000 x g for 5 
minutes and the supernatant removed. The pellet was resuspended in 150μl StemPro™-34 medium. 
Splenocyte suspensions were prepared immediately prior to use and were not stored.  
5.2.2.2.7 Collection of uninfected mouse blood and preparation of washed eryrthrocyte 
suspensions 
Fresh mouse blood was collected by cardiac puncture under terminal anaesthesia as described 
above in 5.2.2.1.4.2 other than the mice were not inoculated with M. haemomuris prior to 
exsanguination. Blood was transported to the laboratory under isothermal conditions and within five 
minutes of collection. When washed erythrocyte suspensions were used, li-heparinised whole blood 
was diluted with 5ml of StemPro™-34 and centrifuged at 1000 x g for 5 minutes. This washing by 
centrifugation, removing the supernatant and resuspending the pellet in fresh medium was 
repeated twice before resuspension of the blood cells, to the volume originally collected, using 
StemPro™-34 to replace plasma. Erythrocyte suspensions were prepared immediately prior to use 
and not stored.  
5.2.2.2.8 Preparation of murine erythroblast progenitor cell (stem cell) suspensions 
A murine cell line of p53-/- erythroblast progenitors was kindly donated by Dr. Ash Toye and Dr. Tim 
Satchwell, School of Biochemistry, University of Bristol and grown as described by von Lindern, 
Deiner (406). In brief, cryopreserved cells were seeded at 5E+05 cells/ml into StemPro™-34 medium 
and supplemented with the following additives: 
Expansion protocol:  
To expand erythroblast progenitor stem cells for mass cultures, the cells were supplemented with 
murine recombinant stem cell factor (SCF, R&D Systems, MN, USA, final concentration 100ng/ml), 
human recombinant erythropoietin (Erypo Cilag AG, Switzerland; final concentration 2U/ml) and 
dexamethasone (Sigma; final concentration 1µM).  
Differentiation protocol:  
To differentiate erythroblast progenitor stem cells to erythroblasts, cells were supplemented with 
human recombinant erythropoietin (Erypo Cilag; final concentration 10U/ml), human recombinant 
insulin (Sigma; final concentration 10μg/ml) and porcine holotransferrin (kindly provided by Dr. Ash 
Toye; final concentration 0.5mg/ml). 
To avoid potential interference with the subsequent M. haemomuris cultivation and avoid additional 
experimental variables, no antibiotics were used at any time. Mass cultures of erythroblast 
progenitor cells were obtained by incubation of cells in Costar® flat bottom plates 3516 (Thermo 
Fisher, recommended working volume of 2000µl per well) in a HERA cell CO2 incubator (Kendro 
Laboratory Products, NC, USA) set to 37°C and a CO2 concentration of 5% (v/v) in room air. Cells 
were monitored daily using a trypan blue exclusion stain (Gibco) and a haemocytometer. In brief, 
viable cells were counted as per manufacturer’s instructions. Cell suspensions were then spun at 
1000 x g for 5 minutes and the pellet resuspended in fresh medium including appropriate additives 
(expansion protocol) to maintain murine erythroblast progenitors at 1.0-2.0E+06 cells/ml (typically 
every 24 to 48 hours).  
5.2.2.3 Inoculation of in vitro cultures 
Prior to inoculation of in vitro cultures, culture media and all additives were aliquoted into Costar® 
flat bottom plates 3536 (Thermo Fisher, recommended working volume 500µl, per well) and plates 
warmed to 37°C by placing them in the CO2 incubator (Kendro) for 30 minutes. Unless otherwise 
specified, 500µl of culture medium was used per well. Wells were inoculated individually with 
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freshly collected M. haemomuris-infected blood, collected from amplifier mice (5.2.2.1.4.2) for each 
study. Prior to inoculation, the vial was inverted five times and unless otherwise specified, 50µl of M. 
haemomuris-infected mouse blood was added to 450µl of liquid culture media in a laminar flow 
hood. The method of mixing M. haemomuris-infected blood and culture media was varied between 
studies and is described later.  
5.2.2.4 Incubation conditions 
Unless otherwise specified, Costar® flat bottom plates 3536 (Thermo Fisher, recommended working 
volume 500µl) were used to incubate M. haemomuris cultures and handled aseptically under 
laminar air flow. Culture plates were incubated in a HERA cell CO2 incubator (Kendro) set to 37°C and 
a CO2 concentration of 5% (v/v) in room air. The unit was run through the built-in sterilisation 
protocol prior to starting the experiments.  Following inoculation, cultures containing M. 
haemomuris were subject to daily partial (typically 80%) media replacements by carefully removing 
the supernatant without disturbing the sedimented cells and resuspending the cells to 500µl with 
fresh media containing the appropriate additives at 37°C.  
5.2.2.5 Sampling protocol of in vitro cultures to determine M. haemomuris genome copies per µl 
culture 
Unless otherwise specified, culture wells were sampled after resuspension/media replacement to a 
500µl total volume, typically once daily or every other day. Ten microlitres were taken after 
resuspension and placed into a 1.5ml tube containing 90µl of sterile PBS. Samples were then stored 
at - 80°C until DNA extraction.  
5.2.2.5.1 DNA extraction from culture samples 
Total nucleic acid was extracted using an automated, magnetic bead system (Chemagic; Chemagen) 
described in 4.2.2.3.2.  
5.2.2.5.2 QPCR conditions 
Conditions of the M. haemomuris-specific qPCR were as described in 3.2.2.3.2.  
5.2.2.5.3 Assessment of culture media for qPCR inhibitors 
To ensure culture media did not inhibit the M. haemomuris-specific qPCR assay, a 1:10 dilution of li-
heparinised, M. haemomuris-infected mouse blood (sourced from an amplifier mouse during the 
cytokine expression study described in Chapter 4; 4.2.1.6.2.3) in StemPro™-34 was prepared and 
subject three times to a 1:10 dilution series in either PBS or StemPro-34™. Samples were subject to 
DNA extraction (see 4.2.2.3.2) and M. haemomuris-specific qPCR (3.2.2.3.2) in triplicate and Ct 
values compared.  
5.2.2.5.4 Calculation of M. haemomuris genome copies per µl culture media 
Relative M. haemomuris genome copies per µl culture medium were calculated as described in 
2.2.1.2.2.2.2. No normalisation for host control DNA (GAPDH) was performed to account for variable 
numbers of nucleated cells within the culture experiments over time. Threshold cycles of the GAPDH 
assay (as part of the duplex assay described in 3.2.2.3.2) were recorded to monitor possible 
extraction failures or failed reactions. All reactions were run in triplicate and genome copy numbers 
averaged before data analysis, unless otherwise specified.  
5.2.2.6 Study 1 using plateau-phase infected blood and murine erythroblast progenitor cell lines 
Six different media compositions were prepared and 450µl aliquots placed into culture wells in 
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100µM None 1.0E+06 cells/ml 5.98E+05 
(* here per 
2000µl well) 
Table 46 Composition of culture media used in the in vitro cultivation study 1, using M. haemomuris-infected blood to try to 
infect murine erythroblast progenitor cell lines. M. haemomuris was collected during plateau-phase bacteraemia from an 
M. haemomuris-infected C57BL/6 mouse at 31 dpi and 50µl blood added to 450µl of media in duplicate, except for medium 
A2, that was trialled at a final volume of 2000µl. SCF, stem cell factor; EPO, human recombinant erythropoietin.  
Li-heparin-anticoagulated blood was collected at 31 dpi from a 15-week-old, female, M. 
haemomuris-infected C57BL/6 mouse and contained 3.73E+03 haemoplasma genome copies per μl 
as determined by qPCR. Duplicate culture wells containing media A1, B1, B2, D1, D2, D3, E1 and E2 
(defined in Table 46) were inoculated with 50µl of M. haemomuris-infected blood each, followed by 
gentle pipetting to mix blood and culture media. Wells were subject to partial media replacements 
daily, followed by gentle pipetting to resuspend sedimented cells in culture media. Wells were 
sampled at 0, 2, 4, 6 and 8 dpi, immediately following passaging (discarding half of the well volume, 
followed by 1:1 dilution in fresh media) of the growing erythroblast progenitors for monitoring of M. 
haemomuris genome copies per µl culture media. Passaging into new medium was required to 
ensure erythroblast suspensions remained between 1.0E+06 and 2.0E+06 cells/ml as required for 
optimal viability and growth (406). When calculating total M. haemomuris genome copies per µl 
medium, passaging was accounted for by multiplying genome copies with the dilution factor. Total 
culture time was eight days.  
An additional, single, larger well ‘A2’ (Costar® flat bottom plates 3516, ThermoFisher, Table 46) was 
included and inoculated with 160µl of infected blood to pilot the differentiation protocol of the 
murine erythroblast progenitors that leads to them being differentiated enough to produce 
haemoglobin (5.2.2.2.8) and become erythroblasts. Inoculation was followed by gentle pipetting to 
mix blood and culture media. Well A2 was subject to partial media replacement daily. Media 
replacement was followed by gentle pipetting to resuspend sedimented cells in culture media. Cells 
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in well A2 were passaged (discarding half of the well volume, followed by 1:1 dilution in fresh media) 
at 2, 4, 6, 8 and 10 dpi and sampled at 0, 1, 2, 4, 6, 8, 10, 12, 14, 17, 18 and 20 dpi. When calculating 
total M. haemomuris genome copies per µl medium, passaging was accounted for by multiplying 
genome copies with the dilution factor. Total culture time was twenty days.  
5.2.2.6.1 Sentinel mice for study 1 
At 8 dpi of culture wells, well ‘A2’ was split into 2 aliquots and centrifuged at 1000 x g for 5 minutes. 
One aliquot was resuspended in 2 x 200 µl of fresh StemPro™-34 medium, forming two inocula. The 
two inocula were inoculated intraperitoneally into two sentinel mice (one inoculum dose per mouse) 
as outlined in Table 47. Inoculation procedure was as described above in 5.2.2.1.5.1 and monitoring 
as described in 5.2.2.1.5.2. The second aliquot was resuspended in 2ml of culture medium A2 and 





(culture well in 
Table 1) 
Dpi of culture at 




dose in 200µl of 
inoculum per 
mouse 
S1, S2 A2 8 1.50E+05 
Table 47 Origin, composition and days post inoculation (dpi) of inocula used to infect sentinel mice during in vitro 
cultivation study 1.  
5.2.2.7 Study 2 using pre-peak infected blood, splenocyte suspensions, differentiated 
erythroblasts, whole blood and erythrocyte suspensions 
Eight different media compositions were prepared and 450µl aliquots placed into culture wells in 


















Splenocytes M. haemomuris 
































100µM 50µl whole 
mouse blood 
(uninfected) 




















100µM 50µl whole 
mouse blood 
(uninfected) 





















100µM 200µl whole 
mouse blood 
(uninfected) 
None None 9.86E+07 (in 
150µl inoculum) 
 
Table 48 Composition of culture media used in the in vitro cultivation study 2, using M. haemomuris-infected blood to try to 
infect differentiated murine erythroblast cell lines, naïve murine blood, washed murine erythrocytes and splenocyte 
suspensions. M. haemomuris was collected during exponential M. haemomuris growth prior to peak-phase bacteraemia 
from an M. haemomuris-infected C57BL/6 mouse at 6 days post inoculation and 50µl blood added to 450µl of media in 
duplicate, except for medium X, that comprised 200µl of uninfected whole mouse blood and 150 µl medium and had 150 µl 
M. haemomuris-infected blood added to it. EPO, human recombinant erythropoietin. 
 
Li-heparin-anticoagulated blood was collected at 6 dpi from a 12-week-old, female, M. haemomuris-
infected C57BL/6 mouse and contained 6.57E+05 M. haemomuris genome copies per µl blood as 
determined by qPCR. Blood collected during exponential in vivo growth prior to peak parasitaemia 
(‘pre-peak’, data not shown) was chosen over plateau-phase collected blood (see Figure 20 ff. for 
phases of M. haemomuris infection). This was because it was not possible to differentiate viable 
haemoplasmas from non-viable haemoplasma DNA when calculating haemoplasma doses by PCR, 
and thus there was a possibility of potentially overestimating inoculum doses for in vitro cultivation. 
By using organisms collected during the exponential phase of growth, it was hoped that these most 
likely represented viable haemoplasmas.  Duplicate culture wells containing media F, G, H, I, J and K 
were inoculated with 50µl of M. haemomuris-infected blood each, followed by centrifugation at 
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1000 x g for 5 minutes to enhance cell-to-cell contact and resuspension by gentle pipetting to mix 
blood and culture media. Wells were subject to partial media replacements daily, followed by gentle 
pipetting to resuspend sedimented cells in culture media. Wells were sampled at 0, 1, 2 and 3 dpi, 
without passaging. Passaging, which effectively resulted in dilution to maintain steady 
concentrations of the stem cells, was omitted due to concerns over providing insufficient cell 
densities for growing haemoplasmas. Total culture time was reduced to three days, compared to the 
8 days in in vitro cultivation study 1, due to concerns arising from haemolysis (and a drop in M. 
haemomuris genome copies per µl medium) that was occurring in the wells when they contained 
more erythrocytes than included in the inoculum dose of 50µl.  
An additional medium composition ‘X’ was included and inoculated with 150µl M. haemomuris-
infected blood to pilot the effect of higher erythrocyte densities (medium composition see Table 48) 
on haemoplasma growth. Inoculation and the protocol of sampling of duplicate wells containing 
medium ‘X’ were identical wells containing media ‘F’ to ‘K’ as described above. 
5.2.2.7.1 Sentinel mice for study 2 
At 12 hours post inoculation of culture wells, well ‘X’’ was centrifuged at 1000 x g for 5 minutes and 
resuspended in 200µl of StemPro™-34 medium, forming one inoculum. This inoculum was 
inoculated intraperitoneally into one sentinel mouse as outlined in Table 49. At 24 hours post 
inoculation of culture wells, well ‘X’ underwent identical processing and inoculation into another 
sentinel mouse.  
At 2 dpi of culture wells, duplicate wells (indicated with an apostrophe) were pooled in the following 
order: G’ + I’ + L’, H’ + J’ whilst K’ and F’ remained separate. Pooled and separate well contents were 
centrifuged at 1000 x g for 5 minutes and resuspended in 200µl of StemPro™-34 medium, forming 
four inocula. These four inocula were inoculated intraperitoneally into four sentinel mice (one 
inoculum per mouse) as outlined in Table 49. The inoculation procedure was as described above in 
5.2.2.1.5.1 and monitoring was as described in 5.2.2.1.5.2.  
Sentinel mouse ID Inoculum composition 
(culture well) 
Dpi of culture at the time 
of sentinel mouse 
inoculation 
M. haemomuris dose in 
200µl of inoculum per 
mouse 
S3 X’ 0.5 (12 hours) 1.98E+06 
S4 X 1 (24 hours) not detected 
S5 G’ + I’ + L’ 2 8.42E+07 
S6 H’ + J’ 2 6.07E+07 
S7 K’ 2 7.92E+07 
S8 F’ 2 5.67E+07 
Table 49 Origin, composition and days post inoculation (dpi) of inocula used to infect sentinel mice during in vitro 
cultivation study 2. 
5.2.2.8 Study 3 (viability study) using StemPro™-34 without cellular supplementation 
As no haemoplasma growth had been observed in the experiments thus far, it was decided to 
determine M. haemomuris viability in a medium composition identical to that of K (containing no 
cellular components, medium composition see Table 48) over time to determine if the medium was 
likely to support and maintain M. haemomuris organisms even in the absence of growth for longer 
than two days as it had been assessed in study 2. No cellular components were added as no 
increased viability had been observed in cell-supplemented media. Five identical wells were 
























100µM None None None  8.73E+06 
Table 50 Composition of culture media used in the in vitro cultivation study 3 (viability study), using M. haemomuris-
infected blood in StemPro™-34 without cellular additives. M. haemomuris was collected prior to peak-phase bacteraemia 
from an M. haemomuris-infected C57BL/6 mouse at 3 dpi and 50µl blood added to 450µl of medium in five identical wells. 
EPO, human recombinant erythropoietin. 
Li-heparin-anticoagulated blood was collected at 3 dpi from a 9-week-old, female, M. haemomuris-
infected C57BL/6 mouse and contained 1.75E+05 M. haemomuris genome copies per µl blood as 
determined by qPCR. Five identical wells were inoculated with 50µl of M. haemomuris-infected 
blood each, followed by gentle rocking of the plate to mix blood and culture media. The mixing 
technique was changed compared to previous studies as concerns existed as to whether the mixing 
was resulting in, or contributing to, the haemolysis. To eliminate any potential effect that removing 
and replacing 10µl of culture every day could have on inoculum viability (due to having to resuspend 
cells to create a uniform suspension), no daily sampling was performed. Wells were subject to partial 
media replacements daily, followed by gentle rocking of the plate to resuspend blood and 
haemoplasmas in the culture media.  
5.2.2.8.1 Sentinel mice for study 3   
At 2, 4, 6, 8 and 10 dpi of culture wells, contents of one well were removed, centrifuged at 1000 x g 
for 5 minutes and resuspended in 200µl of the same medium (V) to form an inoculum. Each 
inoculum generated on days 2, 4, 6, 8 and 10 was inoculated intraperitoneally into one sentinel 
mouse as outlined in Table 51. Inoculation procedure was as described above in 5.2.2.1.5.1 and 






Dpi of culture at 




dose in 200µl of 
inoculum per 
mouse 
S9 V2  2 n/d 
S10 V4 4 n/d 
S11 V6 6 n/d 
S12 V8 8 n/d 
S13 V10 10 n/d 
Table 51 Origin, composition and days post inoculation (dpi) of inocula used to infect sentinel mice during in vitro 
cultivation study 3. 
5.2.2.9 Study 4 (RNA study) using StemPro™-34 without cellular supplementation  
A decision was made to monitor and quantify M. haemomuris RNA during the in vitro cultivation 
attempts, as it was hoped that RNA might potentially better reflect M. haemomuris viability. This is 
because bacterial RNA transcripts are thought to be short-lived and hence represent viable 
organisms, as they would not be produced by dead bacterial cells (410), although their usefulness for 
detecting viable pathogens has recently has been called into question (411). However, an RNA assay 
was hoped to lead to a reduced requirement for sentinel mice for assessment of haemoplasma 
viability. An experiment was designed to repeat the culture conditions outlined in 5.2.2.8 and 
quantify RNA as well as inoculating wells into sentinel mice (at 3 and 7 dpi) in order to see if a fall in 
RNA levels occurred that could be consistent with a reduction in the viable haemoplasmas under in 
vitro conditions.  
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5.2.2.9.1 Digestion of DNA and adaptation of the qPCR assay for RNA work (RT-qPCR) 
The in vivo infection kinetics of M. haemomuris RNA and DNA were determined in a pilot 
experiment, using blood samples (2 x 10µl) collected daily from 0 to 14 dpi with M. haemomuris in 
one 13-week-old mouse. Blood samples, diluted in 90µl of PBS each, were stored at -80°C until TNA 
extraction. The M. haemomuris-specific duplex qPCR assay (3.2.2.3.2) had been designed to amplify 
the DNA of the 16S rRNA gene of M. haemomuris and a transcribed region of the cat/mouse GAPDH 
gene, hence no amendment of primer sequences was required to adapt the assay to detect and 
amplify cDNA transcripts from the same genes following reverse transcriptase (RT) reactions.  
One sample of 10µl blood underwent TNA extraction as described before in 5.2.2.5.1 and was stored 
at –80°C after extraction and before qPCR. The other 10µl blood sample underwent identical TNA 
extraction, followed by DNA-digestion with DNase (1U/µl, RQ1 RNase-free; Thermo Fisher) as per 
manufacturer’s instructions. In brief, 30µl of TNA, 5µl of RNA-se free water, 4µl of 10X RQ1 reaction 
buffer and 1µl of DNAse were gently mixed and incubated at 37°C for 30 minutes. One microlitre of 
RQ1 stop solution (EDTA) was added and the mixture incubated at 65°C for 10 minutes to inactivate 
the DNAse in the sample now containing the total RNA in a volume of 40µl. Reverse transcription 
was performed using a MJ Mini Gradient Termal Cycler and ImProm II Reverse Transcriptase 
(Promega) to the manufacturer’s instructions. In brief, 5µl of total RNA were combined with ImProm 
II 5X reaction buffer, 3mM MgCl2, dNTPs (0.5mM each), random hexamers (25ng/µl) and ImProm II 
reverse transcriptase to a total volume of 20 µl. The mixture was subject to the following thermal 
cycling protocol: 20°C for 5 minutes, 42°C for 30 minutes and 70°C for 15 minutes. The resulting 20μl 
of cDNA was added to 30μl of RNase-free water and stored at −80°C. Five microlites of the original 
total RNA sample were also diluted in 50µl RNAse-free water and stored at –80°C until qPCR.  
Both sets of nucleic acid samples, generated from the originally collected 2 x 10µl blood samples, 
now either containing cDNA and DNA-free RNA or directly extracted TNA (extracted separately, 
diluted 3:4 and 1:10 to account for DNA-digestion and reverse transcription) were subject to M. 
haemomuris-specific duplex qPCR (3.2.2.3.2) to assess the DNA and RNA transcripts over the time 
course of M. haemomuris infection and the efficiency of DNA-digestion. Positive and negative 
(water) controls were included. Calculations of M. haemomuris genome copies per µl blood and 16S 
RNA copies per µl blood were performed as described before in 5.2.2.5.4.  
5.2.2.9.2 In vitro cultivation study 4 











Splenocytes M. haemomuris dose 
in 50µl of inoculum 







100µM None None None 3.92E+08 
(equivalent to 
1.99E+09 16S RNA 
copies as determined 
by RT-qPCR in 
5.2.2.9.1) 
Table 52 Composition of culture media used in the in vitro cultivation study 4 (RNA study), using M. haemomuris-infected 
blood in StemPro™-34 without cellular additives. M. haemomuris was collected during exponential growth prior to peak-
phase bacteraemia from an M. haemomuris-infected C57BL/6 mouse at 7 dpi and 50 µl blood added to 450 µl of medium in 
two identical wells. EPO, human recombinant erythropoietin. 
Li-heparin-anticoagulated blood was collected at 7 dpi from a 14-week-old, female, M. haemomuris-
infected C57BL/6 mouse and contained 7.84E+06 M. haemomuris genome copies per µl blood as 
determined by qPCR. Duplicate blood samples collected from the same mouse undergoing RT-qPCR 
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as described above in 5.2.3.12.1 were determined to contain 3.99E+07 copies of M. haemomuris 16S 
RNA at the same time. Two identical wells were inoculated with 50µl of M. haemomuris-infected 
blood each, followed by gentle rocking of the plate to mix blood and culture media. Wells were 
subject to partial (300µl) media replacements daily, followed by gentle rocking of the plates to 
resuspend sedimented cells in culture media. Suspended cells were then sampled at 0, 1, 2, 3, 4, 5, 6 
and 7 dpi. Total culture time was three days for the first well ‘W1’ and seven days for the second 
well, ‘W2’.  
5.2.2.9.3 Sentinel mice for study 4  
At 3 and 7 dpi of the culture wells, the contents of one well were removed, centrifuged at 1000 x g 
for 5 minutes and resuspended in 200µl of the same medium (‘W’, see Table 52) to form an 
inoculum. Each inoculum generated at 3 and 7 dpi was inoculated intraperitoneally into one sentinel 
mouse as outlined in  Table 53. The inoculation procedure was as described above in 5.2.2.1.5.1 and 






Dpi of culture at 




dose in 200µl of 
inoculum per 
mouse 
S14 W1 3 8.15E+08 
S15 W2 7 6.64E+08 
Table 53 Origin, composition and days post inoculation (dpi) of inocula used to infect sentinel mice during in vitro 
cultivation study 4. 
5.2.2.10 Study 5 (purine/pyrimidine study) using nucleobases, nucleotides, single-stranded DNA 
and whole blood supplementation  
To determine if M. haemomuris exhausted supplies of replaceable substrates or was inhibited 
somehow by its own growth, experiments were designed to assess whether growth in previous 
media compositions could be improved by the addition of nucleobases, nucleosides, nucleotides, 
single-stranded DNA or by dilution and the addition of naïve mouse blood at 3 dpi of in vitro 
cultures. Eight wells were prepared, with duplicate wells for each medium composition, as shown in 

































































100µM 50µl whole 
mouse blood 
(uninfected) 




None None 1.29E+09 
Table 54 Composition of culture media used in the in vitro cultivation study 5 (purine/pyrimidine study), using M. 
haemomuris-infected blood in StemPro™-34 with additional nucleobases, nucleosides, single-stranded DNA (ssDNA) and 
fresh blood replacement during media expansions. M. haemomuris was collected prior to peak-phase bacteraemia from an 
M. haemomuris-infected C57BL/6 mouse at 7 dpi and 50µl blood added to 450µl of medium in two identical wells. EPO, 
human recombinant erythropoietin; CMP, cytosine monophosphate; ssDNA, single-stranded DNA. 
Li-heparin-anticoagulated blood was collected at 7 dpi from a 12-week-old, female, M. haemomuris-
infected C57BL/6 mouse and contained 2.57E+07 M. haemomuris genome copies per µl blood as 
determined by qPCR. Two identical wells were inoculated with 50µl of M. haemomuris-infected 
blood each, followed by gentle rocking of the plate to mix blood and culture media. Wells were 
subject to partial (300µl) media replacements daily, followed by gentle rocking of the plates to 
resuspend sedimented cells in culture media. Suspended cells were then sampled at 0, 1, 2, 3, 4, 5, 
6, 7 and 8 dpi. Total culture time was three days for the first well of each medium (indicated by ‘1’ in 
the well name) and eight days for the second well (indicated by ‘2’ in the well name). At 3 dpi of 
culture wells, one well of each medium composition (‘1’) was inoculated intraperitoneally into one 
sentinel mouse as outlined in 5.2.2.1.5.1. The second well of each composition (‘2’) was maintained 
as before except for well ‘BLO2’. At 3 dpi of culture wells, well ‘BLO2’ was split in two aliquots of 250 
µl and resuspended in 200µl of the same medium with additional 50µl of uninfected mouse blood, 
sourced from a naïve mouse as described above in 5.2.2.2.7. This resulted in two culture wells, 
‘BLO2a’ and ‘BLO2b’ that were maintained and sampled as the remaining wells as illustrated in 




Figure 41 Schematic of the media expansion and blood replacement step at 3 days post culture inoculation of the in vitro 
cultivation study 5. Blood, infected with M. haemomuris was sourced from a donor mouse and used to inoculate the original 
well, undergoing partial media replacement and daily sampling. At 3 dpi, one well containing fresh blood was split equally 
into two new wells, each of which contained 50µl of fresh (uninfected) blood. Dpi, days post inoculation (of culture wells).  
5.2.2.10.1 Sentinel mice for study 5 
At 3 dpi of the culture wells, the contents of one duplicate well per medium composition were 
removed, centrifuged at 1000 x g for 5 minutes and resuspended in 200µl of the same medium 
(inoculum compositions N, NUCLEO, SALMON, BLOOD; see Table 54 for composition descriptions) to 
form an inoculum. Each inoculum generated was inoculated intraperitoneally into one sentinel 
mouse as outlined in Table 55. The inoculation procedure was as described above in 5.2.2.1.5.1 and 
monitoring as described in 5.2.2.1.5.2. 
At 8 dpi of culture wells, well ‘BLO2a’ was inoculated intraperitoneally into one sentinel mouse 
(Table 55) using identical inoculation generation procedure, inoculation procedure and monitoring 
of the sentinel mouse. The remainder of the wells were discarded after sampling and the experiment 






Dpi of culture at 




dose in 200µl of 
inoculum per 
mouse 
S16 N1 3 3.64E+09 
S17 NUC1 3 6.59E+08 
S18 SAL1 3 8.49E+09 
S19 BLO1 3 4.91E+09 
S20 BLO2a 8 1.45E+09 
Table 55 Origin, composition and days post inoculation (dpi) of inocula used to infect sentinel mice during in vitro 
cultivation study 5. 
5.2.2.11 Study 6 (continuous culture pilot) using serial media expansions and blood replacement 
Based on the results of passaging M. haemomuris cultures into media containing fresh mouse blood, 
it was decided to repeat the experiment comprising of media expansion combined with addition of 










Hypoxanthine Blood components M. haemomuris dose in 50µl 
of inoculum per 500µl well 
CONTIN 
(CON1, CON2, 
CON3; all to infect 
new recipient 





100µM 50µl whole mouse 
blood (uninfected) at 
2 dpi, coinciding with 
1:10 dilution 
2.84E+08 
Table 56 Composition of culture media used in the in vitro cultivation study 6 (continuous pilot), using M. haemomuris-
infected blood in StemPro™-34 with fresh blood replacement during media expansions. M. haemomuris was collected prior 
to peak-phase bacteraemia from an M. haemomuris-infected C57BL/6 mouse at 7 dpi and 50µl blood added to 450µl of 
medium in two identical wells. EPO, human recombinant erythropoietin. 
Li-heparin-anticoagulated blood was collected at 7 dpi from a 10-week-old, female, M. haemomuris-
infected C57BL/6 mouse and contained 5.69E+06 M. haemomuris genome copies per µl blood as 
determined by qPCR. Three identical wells were inoculated with 50µl of M. haemomuris-infected 
blood each, followed by gentle rocking of the plate to mix blood and culture media. Wells were 
subject to partial (300µl) media replacements daily, followed by gentle rocking of the plates to 
resuspend sedimented cells in culture media. Suspended cells were then sampled at 0, 1, 2, 3 and 4 
dpi. Total culture time was four days. At 2 dpi of the culture wells, 50µl of each infected culture was 
transferred into a new recipient well, containing 50µl of fresh (uninfected) blood and diluted with 
medium to the original volume of 500µl. Uninfected blood was sourced from a naïve mouse, as 
described above in 5.2.2.2.7. This media expansion and blood replacement step resulted in two new 
culture wells (recipient and donor well) for each original well. The recipient well underwent identical 
partial media replacement and sampling as before for another two days. The donor well (original 
culture) was reconstituted to the original volume of 500µl and maintained for another day. A 
schematic of this part of the experiment is given in Figure 42. At 4 dpi of the culture wells, one 
culture well (recipient well from CON1) was inoculated intraperitoneally into one sentinel mouse.  
 
Figure 42 Schematic of the media expansion and blood replacement step at 2 days post culture inoculation of the in vitro 
cultivation study 6 (continuous culture pilot). Blood, infected with M. haemomuris was sourced from a donor mouse and 
used to inoculate the original well. At 2 dpi, 50µl of infected culture was transferred into a new well, containing 50µl of 
fresh (uninfected) blood and diluted with medium to a volume of 500µl. Dpi, days post inoculation (of culture wells). 
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5.2.2.11.1.1 Sentinel mice 
At 4 dpi of the culture wells, the contents of one well were removed, centrifuged at 1000 x g for 5 
minutes and resuspended in 200µl of the same medium (inoculum composition CONTIN, see Table 
56) to form an inoculum that was then inoculated intraperitoneally into one sentinel mouse as 
outlined in Table 57. The inoculation procedure was as described above in 5.2.2.1.5.1 and 






Dpi of culture at 




dose in 200µl of 
inoculum per 
mouse 
S21 CON1 (recipient 
well) 
4 7.66E+09 
Table 57 Origin, composition and days post inoculation (dpi) of inocula used to infect sentinel mice during in vitro 





5.3.1.1 Intra-assay and inter-assay variation of the M. haemomuris-specific qPCR assay 
Intra-assay % CVs for each dilution are presented in Table 58.  
Dilution 
# 
Mean Ct Stdev Ct %CV 
(Ct) 
Mean relative M. 
haemomuris genome 
copies  






Equivalent variation in 
relative M. haemomuris 
genome copies 
1 22.5 0.060 0.27 1.55E+05 6.70E+03 4.33 6.70E+03 
1:10 25.7 0.118 0.46 1.76E+04 1.50E+03 8.50 1.50E+03 
1:100 28.9 0.185 0.64 1.88E+03 2.77E+02 14.73 2.77E+02 
1:1000 31.8 0.465 1.46 2.67E+02 8.89E+01 33.31 8.89E+01 
Table 58  Intra-assay coefficients of variation (% CV) as based on means and standard deviations (stdev) for each of the four 
amplicon dilutions. There is a typical increase in % CV with increasing Ct values (or lower genome copy numbers). However, 
as qPCR follows exponential amplification, even gradually decreasing % CVs are equivalent to increasing standard 
deviations when calculated on M. haemomuris genome copies rather than Ct values. This means that the assay’s ability to 
quantify M. haemomuris genome copies decreases with increasing template concentrations in absolute numbers.  
As expected, the %CV increased with increasing Ct values, reflecting lower repeatability of Ct values 
at higher template concentrations. Due to the exponential nature of the qPCR reaction, even 
gradually decreasing %CVs of Ct values are equivalent to higher standard deviations and hence 
higher variability of M. haemomuris genome copies when expressed in absolute numbers. This 
means that at the lowest template concentration, the range of measured Ct values was equivalent 
to 8.89E+01 M. haemomuris genome copies, and at the highest template concentration, the range of 
measured Ct values was equivalent to 6.70E+03 M. haemomuris genome copies despite the %CVs 
being lower at higher template concentrations. The %CVs and equivalent M. haemomuris genome 
copy numbers highlighted important considerations for the interpretation of any in vitro culture 
results relating to M. haemomuris genome copy quantification by qPCR, to avoid wrongly 
interpreting any variation of the qPCR assay as M. haemomuris growth.  
In the subsequent studies, growth was only said to be identified when differences in M. haemomuris 
genome copies per µl culture medium were clearly above the assay’s limit of quantification (greater 
Ct difference than calculated %CV) for the obtained Ct value of the three qPCR replicates. Where Ct 
values fell in-between or outside the range of the dilutions used for the current study, linear 
extrapolation (graph not shown) was used to define cut-off values for M. haemomuris growth.  
Inter-assay %CVs for each dilution are presented in Table 59 and showed similar values, however to 
avoid introducing variability due to sample storage, samples from all cultivation studies were 








Equivalent variation in 
relative M. haemomuris 
genome copies 
1 0.26 4.15 6.42E+03 
1:10 0.54 10.05 1.77E+03 
1:100 0.88 19.12 3.59E+02 
1:1000 1.71 38.59 1.03E+02 
Table 59  Inter-assay coefficients of variation (% CV) as based on means and standard deviations for each of the four 
amplicon dilutions from both experimental days.  
Whole intra-assay %CV calculated on Ct values was 0.70%, on the same day, and whole inter-assay % 
CV was 0.79%, spanning both days, independently of the dilution used.  
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5.3.1.2 Application to the M. haemomuris-specific qPCR assay to culture media preparations 
No inhibition of the M. haemomuris-specific qPCR assay was observed using mouse blood dilutions 
of 1:100 to 1:10,000 in StemPro™-34 compared to dilution in PBS following creation of a stock of 
‘mock culture sample’ of 1:10 dilution of li-heparinised mouse blood in StemPro-34™. Threshold 
cycle values derived to assess qPCR performance in PBS and StemPro™-34 are summarised in Table 
60. 
Template Ct Δ Ct 
1:10 dilution of Stock in PBS 20.09 20.02 20.39 - 
1:10 dilution of Stock in StemPro-34™ 20.09 20.88 20.28 - 
1:100 dilution of Stock in PBS 23.67 23.43 23.27 3.29 
1:100 dilution of Stock in StemPro-34™ 23.66 23.74 23.61 3.50 
1:1000 dilution of Stock in PBS 27.19 27.09 27.73 3.88 
1:1000 dilution of Stock in StemPro-34™ 27.18 27.21 28.05 3.81 
Table 60 TEX-threshold cycle values (Ct) for the M. haemomuris-specific qPCR assay on a dilution series of a ‘mock culture 
sample’ comprising a 1:10 dilution of M. haemomuris-infected mouse blood in StemPro™-34 (Stock) in subsequent 1:10, 
1:100 and 1:1000 dilutions of PBS prior to DNA extraction from 100 µl sample through the Chemagic (Chemagen) system as 
described above in 5.2.2.5.1. The difference in Ct between average Ct values of each dilution with the same diluent is 
indicated as Δ Ct and consistent with 3.3 Ct being equivalent to a 1:10 dilution.  
5.3.1.3 Results of in vitro cultivation study 1 using plateau-phase infected blood and murine 
erythroblast progenitor cell lines 
There was no growth detected in any of the 500µl wells inoculated during in vitro cultivation study 1 
(5.2.2.6) using M. haemomuris-infected blood collected from a C57BL/6 mouse at 31 dpi (plateau 
phase) and combinations of murine erythroblast progenitor stem cells, stem cell supplements, 
electrolytes and hypoxanthine (Figure 43). All mean relative M. haemomuris genome copies per µl 
culture medium at 8 dpi of culture wells were lower when compared to M. haemomuris genome 








Figure 43 M. haemomuris genome copies during in vitro cultivation study 1, showing amplification plots of culture wells A1 and A1’, D1 and D1’, D2 and D2’, D3 and D3’, E1 and E1’ as well as 
E2 and E2’ after inoculation of 50µl M. haemomuris-infected mouse blood into 450µl of prepared media A1, D1, D2, D3, E1 and E2. Media compositions are given in Table 1.Days post 
inoculation (dpi; of wells) are plotted on the x-axis and relative haemoplasma genome copies per µl medium are plotted on the y-axis. Connected dots of the same colour represent individual 
culture wells and where indistinguishable are overlapping each other. Wells were subject to partial media replacements daily and passaged, equivalent to a 1:1 dilution every other day. 
Dilution factors were accounted for before creating the plots. As zero values cannot be plotted on logarithmic scales, values of one (1.0E+00) M. haemomuris copy per µl blood (and qPCR 
reaction) are being treated as the equivalent of zero on this and subsequent graphs within this chapter.
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Well A2 contained an increased amount of inoculum (M. haemomuris infected blood from the same 
C57BL/6 mouse as used for the 500 µl wells above) and different stem cell supplements including 
transferrin (see Table 1). The mean relative M. haemomuris genome copy concentration 8 dpi of 
well A2 appeared higher when compared to 0 dpi (Figure 44) but this difference was within the % CV 
of the assay at the measured relative M. haemomuris copies, as previously determined 5.3.1.1. This 
was of interest as it showed a different trend in M. haemomuris genome copies per µl medium, 
especially as well A2 contained differentiated murine stem cells and stem cell factors at different 
concentrations, as well as transferrin, that had not been added previously. Well A2 was maintained 
for 12 additional days of partial media replacement and passaging of growing stem cells (dilution 
factor accounted for) but did not show an increase, but a decrease, in mean M. haemomuris genome 
copies per µl medium over time.  
 
Figure 44 M. haemomuris genome copies during in vitro cultivation study 1, showing amplification plots of culture well A2 
after inoculation of 160µl M. haemomuris-infected mouse blood into 1840µl of prepared medium A2. Days post inoculation 
are plotted on the x-axis and relative haemoplasma genome copies per µl medium are plotted on the y-axis. Well A2 was 
subject to partial media replacement daily and passaged (diluted) 1:1 at 2, 4, 6, 8 and 10 dpi. Dilution factors were 
accounted for before creating the plots. Dpi, days post inoculation.  
Supernatant samples of 100µl, collected at 2 dpi from all wells of in vitro cultivation study 1 were 
subject to DNA extraction and M. haemomuris-specific qPCR to assess for potential growth within 
the media but showed negative or barely detectable (<100) genome copies per µl medium (data not 
shown). Supernatant was hence not further investigated in subsequent studies.  
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The sentinel mice S1 and S2, inoculated at 8 dpi of culture wells, using the contents of well A2, after 
sampling and passaging (inoculation dose per mouse: 1.50E+05 M. haemomuris copies) did not 
establish M. haemomuris infection during the observation period of 14 days (Figure 45).  
 
 
Figure 45 M. haemomuris genome copies following inoculation of sentinel mice S1 and S2 from in vitro culture well A2 at 8 
dpi of culture wells. Days post inoculation (of mice) are plotted on the x-axis and normalised relative M. haemomuris 
genome copies per µl blood are plotted on the y-axis. Lines represent individual mice. Blood sampling occurred once daily.  
5.3.1.4 Results of in vitro cultivation study 2 using pre-peak infected blood, splenocyte 
suspensions, differentiated erythroblasts, whole blood and erythrocyte suspensions 
There was no growth detected in any of the 500µl wells inoculated during in vitro cultivation study 2 
(5.2.2.7) with M. haemomuris-infected blood collected from a C57BL/6 mouse at 3 dpi (pre peak 
phase) and combinations of differentiated murine stem cells, stem cell supplements including 
transferrin and additional hypoxanthine (Figure 46). The mean relative M. haemomuris genome 
copies per µl culture medium at 3 dpi of culture wells were not higher (as defined by the assay’s limit 
of quantification) when compared to M. haemomuris genome copies in the same medium at 0 dpi 
for all wells, which would have defined in vitro growth. However, M. haemomuris genome copies per 
µl medum were still consistently higher at 3 dpi compared to 0 dpi in wells containing media 
compositions H, I, J and K (Figure 46). This was of interest, as media H, I and J contained uninfected 
mouse blood or washed mouse erythrocytes, but medium K did not contain any cellular additives. 
Wells X and X’ (see Figure 46, bottom right corner) showed significant haemolysis following 
pipetting during the inoculation and sampling/resuspension procedures, and a drop in M. 
haemomuris genome copies per µl medium over 12 and 24 hours post inoculation was attributed to 
this. The handling procedures of the subsequent studies were thus amended to ensure haemolysis, 
and the shear stress of cells/haemoplasmas, was minimised by replacing the centrifugation/pipetting 














Figure 46 M. haemomuris genome copies during in vitro cultivation study 2, showing amplification plots of culture wells F and F’, G and G’, H and H’, I and I’, J and J’, K and K’, L and L’ as well 
as X and X’ after inoculation of 50µl M. haemomuris-infected mouse blood into 450µl of prepared media F, G, H, I, J, K, L and X. Media compositions are given in Table 48. Days post inoculation 
(dpi) are plotted on the x-axis and relative haemoplasma genome copies per µl medium are plotted on the y-axis. Connected dots of the same colour represent individual culture wells: 
Apostrophe-labelled wells, terminated and inoculated into mice at 2 dpi (0.5 dpi for medium X) are indicated by darker blue colouring. Wells terminated at 3 dpi (1 dpi for medium X) being 




The sentinel mice (S3, S4) inoculated at 12 hours post inoculation of culture well X’ and 24 hours 
post inoculation of culture well X (see Figure 46, bottom right corner) only established typical M. 
haemomuris infection kinetics (as defined by observations in Chapters 3 and 4, e.g. Figure 21 and 
Figure 32) when inoculated with the 12-hour-culture from well X’. The inability of the inoculum 
derived from culture well X at 24 hours post inoculation to establish infection was attributed to 
declining M. haemomuris genome copies per µl culture medium coinciding with haemolysis 
occurring in the same well. Sentinel mice S5, S6, S7 and S8, inoculated from pooled duplicate 
cultures at 2 dpi (see Table 49) all successfully become infected with M. haemomuris, and the 
infection kinetics plots for these sentinel mice are shown in Figure 47. The result that sentinel mouse 
S7 (inoculated from well K’) did not show any difference in infection kinetics was of interest as well 
K’ did not contain any cellular additives. This means that, for in vitro maintenance of M. haemomuris 
over two days, the addition of uninfected blood or other cellular components (such as stem cells) 
was not required to maintain M. haemomuris viability.  
 
 
Figure 47 M. haemomuris genome copies following inoculation of sentinel mice inoculated during in vitro cultivation study 
2. Media composition is given in Table 48. Sentinel mice S3 and S4 (upper panel) were inoculated from in vitro culture well 
X’ at 12 hours (S3) and well X at 24 hours (S4) post inoculation of culture wells. Sentinel mice S5-S8 (lower panel) were 
inoculated from culture wells G’/I’/L’ (S5), H’/J’ (S6), K’ (S7) and F’ (S8) at 2 dpi of culture wells. Days post inoculation (dpi; 
of mice) are plotted on the x-axis and normalised relative M. haemomuris genome copies per µl blood are plotted on the y-
axis. Lines represent individual mice (mice differentiated by colouring of the lines). Blood sampling occurred once daily but 
was discontinued ahead of the 14-day monitoring period as infection kinetics became apparent.  
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5.3.1.5 Results of in vitro cultivation study 3 (viability study) using StemPro™-34 without cellular 
supplementation 
The sentinel mice S9 and S10, inoculated at 2 and 4 dpi of culture wells, using the contents of wells 
V2 and V4 after daily partial media replacement and careful handling to try and reduce haemolysis, 
established M. haemomuris infection during the observation period of 16 days (Figure 48). Sentinel 
mouse S10 (black dotted line in Figure 48) was found dead at 9 dpi with no other overt signs visible 
other than splenomegaly on post-mortem examination (splenic weight 1.92% bodyweight; normal < 
0.4%). The sentinel mice S11, S12 and S13, inoculated at 6, 8 and 10 dpi of culture wells V6, V8 and 
V10 did not successfully establish infection during the observation period of 16 days. Sentinel mouse 
S11 yielded normalised relative M. haemomuris genome copies per µl blood of 100-1000 copies on 
two occasions, but both of these positive results were flanked by negative results, including for the 
rest of the observation period, thus the typical infection kinetics of M. haemomuris growth were not 
seen. These results of successfully infected sentinel mice are of interest as it suggests that M. 
haemomuris remained viable for at least 4 days outside of the host under the explored in vitro 
conditions. No M. haemomuris genome copies per µl media were available from study 3 as it aimed 
to keep cell disturbance at minimum. Media replacement was followed by gentle horizontal rotation 
of the plates to resuspend sedimented cells in culture media and inoculation was followed by gentle 
horizontal rotation of the plates to mix the blood and culture media and further pipetting of the 
mixture was avoided to minimise haemolysis for all subsequent studies. 
 
Figure 48 M. haemomuris genome copies in the sentinel mice inoculated during in vitro cultivation study 3 (viability study) 
using StemPro™-34 without cellular supplementation (medium V, see Table 50). Days post inoculation (dpi; of mice) are 
plotted on the x-axis and M. haemomuris genome copies per µl of blood are plotted on the y-axis. Lines represent individual 
mice (mice differentiated by colouring of the lines); blood sampling occurred once daily. Mice were monitored daily for 16 
days to determine successful or unsuccessful M. haemomuris amplification. Sentinel mouse S10 (black dotted line) was 
found dead at 9 dpi. Sentinel mouse S11 (grey line) did yield normalised relative M. haemomuris genome copies per µl blood 
of 100-1000 copies at two occasions but this was not flanked by typical infection kinetics.  
5.3.1.6 Results of in vitro cultivation study 4 (RNA study) using StemPro™-34 without cellular 
supplementation 
In vitro cultivation study 4 aimed at providing a methodology of detecting declining M. haemomuris 
viability in culture media that did not involve the use of sentinel mice. The infection kinetics curves 
of M. haemomuris genome copies (DNA; representing copies of the M. haemomuris 16S rRNA gene) 
per µl blood, using the previously described qPCR (see 3.2.2.3.2) and 16S rRNA copies (RNA) per µl 
blood after DNA digestion and RT-qPCR, over the course of two weeks in a 13-week-old mouse are 
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shown in Figure 49. No DNA was detectable in samples following DNase digestion (data not shown), 
confirming a successful DNA removal.  
 
Figure 49 M. haemomuris infection kinetics curves in one 13-week-old SPF, female C57BL/6 mouse after inoculation with M. 
haemomuris. Days post inoculation (dpi) are plotted on the x-axis and normalised relative M. haemomuris genome copies 
(DNA) per µl of blood are plotted on the y-axis as a grey line. Normalised relative M. haemomuris 16S rRNA copies (RNA) 
per µl of blood are plotted as a blue line.  
Two identical wells, inoculated with blood containing 7.84E+06 M. haemomuris genome copies per 
µl blood, sourced at 7 dpi, were monitored for 3 and 7 days before inoculation of well contents into 
two sentinel mice. Relative M. haemomuris genome copies (DNA; representing copies of M. 
haemomuris 16S rRNA gene) per µl of medium and relative M. haemomuris 16S rRNA copies (RNA) 
per µl of medium over the 3- and 7 day incubation period of wells W1 and W2 with partial media 
replacement are shown in Figure 50. An increase in M. haemomuris genome copies per µl medium 
over two days following inoculation of culture wells was observed, representing putative in vitro 
growth for the first time. In contrast to earlier studies, M. haemomuris genome copies showed over 
a 20-fold increase (8.88E+04 genome copies per µl medium to 1.96E+06 genome copies per µl 
medium) over the first 3 days of in vitro conditions, before then showing a gradual decline.   
Relative M. haemomuris 16S rRNA copies per µl of medium mirrored the DNA results but because M. 
haemomuris growth was observed for the first time, work using RT-qPCR was discontinued in favour 
of optimising and replicating M. haemomuris growth under in vitro conditions. Detection of RNA had 
aimed mainly at assessing M. haemomuris viability under the assumption that no growth would 






Figure 50 M. haemomuris genome copies during in vitro cultivation study 4, showing amplification plots of culture wells W1 
(upper panel) and W2 (lower panel) after inoculation of 50µl M. haemomuris-infected mouse blood into 450µl of prepared 
medium of identical composition. Medium composition W is given in Table 52. Days post inoculation (dpi) are plotted on the 
x-axis and relative M. haemomuris genome copies (DNA) per µl of medium as well as relative M. haemomuris 16S rRNA 
copies (RNA) per µl of medium are plotted on the y-axis. Connected dots of the same colour represent individual culture 
wells, grey lines represent DNA (M. haemomuris 16S rRNA gene copies via conventional qPCR) and blue lines represent RNA 
(M. haemomuris 16S rRNA copies via RT-qPCR following DNA digestion). Wells were subjected to partial media 
replacements daily and sampled every day. Dilution factors (through sampling of 10µl per day) were accounted for before 
creating the plots.  
The sentinel mice inoculated at 3 dpi with the contents of well W1 (sentinel mouse S14) and at 7 dpi 
with contents of well W2 (sentinel mouse S15) showed evidence of establishment of M. haemomuris  
infection, but only the sentinel mouse S14 showed typical infection kinetics (Figure 51). Sentinel 
mouse S15 (dark blue line in Figure 51) exhibited similar infection kinetics to what had been 
observed in protective immunity (i.e. lower and fluctuating M. haemomuris genome copies per µl 
blood without a clearly defined peak; see Chapters 3 and 4, e.g. Figure 23and Figure 35).  Due to 
time restrictions in the experiment duration the infection kinetics of sentinel mouse S15 could not 
be followed for longer. This inability to establish typical infection kinetics in the sentinel mouse S15 
coincided with a drop of M. haemomuris 16S rRNA copies per µl medium below the level of M. 
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haemomuris genome copies (DNA) per µl medium suggesting drastically reduced M. haemomuris 
viability in the obtained inoculum (well W2 at 7 dpi, see Figure 50, lower panel) despite comparable 
inoculum doses (M. haemomuris genome copies) received by both sentinel mice (Table 53).  
 
Figure 51 M. haemomuris genome copies following inoculation of sentinel mice inoculated during in vitro cultivation study 
4. Sentinel mice S14 and S15 were inoculated from in vitro culture well W1 at 3 dpi (S14) and well W2 at 7 dpi (S15) of 
culture wells. Days post inoculation (of each mouse although inoculations did not happen at the same day) are plotted on 
the x-axis and normalised relative haemoplasma genome copies per µl blood are plotted on the y-axis. Lines represent 
individual mice (mice differentiated by colouring of the lines).  
5.3.1.7 Results of in vitro cultivation study 5 (purine/pyrimidine study) using nucleobases, 
nucleotides, single-stranded DNA and whole blood supplementation  
This study aimed to determine whether M. haemomuris organisms exhausted nucleobases, 
nucleosides, nucleotides, single-stranded DNA as putatively needed to synthesise DNA and RNA 
under the in vitro conditions previously tested in sections 5.3.1.3 to 5.3.1.6. Media were prepared as 
described in Table 54 to contain a control (N), a nucleobase/nucleoside/nucleotide mixture 
(NUCLEO), single-stranded Salmon sperm DNA (SALMON) and fresh whole blood replacement at 3 
dpi of culture wells (BLOOD). Relative M. haemomuris genome copies per µl over the 8-day 
incubation period with partial media replacement and fresh blood replacement for well BLO2 are 






Figure 52 M. haemomuris genome copies during in vitro cultivation study 5, showing amplification plots of culture wells containing media N (N1/N2), NUCLEO (NUC1/NUC2), SALMON 
(SAL1/SAL2) and BLOOD (BLO1 and BLO2a/BLO2b after splitting well BLO2 in two wells and inoculation of 50µl M. haemomuris-infected mouse blood into 450µl of the newly prepared well). 
Medium composition is given in Table 54. Days post inoculation (dpi) are plotted on the x-axis and relative M. haemomuris genome copies (DNA) per µl per µl medium are plotted on the y-axis. 
Connected dots of the same colour represent individual culture wells. Light blue lines represent wells discontinued at 3 dpi (well names ending in ‘1’) and inoculated into sentinel mice. Dark 
blue lines represent wells continued until 8 dpi. Well BLO2 was split in two identical wells and reconstituted in media containing fresh blood at 3 dpi which is indicated by the separation of 
dashed lines at 3 dpi in the bottom right panel and illustrated in more detail in Figure 54 Well BLO2a was inoculated into a sentinel mouse at 8 dpi. Wells were subject to partial media 
replacements daily and sampled every day. Dilution factors (through daily sampling of 10µl and the 1:10 dilution at 3 dpi) were accounted for before creating the plots.  
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Growth was only apparent in the wells containing media BLOOD and SALMON over the first three 
dpi of the culture wells and not in the wells containing media NUCLEO and N, despite medium N 
comprising identical composition to medium BLOOD until the later wells were split and reconstituted 
with fresh mouse blood (media compositions see Table 54). The failure to amplify M. haemomuris in 
medium N was attributed to potential contamination of the cultures as evidenced from adhered cell 
layers (see Figure 53, left panel). This adhered cell layer could only be resuspended by pipetting, and 
this was avoided in the remaining wells over concerns of inducing haemolysis. Haemolysis was 
evident in well N2 at subsequent days of the experiment (see Figure 53, right panel). 
 
Figure 53 Culture wells N1/N2 and NUC1/NUC2 at 3 days post inoculation of culture wells (left panel) showing an adherent 
layer of cells as red specks in the top half of the wells N1/N2 (indicated by arrows) that was not apparent in the remaining 
wells. The right panel shows the same wells at 5 dpi, after N1 and NUC1 had been inoculated into sentinel mice and 
haemolysis became apparent in well N2.  
After the initial three days of the experiment, growth could only be sustained in wells BLO2a and 
BLO2b after splitting the well contents and reconstituting them in fresh media containing uninfected 
mouse blood (the wells are represented by dashed dark blue lines in Figure 52, bottom right panel). 
For illustration purposes, and to highlight growth on a logarithmic scale, the M. haemomuris 




Figure 54 M. haemomuris genome copies during in vitro cultivation study 5, showing amplification plots of culture wells 
BLO1 (light blue line) and BLO2 (dark blue line) and BLO2a/BLO2b after well BLO2 was split into two wells, supplemented 
with fresh mouse blood at 3 dpi of culture wells. Data to create this graph has already been shown in Figure 52 but is 
presented with an optimised scale to highlight the observed growth pattern of M. haemomuris over time. Days post 
inoculation (dpi) are plotted on the x-axis and relative haemoplasma genome and relative M. haemomuris genome copies 
(DNA) per µl medium are plotted on the y-axis. Connected dots of the same colour represent individual culture wells. Light 
blue lines represent wells discontinued at 3 dpi and inoculated into sentinel mice. Dark (and subsequently dashed) blue lines 
represent wells continued until 8 dpi.  
All sentinel mice, inoculated at 3 dpi of culture wells (N1, NUC1, SAL1 and BLO1) showed typical M. 
haemomuris infection kinetics (see sentinel mice S16 to S19 in Figure 55). Sentinel mouse S16 
(dashed black line in Figure 55) was found dead at 7 dpi (of the mouse) with no other overt signs 
visible other than splenomegaly on post-mortem examination (splenic weight 1.89% bodyweight; 
normal <0.4%). Sentinel mouse S20, inoculated from in vitro culture well BLO2a at 8 dpi of the 
culture well, showed a prolonged lag-phase but ultimately amplified M. haemomuris to similar 
genome copies per µl blood (>1.0E+07/µl) as it is seen during primary infection (see light blue line in 
Figure 55).  
 
Figure 55 M. haemomuris genome copies following inoculation of sentinel mice inoculated during in vitro cultivation study 
5. Sentinel mouse S16 (dashed black line) was inoculated from in vitro culture well N1 at 3 dpi of the culture well and found 
dead at 7 dpi. Sentinel mice S17, S18 and S19 were inoculated from in vitro culture wells NUC1, SAL1 and BLO1 at 3 dpi of 
the culture wells and showed typical M. haemomuris infection kinetics. Sentinel mouse S20 was inoculated from in vitro 
culture well BLO2a at 8 dpi of the culture well and showed a prolonged lag-phase but ultimately amplified M. haemomuris 
to typical levels of primary infection. Days post inoculation (of each mouse although inoculations did not happen at the 
same day) are plotted on the x-axis and normalised relative haemoplasma genome copies per µl blood are plotted on the y-
axis. Lines represent individual mice (mice differentiated by colouring of the lines). 
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The retained viability of the contents of well BLO2a, in conjunction with the observed growth 
following fresh blood supplementation at 3 dpi of culture well BLO2, led to the conclusion that M. 
haemomuris viability was prolonged from that previously reported (4 dpi) in 5.3.1.5 to 8 dpi, likely 
due to the culture media being replaced and supplemented with fresh mouse blood at 3 dpi.  
5.3.1.8 Results of in vitro cultivation study 6 (continuous culture pilot) using serial media 
expansions and blood replacement 
Based on the results of M. haemomuris growth in the preceding experiment it was decided to 
replicate similar experimental conditions comprising of media replacement combined with addition 
of fresh mouse blood at 2 dpi of culture wells as M. haemomuris genome copies per µl culture 
medium started to decline after 2 dpi of consecutive culture (Figure 54). Upon passaging of 50µl of 
infected culture into 450µl of new media containing 50 µl of fresh mouse blood at 2 dpi, M. 
haemomuris showed a 39-fold increase from 5.03E+06 to 1.95E+08 M. haemomuris genome copies 





Figure 56 M. haemomuris genome copies during in vitro cultivation study 6, showing amplification plots of culture wells 
CON1, CON2 and CON3 (solid blue lines) before and after passaging them into recipient wells supplemented with fresh 
mouse blood at 2 dpi of culture wells (dotted blue lines). Medium composition (CONT) is given in Table 56. Days post 
inoculation (dpi) are plotted on the x-axis and relative haemoplasma genome and 16S rRNA copies per µl medium are 
plotted on the y-axis. Connected dots of the same colour represent individual culture wells. Dilution factors have been 
accounted for before creating the plots. The lower panel is based on the same data as the upper panel but uses a smaller 
scale to illustrate M. haemomuris in vitro growth.  
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The sentinel mouse (S21) inoculated at 4 dpi of culture wells with contents of the recipient well from 
CON1 (light blue dashed line in Figure 56) successfully amplified M. haemomuris  and showed typical 
infection kinetics as shown in Figure 57. 
 
Figure 57 M. haemomuris genome copies following inoculation of one sentinel mouse inoculated during in vitro cultivation 
study 6 from the in vitro culture well that had been the recipient well of culture well CON1. Inoculation of the sentinel 
mouse happened at 4 dpi of the original culture well. Days post inoculation (dpi) are plotted on the x-axis and normalised 





With the cultivation pilot studies described in this chapter, we have managed to fulfil two of four of 
Robert Koch’s postulates (412) for a haemoplasma species, namely M. haemomuris. The first 
postulate calls for the pathogen to always be present in cases of the disease, which can be 
considered already established for the disease haemoplasmosis (11) and has not been investigated 
in the current study. The second postulate states that a pathogen must be isolated from the host 
and grown in culture to be called the causative agent of the disease as has been demonstrated in the 
present study. The third postulate states that the pathogen isolated in culture must cause the 
disease when inoculated into a healthy, susceptible laboratory animal (405), which is consistent with 
successful infection of sentinel mice with cultured M. haemomuris described in the present study. 
The fourth postulate states that the newly, experimentally infected host must allow recovery of the 
same organism which, although assumed to be true, has not been attempted in the current study as 
no sentinel-mouse-derived M. haemomuris inocula were used for subsequent in vitro cultivation 
attempts. Whilst these postulates might be considered incomplete in terms of defining ‘causation’ 
by either a non-cultivatable pathogen or a defined community of synergistic pathogens, they still 
hold relevance for the scientific rigor that goes into their application to investigating novel 
pathogens and diseases (413).  
5.4.1 Successful M. haemomuris in vitro maintenance and in vitro cultivation 
Previous reports on the in vitro maintenance of haemoplasmas were incomplete, due to the lack of 
fulfilment of Koch’s third postulate showing viability of the organism (216, 241, 242), or due to the 
methodology used (i.e. blood smear examination and non-molecular detection techniques for the 
haemoplasmas as employed by Nonaka, Thacker (241) for M. suis) that did not allow repetition of 
the experiment due to a failure to define the pathogens in question (239, 240). In this chapter we 
were able to inoculate naïve laboratory mice with M. haemomuris that had its viability conserved 
under in vitro conditions for a period of eight days; additionally, we were able to vary the in vitro 
conditions and show not just maintenance of M. haemomuris genome copies within the medium but 
actual growth.  
Due to limitations in the volume of available inoculum i.e. M. haemomuris-infected mouse blood,  
that could be obtained at various experimental steps and the limitations in the sample volumes that 
could be taken from the same culture to monitor for change (e.g. growth) over time, the 
experimental approach was not always linear in terms of varying only one condition at a time, but 
focused on creating an environment that favoured the survival of the blood cells in culture. A more 
stepwise approach, using dilution series of various additives and varying culture conditions for each 
dilution, might have provided a more straightforward approach. However, serial dilutions of various 
additives and culture conditions, and exploring all possible variations, were very unlikely to have 
been possible due to the large mouse blood volumes that would have been needed for all of the 
experiments, and limitations in the repeated sampling of wells that would have had to have been set 
up in smaller volume formats (i.e. 96-well plates with 0.1 ml culture volumes per well) to alleviate 
the limitations in available mouse blood of identical origin. After having established the conditions 
that favoured M. haemomuris maintenance and growth, we have established a baseline from which 
to improve conditions in future experiments. This baseline will allow for future studies to be 
performed that vary just single additives and culture conditions in order to refine and better define 
the growth requirements of M. haemomuris; such findings could also inform potentially successful 
culture conditions for other haemoplasmas of veterinary relevance.  
When using automated TNA extraction (Chemagen, see 4.2.2.3.2) to extract nucleic acids from 
undiluted heparinised mouse blood, the heparin remaining within the blood acts as a potent qPCR 
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inhibitor (414). In the current study (data not shown) it was found that heparin-induced inhibition of 
qPCR no longer occurred if less than 2.5% (v/v) heparinised blood was present in the sample used for 
automated TNA extraction.  This consideration of qPCR inhibition led to EDTA-anticoagulated blood 
samples being used for the cytokine expression and haematology studies in which high-throughput, 
and thus automated, TNA extraction was required, and samples contained 10% (v/v) heparinised 
blood. However, concentrations of heparinised blood above 2% (v/v) were not achieved in the 
culture protocols. It has not yet been determined whether EDTA, heparin or other anticoagulants are 
more or less likely to interfere with haemoplasma viability or growth. The anticoagulant (li-heparin) 
used in this chapter was chosen based on anecdotal observations that M. haemofelis adherence to 
erythrocytes is decreased in the presence of EDTA, which could reflect reduced viability in EDTA; 
published rigorous evidence of this hypothesis is lacking (241). Future experiments should include a 
range of anticoagulants or immediate (within seconds) high dilutions of donor blood into 
experimental media to avoid the use of anticoagulants and prevent the blood clotting that occurs 
with low dilutions of blood in saline or other media (415). 
5.4.2 Defining growth parameters for M. haemomuris and other haemoplasmas 
It is not known which substrates in the media combinations used in the current studies in this 
chapter allowed M. haemomuris to have short-lived growth that were not provided in previous 
attempts at M. suis cultivation by Nonaka, Thacker (241) in Eagle’s medium and RPMI-1640, and by 
Schreiner, Hoelzle (242) in the mycoplasma media SP-4 medium and Hayflick’s medium, or in 
attempts at M. haemofelis cultivation by Hicks (216) in RPMI-1640 and the proprietary MEXp (243) 
media. Because the base medium, StemPro™-34, used in the current studies contains various 
proprietary nutrient supplements that also specifically favour stem cell proliferation (416) one can 
speculate that these supplements may have had a positive influence on haemoplasma viability. In 
contrast, the base medium RPMI-1640 does not contain glucose, nucleotide precursors or fatty acids 
and hence is dependent on the addition of serum (typically foetal calf serum) to provide these in 
cultivation studies (417), as used in cultivation experiments for M. haemofelis by (216). RMPI-1640 is 
suitable for cultivation of mammalian lymphocytes but requires them to have considerable 
metabolic capabilities to synthesise substrates not provided in the basal formulation. Eagle’s 
medium (and modified versions, such as DMEM) is similar to RMPI-1640 and contains amino acids, 
vitamins and glucose but no fatty acids or other nutrients such as nucleotide precursors or growth 
factors, potentially required by haemoplasmas, as it was originally developed for a variety of 
mammalian cell lines of higher metabolic capability than haemoplasmas (418). Mycoplasma media 
(i.e. SP-4 medium and Hayflick’s medium) are richer in nutrients and typically contain yeast extract 
to provide a source of fatty acids, cholesterol and nucleotides (242). However, haemoplasmas may 
not have been able to utilise yeast extract when not attached to erythrocytes as some studies 
suggest haemoplasmas scavenge these molecules directly off the host erythrocyte membrane (116, 
419). The latter was suggested by our preliminary results that showed no growth but a rapid decline 
in M. haemomuris genome copies in the presence of overt haemolysis and is supported by the 
findings by Schreiner, Hoelzle (242) that describe nanotransformation, but not growth, when using 
these media. Furthermore, our studies found that sources of iron (transferrin) appear to be crucial 
for haemoplasma maintenance/growth, as we found growth only in culture media compositions 
containing 0.5mg/ml transferrin. Additionally, nucleotides (or their precursors) may be utilised from 
single-stranded DNA (see 5.3.1.7), as we found an increase in M. haemomuris copies in the culture 
wells, supplemented with it. However, the role of these additives, including insulin (which is also 
included in the basic formulation of StemPro™-34, but in none of the other media previously tried 
with haemoplasma cultures) will have to be explored in future experiments. The role of 
hypoxanthine is equally unclear despite our preliminary data from a study (data not shown) that 
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tried to reproduce the results described in 5.3.1.8 but unintentionally (due to human error) used a 
much lower concentration of hypoxanthine and did not result in M. haemomuris growth. However, 
hypoxanthine is also produced by erythrocytes, so the minimal PCV to support M. haemomuris 
viability and growth is yet to be determined. Hicks (216) supplemented SP-4 and undefined (due to 
proprietary nature of these culture media) MEXp culture media with non-infected, heparinised feline 
blood, but it could be that the concentration used, 20µl heparinised blood in 1ml culture wells, was 
simply too low a concentration of blood to allow for M. haemofelis propagation in vitro. Ideally, in 
vitro cultivated erythrocytes could be utilised for future cultivation attempts, however the current 
technology cannot mature erythrocytes beyond the erythroblast stage. Our results that showed no 
growth in the presence of mouse erythroblast precursors or differentiated erythroblasts (5.3.1.4) 
appear to be consistent with M. haemomuris’ inability to infect erythrocyte precursors. We did not 
attempt to cultivate E. coccoides in vitro because our mouse model focused on M. haemomuris. 
Additionally, we do not have whole genome sequences available for E. coccoides nor M. 
haemomuris, to allow us to compare and deduce the metabolic abilities of these haemoplasmas. It 
remains to be explored what factors favoured the ability of E. coccoides to be propagated in chicken 
embryos (9), when similar propagation could not be demonstrated for M. haemomuris in later 
studies using an identical approach (197).  
5.4.3 Limitations of the current in vitro cultivation system and suggestions for further work 
using M. haemomuris in vitro cultivation 
One major limitation of the current in vitro cultivation work of M. haemomuris is that the growth 
requirements of M. haemomuris have not yet been clearly defined and we have not been able to 
create a truly continuous in vitro cultivation system that would allow for log-fold increases in M. 
haemomuris genome copies per µl media as is seen in vivo during experimental infection. It would 
be beneficial if future experiments concentrated on:  
a) defining the growth requirements of M. haemomuris by selectively removing additives and 
comparing increases or decreases in M. haemomuris organism numbers to the conditions used to 
produce M. haemomuris in vitro growth in the current study and  
b) use serial passaging and media expansion (dilution of primary cultures rather than inoculation of 
new recipient wells) to allow for growth curves over longer time periods than the 4 days used in the 







The studies presented within this thesis used a range of techniques to establish and characterise a 
mouse model of haemoplasma infection. Prior to this work, rodent haemoplasma infections had 
been described but no model had been established. Additionally, the lack of an in vitro cultivation 
system was a huge barrier to haemoplasma research. Haemoplasmas could only be generated and 
assessed for viability within their natural (usually larger and more expensive) host species, which 
further slowed down in vitro cultivation attempts. In the presented studies, wild source rodent 
haemoplasmas were collected and phylogenetically identified. These haemoplasmas were passaged 
into laboratory rodents and infection kinetics monitored by qPCR. One isolate of M. haemomuris 
was chosen to establish a surrogate model of (particularly feline) haemoplasma infection and cross-
protection following E. coccoides-infection and protection from re-infection with the same M. 
haemomuris isolate assessed in mice. The finding of partial protection from re-infection was then 
used to design a larger study to characterise the mouse immune response to naïve M. haemomuris-
infection and to re-inoculation. Principal component analysis was used to describe the cytokine 
response in naïve M. haemomuris infection and partial protection from re-infection with the same 
M. haemomuris isolate. Additionally, the mouse model enabled generation of viable M. haemomuris 
organisms for in vitro cultivation studies, leading to the first ever successful in vitro cultivation of a 
haemoplasma over a period of four days.  
6.2 MOUSE MODEL 
Initial studies (Chapter 2) sourced viable haemoplasmas from wild rodents and transferred them into 
laboratory rodents, using DMSO cryopreservation previous used for other haemoplasmas (13, 107, 
420). The cryopreservation methods used changed during subsequent studies due to the infection 
failures seen (Chapter 3) that were attributed to the cytotoxic effects of DMSO on viable 
haemoplasma genome copy numbers in the inocula. These studies highlighted the need to describe 
haemoplasma copy numbers based on viability rather than those detected by qPCR, as the latter can 
be an overestimation. The ideal would be to assess haemoplasma copy numbers by determination of 
colony forming units, but this requires an in vitro cultivation system.   
Phylogenetic classification of the wild rodent haemoplasma isolates (Chapter 2) was based on 16S 
rRNA gene sequences, which may not accurately reflect species-versus-strain separation (outlined in 
Chapter 1). However, very few rodent haemoplasma sequences are available for non-16S rRNA 
genes (16, 277, 280, 289), so comparison based on other genes to clearly define novel species was 
not possible in the current studies.  
The ability of M. haemomuris to change rodent host species, more specifically from Apodemus spp. 
into Mus musculus, has been demonstrated in a previous study using molecular methods (197). Rats 
however, were not able to amplify this M. haemomuris isolate in the same study (197). The 
presented studies detected short-lived bacteraemia after intraperitoneal inoculation of M. 
haemomuris in one rat. Older reports of infection with different haemoplasma species are difficult to 
interpret as we now know that haemoplasma infections may have pre-existed in the laboratory 
animals used in studies (35) and a lack of molecular identification of the haemoplasmas in these 
studies make it very difficult to confirm that different haemoplasma infections had been established 
(236, 240). With ongoing reports of novel haemoplasmas in varied host species (Table 1, Chapter 1) 
the host specificity of haemoplasmas may have to be re-evaluated. More sequence data from 
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previously published isolates and ideally, cross-infection studies are required to define each 
haemoplasma isolate. Our M. haemomuris isolate showed 99% identity on 16S rRNA gene sequence 
to other M. haemomuris isolates, which is said to indicate identical species (19). However, our E. 
coccoides isolate showed only 97% identity on 16S rRNA gene sequencing to previously published 
sequences, and hence could represent a novel species. On 16S rRNA gene sequencing our M. 
haemomuris-like haemoplasma isolate showed 99% identity to a UK ‘vole haemoplasma’ (277) and 
98% identity to an Israeli gerbil haemoplasma (34), and so it is not clear as to whether this 
represents a novel species.  
Quantitative PCR assays are designed to detect and quantify species-specific gene sequences. 
Validation of qPCRs should use samples collected from the natural host species to ensure cross-
reaction with other pathogens or host DNA sequences does not occur. The novel qPCR assays 
developed in the presented studies (Chapter 3) were specific for M. haemomuris and E. coccoides 
and sensitive, detecting down to one to ten genome copies per reaction. The reliability of the M. 
haemomuris duplex qPCR assay (Chapter 5) was confirmed by its average %CV being less than 0.79% 
(Table 13 and Table 14, Chapter 5), but %CV was not assessed for the E. coccoides qPCR assay. Both 
the M. haemomuris and E. coccoides qPCR assays were duplexed with an internal host control qPCR 
to enable the concurrent detection of mouse DNA, helping to screen for, for example, pipetting 
errors or qPCR inhibitors. The specificity of species-specific qPCRs does mean that novel 
haemoplasma species may not be detected when these assays are applied to e.g. prevalence 
surveys. Such studies should also include generic PCR assays to potentially detect novel 
haemoplasma species that can then be further characterised by DNA sequencing. The species-
specific duplex qPCR assays in the presented studies were used to describe the infection kinetics of 
M. haemomuris and E. coccoides (Chapter 3). We were also able to demonstrate that partial 
protection from re-infection with M. haemomuris occurs but that cross-protection from M. 
haemomuris following previous E. coccoides infection does not occur. These findings agree with 
previous studies in cats demonstrating partial protection from re-infection with the same 
haemoplasma species of M. haemofelis (107) and ‘Ca. M. turicencis’ (124) and the lack of cross-
protection from M. haemofelis following previous ‘Ca. M. turicensis’ infection (295). 
The presented studies (Chapter 4) represent the first steps in the validation of a mouse 
haemoplasma model that can be used for translational studies (drawing conclusions from mouse 
haemoplasma infection and host response to investigate the pathophysiology and prevention of 
feline and porcine haemoplasmosis) to assess protective immunity to infection and haematological 
changes during infection. The haematological data we generated in our studies was not complete as 
the small sample sizes and limited sampling days in the study meant that we may have missed 
troughs and/or peaks in certain parameters. Nonetheless, anaemia developed, and six out of 214 
haemoplasma-inoculated mice died at peak parasitaemia, so this mouse haemoplasma model would 
likely allow for future studies of potential therapeutic interventions and haemoplasma virulence 
factors. However, the lack of ante-mortem blood samples in the mice that died means that we are 
unable to confirm whether severe anaemia was the cause of death in those mice.   
The cytokine expression study (Chapter 4) described cytokine signatures associated with naïve 
haemoplasma infection and after re-inoculation with the same M. haemomuris isolate. A Th17-
driven immune response, that is often seen in autoimmunity and may occur with infections, 
inappropriately handled by Th1 and Th2 pathways (375), was identified in naïve infection that was 
absent during partial protection. Hence the Th17-driven immune response may be associated with 
the development of clinical haemoplasmosis. Unfortunately, a lack of samples available from the 
mice that died means that we could not assess whether dysregulation or an inappropriate immune 
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response was a contributor to clinical severity and mortality. The similarities in the cytokine 
response (e.g. increased proinflammatory cytokines IL-6 and TNF-α following re-inoculation) seen in 
the cytokine expression study (Chapter 4) and following M. haemofelis-infection in cats, but not 
following infection with the less pathogenic ‘Ca. M. turicensis’ (124), further helps validate that our 
mouse model could be used as a translational model for pathogenic haemoplasma infection in cats. 
Our cytokine signature findings in M. haemomuris-infection also could help with the design and 
assessment of the efficacy of possible vaccines, as cytokine patterns can be used to identify 
desirable responses to vaccination during vaccine development and before large-scale trials. Further 
studies are needed to confirm the role of the Th17-pathway in clinical haemoplasmosis and 
investigate the potential for Th17-induced autoimmunity. Our dataset is limited by its small size and 
the identified cytokine signatures will need to be confirmed using larger numbers and statistical 
analysis before being used as part of vaccination development attempts. Additionally, we should 
remember that cytokine profiles at a tissue level (e.g. in the spleen) were not assessed, and these 
could provide further insights into haemoplasma virulence.  
To further our knowledge of haemoplasma virulence, comparative studies using E. coccoides and 
different strains of M. haemomuris, i.e. haemoplasmas of differing pathogencity, could be used. 
Such studies would require haemoplasma genome and encoded protein data to assess the roles of 
different haemoplasma proteins during infection. Whole genome sequences have only been derived 
for haemoplasmas grown in sizeable hosts that allowed comparably easy collection of larger blood 
volumes from which to attain enough haemoplasma DNA for whole genome sequencing. This could 
not be attempted with our mouse model due to the large number of infected mice that would be 
required. However, once putative haemoplasma virulence proteins are known, their role in infection 
in mice could be explored similarly to previous attempts in cats (85, 94) and pigs (93, 117) that used 
a combination of screening protein preparations, mass spectrometry and recombinant expression of 
putatively immunoreactive proteins but would benefit from already existing methods of 
investigating the mouse immune system, their low costs and the availability of inbred strains. 
However, such studies would still be limited by the small volumes of blood that can be collected in 
mice. An alternative approach to investigate haemoplasma pathogenicity would be to evaluate 
haemoplasma attachment to erythrocytes in vitro but this requires successful in vitro cultivation of 
M. haemomuris.  
6.3 IN VITRO CULTIVATION OF M. HAEMOMURIS 
We focused some of our studies (Chapter 5) on techniques to cultivate M. haemomuris in vitro. We 
used the mouse haemoplasma model to generate viable haemoplasmas and used sentinel mice as 
binary assays (i.e. infected versus uninfected) to detect in vitro maintenance and viability of 
haemoplasmas despite the absence of in vitro growth. Culture media compositions and additives 
were partially dictated by our objective to infect murine erythroblast precursors (e.g. StemPro™-34 
serum-free medium, insulin, EPO) and partially based on genome analysis results to define the 
metabolic pathways present or absent (79). Previous in vitro culture experiments that had delivered 
promising results were also used to inform which additives to use e.g. hypoxanthine (216, 241) and 
transferrin (242).  
We were able to maintain M. haemomuris viability for 8 days under in vitro conditions and support 
its in vitro growth for 4 consecutive days (in vitro cultivation studies 5 and 6, Chapter 5). A 
continuous in vitro cultivation amplification system could not be developed in the present study, so 
this does present a continued challenge in haemoplasma research. Such a system would allow for 
log-fold increases in M. haemomuris genome copies in vitro to generate haemoplasma numbers 
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large enough to be suitable for whole genome sequencing and proteomic studies. Future 
experiments could comprise the systematic removal of additives from media (e.g. insulin but also 
components included within the StemPro™-34 medium) to clearly define growth requirements 
before attempting to increase culture yields. Ideally, the use of mouse blood in cultivation studies 
could be avoided by adding substrates containing putative receptors and other growth requirements 
that are normally provided in blood. However, it is possible that M. haemomuris requires 
metabolically active erythrocytes to grow, and future research may need to focus on the 
development of erythroblast precursors to a suitable level of maturation to express putative 
receptors and provide metabolic susbstrates for the growth of M. haemomuris. The application of 
our in vitro cultivation system to other haemoplasma species, such as M. haemofelis or M. suis, 
could well be successful, but has not yet been attempted due to this needing a source of viable 
haemoplasmas from respective hosts (i.e. cats or pigs). However, sourcing such haemoplasmas 
experimentally poses ethical and economic problems unfortunately.  
6.4 FUTURE WORK 
Obtaining the whole genome sequence of our M. haemomuris isolate should be a priority of any 
future work with the mouse model and in vitro cultivation system presented within this thesis. Gene 
sequences would allow direct inference of metabolic needs for in vitro cultivation work and 
subsequently enable translatability of in vitro cultivation and any mouse model findings to other 
haemoplasma species. With a sufficiently developed in vitro cultivation system, e.g. comprising 
expontential haemoplasma expansion and the addition of recombinantly expressed host erythrocyte 
or host plasma components, haemoplasma proteins could be produced using the haemoplasmas 
themselves as an expression system. This would lead to the first ever accurate mass spectrometric 
analysis of a haemoplasma proteome, providing viable insights into all haemoplasma species as no 
such data is available to this date.  
Since the whole genome sequence of the feline haemoplasma M. haemofelis is already available, an 
alternative to further developing a translatable in vitro cultivation system of M. haemomuris would 
comprise the in vitro cultivation of M. haemofelis, using red blood cells from cats diagnosed with 
polycythaemia vera (a neoplasm of the red blood cell lineage) which could replace the murine 
erythrocytes used in the current studies with M. haemomuris. As a very first step, the experiment 
presented in 5.2.2.7 would need to be repeated with the refined methodology of later experiments 
(gentle rocking and timing of blood collection) to answer the question as to whether M. haemomuris 
requires red blood cells alone or other plasma components to grow. If red blood cells are the only 
substrate requirement (apart from already added components and media) a clonal population from 
a polycythaemic cat could be used to rapidly source substrate for in vitro cultivation of M. 
haemofelis.  
Once in vitro cultivation has led to genome sequencing and increased our knowledge of the M. 
haemomuris proteome, immunogenic M. haemomuris proteins can be assessed for their ability to 
establish a protective immune response. The knowledge of involved immunological pathways will 
hereby help keep mouse numbers at a minimum as cytokine measurements during infection can be 
used to further these experiments even in the absence of protection from infection.  
Ultimately the work presented in this thesis will lead to in vitro cultivation of non-murine 
haemoplasmas, allowing generation of DNA for haemoplasma whole genome sequencing and 
proteins for mass spectrometry. These will inevitable lead to closer insights into host-pathogen 
interaction of veterinary relevant haemoplasmas and the development of vaccination or more 
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8 APPENDIX A 
ABBREVIATIONS 
 
Abbreviations and acronyms used in the main text: 
Abbreviation Meaning 
cDNA Complementary DNA (derived from reverse transcription) 
COG Clusters of Orthologous Groups  
IL-10 Interleukin-10 
IL-1b Interleukin-1b 
LI Lobularity Index  
APC Antigen Presenting Cells  
AUC Area Under the Curve  
BLAST Basic Local Alignment Search Tool  
BHQ2 Black Hole Quencher 2  
CHCM Cell Haemoglobin Concentration Mean  
CH Cell Haemoglobin Content  
CI Confidence Interval 
%CV Coefficient of Variation  
CRFK Crandell Rees Feline Kidney (cell line) 
CMP Cytidine Monophosphate  
DNA Deoxyribonucleic Acid  
Df Degrees of Freedom 
DMSO Dimethyl Sulfoxide  
DDH DNA-DNA Hybridisation 
dpi Days Post Inoculation 
DMEM Dulbecco’s Modified Eagle’s Medium  
RDW Red Cell Distribution Width  
EDTA Ethylenediaminetetraacetic Acid 
ELISA Enzyme-Linked Immunosorbent Assay 
EPO Erythropoietin (human recombinant) 
F F-Statistic 
FAM 6-Carboxyfluorescein;  
BHQ Black Hole Quencher 
FIV Feline Immunodeficiency Virus 
GCSF Granulocyte Colony Stimulating Factor  
gDNA Genomic DNA 
GAPDH Glyceraldehyde-3-Phosphate Dehydrogenase  
DNAK Heat-Shock Protein 70  
GMCSF Granulocyte-Macrophage Colony Stimulating Factor  
HCT Haematocrit  
Hb Haemoglobin Concentration 
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HDW Haemoglobin Concentration Distribution Width  
HF So-called ‘Haemofelis’ (HF)-Group of Haemoplasmas 
HM So-called ‘Haemominutum’ (HM)-Group of Haemoplasmas 
HIV Human Immunodeficiency Virus 
IFN-γ Interferon Gamma 
Ig Immunoglobulin 
IL Interleukin 
IL-12p40 Interleukin-12 Subunit p40 










IVC Individually Ventilated Cage  
ITS Internally Transcribed Spacer (region)  
KC Keratinocyte Chemoattractant (CXCL1) 
Li-heparin Lithium-heparin 
LoD Limit of Detection 
LoQ Limit of Quantification 
LUC Large Unstained Cells 
MIP1 Macrophage Inflammatory Protein 1  
MWU Mann-Whitney-U statistic 
MCP1 Mast Cell Protease 1 (CCL2) 
MCH Mean Corpuscular Haemoglobin  
MCHC Mean Corpuscular Haemoglobin Concentration  
MCV Mean Corpuscular Volume  
MPC Mean Platelet Component  
MPM Mean Platelet Mass  
MPV Mean Platelet Volume 
mRNA Messenger RNA  
MFE Minimum Free Energy  
MIP1a Macrophage Inflammatory Protein 1a 
MIP1b Macrophage Inflammatory Protein 1b 
MSG1  GAPDH 
MLSA Multi-locus Sequence Analysis  
MSA Multiple Sequence Alignments  
MPXI Myeloperoxidase Index  
NCBI National Center for Biotechnology Information  
NK) Natural Killer Cells  
PCA Principal Component Analysis 
PCR Polymerase Chain Reaction 
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PBS Phosphate-Buffered Saline  
PLT Platelet Count  
PDW Platelet Distribution Width  
PCT Plateletcrit  
PP Polypropylene  
qPCR Quantitative PCR 
RANTES Regulated on Activation Normal T Cell Expressed and Secreted (cytokine) 
RBC Red Blood Cell Count  
RT-qPCR Reverse Transcriptase qPCR  
RPMI Roswell Park Memorial Institute (culture medium) 
RNA Ribonucleic Acid 
SCF Stem Cell Factor 
SPF Specified-Pathogen-Free  
stdev Standard Deviations  
streptavidin-PE Streptavidin-Phycoerythrin  
TEX Texas Red  
Th T-helper Cell 
Ct Threshold Cycle  
Tm Melting Temperature 
TNF-α Tumor Necrosis Factor Alpha 
WBC Total Nucleated Cell Count  
Tregs T-regulatory Cells 
WBCP White Blood Cell Count by Peroxidase  
 
Nucleotide symbols as applied by the International Union of Applied Chemistry (IUPAC): 






R G or A 
Y T or C 
M A or C 
K G or T 
S G or C 
W A or T 
H A or C or T 
B G or T or C 
V G or C or A 
D G or A or T 






9 APPENDIX B 
DNA SEQUENCES USED FOR INITIAL IDENTIFICATION OF NOVEL RODENT HAEMOPLASMA 
ISOLATES 
Sequence Name DNA Sequence 
Isolate. #6 ATATATTCAAGAACACCAGAGGCGAAGGCGAAAACTTAGGCCGATATTGACGCTTAGGCTCGAAAGTGTGGGGA 
Isolate #8 ATATATTCAAGAACACCAGAGGCGAAGGCGAAAACTTAGGCCGATATTGACGCTTAGGCTCGAAAGTGTGGGGA 
Isolate #9 ATATATCCAAGAACACCAGAGGCGAAGGCGGAAACTTATACCGACATTGACGCTTAGGCTCGAAAGCGTGGGTA 
Isolate #13 ATATATTCAAGAACACCAGAGGCGAAGGCGGAAACTTAGGCCGCTATTGACGCTTAGGCTTGAAAGTGTGGGGA 
Isolate #18 ATATATTTAAGAACACCAGAGGCGAAGGCGAAAACTTAGGCCATTATTGACGCTTAGGCTTGAAAGTGTGGGTA 
Table A-B1 DNA sequences of amplicons of the partial 16S rRNA gene of the five rodent haemoplasma isolates as amplified 
from the generic haemoplasma qPCR assay.  
ISOLATE #6 (M. HAEMOMURIS) 16S RRNA GENE SEQUENCE 
The near-complete 16S rRNA gene sequence, ITS sequence and partial 23S rRNA gene sequence for 

































ISOLATE #18 (E. COCCOIDES) 16S RRNA GENE SEQUENCE 




















ISOLATE #13 (M. HAEMOMURIS-LIKE HAEMOPLASMA) 16S RRNA GENE SEQUENCE 
The near-complete 16S rRNA gene sequence, ITS sequence and partial 23S rRNA gene sequence for 


























For comparison, the corresponding 16S rRNA sequence of the previously unpublished ‘vole 





















ISOLATE #9 (NOVEL RODENT HAEMOPLASMA) 16S RRNA GENE SEQUENCE 









ISOLATE #8 (M. HAEMOMURIS) 16S RRNA GENE SEQUENCE 











PHYLOGENY OF ALL NOVEL RODENT HAEMOPLASMAS PRESENTED WITHIN THIS STUDY 
A phylogenetic tree of all five novel haemoplasma isolates was constructed using a partial, 463bp 
16S rRNA gene sequence and is presented in Figure A-B1.  
 
Figure A-B1 Maximum likelihood phylogenetic tree of 16S rRNA gene sequences based on a 463 bp sequence that was 
analysed for haemoplasmas and other Mycoplasma species. The dataset was sampled 1000 times and bootstrap values are 
given as percentages where nodes occur. HF, haemofelis subgroup of haemoplasmas; HM, haemominutum subgroup of 
haemoplasmas. Isolates derived from this study are highlighted in blue. Branches comprising bootstrap values of less than 





10 APPENDIX C 
Additional data and interpretations of the PCA carried out as part of the cytokine expression study 
will be presented within this appendix.  
SCREE PLOT 
A Scree plot, listing eigenvalues of the extracted components was constructed to allow visual 
assessment of ‘breaks’ in eigenvalue to limit the number of meaningful components and is 
presented in Figure A-C1.   
 
Figure A-C1 Scree plot of extracted components. Eigenvalues are plotted on the y-axis and their respective components on 
the x-axis. Components 1, 2, 3 and 4 were selected based on eigenvalues > 1 and no further observed ‘breaks’ (sudden 




UNROTATED PCA SOLUTION DERIVED FROM % CHANGE   
Component loadings, derived from percentage of change from baseline (represented by values 
obtained on day 0 of the experiment) are presented in Table A-C1. The component loadings did not 
exhibit a different pattern or change the interpretation of extracted components when compared to 
component loadings extracted from absolute cytokine values and were hence not explored further.  
Cytokine Component 
 1 2 3 4 
IL1a % 0.803 -0.012 0.305 0.092 
IL1b % 0.825 -0.446 0.076 0.004 
IL2 % 0.263 0.674 0.437 -0.184 
IL3 % 0.912 -0.128 -0.079 0.309 
IL4 % 0.894 0.153 0.072 0.082 
IL5 % 0.832 -0.271 -0.082 0.028 
IL6 % 0.723 -0.027 -0.183 0.418 
IL9 % 0.918 -0.064 0.139 -0.075 
IL10 % 0.614 0.301 -0.273 -0.477 
IL12p40 % 0.550 0.481 -0.343 -0.141 
IL12p70 % 0.832 -0.138 0.241 -0.057 
IL13 % 0.691 -0.304 0.466 -0.079 
IL17 % 0.057 0.756 0.265 0.208 
Eotaxin % -0.429 0.298 0.395 0.420 
GCSF % 0.583 0.308 -0.423 0.170 
GMCSF % 0.816 -0.112 -0.249 0.032 
IFNgamma % 0.915 0.088 0.204 -0.007 
KC % 0.514 -0.166 0.609 -0.322 
MCP1 % 0.763 0.024 0.054 -0.157 
MIP1a % 0.708 0.361 -0.306 -0.399 
MIP1b % 0.854 0.256 -0.212 0.152 
RANTES % -0.155 0.869 0.179 0.082 
TNFalpha % 0.878 0.003 -0.022 0.379 
Table A-C1 Component matrix as extracted by PCA for components with eigenvalues > 1 when using % change instead of 
absolute values (pg/ml). Factor loadings represent the correlation between the original variables and the extracted 
component and were considered significant for their respective components if they exhibited a loading greater than 0.5 for 
that component and less than 0.5 for all other components. These are indicated by shaded cells and bolded text.  
Cumulatively explained variance amounted to 77.413 %, comprising 50.074 % through factor 1, 13.380 % through factor 2, 
8.528 % through factor 3 and 5. 431% through factor 4). This PCA was not significantly different to the solution derived 
from absolute values so was not further explored.  
MULTIVARIATE ASSESSMENT OF CHRONOLOGICAL CHANGES IN CYTOKINE EXPRESSION 
Unrotated component scores were calculated and visually assessed for distribution of errors and 
homogeneity of variance as before. Results of univariate analyses on the first four unrotated 
component scores (assigning each individual cytokine value a score on a given component) and 
experimental groups (re-inoculation group versus naïve group), time (dpi) and interactions between 
the experimental group and dpi are presented in Table A-C2. In contrast to Table 19, the time (dpi) 
variable was entered as a covariate (rather than a fixed factor), hence forcing the analysis to assess 





Dependent variable: Component scores on principal component 1 





Corrected model 18.256 3 6.085 8.421 0.000 
Intercept 3.012 1 3.012 4.168 0.046 
Group 2.225 1 2.225 3.080 0.085 
Dpi 6.709 1 6.709 9.284 0.004 
Group * Dpi 1.212 1 1.212 1.678 0.201 
Error 39.744 55 0.723   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .315 (Adjusted R Squared = .277)  
Dependent variable: Component scores on principal component 2 





Corrected model 12.909 3 4.303 5.249 0.003 
Intercept 0.034 1 0.034 0.041 0.841 
Group 3.711 1 3.711 4.526 0.038 
Dpi 0.006 1 0.006 0.007 0.932 
Group * Dpi 0.542 1 0.542 0.661 0.420 
Error 45.091 55 0.820   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .223 (Adjusted R Squared = .180)     
Dependent variable: Component scores on principal component 3 





Corrected model 8.089 3 2.696 2.971 0.040 
Intercept 0.100 1 0.100 0.111 0.741 
Group 1.908 1 1.908 2.103 0.153 
Dpi 0.246 1 0.246 0.271 0.605 
Group * Dpi 7.320 1 7.320 8.066 0.006 
Error 49.911 55 0.907   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .139 (Adjusted R Squared = .093)  
Dependent variable: Component scores on principal component 4 





Corrected model .853 3 0.284 0.274 0.844 
Intercept 0.432 1 0.432 0.416 0.522 
Group 0.001 1 0.001 0.001 0.970 
Dpi 0.832 1 0.832 0.801 0.375 
Group * Dpi 0.003 1 0.003 0.002 0.961 
Error 57.147 55 1.039   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .015 (Adjusted R Squared = .039 ) 
Table A-C2 Univariate analyses of component scores (dependent variable) and experimental groups (naïve group versus re-
inoculation group) and dpi (dpi in Phase 2 of the cytokine expression study). Significance was defined as p<0.05 and 
significant results are indicated by shaded cells and bolded text, results that became significant due to the interaction effect 
are indicated by bolded text alone. Note, that component scores reflect cytokine concentrations but cannot be interpreted 
as such. Group, experimental group (naïve group versus re-inoculated group); df, degrees of freedom; F, F-statistic; Dpi, 
days post inoculation.  
Another analysis, allowing for quadratic interactions of the time variable (indicated as ‘Dpisqu’) is 
presented in Table A-C3. Overall, no improved representation of the dataset was achieved by those 
additional analyses.  
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Dependent variable: Component scores on principal component 1 





Corrected model 19.858 5 3.972 5.519 0.000 
Intercept 0.011 1 0.011 0.016 0.900 
Group 1.039 1 1.039 1.444 0.235 
Dpi 5.936 1 5.936 8.249 0.006 
Dpisqu 1.600 1 1.600 2.223 0.142 
Group * Dpi 1.025 1 1.025 1.424 0.238 
Group * Dpisqu 0.003 1 0.003 0.004 0.949 
Error 38.142 53 0.720   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .342 (Adjusted R Squared = .280)  
Dependent variable: Component scores on principal component 2 





Corrected model 14.441 5 2.888 3.514 0.008 
Intercept 0.425 1 0.425 0.518 0.475 
Group 2.758 1 2.758 3.356 0.073 
Dpi 7.677E-05 1 7.677E-05 0.000 0.992 
Dpisqu 1.031 1 1.031 1.255 0.268 
Group * Dpi 0.527 1 0.527 0.641 0.427 
Group * Dpisqu 0.391 1 0.391 0.475 0.494 
Error 43.559 53 0.822   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .249 (Adjusted R Squared = .178)     
Dependent variable: Component scores on principal component 3 





Corrected model 18.322 5 3.664 4.895 0.001 
Intercept 6.715 1 6.715 8.969 0.004 
Group 0.325 1 0.325 0.435 0.513 
Dpi 0.614 1 0.614 0.820 0.369 
Dpisqu 9.656 1 9.656 12.899 0.001 
Group * Dpi 7.926 1 7.926 10.587 0.002 
Group * Dpisqu 0.263 1 0.263 0.351 0.556 
Error 39.678 53 0.749   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .316 (Adjusted R Squared = .251)  
Dependent variable: Component scores on principal component 4 





Corrected model 9.503 5 1.901 2.077 0.083 
Intercept 0.053 1 0.053 0.058 0.811 
Group 5.050 1 5.050 5.519 0.023 
Dpi 1.079 1 1.079 1.179 0.282 
Dpisqu 0.127 1 0.127 0.138 0.711 
Group * Dpi 0.052 1 0.052 0.056 0.813 
Group * Dpisqu 8.309 1 8.309 9.081 0.004 
Error 48.497 53 0.915   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .164 (Adjusted R Squared = .085 ) 
Table A-C3 Univariate analyses of component scores (dependent variable) and experimental groups (naïve group versus re-
inoculation group) and dpi (dpi in Phase 2 of the cytokine expression study). Significance was defined as p<0.05 and 
significant results are indicated by shaded cells and bolded text, results that became significant due to the interaction effect 
are indicated by bolded text alone. Note, that component scores reflect cytokine concentrations but cannot be interpreted 
as such. Group, experimental group (naïve group versus re-inoculated group); df, degrees of freedom; F, F-statistic; Dpi, 
days post inoculation.  
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FACTOR ROTATION AND PATTERN MATRICES (FROM ABSOLUTE VALUES) 
Solutions for the rotated PCA have been summarised in XXX and are presented below. Table A-C4 
lists the revised pattern matrix following promax rotation.  
Cytokine Rotated component 
 1 2 3 4 
IL1a .458 .334 -.148 .593 
IL1b .515 .467 -.069 -.344 
IL2 -.152 .374 .139 .852 
IL3 1.002 .014 -.090 -.110 
IL4 .684 .274 .058 .169 
IL5 .583 .221 .104 -.312 
IL6 1.101 -.205 -.214 -.062 
IL9 .497 .516 .070 -.024 
IL10 -.283 .040 1.048 -.017 
IL12p40 .126 -.274 .755 .263 
IL12p70 .280 .528 .189 .050 
IL13 .022 .767 -.142 -.063 
IL17 -.019 -.103 .063 .872 
Eotaxin .019 -.062 -.575 .558 
GCSF .710 -.486 .313 .100 
GMCSF .717 .110 .129 -.225 
IFNgamma .522 .471 .083 .192 
KC -.321 1.021 .009 .150 
MCP1 .034 .297 .573 .042 
MIP1a .070 .090 .849 -.023 
MIP1b .691 -.221 .429 .145 
RANTES -.011 -.089 .039 .882 
TNFalpha 1.056 -.073 -.105 .098 
 
Component correlation matrix 
Component 1 2 3 4 
1 1.000 .616 .641 -.042 
2 .616 1.000 .396 -.151 
3 .641 .396 1.000 .132 
4 -.042 -.151 .132 1.000 
Table A-C4 Revised pattern matrix (Promax rotation with Kaiser normalisation) for components with eigenvalues > 1. Factor 
loadings considered significant are indicated by shaded cells and bolded text.  
It must be noted that the corresponding components (rotated component 1 to 4) of the rotated 
solution, although representing the same variance within the datapoints, do not correspond exactly 
with the unrotated component loading patterns. Non-orthogonal rotation was used which tries to 
optimise loadings by placing the axes in a way that maximises observed variance, even if factors are 
correlated and would show up more closely without or in an orthogonal rotation. As a result, 
individual cytokines may load on different components following rotation. Overall, no increase in 
interpretability was observed following rotation.  
Visualisation of rotated component loadings after non-orthogonal (Promax) rotation 
Rotated component scores are visualised in Figure A-C2 (plotting rotated component scores over 





Figure A-C2 Rotated component scores over time. Extracted component scores for each of the four rotated (Promax with 
Kaiser normalisation) components are plotted on the y-axis and days post inoculation (DPI) are plotted on the x-axis. Green: 








Figure A-C3 Scatterplot matrix of unrotated component scores plotted against each other illustrating the relationships 
between the extracted components and clustering of the underlying dataset. Green circles represent component scores of 
the naïve group and blue circles represent component scores for the re-inoculation group. Component scores 1, component 
scores on rotated principal component 1; component scores 2, component scores on rotated principal component 2; 
component scores 3, component scores on rotated principal component 3; component scores 4, component scores 4 on 




Univariate analyses after non-orthogonal (Promax) rotation 
Rotated component scores were subject to univariate analyses as presented for the unrotated 
solution (4.3.4.2.3) and results are presented in Table A-C5.  
Dependent variable: Component scores on rotated principal component 1  





Corrected model 24.173 13 1.859 2.474 0.012 
Intercept 0.591 1 0.591 0.786 0.380 
Group 11.258 1 11.258 14.977 0.000 
Dpi 8.472 6 1.412 1.878 0.105 
Group * dpi 6.421 6 1.070 1.424 0.227 
Error 33.827 45 0.752   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .417 (Adjusted R Squared = .248) 
Dependent variable: Component scores on rotated principal component 2 





Corrected model 35.497 13 2.731 5.461 0.000 
Intercept 0.048 1 0.048 0.097 0.757 
Group 12.289 1 12.289 24.576 0.000 
Dpi 9.688 6 1.615 3.229 0.010 
Group * dpi 12.808 6 2.135 4.269 0.002 
Error 22.503 45 0.500   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .612 (Adjusted R Squared = .500) 
Dependent variable: Component scores on rotated principal component 3 





Corrected model 30.772 13 2.367 3.912 0.000 
Intercept 0.565 1 0.565 0.934 0.339 
Group 0.172 1 0.172 0.284 0.597 
Dpi 14.517 6 2.419 3.999 0.003 
Group * dpi 11.487 6 1.915 3.164 0.011 
Error 27.228 45 0.605   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .531 (Adjusted R Squared = .395) 
Dependent variable: Component scores on rotated principal component 4 





Corrected model 10.610 3 3.537 4.105 0.011 
Intercept 0.017 1 0.017 0.020 0.887 
Group 5.042 1 5.042 5.852 0.019 
Dpi 0.001 1 0.001 0.001 0.981 
Group * dpi 0.002 1 0.002 0.002 0.966 
Error 47.390 55 0.862   
Total 58.000 59    
Corrected total 58.000 58    
R Squared = .183 (Adjusted R Squared = .138) 
Table A-C5 Univariate analyses of rotated component scores (dependent variable) and experimental groups (naïve vs. re-
infected) and dpi (days post inoculation/re-inoculation). Rotated scores allow for correlations between the scores but no not 
correspond directly to the unrotated solution. Significant results are highlighted in bold. Note, that regression factor scores 
reflect cytokine concentrations but cannot be interpreted as such.  Rotation did not greatly help interpretation so was not 
further explored for analysis. 
Interpretation of Promax rotated PCA component loadings 
Rotation is employed to increase interpretability. In the current case a non-orthogonal rotation 
matrix was explored to allow for correlation between individual cytokines and plot the intrinsic 
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variation of the dataset on coordinates, optimised for their differentiation. However, factors did not 
appear to allow further differentiation of immunological pathways, in fact, the Th17 pathway did not 
come up with significant effects on groups or days post inoculation after the rotation operation was 
executed. One may speculate that these non-orthogonal factors were more suitable to detect 
distinct peak-and-through patterns within the cytokine values over time, however, immunological 




CYTOKINE DECREASE/INCREASE OVER TIME (% CHANGE) 
Individual cytokine concentrations of the naïve and re-inoculated group mice, exsanguinated at 0, 1, 2, 3, 7, 10 and 14 dpi as % change from baseline in are 
presented in Figure A-C5.  
 
Figure A-C5: Change in cytokine concentration over time for cytokines loading on principal component 1. A baseline value was defined as the median value of group 0 for each respective 
cytokine. Change over time was then calculated by subtracting the baseline from individually measured cytokines and dividing them by the baseline value. Cytokine concentrations (change 
from baseline, 1 = +100%) are plotted on the y-axis and days post inoculation are plotted on the x-axis. Bars represent the interquartile range, medians are highlighted. Whiskers represent 





Figure A-C5 (continues): Change in cytokine concentration over time for cytokines loading on principal component 1. A baseline value was defined as the median value of group 0 for each 
respective cytokine. Change over time was then calculated by subtracting the baseline from individually measured cytokines and dividing them by the baseline value. Cytokine concentrations 
(change from baseline, 1 = +100%) are plotted on the y-axis and days post inoculation are plotted on the x-axis. Bars represent the interquartile range, medians are highlighted. Whiskers 





Figure A-C5 (continued): Change in cytokine concentration over time for cytokines loading on principal component 2. A baseline value was defined as the median value of group 0 for each 
respective cytokine. Change over time was then calculated by subtracting the baseline from individually measured cytokines and dividing them by the baseline value. Cytokine concentrations 
(change from baseline, 1 = +100%) are plotted on the y-axis and days post inoculation are plotted on the x-axis. Bars represent the interquartile range, medians are highlighted. Whiskers 







Figure A-C5 (continued): Change in cytokine concentration over time for cytokines loading on principal component 5 (KC) and not loading significantly on any of the first four principal 
components (Eotaxin, IL-13). A baseline value was defined as the median value of group 0 for each respective cytokine. Change over time was then calculated by subtracting the baseline from 
individually measured cytokines and dividing them by the baseline value. Cytokine concentrations (change from baseline, 1 = +100%) are plotted on the y-axis and days post inoculation are 
plotted on the x-axis. Bars represent the interquartile range, medians are highlighted. Whiskers represent total variation and outliers (more than 1.5 times the interquartile range from the 
median) are indicated. Green: naïve group, blue: re-infected group.  
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11 APPENDIX D 
CULTURE WELLS DESCRIBED DURING IN VITRO CULTIVATION STUDIES 
 
Figure A-D1 Culture plate showing wells of the in vitro cultivation study 1, using plateau-infected blood and murine 
erythroblast progenitor cell lines. Duplicated wells are indicated with an apostrophe (‘). The left panel shows culture wells 
A1 to E2 and the right panel shows culture well A2.  
 
Figure A-D2 Culture plate showing wells of the in vitro cultivation study 2, using M. haemomuris-infected blood to try to 
infect murine erythroblast cell lines, naïve murine blood, washed murine erythrocytes and splenocyte suspensions. 
Duplicated wells are indicated with an apostrophe (‘).  
  
Figure A-D3 Culture plate showing wells of the in vitro cultivation study 5 (purine/pyrimidine study). Left panel: Day of 
inoculation of culture wells. Right panel: Three days post inoculation of culture wells, after inoculation of half of the wells 
into sentinel mice and splitting well BLO2 in two identical wells supplemented with fresh mouse blood.  
